# EAU26 | LONDON, GB

13-16 March 2026

Cutting-edge Science at Europe's largest Urology Congress

www.eau26.org

European Association of Urology

# Management of oligometastatic prostate cancer: Not as easy as it seems

Plenary Session

**Friday 13 March**
**08:00 - 10:00**

**Location** Orange Area, eURO Auditorium 1

**Chairs** A. Briganti, Milan (IT)
C. Gratzke, Freiburg (DE)

**08:00 - 08:03** **Welcome and introduction**
A. Briganti, Milan (IT)

**08:03 - 08:12** State-of-the-art lecture **The biology of oligometastatic disease**
P. Tran, Houston (US)

**08:12 - 08:50** Debate **Optimal management of de-novo oligometastatic disease**

08:12 - 08:15 Case presentation **ISUP 5, young patient, five bone mets on CT and bone scan**
R. Nicoletti, Florence (IT)

08:15 - 08:20 **Can´t say we always need PSMA PET/CT imaging in this setting!**
R. Eapen, Melbourne (AU)

08:20 - 08:25 **Surgery is still an option in 2025**
M. Graefen, Hamburg (DE)

08:25 - 08:30 **Radiotherapy: Treat all you can see**
A. Kishan, Los Angeles (US)

08:30 - 08:35 **Intensified systemic therapy is still mandatory**
J. Casuscelli, München (DE)

08:35 - 08:40 Live interview **Optimal trial design in oligometastatic disease at diagnosis**

*Interviewer* V. Parry, Carterton (GB)

*Speaker* B.F. Chapin, Houston (US)

08:40 - 08:50 **Panel discussion and voting**

**08:50 - 09:46** Debate **Optimal management of oligorecurrent disease**

08:50 - 08:59 State-of-the-art lecture **The road to cure: Does intensification matter?**
B. Tombal, Brussels (BE)

08:59 - 09:08 State-of-the-art lecture **Who can really benefit from metastasis directed therapies?**
B.A. Jereczek-Fossa, Milan (IT)

09:08 - 09:11 Case presentation **Node only recurrence - 3 lymph nodes in the pelvis at PSMA PET**
I. Heidegger, Innsbruck (AT)

09:11 - 09:16 **Take them out! Radioguided surgery**
H.G. Van Der Poel, Amsterdam (NL)

09:16 - 09:21 **Irradiate them!**
G. Marvaso, Milan (IT)

09:21 - 09:26 **Too late! Systemic treatment**
U. Vogl, Bellinzona (CH)

09:26 - 09:31 **Is there a role for Lutetium PSMA?**
W. Fendler, Essen (DE)

09:31 - 09:36 Live interview **What if the patient had two bone mets in addition?**

*Interviewer* V. Parry, Carterton (GB)

*Speaker* A. Bossi, La Garenne Colombes (FR)

09:36 - 09:46 **Panel discussion and voting**

**09:46 - 09:55** State-of-the-art lecture **Ongoing practice changing trials in the oligorecurrent setting**
A. Kishan, Los Angeles (US)

**09:55 - 10:00** **Closing remarks**
C. Gratzke, Freiburg (DE)

## Cutting-edge developments in functional and neurourology: Shaping the future

Plenary Session

**Friday 13 March**
**08:00 - 10:00**

**Location** Orange Area, eURO Auditorium 2

**Chairs** T.M. Kessler, Zurich (CH)
B. Peyronnet, Rennes (FR)

**Learning objectives**
The aim of this session will be to provide the audience with a comprehensive overview of the latest developments in functional urology and neurology with emphasis on the new technology that have arrived on the market within the past three years.

**08:00 - 08:02** **Welcome and introduction**

**08:02 - 08:10** Spotlight talk **To know where you're going, know where you come from: Insights in functional and neurourology**
P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

**08:10 - 08:18** State-of-the-art lecture **Ketamine cystitis: What all urologists should know**
L. De Kort, Utrecht (NL)

**08:18 - 08:52** Round-table discussion **Bladder dysfunction: Who will win the battle of neuromodulation?**

08:18 - 08:22 **Transcutaneous tibial**
J-N.L. Cornu, Rouen (FR)

08:22 - 08:26 **Peroneal**
J. Krhut, Ostrava (CZ)

08:26 - 08:30 **Implantable tibial with anklet**
J. Heesakkers, Maastricht (NL)

| | |
|---|---|
| 08:30 - 08:34 | **Implantable tibiale without anklet**<br>U. Lee, Seattle, WA (US) |
| 08:34 - 08:38 | **Pudendal**<br>S. De Wachter, Edegem (BE) |
| 08:38 - 08:42 | **Newer sacral**<br>S. Musco, Florence (IT) |
| 08:42 - 08:52 | **Case based discussion**<br>A. Nic An Riogh, Dublin (IE) |
| **08:52 - 09:02** | State-of-the-art lecture **Intermittent catheterisation > 50 years letter: Can we still do better?**<br>B. Blok, Rotterdam (NL) |
| **09:02 - 09:12** | State-of-the-art lecture **Wireless urodynamic: Are we there yet?**<br>M. Damaser, Cleveland (US) |
| **09:12 - 09:17** | **Discussion and Q&A** |
| **09:17 - 09:37** | Debate **What is the best way to approach OAB in 2026?**<br>*Moderator* B. Peyronnet, Rennes (FR) |
| 09:17 - 09:19 | **Case presentation**<br>B. Peyronnet, Rennes (FR) |
| 09:19 - 09:24 | **The stepwise approach is still the way to go: Defending the EAU guidelines**<br>C. Harding, Newcastle upon Tyne (GB) |
| 09:24 - 09:29 | **It is time for a nonstep approach: Defending the AUA guidelines**<br>A. Pelletier Cameron, Ann Arbor (US) |
| 09:29 - 09:37 | **Rebuttal** |
| **09:37 - 09:47** | Spotlight talk **Latest advancement in robotic functional and reconstructive urology**<br>A. Sahai, London (GB) |
| **09:47 - 09:57** | State-of-the-art lecture **Update on electromechanical sphincter: From bench to bedside?**<br>E. Chartier-Kastler, Paris (FR) |
| **09:57 - 10:00** | **Summary and conclusion** |

## Patient Advocacy Poster Session with Top 3 Awards

Patient Advocacy Focused - Poster Session

**Friday 13 March**
**08:30 - 09:30**

**Location** Red Area, Room 17

**Chairs**
J. Daly, Galway (IE)
R. Greene, Amsterdam (NL)

| | |
|---|---|
| **08:30 - 08:31** | **Introduction**<br>J. Daly, Galway (IE)<br>R. Greene, Amsterdam (NL) |
| PA1 | **Bladder health and lived experience in multiple sclerosis outcome measurement**<br>L. Makaroff, London (GB) |
| PA2 | **Education materials on bladder cancer: A scoping review and recommendations for future initiatives**<br>R.C.A. Leenen, Rotterdam (NL) |
| PA5 | **Supporting men on androgen deprivation therapy (ADT) for prostate cancer: a patient centred innovation**<br>L. Fleure, London (GB) |
| PA4 | **What prostate cancer patients find important when making treatment decisions**<br>P. Nasseri, Rotterdam (NL) |
| PA3 | **Key determinants influencing treatment decision-making for and adherence to active surveillance for prostate cancer: A qualitative study**<br>P. Nasseri, Rotterdam (NL) |
| PA6 | **Impact of behavioural factors on care seeking for urinary symptoms linked to bladder cancer**<br>A. Filicevas, Brussels (BE) |
| **09:25 - 09:30** | **Top 3 award winners**<br>E. Rogers, Roscommon (IE) |
| | **Closing**<br>E. Rogers, Roscommon (IE) |

## Advanced endourology in non-standard patients with urolithiasis

ESU Course 03

**Friday 13 March**
**08:30 - 11:30**

**Location** Red Area, Room 10

**Chair** S. Doizi, Paris (FR)

Voting will be available via the EAU26 App or via www.qna.at/eau

**Learning objectives**

The course will discuss available literature and practical management options and examples treatment of urolithiasis in ‘non-index’ patients. The course will cover:

- Horseshoe kidney, caliceal diverticula duplicate urinary system
- Pregnancy and complex metabolic patients
- After bladder substitution/ileal conduit/reimplanation
- Transplanted kidneys and spinal malformation

**Introduction**
S. Doizi, Paris (FR)

**Urolithiasis in urinary system anomalies: Horseshoe kidneys**
A. Tsaturyan, Yerevan (AM)

**Urolithiasis in urinary system anomalies: After bladder substitution/ ileal conduit/ ureteral reimplantation**
A. Tsaturyan, Yerevan (AM)

**Urolithiasis in urinary system anomalies: Calyceal diverticula stones**
S. Doizi, Paris (FR)

**Bilateral stone treatment; Do's and don'ts**
A. Tsaturyan, Yerevan (AM)

**Urolithiasis in pregnancy**
O. Angerri Feu, Barcelona (ES)

**Medullary sponge kidneys**
S. Doizi, Paris (FR)

**Urolithiasis in transplant kidneys**
O. Angerri Feu, Barcelona (ES)

**Urolithiasis in urinary system anomalies: Duplicate urinary system and ectopic kidney**
S. Doizi, Paris (FR)

**Patients with relative contraindications: Spinal and skeletal malformations**
O. Angerri Feu, Barcelona (ES)

## Advanced course on upper tract laparoscopy

ESU Course 01

**Friday 13 March**
**08:30 - 11:30**

**Location** Red Area, Room 8

**Chair** P.J. Zondervan, Amsterdam (NL)

**Learning objectives**
This ESU course is designed for experienced urologists looking to develop their skills in laparoscopic surgery of the upper urinary tract. The course covers transperitoneal and retroperitoneal approaches in depth, including laparoscopic management of renal tumours, UPJ obstruction, ureteral pathology and stone disease. The course also covers intraoperative complications, complex case management and special scenarios, combining expert-led discussions with practical insights to improve surgical decision-making and technique.

**Introduction**
P.J. Zondervan, Amsterdam (NL)

**Transperitoneal versus retroperitoneal upper tract laparoscopic surgery**
J. Gómez Rivas, Madrid (ES)
P.J. Zondervan, Amsterdam (NL)

**Laparoscopic advanced renal oncology (radical, partial and nephroureterectomy), tips & tricks**
A. Celia, Bassano Del Grappa (IT)
J. Gómez Rivas, Madrid (ES)
P.J. Zondervan, Amsterdam (NL)

**Laparoscopic complex UPJ, ureter and stones**
A. Celia, Bassano Del Grappa (IT)
J. Gómez Rivas, Madrid (ES)
P.J. Zondervan, Amsterdam (NL)

**Complications, interactive be prepared**
A. Celia, Bassano Del Grappa (IT)
J. Gómez Rivas, Madrid (ES)
P.J. Zondervan, Amsterdam (NL)

**Complex cases tips & tricks**
A. Celia, Bassano Del Grappa (IT)
J. Gómez Rivas, Madrid (ES)

**Special case: What can we learn from this?**
P.J. Zondervan, Amsterdam (NL)

## Complications in BPO management. A guide on how to mess up BPO management (fast)

ESU Course 04

**Friday 13 March**
**08:30 - 11:30**

**Location** Red Area, Room 11

**Chair** C. Netsch, Hamburg (DE)

**Introduction: A guide to messing up BPO surgery (from informed hand)**
C. Netsch, Hamburg (DE)

**EAU BPO surgery: The current pathway**
K.A.O. Tikkinen, Helsinki (FI)

**Critical appraisal of energy sources (lasers, HF, water yet and steam)**
C. Netsch, Hamburg (DE)

**The role of preoperative assessment (patient self-reported questionnaires, uroflowmetry, DRE and urodynamics)**
K.A.O. Tikkinen, Helsinki (FI)

**Perioperative safety considerations in BPO surgery**
K.A.O. Tikkinen, Helsinki (FI)

**MIST, new ultra minimal invasive, minimal invasive, endoscopic and open surgery. Coining and reality**
I. Kartalas Goumas, Vigevano (IT)

**Complications and how to avoid them in TURP**
K.A.O. Tikkinen, Helsinki (FI)

**Complications and how to avoid them in vaporisation**
C. Netsch, Hamburg (DE)

**Clinical cases**
K.A.O. Tikkinen, Helsinki (FI)

**Complications and how to avoid them in enucleation and morcellation. Training, setup and safety measures**
C. Netsch, Hamburg (DE)

**Clinical case**
C. Netsch, Hamburg (DE)

**Complications and how to avoid them in laparoscopic and robotic enucleation. A reference to open prostatectomy**
I. Kartalas Goumas, Vigevano (IT)

**Clinical case**
I. Kartalas Goumas, Vigevano (IT)

Case discussion **Interactive case discussions on salvage manoeuvres after failed 1st treatment**
I. Kartalas Goumas, Vigevano (IT)
C. Netsch, Hamburg (DE)
K.A.O. Tikkinen, Helsinki (FI)

**Closing remarks**
C. Netsch, Hamburg (DE)

## How we manage upper tract tumours

ESU Course 06

**Friday 13 March**
**08:30 - 10:30**

**Location** Red Area, Room 13

**Chair** A. Masson-Lecomte, Paris (FR)

**Learning objectives**
This course will address contemporary concepts and controversies in UTUC such as:
• Accurate staging and its role in clinical decision-making/risk stratification.
• Risks, benefits, and side effects of current and novel therapeutic approaches including endoscopic and minimal-invasive surgery.
• Optimal management of the bladder cuff as well as indication and extent of lymphadenectomy.
• Systemic therapy for high-risk and metastatic patients.

**Epidemiology, pathology and risk stratification**
A. Masson-Lecomte, Paris (FR)

**Diagnosis and evaluation**
J. Baard, Amsterdam (NL)

**Kidney sparing treatments of low-risk and selected high risk cancers**
J. Baard, Amsterdam (NL)

**Treatment of localised high-risk (invasive) and metastatic cancer**
A. Masson-Lecomte, Paris (FR)

## Chronic pelvic pain in men and women

ESU Course 02

**Friday 13 March**
**08:30 - 11:30**

**Location** Red Area, Room 9

**Chair** B. Parsons, Exeter (GB)

**Learning objectives**
The urologist is often dealing with patients having Chronic Pelvic Pain. This course will offer the urologist practical guidance in treating these patients. In the case discussion the participants will have the opportunity to help outlining the problem. In the lectures, theoretical knowledge will be translated into daily guidelines for diagnostics and treatment of patients with pelvic pain.
At the end of this course the participant will:

- Know the basic principles of treating patients with chronic pelvic pain.
- Know how to rule out well-known causes.
- Have knowledge of the myofascial and psychological aspects.
- Be able to refer patients at the right time to the right team.

**Chronic pelvic pain, the basics: Mechanisms and terminology**
P. Abreu-Mendes, Porto (PT)

**Chronic pelvic pain in men: Case presentation and discussion**
B. Parsons, Exeter (GB)

**Chronic pelvic pain in men: Practical guidelines on diagnostics and treatment**
B. Parsons, Exeter (GB)

**Chronic pelvic pain in women: Case presentation and discussion**
P. Abreu-Mendes, Porto (PT)

**Chronic pelvic pain in women: Practical guidelines on diagnostics and treatment**
P. Abreu-Mendes, Porto (PT)

**The interdisciplinary approach: Team members and organisation**
B. Parsons, Exeter (GB)

# Innovations and insights in andrological research: From erectile dysfunction to sexual well-being

EGPT 02

**Friday 13 March**
**08:30 - 10:00**

**Location** Orange Area, EGPT 2

**Chairs**
J.I. Martínez Salamanca, Majadahonda (ES)
R. Sandher, London (GB)
H.C. Son, Seoul (KR)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**08:30 - 08:55** **Translational biomedicine**

P0019 **Innovative Noninvasive Assessment of Erectile Function in Mice: A Methodological Study Integrating Optogenetics and Chemogenetics**
P. Hu, Wuhan (CN)

P0020 **A novel mechanism underlying the emission phase of ejaculation: Purinergic stimulation potentiates oscillatory and tonic contraction during α1-receptor activation by phenylephrine in Human seminal vesicle smooth muscle.**
S. Kajioka, Fukuoka (JP)

P0021 **Extracellular matrix remodeling mediates cavernosal fibroblast senescence and erectile dysfunction under diabetic conditions**
Z Han, Zhuhai (CN)

P0023 **Urinary microbiome dysbiosis in erectile dysfunction: Enrichment of stress-tolerant genera in a 16S rRNA-based analysis**
W.K. Hwang, Seoul (KR)

**08:55 - 09:10** **Ejaculation disorders**

P0024 **Exploring the impact of sexual positions on ejaculation: Insights from a survey study by the Andrology Working Group of the Society of Urological Surgery in Turkey**
M. Gül, Konya (TR)

P0025 **Effect of a silicone patch applied to the penile frenulum for premature ejaculation: a prospective, randomised controlled trial assessing functional outcomes, safety, and satisfaction**
T. Dogan, Istanbul (TR)

P0026 **Ejaculatory Dysfunction after Post-Chemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND): Prognostic Factors and Clinical Impact of Nerve-Sparing Technique**
K. Tsubotani, Kobe (JP)

**09:10 - 09:45** **Sexual dysfunction**

P0027 **Lack of association between oxidative stress and erectile dysfunction in diverse male populations**
N. Fujita, Hirosaki (JP)

P0028 **Validation of optimal peak systolic velocity thresholds for the diagnosis of arteriogenic erectile dysfunction via penile Color Doppler Duplex Ultrasound: insights from a single-center comparative cohort study**
E. Pozzi, Milan (IT)

P0029 **AI-Powered Chatbot for Personalized Sexual Health Education in Adolescent Males: A Randomized Controlled Trial in a Resource-Limited Urban Setting**
A. Patil, Mumbai (IN)

P0030 **From Erectile Dysfunction Treatment to Heart Outcomes: Risk Ratios Linking Phosphodiesterase Type 5 Inhibitors to 1-Year Major Adverse Cardiac Events in Routine Care**
P.H. Wang, Taichung (TW)

P0031 **Asymptomatic hyperuricemia signals higher erectile-dysfunction risk: A multicenter propensity-matched cohort with a parallel treatment comparison**
P.C. Liu, Taichung (TW)

P0032 **Minimally invasive; Functionally Preserved: Sexual health after focal brachytherapy in prostate cancer patients**
L. Boesen, Herlev (DK)

**09:45 - 10:00** **Penile implant**

P0034 **Determinants of Decision Regret and Quality of Life After Penile Prosthesis Implantation: Insights From a Prospective Single-Center Study**
A. Franco, Roma (IT)

P0035 **Does extending postoperative antibiotic prophylaxis reduce penile prosthesis infection? A retrospective institutional analysis**
A. Henriques, Porto (PT)

P0036 **A 15-year analysis of the economic burden of postoperative infection following inflatable penile prosthesis implantation**
V. Nguyen, Seattle (US)

## Urolithiasis: Infections, genetics and the microbiome

EGPT 01

**Friday 13 March**
**08:30 - 10:00**

**Location** Orange Area, EGPT 1

**Chairs**
W. Kamal, Jeddah (SA)
A. Sierra Del Rio, Barcelona (ES)
K. Thomas, London (GB)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**08:30 - 08:45** **Infections and stones: Clinical**

P0001 **Predictive value of perinephric fat stranding for obstructive pyelonephritis and septic shock**
C. Kottooran, Boston (US)

| | |
|---|---|
| P0002 | **Percutaneous nephrostomy or ureteral stenting in septic obstructive urolithiasis: a propensity-matched comparative study**<br>M. Menozzi, (IT) |
| P0003 | **Are SGLT2 inhibitors a new risk factor for urinary tract infections after ureteroscopy in diabetic patients?**<br>N. Fazaa, Haifa (IL) |
| **08:45 - 09:00** | **Infections and stones: Research** |
| P0004 | **Multimodal integration of CT-derived 3D morphology, radiomics, and deep learning features for predicting urine culture positivity and clinical stratification in ureteral stone patients**<br>S. Ikuma, tokyo (JP) |
| P0005 | **Evaluation of new-generation systemic immune markers for predicting positive urine culture in urolithiasis patients**<br>C. Li, Tianjin (CN) |
| **09:00 - 09:40** | **Genetics and stones** |
| P0007 | **Exome-wide association of kidney stone disease in the UK Biobank**<br>C. Lovegrove, Glasgow (GB) |
| P0008 | **Bidirectional Association Between Nephrolithiasis and Osteoporosis: Evidence From a Large Prospective Cohort Study in the UK Biobank**<br>C-Y. Huang, Taipei (TW) |
| P0009 | **Mendelian disorders are an uncommon cause of kidney stone disease**<br>C. Lovegrove, Glasgow (GB) |
| P0010 | **Bidirectional Association Between Kidney Stones and Atherosclerosis: A Study on Mediation, Genetics, and Risk Prediction**<br>Z. He, Shenzhen (CN) |
| P0011 | **Kidney stone disease-associated genetic variant may regulate CYP24A1 expression**<br>C. Lovegrove, Glasgow (GB) |
| P0012 | **Polygenic Risk scores Perform poorly in Prediction of Kidney Stone Disease: Cross-over validation in All of Us and UK Biobank**<br>R. Geraghty, Newcastle upon Tyne (GB) |
| P0014 | **Prevalence and biochemical associations of pathogenic genetic variants in a targeted population of high-risk kidney stone formers**<br>R. Geraghty, Newcastle upon Tyne (GB) |
| **09:40 - 10:00** | **The microbiome** |
| P0016 | **Distinct urinary microbial profiles in calcium oxalate urolithiasis: A 16S rRNA-based comparative study**<br>W.K. Hwang, Seoul (KR) |
| P0018 | **Gut microbiome and metabolome signatures in renal stone recurrence: A multi-omics study**<br>K. Dang, Beijing (CN) |

# BALANCE: Embracing diversity in prostate cancer - Our journey so far

Patient Advocacy Roundtable

**Friday 13 March**
**09:45 - 10:45**

**Location** Red Area, Room 17

**Chair** D. James, London (GB)

**Learning objectives**

In this session, participants will explore the journey of the BALANCE study - from its design and stakeholder engagement to the rollout of questionnaires and key insights from participating countries. Faculty members will share experiences and lessons learned, offering an honest reflection on the project's progress so far.

The discussion will highlight the importance of transparency in collaborative research, addressing challenges and obstacles encountered along the way. Participants will also gain insight into effective community involvement and co-creation, drawing on best practices from both researchers and patient representatives.

Finally, the session will look ahead to the project's next steps, examining how BALANCE can inform future education, policy, and research efforts to promote stronger patient–clinician collaboration in urology.

| | |
|---|---|
| **09:45 - 09:50** | **Welcome & introduction**<br>D. James, London (GB) |
| **09:50 - 10:00** | **How "place" shapes lived experience: Why region matters in prostate cancer research**<br>M. Caitano Maia, Belém (BR)<br>C. Warning, Paramaribo (SR) |
| **10:00 - 10:10** | **Designing studies that reflect real lives, not just clinical pathways**<br>T. Davies OBE, Waltham Cross (GB) |
| **10:10 - 10:25** | **Recruitment, trust, and participation: Meeting communities where they are**<br>*Panel*<br>M. Caitano Maia, Belém (BR)<br>T. Davies OBE, Waltham Cross (GB)<br>N Natalia, London (GB)<br>L. Thompson, (GB)<br>C. Warning, Paramaribo (SR) |
| **10:25 - 10:35** | **From data to meaning: understanding patient-reported outcomes through an equity lens**<br>N Natalia, London (GB) |
| **10:35 - 10:45** | **Q&A and closing**<br>D. James, London (GB) |

## Game Changer Session

**Friday 13 March**
**10:00 - 10:30**

**Location** Orange Area, eURO Auditorium 1

**Chairs**
A. Briganti, Milan (IT)
C. Gratzke, Freiburg (DE)

**10:00 - 10:15**

**Impact of [68Ga]Ga-PSMA-11 PET/CT in the diagnosis of prostate cancer in men with equivocal or non-suspicious findings on multi-parametric MRI (PRIMARY2): a multi-centre, phase III, randomised trial**

*Speaker* J.P. Buteau, Melbourne (AU)

*Discussant* J. Walz, Marseille (FR)

**10:15 - 10:30**

**A Phase II, Randomized, Controlled Trial of Best Systemic Therapy vs Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer**

*Speaker* B.F. Chapin, Houston (US)

*Discussant* M. Graefen, Hamburg (DE)

## Game Changer Session

**Friday 13 March**
**10:00 - 10:15**

**Location** Orange Area, eURO Auditorium 2

**Chairs**
T.M. Kessler, Zurich (CH)
B. Peyronnet, Rennes (FR)

**10:00 - 10:15**

**Safety of Reusable vs. Single-Use Catheters for Intermittent Catheterization in Patients with Urinary Retention: A Multicenter, Randomized Non-Inferiority Trial (COMPaRE)**

*Speaker* B. Blok, Rotterdam (NL)

*Discussant* T.M. Kessler, Zurich (CH)

# Beyond the stone: Metabolic management of urolithiasis

Thematic Session

**Friday 13 March**
**10:45 - 12:15**

**Location** Orange Area, eURO Auditorium 1

**Chairs** S. Proietti, Milan (IT)
A. Skolarikos, Athens (GR)

**Learning objectives**
By the end of this session, delegates will: Recognize how climate change and environmental factors are shifting the epidemiology of kidney stones. Know how, who and when to undertake metabolic screening, and when genetic testing is warranted. Weigh prevention strategies - 24-hour urine-guided medical therapy versus treatment of residual fragments -through debate. Apply practical recurrence-reduction measures: Optimal drinking water choices, OTC supplements, and the potential role of SGLT-2 inhibitors. Tailor metabolic evaluation and therapy to paediatric, infection/struvite, and hypercalciuric calcium stones, including indications for thiazides.

**10:45 - 10:46** **Introduction**

**10:46 - 10:54** State-of-the-art lecture **Climate change, the environment and incidence of urolithiasis**
G. Tasian, Philadelphia (US)

**10:54 - 11:02** State-of-the-art lecture **How, who and when to undertake metabolic screening in stone formers?**
H.U. Jung, Vejle (DK)

**11:02 - 11:10** State-of-the-art lecture **Who should have genetic testing in kidney stone disease?**
S. Howles, High Wycombe (GB)

**11:10 - 11:25** Debate **To prevent stone recurrence, it is more important to:**

*Moderator* B. Ballesta Martinez, Alicante (ES)

11:10 - 11:12 **Introduction**
B. Ballesta Martinez, Alicante (ES)

11:12 - 11:17 **Obtain a 24-hour urine and optimise medical management**
M.A. Corrales Acosta, Clemont Ferrand (FR)

11:17 - 11:22 **Treat the residual stone fragments**
S. Tonyali, Istanbul (TR)

11:22 - 11:25 **Summary**

**11:25 - 11:50** Panel discussion **Reducing the risk of stone recurrence**

*Moderator* E. Ventimiglia, Uppsala (SE)

11:25 - 11:27 **Introduction**
E. Ventimiglia, Uppsala (SE)

11:27 - 11:32 **What water should our patients drink?**
S. Willis, London (GB)

11:32 - 11:37 **Over-the-counter supplements to reduce stone formation**
G. Kamphuis, Amsterdam (NL)

11:37 - 11:42 **Should we offer SGLT-2 inhibitors to reduce kidney stone risk?**
D. Fuster, Bern (CH)

11:42 - 11:50 **Discussion**

**11:50 - 12:14** **Management of stones in specific situations**

11:50 - 11:58 State-of-the-art lecture **Paediatric stones: Specifications in metabolic evaluation and management**
T.M. Oktar, Istanbul (TR)

11:58 - 12:06 State-of-the-art lecture **Infection stones: Metabolic evaluation, medical management and prevention**
E. Mazzucchi, Sao Paulo (BR)

12:06 - 12:14 State-of-the-art lecture **Calcium stones: When to use thiazides in hypercalciuria?**
J. Sayer, Newcastle upon Tyne (GB)

**12:14 - 12:15** **Conclusion**

## Common problems and controversies in bladder cancer: Rapid-fire debates

Thematic Session

**Friday 13 March**
**10:45 - 12:15**

**Location** Orange Area, eURO Auditorium 2

**Chairs** A.M. Kamat, Houston (US)
A. Stenzl, Stuttgart (DE)

**10:45 - 10:48** **Introduction**
A.M. Kamat, Houston (US)

**10:48 - 11:05** **Urinary markers vs. cystoscopy: Is it time to ditch the scope?**

*Moderator* P. Gontero, Turin (IT)

10:48 - 10:50 **Case presentation**
P. Gontero, Turin (IT)

10:50 - 10:54 **Debater 1: Yes, urinary markers are ready to replace cystoscopy**
J.Y.C. Teoh, Hong Kong (HK)

10:54 - 10:58 **Debater 2: Not yet, cystoscopy remains the gold standard for a reason**
L.S. Mertens, Amsterdam (NL)

10:58 - 11:05 **Discussion and Q&A**

*Speakers* P. Gontero, Turin (IT)
M.C. Mir Maresma, New York (US)

**11:05 - 11:22** **High-risk BCG naïve NMIBC: BCG + IO – Bold new standard or overreach?**

*Moderator* A.M. Kamat, Houston (US)

11:05 - 11:07 **Case presentation**
A.M. Kamat, Houston (US)

11:07 - 11:11 **Debater 1: BCG + IO: The next logical step for high-risk NMIBC**
N. Shore, Myrtle Beach (US)

11:11 - 11:15 **Debater 2: Not so fast: BCG + IO is overkill**
E. Laukhtina, Vienna (AT)

11:15 - 11:22 **Discussion and Q&A**

*Speakers*
A.M. Kamat, Houston (US)
A. Stenzl, Stuttgart (DE)

---

**11:22 - 11:39** **TMT for MIBC: Radiation, responsibility, and recurrences – who manages the fallout, and how?**

*Moderator*
P. Mariappan, Edinburgh (GB)

11:22 - 11:24 **Case presentation**
P. Mariappan, Edinburgh (GB)

11:24 - 11:28 **Debater 1: Radiation toxicity is real and it's urologists who manage the consequences**
A. Van Der Heijden, Nijmegen (NL)

11:28 - 11:32 **Debater 2: Toxicity happens but is manageable - radiation oncologists can and should take responsibility**
N. Vapiwala, Philadelphia (US)

11:32 - 11:39 **Discussion and Q&A**

*Speakers*
A.J Birtle, Preston (GB)
P. Mariappan, Edinburgh (GB)

---

**11:39 - 11:56** **Bladder preservation post-NAC: Smart strategy or risky business?**

*Moderator*
B. Pradère, Toulouse (FR)

11:39 - 11:41 **Case presentation**
B. Pradère, Toulouse (FR)

11:41 - 11:45 **Debater 1: Bladder preservation in cCR patients: A smart, data-driven strategy**
F.C. Maluf, Sao Paulo (BR)

11:45 - 11:49 **Debater 2: Bladder preservation post-NAC: Risky business**
B. Schmidt, Salt Lake City (US)

11:49 - 11:56 **Discussion and Q&A**

*Speakers*
B. Pradère, Toulouse (FR)
A. Stenzl, Stuttgart (DE)

---

**11:56 - 12:13** **MIBC systemic therapy: Maximise early or strategise post-op?**

*Moderator*
M. Galsky, New York (US)

11:56 - 11:58 **Case presentation**
M. Galsky, New York (US)

11:58 - 12:02 **Debater 1: Peri-operative IO based therapy for all**
T. Powles, London (GB)

| | | |
|---|---|---|
| 12:02 - 12:06 | **Debater 2: NAC + Risk-adapted adjuvant IO**<br>P. Giannatempo, Milan (IT) | |
| 12:06 - 12:13 | **Discussion and Q&A** | |
| | *Speakers* | M. Galsky, New York (US)<br>F. Guerrero-Ramos, Madrid (ES) |
| **12:13 - 12:15** | **Closure** | |

# 5 top tips for genital surgery

Thematic Session

**Friday 13 March**
**10:45 - 12:15**

**Location** Orange Area, Room 3

**Chairs** S.C. Morgenstern, Frankfurt am Main (DE)
O.J. Nilsen, Oslo (NO)

**Learning objectives**
The session aims to increase the participants' knowledge of a wide range of important topics in the area of genital surgery. Learning by past mistakes, updated management, avoiding pitfalls and managing complications is offered by experts within their field.

| | |
|---|---|
| **10:45 - 10:47** | **Introduction** |
| **10:47 - 11:28** | **Andrology** |
| 10:47 - 10:57 | History lecture **What can we learn from past mistakes in genital surgery?**<br>J.C. Goddard, Leicester (GB) |
| 10:57 - 11:04 | **Peyronie's disease: Straight to the point**<br>M.Y. Ortega González, San Cristóbal de La Laguna (ES) |
| 11:04 - 11:11 | **Erectile prosthesis: Avoiding disaster**<br>J. Torremade Barreda, Barcelona (ES) |
| 11:11 - 11:18 | **Managing complications after penile surgery: When things don't go as planned...**<br>D.J. Ralph, London (GB) |
| 11:18 - 11:28 | **Panel discussion and Q&A** |
| **11:28 - 12:13** | **Reconstruction** |
| 11:28 - 11:35 | **Grafting in penile cancer patients**<br>S. Yan, London (GB) |
| 11:35 - 11:42 | **Distal urethral stricture: The final frontier**<br>M.W. Vetterlein, Hamburg (DE) |
| 11:42 - 11:49 | **When there's not enough skin**<br>M. Skrodzka, London (GB) |
| 11:49 - 11:56 | **FTM gender affirming surgery**<br>R. Djinovic, Belgrade (RS) |
| 11:56 - 12:03 | **Fournier's gangrene**<br>M. Falcone, Turin (IT) |
| 12:03 - 12:13 | **Panel discussion and Q&A** |
| **12:13 - 12:15** | **Closing remarks** |

# Advancements in mCRPC Therapy

Abstract Session 01

**Friday 13 March**
**10:45 - 12:15**

**Location** Red Area, Room 14

**Chairs**

F. Lopez Campos, Madrid (ES)

A. Omlin, Zürich (CH)

P. Rescigno, Newcastle Upon Tyne (GB)

**10:45 - 11:05** **ARPi and chemotherapy**

A0001 **(ARTO trial-NCT03449719): Long-term overall survival analysis from a randomized phase II trial testing the benefit of stereotactic body radiotherapy addition to abiraterone acetate in oligometastatic castrate resistant prostate cancer patients**

G. Francolini, Firenze (IT)

A0002 **Long-term effects of enzalutamide and abiraterone acetate in men with metastatic castration-resistant prostate cancer: Results from a randomised clinical trial (HEAT)**

K. Kvorning Ternov, Herlev (DK)

A0003 **CABPOSTAAT: A randomized phase II study of Docetaxel versus Cabazitaxel post Androgen Receptor Pathway Inhibitor (ARPI) progression**

M. De vries-brilland, Angers (FR)

A0004 **Clinical efficacy of combining novel hormonal therapy with docetaxel and carboplatin in neuroendocrine prostate cancer**

Y. Shao, Tianjin (CN)

---

**11:05 - 11:30** **Radium-223**

A0005 **Time-dependent survival benefit of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: reconstructed analysis of the PEACE-3 trial**

W. Chen, Tokyo (JP)

A0006 **External validation of a prognostic risk model for overall survival after Radium-223 treatment in metastatic castration-resistant prostate cancer**

N. Fujita, Hirosaki (JP)

**Study Group**
FRONTIER study group(Kagawa, Japan)

A0007 **A Clinically Accessible Risk Calculator for Radium-223 Non-Completion and Overall Survival Stratification in Bone-metastatic Castration-resistant Prostate Cancer**

H. Yaegashi, Kanazawa (JP)

**Study Group**
FRONTIER study group(Miki-Cho, Japan)

A0008 **Safety and Skeletal Event Profile of Radium-223 Combined with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis in Japan**

T. Kato, Kagawa (JP)

**Study Group**
FRONTIER study group(Miki-cho, Japan)

| | |
|---|---|
| A0009 | **Impact of Germline Mutations in Homologous Recombination Genes on Efficacy of Radium-223 in mCRPC: Results from PRORADIUM study**<br>I. González Ginel, Madrid (ES) |
| **11:30 - 11:45** | **Radioligands** |
| A0010 | **Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics**<br>C. Le, Frankfurt am Main (DE) |
| A0011 | **PSMA-RLT vs. Cabazitaxel for Japanese metastatic castration resistance prostate cancer : Comparison of oncological outcomes using propensity score matching**<br>Y. Enei, Minato-ku (JP) |
| A0012 | **Prognostic role of site specific volumetric response in mCRPC treated with Lu-177-PSMA radioligand therapy**<br>M. Pikul, Cologne (DE) |
| **11:45 - 12:15** | **Biomarkers in mCRPC** |
| A0013 | **Nationwide genomic data analysis of Japanese advanced prostate cancer ~analyzing C-CAT database~**<br>S. Tsukahara, Fukuoka (JP) |
| A0014 | **Concordance between tissue and ctDNA of homologous recombination repair gene alterations (HRRm) in a prospective molecular characterization initiative for metastatic castration resistant prostate cancer (mCRPC)**<br>N. Mehra, Nijmegen (NL) |
| A0015 | **Heterogeneity and Synergistic Inhibition of the Poly(ADP-ribose) Polymerase and Androgen Receptor Signaling Pathway in Patients with Metastatic Castration-resistant Prostate Cancer**<br>L. Ding, Shanghai (CN) |
| A0016 | **Quantitative Functional RAD51 Foci Outperform Genomic Alterations in Predicting PARPi Response in mCRPC: A Multicenter Real-world Study**<br>H. Guo, Shanghai (CN) |
| A0017 | **Artificial intelligence-driven molecular subtyping for precision treatment of metastatic castration-resistant prostate cancer**<br>Y. Shao, Tianjin (CN) |
| A0018 | **Assessment of Neuroendocrine Differentiation at Prostate Cancer Diagnosis: An Investigation of Histological Neuroendocrine Tumor Markers**<br>T. Shimomura, Tokyo (JP) |

## The new era of robotic prostate surgery: Guidance, precision and global connectivity

Video Session 01

**Friday 13 March**
**10:45 - 12:15**

| | |
|---|---|
| **Location** | Blue Area, George 3 |
| **Chairs** | To be confirmed<br>J. Stranne, Göteborg (SE)<br>I. Van Oort, Groningen (NL) |

V001 (▢1: 8 min.)
**Augmented Reality PSMA-3D guided robotic pelvic lymph node dissection (PLND) in prostate cancer patients**
L. Bianchi, Bologna (IT)

V002 (▢1: 8 min.)
**Sentinel lymph node biopsy in prostate cancer**
L. Viver Colet, Barcelona (ES)

V003 (▢1: 8 min.)
**Dual Sphincter Preservation Technique – The Victory Technique: An Extraperitoneal, Single-Site Robot Assisted Radical Prostatectomy**
V. Stankov, Skopje (MK)

V004 (▢1: 7 min.)
**Single-port extraperitoneal versus multiport transperitoneal robot-assisted radical prostatectomy: a pair-matched analysis of perioperative, pathological and early functional outcomes**
M. Oderda, Turin (IT)

V005 (▢1: 6 min.)
**Simultaneous Step-by-Step Comparison of Four Robotic Platforms in Radical Prostatectomy: Da Vinci Xi, Da Vinci SP, Hugo™ RAS, and TOUMAI®**
R. Brime Menendez, Madrid (ES)

V007 (▢1: 5 min.)
**First Experience with the Edge MP1000/OMNIBOT Robotic System in Urological Surgery**
S. Orellana, Santiago (CL)

## Minimally invasive surgery in urology: Urethral strictures

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Maghreb Union countries

**Friday 13 March**
**10:45 - 12:45**

**Location** Blue Area, Victoria 6

**Chairs**
A. Belkacem Nacer, Algiers (DZ)
K. Benakila, Alger (DZ)
P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

**Learning objectives**
This session will deal with two distinct topics relevant in clinical urologic practice in 2026. In the first part speakers form Maghreb countries as well as the EAU will discuss key techniques and benefits minimal invasive urologic surgery such as laparascopic partial nephrectomy and review current management strategies for benign prostatic hyperplasia. Furthermore an update will be given on the diagnosis and treatment of upper urinary tract urothelial carcinoma and innovations in the treatment of urethral strictures will be presented. In a second session clinical guidelines and perspectives shaping contemporary urologic practice will be discussed.

**10:45 - 11:50** **Minimally invasive surgery in urology**

*Moderators*
A. Belkacem Nacer, Algiers (DZ)
S. Ben Rhouma, Tunis (TN)

10:45 - 10:55
**Laparoscopic partial nephrectomy: Key techniques and outcomes**
S. Rezkallah, Alger (DZ)

10:55 - 11:05 **Benign prostatic hyperplasia: Current advances in minimally invasive therapies for BPH**
H. Ben Hadj Alouane, Ariana (TN)

11:05 - 11:15 **Upper urinary tract urothelial carcinoma: Endoscopic management**
C. Ouanezar, Oran (DZ)

11:15 - 11:25 **Minimal invasive urologic surgery and the lower urinary tract**
V. Phé, Paris (FR)

11:25 - 11:50 **Discussion**

**11:50 - 12:45** **Urethral strictures**

*Moderator* K. Benakila, Alger (DZ)

11:50 - 12:00 **Complex urethral reconstruction: Current standards**
Z. Abouelfadel, Agadir (MA)

12:00 - 12:10 **Urethral stricture guidlines: 2025 Update**
A. Sakly, Monastir (TN)

12:10 - 12:20 **Tips, tricks and pitfalls in urethral surgery**
M. Waterloos, Ghent (BE)

12:20 - 12:45 **Discussion and conclusion**

## Prostate cancer 2036: A global outlook

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Urological Society of Australia and New Zealand (USANZ)

**Friday 13 March**
**10:45 - 12:45**

**Location** Blue Area, Victoria 2

**Chairs** M. Albersen, Leuven (BE)
L.M. Wong, Melbourne (AU)

**Learning objectives**
After this session delegates should be able to think more creatively about the options available in management of prostate cancer in the future, in particular about what novel alternatives in management and emerging technologies may warrant consideration in the future

**10:45 - 10:53** **Screening & early detection in 2036**

*Moderators* N. Lawrentschuk, Melbourne (AU)
R. Van Den Bergh, Rotterdam (NL)

10:45 - 10:53 **State of the art: Modern early detection: How will we do it in 2036?**
T. Nordström, Stockholm (SE)

**10:53 - 11:19** **Current implementation: A global perspective:**

*Moderators* N. Lawrentschuk, Melbourne (AU)
R. Van Den Bergh, Rotterdam (NL)

10:53 - 11:01 **USANZ perspective**
N. Lawrentschuk, Melbourne (AU)

11:01 - 11:09 **EAU perspective: PRAISE-U and more**
M.J. Roobol, Rotterdam (NL)

11:09 - 11:19 **Panel Discussion**
N. Lawrentschuk, Melbourne (AU)
T. Nordström, Stockholm (SE)
M.J. Roobol, Rotterdam (NL)

---

**11:19 - 11:27** **Local therapy in 2036: What innovations can we expect?**

*Moderators* D. Murphy, Melbourne (AU)
H.G. Van Der Poel, Amsterdam (NL)

11:19 - 11:27 **State of the art: Localised prostate cancer in 2036: Innovation outlook**
N. Sathianathen, Melbourne (AU)

---

**11:27 - 11:51** **Case-based DEBATE: Is radical prostatectomy still a relevant surgery in 2036?**

*Moderators* D. Murphy, Melbourne (AU)
H.G. Van Der Poel, Amsterdam (NL)

11:27 - 11:30 **Decision support RT vs. Surgery**

*Case presenter* E. Dinneen, London (GB)

11:30 - 11:38 **PRO**
W. Everaerts, Leuven (BE)

11:38 - 11:46 **CON**
S. Siva, Melbourne (AU)

11:46 - 11:51 **Discussion**

---

**11:51 - 12:25** **Tracers and theranostics 2036**

*Moderators* L. Emmett, Sydney (AU)
K. Goffin, Leuven (BE)

11:51 - 11:59 **State of the art: Standardizing PSMA PET/CT for better outcomes in 2036: The SPARC initiative**
A.S. Bjartell, Malmö (SE)

11:59 - 12:07 **State of the art: Diagnostic PSMA trials: Where are we coming from and where are we going?**
R. Eapen, Melbourne (AU)

12:07 - 12:15 **State of the art: Theranostic PSMA trials: Where are we coming from and where are we going?**
W. Fendler, Essen (DE)

12:15 - 12:25 **Discussion**

# From MRI to Post-treatment care: A global perspective on prostate cancer in 2026

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Société Internationale d'Urologie (SIU)

**Friday 13 March**
**10:45 - 12:45**

**Location** Blue Area, Victoria 4

**Chairs** W. Lynch, Sydney (AU)
H. Van Poppel, Leuven (BE)

**Learning objectives**
The optimal imaging techniques and markers for prostate cancer diagnosis and staging including MRI, PET and biomarkers will be discussed. There will be an ample overview of the status of prostate cancer screening all over the globe. Active surveillance and functional disturbances after treatment are discussed.

**10:45 - 11:15** **Imaging and biomarkers in 2026**

*Moderator* J. Luo, Hangzhou (CN)

10:45 - 10:55 **The current role of MRI**
C. Moore, London (GB)

10:55 - 11:05 **The current role of PSMA PET imaging**
D. Murphy, Melbourne (AU)

11:05 - 11:15 **The evolving role of biomarkers**
K.J. Tay, Singapore (SG)

**11:15 - 11:55** **Where does screening and early detection sit today?**

*Moderator* F. Kim, Riverview (US)

11:15 - 11:20 **Europe**
H. Van Poppel, Leuven (BE)

11:20 - 11:25 **North America**
F. Kim, Riverview (US)

11:25 - 11:30 **Middle East / Africa**
Y. Farahat, Umm Al Quwain (AE)

11:30 - 11:35 **Asia**
J. Luo, Hangzhou (CN)

11:35 - 11:40 **South America**
G. Vitagliano, Buenos Aires (AR)

11:40 - 11:55 **Panel discussion**

*Moderators* W. Lynch, Sydney (AU)
H. Van Poppel, Leuven (BE)

*Panel* J. Luo, Hangzhou (CN)

**11:55 - 12:45** **Managing localized prostate cancer and functional outcomes**

*Moderator* A. Chung, St Leonards (AU)

11:55 - 12:05 **Active Surveillance in 2025**
A.S. Rannikko, Espoo (FI)

12:05 - 12:15 **Post-prostatectomy incontinence: Advances and challenges**
A. Chung, St Leonards (AU)

12:15 - 12:25 **Post-radiation incontinence: Current approaches**
A. Chung, St Leonards (AU)

12:25 - 12:35 **Bladder emptying disorders / dysfunction after treatment**
W. Lynch, Sydney (AU)

12:35 - 12:45 **Discussion**

## Reconstructive urology in developing world

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Urological Society of India (USI)

**Friday 13 March**
**10:45 - 12:45**

**Location** Blue Area, Victoria 1

**Chairs** P. Albers, Düsseldorf (DE)
R. Keshavamurthy, Bangalore (IN)

**Learning objectives**
This session will update the audience in special topics of reconstructive urology in complex urethral strictures and hot topics in GU oncology (penile cancer, prostate cancer, renal cancer).

**10:45 - 11:45** **Reconstructive urology**

**Redo hypospadias - Managing the unmanageable**

10:45 - 10:50 **Novel flaps and graft techniques**
A. Bhatt, Jaipur (IN)

10:50 - 10:55 **Dealing with fibrosis and complications**
M. Fisch, Hamburg (DE)

10:55 - 11:05 **Complex urethral stricture - Lessons learnt**
G. Gopalakrishnan, Coimbatore (IN)

11:05 - 11:15 **Pelvic fracture urethral distraction injuries - Optimising timing and approach**
P. Mukherjee, Vellore (IN)

11:15 - 11:45 **Panel discussion**

*Discussant* R. Nayyar, New Delhi (IN)

*Panel* P. Mukherjee, Vellore (IN)
B.V. Sistla, Coimbatore (IN)
M. Waterloos, Ghent (BE)

**11:45 - 12:35** **Uro-oncology**

11:45 - 11:55 **Penile cancer - Lessons from indian subcontinent**
K.N. Patel, Ahmedabad (IN)

Debate **Should Sentinel lymph node biopsy be the new standard for CN0 groin in carcinoma penis?**

11:55 - 12:00 **Yes**
A. Tamhankar, Delhi (IN)

12:00 - 12:05 **No**
O. Brouwer, Amsterdam (NL)

12:05 - 12:15 **Role of radical prostatectomy as part of multimodal treatment in locally advanced and oligometastatic prostate cancer**
U. Mete, Chandigarh (IN)

Debate **Can PSMA PET/CT spare extended pelvic lymph node dissection in high risk prostate cancer**

12:15 - 12:20 **Yes**
G.K. Pooleri, Kochi (IN)

12:20 - 12:25 **No**
J.P. Radtke, Düsseldorf (DE)

12:25 - 12:35 **Role of artificial intelligence in renal tumour detection and prognostication - Leapfrogging the gap**
A. Bex, London (GB)

**12:35 - 12:45** **Management of advanced renal cell cancer**

*Moderator* A. Volpe, Novara (IT)

12:35 - 12:40 **Sequencing and evidence**
N. Ragavan, Chennai (IN)

12:40 - 12:45 **Discussion**

## Open vs. minimally invasive diagnosis and treatment

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Caucasus/Central Asian countries

**Friday 13 March**
**10:45 - 12:45**

**Location** Red Area, Room 7

**Chairs**
A. Amanov, Almaty (KZ)
D. Nikoleishvili, Tbilisi (GE)
J.O.R. Sønksen, Herlev (DK)

**Learning objectives**
The best techniques in a given situation, both open and minimally invasive

**10:45 - 11:34** **Laparoscopy and oncology**

*Moderators*
N. Monolov, Bishkek (KG)
J.O.R. Sønksen, Herlev (DK)
A. Tsaturyan, Yerevan (AM)

10:45 - 10:52 **Comparative analysis of open and laparoscopic partial nephrectomy**
S. Kussymzhanov, Almaty (KZ)
R. Nurzhan, Almaty (KZ)

10:52 - 10:59 **The HoLEP gold standard: The surgical experience from Azerbaijan**
E. Mammadov, Baku (AZ)

10:59 - 11:06 **Female urethral diverticulectomy: Tips and tricks with surgical video demonstration**
G. Shadyan, Yerevan (AM)

11:06 - 11:13 **Robotic partial nephrectomies**
D. Yunusov, Tashkent (UZ)

11:13 - 11:20 **Open vs. robotic assisted partial nephrectomy in IR/HR renal cell cancer: A prospective randomized study**
M-O. Grimm, Jena (DE)

11:20 - 11:27 **Laparoscopic radical cystectomy the experiences of National Center of Urology**
A. Pertia, Tbilisi (GE)

11:27 - 11:34 **Discussion**

---

**11:34 - 12:16** **Andrology**

*Moderators*
F. Ahmedov, Baku (AZ)
A. Chkhotua, Tbilisi (GE)
To be confirmed

11:41 - 11:48 **Comparative efficacy and safety of intracavernosal PRP terapy and autologous bone marrow mesenchymal stem cells in patients with moderate to severe erectile dysfunction**
Y. Iskakov, Astana (KZ)
R. Nugumanov, Astana (KZ)
R. Omarbayev, Astana (KZ)

11:48 - 11:55 **Prostate enucleation**
J-N.L. Cornu, Rouen (FR)

12:09 - 12:16 **Discussion**

---

**12:16 - 12:44** **Stones**

*Moderators*
A. Amanov, Almaty (KZ)
J. Rassweiler, Tübingen (DE)
A. Tursunkulov, Tashkent (UZ)

12:16 - 12:23 **Do you follow ALARA principles?**
A. Tursunkulov, Tashkent (UZ)

12:23 - 12:30 **3D Laparoscopic adrenalectomy: How we can manage adrenal diseases**
D. Nikoleishvili, Tbilisi (GE)

12:30 - 12:37 **Lower cayceal stone management**
J. Rassweiler, Tübingen (DE)

12:37 - 12:44 **Discussion**

---

**12:44 - 12:45** **Closing remarks**

# Foundation skills in urologic excellence

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Federation of ASEAN Urological Associations (FAUA)

**Friday 13 March**
**10:45 - 12:45**

**Location** Blue Area, Victoria 5

**Chairs**
B. Malavaud, Toulouse (FR)
S.V. Yrastorza, Quezon City (PH)

**Learning objectives**

*Walking a thin line between addiction and traction, surgical advances transformed the landscape of Urology. However, advanced technology may not always be best suited for reasons of availability, cost or sustainability further emphasizing the core importance of "foundation skills ». From open surgery to 2D-3D laparoscopy or expert endo-urology, leading surgeons will share their vision on the distinctive qualities that allow urologists to master the complexity of real-life urology*

**10:45 - 10:50** **Introduction**

**10:50 - 11:20** **Radical prostatectomy beside robotics**

*Moderators*
A. Martini, Cincinnati (US)
Y. Noor Ashani, Kuala Lumpur (MY)

10:50 - 11:05 **Open surgery – a lost art?**
F. Safriadi, Bandung (ID)

11:05 - 11:20 **Laparoscopy in the age of robotics: Is it still relevant?**
C.C. Toh, Kuala Lumpur (MY)

**11:20 - 12:15** **Challenges in renal & ureteric surgery**

*Moderators*
A. Bex, London (GB)
H.G. Sim, Singapore (SG)

11:20 - 11:35 **Staghorn calculi – any alternatives to PCNL & RIRS?**
T. Bejrananda, Songklanagarind (TH)

11:35 - 11:45 **Partial nephrectomy when there is no robot**
A. Bex, London (GB)

11:45 - 12:00 **Ablation for complex renal tumours**
S. Kuppusamy, Shah Alam (MY)

12:00 - 12:15 **Foundation skills for complex renal masses**
A. Martini, Cincinnati (US)

**12:15 - 12:35** **Reconstruction for ureteral injuries**

*Moderators*
P. Gontero, Turin (IT)
K.M. Tan, Quezon (PH)

12:15 - 12:25 **Distal 3rd ureteral reconstruction**
R. Andutan, Cagayan de Oro city (PH)

| | |
|---|---|
| 12:25 - 12:35 | **Upper ureter**<br>A. Skolarikos, Athens (GR) |
| **12:35 - 12:40** | **Conclusion** |

## Urology innovations at a glance

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the World Chinese Urologists

**Friday 13 March**
**10:45 - 12:45**

**Location** Blue Area, George 1

**Chairs**

P.K-F. Chiu, Hong Kong (HK)
J. Chueh, Taipei (TW)
H.F. Lao, MACAU (CN)
E. Liatsikos, Patras (GR)
X. Ma, Beijing (CN)

**Learning objectives**

This joint EAU-World Chinese Urologists session will provide delegates with cutting-edge knowledge and shared expertise from leading urological centres in Asia and Europe. Participants will gain insights into the application of artificial intelligence for precision diagnostics and treatment recommendations, explore the latest innovations in robotic and minimally invasive surgery, and review novel strategies in uro-oncology management. The session aims to foster cross-continental dialogue on advancing clinical practice and research, highlighting both technological frontiers and practical surgical experiences.

| | |
|---|---|
| **10:45 - 11:06** | **Artificial intelligence & precision diagnostics** |
| 10:45 - 10:51 | **An AI-agent decision support system for precision treatment recommendation of urological cancer management**<br>C.Y. Tsai, New Taipei City (TW) |
| 10:51 - 10:57 | **Intraoperative navigation systems facilitate precise management of urological tumors: Current applications and single-center experience**<br>M. Zhang, Shenyang (CN) |
| 10:57 - 11:06 | **Discussion** |
| **11:06 - 11:51** | **Robotic and Surgical Innovation** |
| 11:06 - 11:12 | **Robotic transurethral en-bloc resection of bladder tumour**<br>P.K-F. Chiu, Hong Kong (HK) |
| 11:12 - 11:18 | **Robotic autonomous suturing in renal surgery: How far are we?**<br>X. Ma, Beijing (CN) |
| 11:18 - 11:24 | **The long-term follow-up for 700 cases of RNRS-RARP (retrograde release of neurovascular bundle technique in Retzius-sparing RARP)**<br>Y-J. Niu, Tianjin (CN) |
| 11:24 - 11:30 | **Robotic Telesurgery: A tool or a tale?**<br>A. Breda, Barcelona (ES) |
| 11:30 - 11:36 | **Tension free BN-U(bladder neck-urethra) anastomosis in SPTV-RARP**<br>S.F. Ho, Macau (MO) |

| | |
|---|---|
| 11:36 - 11:42 | **Will FANS take over PCNL for stone treatment?**<br>G.H. Zeng, Guangzhou (CN) |
| 11:42 - 11:51 | **Discussion** |
| **11:51 - 12:18** | **Urooncology** |
| 11:51 - 11:57 | **Kidney tumour with level III–IV IVC thrombus: What options do we have?**<br>C.H. Yee, Hong Kong (HK) |
| 11:57 - 12:03 | **Bipolar androgen therapy for mCRPC: initial experience from Beijing Hospital**<br>M. Liu, Beijing (CN) |
| 12:03 - 12:09 | **Update on bladder sparing treatments**<br>E.N. Xylinas, Paris (FR) |
| 12:09 - 12:18 | **Discussion** |
| **12:18 - 12:45** | **Functional and reconstructive urology** |
| 12:18 - 12:24 | **An alternative approach for treating female underactive bladders with chronic urine retention: A pilot study on combined transvaginal ultrasound-guided botulinum Toxin A external sphincter injection and transurethral incision of the bladder neck**<br>E. Chou, Taichung (TW) |
| 12:24 - 12:30 | **Innovations and practices in ureteral stricture reconstruction**<br>Y. Fan, Beijing (CN) |
| 12:30 - 12:36 | **Innovations and advances in the treatment of complex posterior urethral strictures**<br>Q. Fu, Shanghai (CN) |
| 12:36 - 12:45 | **Discussions and closing remarks** |

## Meeting of the Young Academic Urologists (YAU): Spotlight on innovation, evidence, and education in modern medicine

Special Session

**Friday 13 March**
**10:45 - 14:45**

**Location** Blue Area, George 4

**Chair** G.I. Russo, Catania (IT)

**Learning objectives**
This session will explore how young academic urologists are shaping the future of urology through cutting-edge research, innovative clinical practices, and educational initiatives. Delegates will learn about emerging technologies, collaborative research opportunities, and strategies for integrating evidence-based medicine into daily practice. The session will also emphasize the importance of mentorship, global networking, and academic leadership in advancing modern urological care.

| | |
|---|---|
| **10:45 - 10:50** | **Introduction**<br>G.I. Russo, Catania (IT) |

**10:50 - 11:25** **Precision, progress, and partnership: YAU and oncology**

*Moderators*
L.A. 't Hoen, Rotterdam (NL)
S. Albisinni, Rome (IT)
M. Przydacz, Krakow (PL)

10:50 - 11:00 **How to design a clinical study: From hypothesis to protocol**
K-F. Kowalewski, Mannheim (DE)

11:00 - 11:10 **How to present a paper for publication: "to AI or not to AI"**
N.R. Bhatt, Dublin (IE)

11:10 - 11:20 **Basic biostatistics: Power, p-values, and pitfalls**
A.J. Vickers, New York (US)

11:20 - 11:25 **Questions and Answers**

---

**11:25 - 12:20** **Digital disruption in urology and oncology**

*Moderators*
I. Andras, Cluj (RO)
M. Frankiewicz, Gdańsk (PL)
A. Morgado, Porto (PT)

11:25 - 11:35 **Multidisciplinary tumour boards: From cancer profiling to virtual oncology networks**
E. Grobet-Jeandin, Geneva (CH)

11:35 - 11:45 **Cutting-edge technologies in robotic surgery: From digital twins to the next-gen platforms**
D. Amparore, Orbassano (Turin) (IT)

11:45 - 11:55 **Digital health solutions: Enhancing functional recovery after surgery**
S.T. De Cillis, Turin (IT)

11:55 - 12:05 **Digital training in urology: Building the next-generation endourologist**
A. Pietropaolo, Southampton (GB)

12:05 - 12:15 **Data-driven conception: The AI era in fertility and ART**
E. García Rojo, Madrid (ES)

12:15 - 12:20 **Questions and answers**

---

**12:20 - 12:34** Non oncology **From rejection to revision: Turning abstract setbacks into success**

*Moderators*
B. Ballesta Martinez, Alicante (ES)
E. García Rojo, Madrid (ES)
M. Vallée, Poitiers (FR)
M.G. Çulha, Istanbul (TR)

12:20 - 12:25 **Endourology: Flexible ureteroscopy with integrated suction, a useful innovation: A systematic review by the YAU and EAU endourology sections**
E. Ventimiglia, Uppsala (SE)

12:25 - 12:27 **Questions and Answers**

12:27 - 12:32 **Endourology: Impact of lithotomy position on ureteral course and psoas muscle: A combined survey and radiological evaluation by the EAU endourology & YAU endourology working groups**
A. Tsaturyan, Yerevan (AM)

12:32 - 12:34 **Questions and Answers**

**12:34 - 12:58** Oncology: Part one **From rejection to revision: Turning abstract setbacks into success**

*Moderators*
A. Territo, Barcelona (ES)
W. Verla, Ghent (BE)

12:34 - 12:39 **Urothelial cancer: Bladder tumor location matters: Trigone and bladder neck involvement predict worse outcomes in high-grade non-muscle-invasive bladder cancer**
A. Ślusarczyk, Warsaw (PL)

12:39 - 12:41 **Questions and Answers**

12:41 - 12:46 **Urotechnology: "Artificial intelligence in the diagnosis of urinary stone disease: A systematic review from EAU & YAU endourology"**
R.B. Ergül, Istanbul (TR)

12:46 - 12:51 **Questions and Answers**

12:51 - 12:56 **Urothelial: Patient's selection to endoscopic kidney-sparing surgery vs upfront radical nephroureterectomy according to diagnostic ureteroscopy: insight from large multicenter EAU-YAU urothelial working group**
B. Pradère, Toulouse (FR)

12:56 - 12:58 **Questions and Answers**

**12:58 - 13:14** Oncology: Part two **From rejection to revision: Turning abstract setbacks into success**

*Moderators*
M. Christodoulidou, Leicester (GB)
A. Cimadamore, Udine (IT)
E. Roussel, Leuven (BE)
C. Würnschimmel, Lucerne (CH)

12:58 - 13:02 **Renal cancer: Histopathological outcomes after renal surgery: insights from the EAU–YAU RCC and US-KIDNET collaborative**
D. Amparore, Orbassano (Turin) (IT)

13:02 - 13:04 **Questions and Answers**

13:04 - 13:07 **Robotic: Comprehensive intraoperative checklist—pharmacologic and non-pharmacologic factors to reduce postoperative pain in robotic urologic surgery: a 3-round Delphi from the YAU/J-ERUS**
G. Sorce, Tarragona (ES)

13:07 - 13:09 **Questions and Answers**

13:09 - 13:12 **Robotic: Performance metrics and error-analysis in patient-side assistance during robotic surgery: A J-ERUS/YAU construct validation study**
C. Würnschimmel, Lucerne (CH)

13:12 - 13:14 **Questions and Answers**

**13:14 - 13:38** **YAU awards**

13:14 - 13:22 **YAU reviewer of the year: How to perform the perfect peer-review**
E. Laukhtina, Vienna (AT)

13:22 - 13:30 **YAU best paper published in 2025**
L. Bianchi, Bologna (IT)

| | |
|---|---|
| 13:30 - 13:38 | **Best abstract at EAU 2026 by a YAU Group**<br>G. Margue, Bordeaux (FR) |
| **13:38 - 14:45** | **Joint session by ESUR and YAU "From Bench to Bedside: Translational Research and Imaging in Urology"** |
| | *Moderators* G. Marra, Turin (IT)<br>B. Pradère, Toulouse (FR) |
| 13:38 - 13:50 | **Beyond mCRPC: PARP inhibition in earlier stages of prostate cancer**<br>J. Gómez Rivas, Madrid (ES) |
| 13:50 - 14:02 | **Redefining intravesical therapy: From BCG to novel agents in NMIBC**<br>E. Compérat, Vienna (AT) |
| 14:02 - 14:14 | **Imaging and AI: when integrated data meets precision diagnostics**<br>V. Panebianco, Rome (IT) |
| 14:14 - 14:26 | **NGS in urologic tumours: What every clinician should know**<br>C. Jerónimo, Porto (PT) |
| 14:26 - 14:38 | **MicroRNA signatures in prostate and bladder cancer: Biomarkers in action**<br>E.S. Martens-Uzunova, Rotterdam (NL) |
| 14:38 - 14:45 | **Questions and Answers** |

## Renal cell carcinoma: Advancements in diagnosis, prognosis, and personalized treatment

EGPT 05

**Friday 13 March**
**10:45 - 12:15**

**Location** Orange Area, EGPT 3

**Chairs** S. Fernández-Pello Montes, Gijón (ES)
A. Govorov, Moscow (RU)
To be confirmed

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

| | |
|---|---|
| **10:45 - 11:30** | **VHL and other genetic disorders - diagnosis and treatment** |
| P0074 | **Overtaking Intra and Inter Tumoral Heterogeneity in von Hippel-Lindau related Renal Cancer: a Multi Modal Data Integration Approach**<br>M. Uggè, Milano (IT) |
| P0075 | **Natural history of Von Hippel–Lindau Disease receiving local treatment before systemic therapy with HIF-2a inhibitors: updated data reporting system from a large VHL Care Center**<br>A. Barretta, Cava de Tirreni (IT) |
| P0078 | **Multidisciplinary Management of Von Hippel–Lindau Disease Throughout the Patient's Lifetime: Observational Analysis from a Large Comprehensive Care Center**<br>F. Cei, Segrate (IT) |

P0080 **Long-term outcomes of repeated renal interventions in von Hippel–Lindau–associated renal cell carcinoma**
S.C. Astheimer, Freiburg (DE)

P0081 **Androgen–Receptor Axis Drives Tumor Initiation in VHL-Associated Early-Onset Renal Cell Carcinoma: Mechanistic Basis and Preventive Implications**
Z. Song, Beijing (CN)

**11:30 - 11:40** **Improvng imaging RCC Diagnosis**

P0082 **Development of a Novel 68Ga-Labeled Radiotracer Targeting Carbonic Anhydrase IX for Diagnosis of Clear Cell Renal Cell Carcinoma**
T. Liu, Beijing (CN)

P0083 **Impact of girentuximab based radionuclide imaging in patients with renal cell carcinoma on virtual tumor board decision making - an interim analysis**
T.J. van der Werff, Nijmegen (NL)

**11:40 - 11:50** **Molecular Characterization of RCC**

P0084 **Pre-Diagnostic Plasma Proteomics Profile Uncovers New Biomarkers and Mechanistic Insights for Incident Kidney Cancer**
L. Wen, Beijing (CN)

P0085 **Decoding Metabolic Causality Across Kidney Cancer Subtypes: An Integrative Mendelian Randomization and Metabolomic Validation Study**
Z. Wang, Shanghai (CN)

**11:50 - 12:15** **Prognosis and other therapies**

P0086 **Machine Learning–Derived CART Reclassification Improves Prognostic Accuracy in Stage III Renal Cell Carcinoma**
C. Saitta, Pieve Emanuele (IT)

P0087 **Comparative Prognostic Performance of KEYNOTE-564 and AUA Risk Stratification in Non-Metastatic Clear Cell Renal Cell Carcinoma**
G. Garofano, Pieve Emanuele (IT)

P0088 **The accuracy of KEYNOTE-564 study eligibility criteria on recurrence prediction in papillary renal cell carcinoma: A multi-institutional comparative analysis with prognostic scores**
S. Erdem, Istanbul (TR)

P0089 **Predicting disease-free survival (DFS) after surgery for non-metastatic clear cell renal cell carcinoma (ccRCC): KEYNOTE-564 criteria vs Leibovich, ASSURE, and UroPredict prognostic models**
S. Granata, Acireale (IT)

# From translational research to Functional Repair: A Comprehensive analysis of Urethral Reconstruction

EGPT 04

**Friday 13 March**
**10:45 - 12:15**

**Location** Orange Area, EGPT 2

**Chairs** To be confirmed
W. Verla, Ghent (BE)
B.R. Viers, Rochester (US)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**10:45 - 11:00** **Deeper insights Urethral stricture pathogenesis**

P0055 **BULBOSPONGIOSUS MUSCLE STRUCTURE DURING THE HUMAN FETAL PERIOD: A TRANSLATIONAL RESEARCH**
L.A. Favorito, Rio de Janeiro (BR)

P0056 **A Missing Link in Urethral Stricture Pathogenesis? The Role of Serum Testosterone**
A.K. Chawla, Manipal (IN)

**11:00 - 11:30** **Translating basic research in clinical practice**

P0058 **Two-year results from a completed First-in-Human study of an engineered collagen-based mesh for urethral reconstruction**
G. Vythilingam, London (GB)

P0060 **Integrative multi-omics analysis reveals THBS1-positive fibroblasts as therapeutic targets to inhibit ureteral fibrosis progression after thermal injury**
Z. Fangzhou, Beijing (CN)

P0061 **A Multilayered Urethral Construct with Functional Tissue Engineered Vasculature and Epithelial Barrier**
Z. Xing, Utrecht (NL)

P0062 **Autologous Live-Cultured Buccal Epithelial Cells for Bulbar Urethral Strictures: 24-Months Follow-Up Results**
M. Huzaifa, Bhubaneswar (IN)

P0063 **Low-dose ionizing radiation and low-intensity shock wave therapy as adjunctive promoters of buccal mucosa urethral graft take in a rat model.**
P.M. Simoes De Oliveira, Lisbon (PT)

**11:30 - 12:15** **Urethral reconstruction: special situations and uncommon scenarios**

P0064 **Treatment Outcomes of Pelvic fracture urethral injury: a 10-Year Experience at Binh Dan Hospital**
L.H. Do, Ho Chi Minh City (VN)

P0065 **Orandi and Asopa Techniques for Anterior Urethral Stricture Repair: Comparative Analysis From a Single-Center Experience**
V. Talavera Cobo, Pamplona (ES)

P0066 **Resection urethroplasty for extended bulbar urethral strictures: Complications and factors of their development**
V.P. Glukhov, Rostov-on-Don (RU)

P0067 **Urethroplasty After Kidney Transplantation: A reconstructive Challenge in a high risk population**
C. Martinez Garcia, Barcelona (ES)

P0068 **Comparative outcomes of dorsal, ventral buccal mucosal graft, and non-transecting anastomotic urethroplasties in bulbar urethral strictures: A multicenter retrospective analysis**
O. Gülpinar, Ankara (TR)

P0069 **The injectable gelatin-sodium alginate drug delivery systems for urethral stricture disease through the enhancement of tissue repair and prevention of fibroblast-driven extracellular matrix remodeling**
Z. Zhu, Beijing (CN)

P0071 **Environmental impact of digitizing post-operative monitoring: development of a model applied to urethroplasty.**
E. Tokarski, Paris (FR)

P0072 **Factors associated with donor site morbidity after oral mucosal graft urethroplasty**
O. Gülpinar, Ankara (TR)

**Study Group**
Reconstructive Urology, Minimally Invasive and "Hands-On Training" Working Group of Turkish Continence Society(Ankara, Turkey)

## Prostate cancer - Basic and translational research

EGPT 07

**Friday 13 March**
**10:45 - 12:15**

**Location** Blue Area, EGPT 5

**Chairs**
I. Heidegger, Innsbruck (AT)
J. Linxweiler, Homburg/saar (DE)
A.R. Rodriguez, Winston Salem (US)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

P0109 **A Transformer-Enabled Multimodal Framework Integrating MRI Radiomics and Clinical Features for Predicting Biochemical Recurrence After Radical Prostatectomy: Development and Multi-Institutional Validation**
R. Chen, shanghai (CN)

P0110 **A single-cell spatial atlas of the PCa immune microenvironment identifies CCL18⁺ macrophages as a favorable subset**
J-H. Pan, Shanghai (CN)

P0111 **Hypoxia-Induced CAF-Derived CALR+ Extracellular Vesicles Drive Endothelial-Mesenchymal Transition and Aggressive Progression in Non-Metastatic Hormone-Sensitive Prostate Cancer via ITGA3/β1 Integrin Signaling**
L. Dong, Shanghai (CN)

P0112 **ACOT8 Drives Senescent Cell Carcinogenesis by Promoting Histone Glutarylation in Prostate Epithelial Cells**
C. Zheng, Wuhan (CN)

P0114 **Prostatic Fluid DNA Methylation Biomarkers Enable High-Accuracy Prostate Cancer Diagnosis: A Prospective Pilot Study**
y. Peng, Chongqing (CN)

P0115 **Luminal stem-like cells in high-risk/locally advanced prostate cancer promote resistance to hormonal therapy**
Y. Cai, Changsha (CN)

P0117 **PSMA-Targeted Silicasome Co-delivery of Rucaparib and Tazemetostat Enhances Synergistic Treatment of Metastatic Castration-Resistant Prostate Cancer**
Q. Huang, Shenyang (CN)

P0118 **Co-targeting β-catenin and CTHRC1 disrupts the stromal-epithelial crosstalk to overcome enzalutamide resistance in CRPC**
J. Zhuang, Nanjing (CN)

P0119 **Bipolar androgen therapy reverses neuroendocrine lineage differentiation of prostate cancer through inhibition EZH2**
H. Hou, Beijing (CN)

P0120 **De Novo Design Delivers ACP3-Specific Macrocycle Peptide for $^{68}$Ga-Based PET Imaging of Metastatic Castration-Resistant Prostate Cancer**
Z. Sihan, Wuhan (CN)

P0121 **Blood-Based Epigenetic Profiling Predicts Recurrence and Survival in Prostate Cancer Patients via ctDNA Methylation**
J.H. Choi, Busan (KR)

P0122 **Circulating Tumor Cell Micronuclei as a Potential Surrogate Marker of DNA Repair Gene Deficiency in Prostate Cancer**
R. Wenta, Gdańsk (PL)

P0123 **Prospective comparison of AR-V7 transcripts from whole blood and circulating tumor cells in castration-resistant prostate cancer patients undergoing treatment with androgen-receptor signaling inhibitors (PEARL Trial)**
M. Heck, Augsburg (DE)

P0125 **Bone metastasis enrichment factor SHMT2 mediates immunosuppressive microenvironment and drives prostate cancer progression via the PI3K/AKT/mTOR pathway**
Z. Wu, Guangzhou (CN)

# Advancing prognostics and therapeutics: From biomarkers to novel treatments in metastatic prostate cancer

EGPT 03

**Friday 13 March**
**10:45 - 12:15**

**Location** Orange Area, EGPT 1

**Chairs**
L. Pacheco-Figueiredo, Braga (PT)
D. Penson, Nashville (US)
U. Vogl, Bellinzona (CH)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**10:45 - 11:05** **Estimating prognosis in advanced prostate cancer**

P0037 **Bone scan index as a better prognostic imaging biomarker for disease progression among patients with CHAARTED high-volume metastatic castration sensitive prostate cancer**
Y. Horiguchi, Tokyo (JP)

P0038 **Clinical significance of the De Ritis ratio in patients with metastatic hormone-sensitive prostate cancer treated with upfront therapy**
N. Fujita, Hirosaki (JP)

P0039 **Beyond First Progression: PFS2 as a Strong Surrogate of Overall Survival in Real-World Apalutamide-Treated mHSPC patients**
A. Sanchis-Bonet, Madrid (ES)

**Study Group**
Spanish multicentre registry of real-world use of Apalutamide(Madrid, Spain)

P0040 **Prognostic Impact of TP53 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with [$^{177}$Lu]Lu-PSMA-617 Radioligand Therapy**
H. Ofner, Vienna (AT)

**11:05 - 11:40** **Optimizing therapies for advanced prostate cancer**

P0041 **Opportunistic CT as a tool for evaluation and monitoring bone mineral density in patients undergoing androgen deprivation therapy and androgen receptor pathway inhibitor for metastatic hormonosensitive prostate cancer**
C. Gomez De Segura Melcon, Barcelona (ES)

P0042 **Real-world access to genotype-matched therapy through comprehensive cancer genomic profiling test in patients with metastatic prostate cancer: Analysis of the nationwide genomic database in Japan**
D. Koguchi, Sagamihara (JP)

P0043 **[18F]PARPi PET/CT for Precision Guidance of PARP-Inhibitor Therapy in HRR-Mutated and Non-Mutated Metastatic Castration-Resistant Prostate Cancer**
S. Rasul, Vienna (AT)

P0045 **Analysis of PSA Superresponders in a Single-Center Study of $^{177}$Lu-PSMA-617 Therapy**
T.H. Lin, Taipei City (TW)

P0046 **Optimizing the timing of Docetaxel after AR pathway inhibitor therapy: Development and validation of a novel prognostic model in metastatic castration-resistant prostate cancer**
R. España Navarro, Málaga (ES)

P0047 **Clinical Investigation of Docetaxel Therapy for Castration-Resistant Prostate Cancer in Patients Aged 75 Years or Older**
M. Kyono, Kobe (JP)

P0044 **Early Prediction of Response to ADT Plus ARPI in mHSPC Using Interpretable Machine Learning on PSMA PET/CT: A Real-World Study**
Y. Cai, Changsha (CN)

---

**11:40 - 11:55** **Prevention and management of treatment-related side effects in advanced prostate cancer**

P0048 **Clinical features of medication-related osteonecrosis of the jaw in prostate cancer management: Results From a multicenter cohort study**
M. Nakata, Tokyo (JP)

P0049 **SPoRT-MU Study: Velocity-Based Resistance Training Improves Multiple Quality-of-Life Domains in Prostate Cancer Patients on Androgen Deprivation Therapy**
L. Herrero Vidal, Murcia (ES)

P0050 **Cardiologic and Oncologic Outcomes with GLP-1 Receptor Agonists in Men Receiving Androgen Deprivation Therapy for Prostate Cancer**
Á. Lénárt, Szombathely (HU)

---

**11:55 - 12:15** **New treatment strategies in mCRPC**

P0053 **A Phase II Single-Arm, Open-Label Trial of Pamiparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with Deleterious Germline or Somatic BRCA1/2 Alterations or Homologous Recombination Deficiency (HRD)**
D. Zhao, Guangzhou (CN)

P0054 **Long-term Clinical Outcomes and Genomic Predictors of PSMA-PET/CT-Guided Cytoreductive Progression-Directed Therapy in Patients with Oligoprogressive Castration-Resistant Prostate Cancer**
B. Shen, Shanghai (CN)

# Innovations in urology: Advancements and outcomes in lower urinary tract dysfunction

EGPT 06

**Friday 13 March**
**10:45 - 12:15**

**Location** Blue Area, EGPT 4

**Chairs** To be confirmed
S. Musco, Florence (IT)
M.I. Omar, Aberdeen (GB)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**10:45 - 11:20** **Chronic pelvic pain**

P0107 **Radiofrequency Therapy at 448 kHz as a Novel Treatment for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS): Results from a Prospective Multicentre Pilot Study**
E. García Rojo, Madrid (ES)

P0103 **In situ urethroplasty during artificial urinary sphincter explantation for erosion: early findings from the Systematic assessment of Artificial urinary sphincter Failure and Erosion Recovery (SAFER) collaborative**
M. Frankiewicz, Gdańsk (PL)

**Study Group**
Trauma and Reconstructive Urology Working Party of the European Association of Urology Young Academic Urologists(Amsterdam, The Netherlands)

P0102 **Urine proteomic study for identifying promising biomarkers in Asian male with urologic chronic pelvic pain syndrome**
Y-H. Lin, New Taipei City (TW)

P0104 **Post-massage PSA kinetics predict therapeutic response in chronic prostatitis/chronic pelvic pain syndrome**
Y.C. Shih, New Taipei City (TW)

P0105 **Cases of Pudendal Neuropathy (PN) after robot-assisted radical prostatectomy (RARP).**
IF Ferrari , Pavia (IT)

P0106 **Efficacy of Combined Inferior Hypogastric Plexus and Pudendal Nerve Elongated Needle Electrical Stimulation for Chronic Refractory Pelvic and Perineal Pain: A Pilot Study**
R. Lyu, Shanghai (CN)

**11:20 - 11:55** **Neuromodulation from basic science to clinical practice**

P0092 **Predicting treatment success at time of referral for sacral neuromodulation for overactive bladder: a retrospective audit of a tertiary UK referral centre**
F. Mazhar, Huddersfield (GB)

P0093 **Get Ready™ for Better Care: Enhancing Patient Engagement in Sacral Neuromodulation via Digital Tools – Two-Year Experience from an University Hospital**
C. Thuillier, Corenc (FR)

| | |
|---|---|
| P0094 | **Identifying positive predictive factors for the outcome of therapy with Botuliniumtoxin for iOAB and NDO in a real world study**<br>S. Nestler, Darmstadt (DE) |
| P0095 | **Advancing Sacral Neuromodulation: Clinical Efficacy of a Next-Generation System in Lower Urinary Tract Dysfunction**<br>G. ciavarella, San Marco in Lamis (IT) |
| P0096 | **Wireless on-demand electrostimulation implants enable sphincter neuromuscular restoration from mixed urinary incontinence**<br>Y. Shao, Shanghai (CN) |
| P0097 | **The Impact of Right or Left Handedness on Sacral Neuromodulation Outcomes for Lower Urinary Tract Dysfunction: Does Ipsilateral or Contralateral Lead Placement Matter?**<br>H.J. Kendall, Maastricht (NL) |
| **11:55 - 12:10** | **OAB and SUI** |
| P0098 | **The Negative Feedback of the Glutamine/Prostatitis Loop Identified among 1,400 Metabolites and Prostatitis via Mendelian Randomization**<br>Y. Wang, Changzhou (CN) |
| P0099 | **SATURN Registry for mSUI – 3 years outcome**<br>R. Hamid, London (GB)<br>**Study Group**<br>EAU Research Foundation SATURN Registry Study Group(Arnhem, The Netherlands) |
| P0101 | **Contemporary surgical management and trends of male stress urinary incontinence - Results from the GRAND study**<br>Y. Volz, München (DE) |
| **12:10 - 12:10** | **Late-breaking abstract presentation** |

# BCLEAR: Shared decisions, stronger care in bladder cancer: Addressing clinician needs across Europe

Patient Advocacy Roundtable

**Friday 13 March**
**11:00 - 12:00**

**Location** Red Area, Room 17

**Chair** M.R. Van Balken, Arnhem (NL)

**Learning objectives**

This session will present the BCLEAR project, a multi-country initiative designed to strengthen shared decision-making (SDM) in bladder cancer care across Europe. Participants will gain insight into the project's goals, methodology, and early outcomes, with a focus on the differences identified between the participating member states and their implications for future education and practice.

Faculty will share findings from the Needs Assessment survey, offering a detailed look at clinicians' experiences, perceived barriers, and key areas for improvement. The discussion will explore how these results are shaping the development of the HCP Educational Toolbox—a resource aimed at supporting healthcare professionals in facilitating better communication and collaboration with patients.

By the end of the session, participants will understand how these insights can help bridge existing gaps in SDM, strengthen patient–clinician relationships, and promote more consistent, person-centred care across Europe.

| | |
|---|---|
| **11:00 - 11:05** | **Welcome & introduction**<br>M.R. Van Balken, Arnhem (NL) |
| **11:05 - 11:20** | **Lived experience of SDM: Where conversations work and where they fail**<br>M. Costin, Chinnor (GB)<br>A. Filicevas, Brussels (BE) |
| **11:20 - 11:30** | **The GP as guide: supporting SDM before and after the urology visit**<br>J. Vilaseca, Barcelona (ES) |
| **11:50 - 12:00** | **Q&A and closing**<br>M.R. Van Balken, Arnhem (NL) |

# Medical writing for urologists: An interactive workshop on how to write, publish and promote the “perfect” manuscript

ESU Course 07

**Friday 13 March**
**11:00 - 13:00**

**Location** Red Area, Room 12

**Chair** A. Briganti, Milan (IT)

**Learning objectives**

This ESU course is a collaboration between *European Urology* and the *The Lancet*

This course will offer an expansive and interactive overview of the entire scholarly publishing procedure, specifically focusing on the writing process and what it means to be an outstanding author. The Faculty will offer instruction on how to construct a well-written introduction and methods section for your manuscript, learn how to present statistical analyses, understand key points when writing and how to use Social Media to best promote important work. Participants will obtain insight directly from editors on what they expect to see. The course will be structured into two modules including lectures and breakout sessions.

- To learn how to write a full lenght aricle from the Author and Editor perspective
- To understand systematic reviews and meta-analysis.
- Using Social Media platforms in a responsible and successful manner.
- To learn from experienced editors.

**Welcome and introduction**
A. Briganti, Milan (IT)

**Beyond the scientific manuscript: The role of social media in 2026**
R. Eapen, Melbourne (AU)

**How to capture the Editor’s attention**
V. Wisdom, London (GB)

**How to report statistical analyses for publication**
M. Assel, New York (US)

**Interactive example-based discussion**

**What did I do wrong? Practical examples on "How to improve the methodological approach to your research question**
R. L. Dunn, Ann Arbor (US)

**Captivating the reader: Unlocking the power of abstracts and introductions**
L. Bukavina, Cleveland (US)

**Contextualising results and crafting impactful discussions**
B.F. Chapin, Houston (US)

**Conclusion**
A. Briganti, Milan (IT)

## Practical tips for pelvic laparoscopic surgery: Cystectomy, radical prostatectomy adenomectomy and sacrocolpopexy

ESU Course 26

**Friday 13 March**
**11:00 - 13:00**

**Location** Red Area, Room 3

**Chair** J.M. Gaya Sopena, Barcelona (ES)

**Learning objectives**

**Patient positioning and trocar placement**
J.M. Gaya Sopena, Barcelona (ES)

**Laparoscopic adenomectomy and radical prostatectomy**
P. Kallidonis, Patras (GR)

**Laparoscopic radical cystectomy**
J.M. Gaya Sopena, Barcelona (ES)

**Laparoscopic reconstructive surgery of the pelvic floor and sacrocolpopexy**
P. Kallidonis, Patras (GR)

**Identify and solve complications**
J.M. Gaya Sopena, Barcelona (ES)

## Ultrasound in Urology: From basics to proficiency

ESU Course 08

**Friday 13 March**
**11:00 - 13:00**

**Location** Red Area, Room 13

**Chair** K.F. Stock, Munich (DE)

**Learning objectives**

· To understand principles of US imaging acquisition and interpretations, avoiding pitfalls
· To learn how and in which clinical scenarios of urological emergency care US scan plays a role for patients' management
· To learn how US should be used in the outpatients setting to implement patients' diagnostic pathway
· To understand how US imaging can support imaging-guided interventions

**Intro of probes**
K.F. Stock, Munich (DE)

**Point-of-care ultrasound (POCUS) in emergency care**
K.F. Stock, Munich (DE)

**Ultrasound at outpatient office**
G. Fojecki, Odense (DK)

**Ultrasound to guide interventions**
G. Fojecki, Odense (DK)

**Tips and tricks of ultrasound exploration**
K.F. Stock, Munich (DE)

**Closure**
K.F. Stock, Munich (DE)

## Male prosthetic urology

ESU Course 10

**Friday 13 March**
**11:45 - 14:45**

**Location** Red Area, Room 9

**Chair** S. Malde, London (GB)

**Learning objectives**
This is a state of the art course on the use of prosthetics in the management of erectile dysfunction and urinary incontinence. The main learning objectives are:

- Step-by-step preparation and insertion of a penile prosthesis
- Complications and difficult situations for IPP
- Step-by-step options and techniques in the surgical management of incontinence
- Complications and difficult situations for GSI management

**Introduction to the course**
S. Malde, London (GB)

**Penile prosthesis**

**Development of different types of penile prosthesis**
A. Fraile Poblador, Madrid (ES)

**Selection of patients for penile prosthesis surgery**
J. Romero-Otero, Madrid (ES)

**Theatre set-up and preparation of patients**
J. Romero-Otero, Madrid (ES)

**Surgical techniques and intraoperative complications**
P. Świniarski, Warsaw (PL)

**Penile prosthesis training - role of modular training and training tools**
P. Świniarski, Warsaw (PL)

**The difficult implant: Peyronie's, priapism, fibrotic penis**
A. Fraile Poblador, Madrid (ES)

**Revision surgery and managing post operative complications**
J. Romero-Otero, Madrid (ES)

**Prosthetic surgery for male urinary incontinence**

**AUS: Indications, types, techniques and complications**
S. Malde, London (GB)

**Slings: Indications, types, techniques and complications**
S. Malde, London (GB)

**Future of prosthetic urology**
S. Malde, London (GB)
P. Świniarski, Warsaw (PL)

## Focal therapy for beginners: How to start with focal therapy

ESU Course 09

**Friday 13 March**
**12:00 - 15:00**

**Location** Red Area, Room 8

**Chair** R. Sanchez-Salas, Montreal (CA)

**Learning objectives**
- Explain focal therapy as a disruptive treatment option for localized prostate cancer
- Interpret MRI for lesion targeting and prepare patients for focal treatment
- Perform practical steps for transperineal and transrectal focal therapy procedures
- Advocate for focal therapy in tumor boards and multidisciplinary care pathways.

**Welcome and introduction**
R. Sanchez-Salas, Montreal (CA)

**Imaging and index lesion concept**
L. Rodriguez-Sanchez, Paris (FR)

**Technologies, approaches and practical Steps**
H.U. Ahmed, London (GB)

**Building a programme and facing your peers**
R. Sanchez-Salas, Montreal (CA)

**Interactive case-based discussion**
H.U. Ahmed, London (GB)
L. Rodriguez-Sanchez, Paris (FR)
R. Sanchez-Salas, Montreal (CA)

**Wrap-up and take-home messages**
R. Sanchez-Salas, Montreal (CA)

# A conversation with Stephen Fry on gods, genitals and the burden of being human: An essential mythological companion for urologists

Special Session

**Friday 13 March**
**12:25 - 12:55**

**Location** Orange Area, eURO Auditorium 2

**Learning objectives**

Stephen Fry (born 1957) is a British writer, broadcaster, actor, and public intellectual widely admired for his wit, linguistic virtuosity, and ability to make complex subjects - especially classical mythology - accessible to modern audiences.

Fry first rose to prominence through comedy and television, notably via collaborations with Hugh Laurie and appearances in British cultural staples of the 1980s and 1990s. Alongside his screen work, he built a parallel career as an essayist, memoirist, and novelist, known for combining erudition with warmth and self-deprecating humour.

In the last decade, Fry has become particularly influential as a populariser of classical mythology. His trilogy—*Mythos* (Greek creation myths and early gods), *Heroes* (Greek heroic cycles), and *Troy* (the Trojan War) - reframes ancient stories in contemporary, conversational English while remaining faithful to classical sources. His approach emphasises narrative clarity, human psychology, and the timelessness of myth, making Greek mythology newly accessible to readers who might otherwise find primary sources daunting. He often frames myths not as distant religious artefacts, but as early attempts to explain power, fate, desire, and mortality - themes that resonate strongly with modern audiences.

Beyond literature, Fry has been open about his personal health journey. In 2018, he publicly disclosed that he had undergone surgery for prostate cancer after detection through screening. He spoke candidly about the emotional shock of diagnosis, the role of PSA testing and imaging in detection, and the relief following successful treatment. Since then, he has contributed to public conversations about prostate cancer awareness, early detection, and reducing stigma around male health - typically approaching the topic with the same mixture of honesty, humour, and intellectual reflection that characterises his writing.

Across disciplines - comedy, literature, classical education, and advocacy - Fry's enduring contribution lies in translation in the broadest sense: translating complex culture, history, and personal experience into language that is precise, humane, and widely understood.

**Gods, genitals and the burden of being human: An essential mythological companion for urologists**


*Interviewer* B.J. Challacombe, London (GB)

*Speaker* S. Fry, London (GB)

# Male genital diseases

ESU Course 11

**Friday 13 March**
**12:30 - 15:30**

**Location** Red Area, Room 10

**Chair** M. Skrodzka, London (GB)

Voting will be available via the EAU26 App or via www.qna.at/eau

**Learning objectives**

This novel and revised course will give a state-of-the-art update on the variety of genital diseases that urologists will encounter in daily clinical practice. The faculty consists of a group of internationally renown experts in this field.

A spectrum of pathologies can affect the male genitals, from benign disorders to cancers. There will be particular focus and emphasis on interactive case-based discussions and surgical videos of the latest surgical techniques used in this evolving field. The course will also deal with the surgical management of these diseases including the surgical indications and techniques used in genital reconstructive surgery. Particular focus will be on:

• The aetiology, diagnosis and medical management of the common gentital skin diseases including inflammatory conditions.
• The medical and surgical management of HPV, BXO and pre-malignant conditions of the penis, including the techniques of circumcision, skin grafting, glans resurfacing, surgery for buried penis and the correction of genital lymphoedema.
• The surgical management of Peyronie's disease including plication procedures and grafting
• The management of penile carcinoma including the aetiopathogenesis, techniques/outcome of organ-sparing surgery and ilioinguinal lymphadenectomy will be discussed and illustrated.

**Surgical management of Peyronie's disease**
K. Van Renterghem, Hasselt (BE)

**Penile and scrotal dermatology for the urologist**
M. Skrodzka, London (GB)

**Circumcision, frenuloplasty and preputioplasty**
K. Van Renterghem, Hasselt (BE)

**The buried penis**
K. Van Renterghem, Hasselt (BE)

**Management of genital lymphoedema**
M. Skrodzka, London (GB)

**Premalignant lesions of the penis and scrotum**
A. Parnham, Manchester (GB)

**Penile cancer: Penile preserving surgery**
M. Skrodzka, London (GB)

**Penile cancer: Management of lymph nodes**
A. Parnham, Manchester (GB)

# Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 1.1

**Friday 13 March**
**12:45 - 13:35**

**Location** Red Area, Room 1

**Coordinator** L.B. Dragoş, Cambridge (GB)

**Tutors** V. Novak, Praha (CZ)
O. Stakhovskyi, Kyiv (UA)

**Learning objectives**
This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

# Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 1.1

**Friday 13 March**
**12:45 - 13:35**

**Location** Red Area, Room 1

**Tutors** S. García Barreras, Madrid (ES)
M. Jarzemski, Bydgoszcz (PL)

**Learning objectives**
The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 1.1

**Friday 13 March**
**12:45 - 13:35**

**Location** Red Area, Room 1

**Tutor** F. Al Jaafari, Kirkcaldy (GB)

**Learning objectives**

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

# Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 1.1

**Friday 13 March**
**12:45 - 13:35**

**Location** Red Area, Room 1

**Tutors** M. Goossens, Aalst (BE)
M.C. Klitsch, Vienna (AT)

**Learning objectives**

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 1.1

**Friday 13 March**
**12:45 - 13:35**

**Location** Red Area, Room 1

**Tutors**

A.C. Bouma - Houwert, Amsterdam (NL)
I.M. Tjiam, Poortugaal (NL)
S. Yuen, Hong Kong (HK)

**Learning objectives**

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

## Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 1.1

**Friday 13 March**
**12:45 - 13:35**

**Location** Red Area, Room 1

**Tutors**

I. Kartalas Goumas, Vigevano (IT)
D. Perri, Como (IT)
B.M. Schoensee, Berlin (DE)

**Learning objectives**

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

# Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 1.1

**Friday 13 March**
**12:45 - 13:35**

**Location** Red Area, Room 1

**Tutors**
M. Paciotti, Rozzano, Milan (IT)
M.E. Rodríguez Socarrás, Madrid (ES)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# HOT debates: Blades vs. Beams in urological cancers

Thematic Session

**Friday 13 March**
**13:00 - 14:30**

**Location** Orange Area, eURO Auditorium 2

**Chairs**
M. Albersen, Leuven (BE)
J. Walz, Marseille (FR)

**Learning objectives**
Compare the role of surgery (“blades”) and radiotherapy (“beams”) in the management of prostate, bladder, testicular, and renal cancer. Recognize the key advantages, limitations, and toxicity profiles of surgical and radiotherapeutic approaches. Identify clinical scenarios where either modality represents a valid treatment option. Improve patient counselling and shared decision-making by clearly explaining the trade-offs between surgery and radiotherapy.

| | |
|---|---|
| **13:00 - 13:02** | **Introduction and concept** |
| **13:02 - 13:22** | Debate **Kidney** |
| 13:02 - 13:05 | **Case presentation by chairs** |
| 13:05 - 13:06 | **Voting** |
| 13:06 - 13:16 | **Blades vs. Beams** |
| | *Speakers* K. Haq, London (GB); S. Siva, Melbourne (AU) |
| 13:16 - 13:21 | **Rebuttal** |
| 13:21 - 13:22 | **Voting** |

| | | |
|---|---|---|
| **13:22 - 13:42** | **Debate Bladder** | |
| 13:22 - 13:25 | **Case presentation by chairs** | |
| 13:25 - 13:26 | **Voting** | |
| 13:26 - 13:36 | **Blades vs. Beams** | |
| | *Speakers* | V. Fonteyne, Ghent (BE)<br>S. Psutka, Seattle (US) |
| 13:36 - 13:41 | **Rebuttal** | |
| 13:41 - 13:42 | **Voting** | |
| **13:42 - 14:02** | **Debate Prostate** | |
| 13:42 - 13:45 | **Case presentation by chairs** | |
| 13:45 - 13:46 | **Voting** | |
| 13:46 - 13:56 | **Blades vs. Beams** | |
| | *Speakers* | B.A. Jereczek-Fossa, Milan (IT)<br>J. Stranne, Göteborg (SE) |
| 13:56 - 14:01 | **Rebuttal** | |
| 14:01 - 14:02 | **Voting** | |
| **14:02 - 14:22** | **Debate Testis** | |
| 14:02 - 14:05 | **Case presentation by chairs** | |
| 14:05 - 14:06 | **Voting** | |
| 14:06 - 14:16 | **Blades vs. Beams** | |
| | *Speakers* | A. Heidenreich, Cologne (DE)<br>A. Papachristofilou, Basel (CH) |
| 14:16 - 14:21 | **Rebuttal** | |
| 14:21 - 14:22 | **Voting** | |
| **14:22 - 14:30** | **Conclusions** | |

# Emerging Europe: Organising top-notch prostate cancer care in resource-limited environments

Thematic Session

**Friday 13 March**
**13:00 - 14:30**

**Location** Blue Area, Victoria 4

**Chairs**
M. Hora, Plzen (CZ)
P. Rajwa, Warsaw (PL)

**Learning objectives**
The EAU guidelines provide clear instructions on how to proceed in the diagnosis and treatment of prostate cancer based on evidence-based medicine. In real practice, however, these procedures cannot be implemented for a number of reasons. Among other things, financial and human resources are limiting factors. The thematic session will address this issue.

| | |
|---|---|
| **13:00 - 13:02** | **Introduction** |
| **13:02 - 13:43** | **Multidisciplinary management of prostate cancer: Building teams without borders** |
| 13:02 - 13:09 | **Setting the scene: Why MDTs are central to modern prostate cancer care**<br>B.W. Lamb, London (GB) |
| 13:09 - 13:16 | **Establishing MDTs in resource limited environments**<br>M. Miszczyk, Vienna (AT) |
| 13:16 - 13:23 | **Integrating radiologists into prostate cancer MDTs**<br>I.G. Schoots, Rotterdam (NL) |
| 13:23 - 13:30 | **Delivering value-based prostate cancer care in resource-limited settings**<br>D. Penson, Nashville (US) |
| 13:30 - 13:33 | Case presentation **Unfavorable prostate cancer**<br>M. Miszczyk, Vienna (AT) |
| 13:33 - 13:43 | Case-based panel discussion **MDT decision-making with conventional imaging only**<br>B.W. Lamb, London (GB)<br>M. Miszczyk, Vienna (AT)<br>D. Penson, Nashville (US)<br>I.G. Schoots, Rotterdam (NL) |
| **13:43 - 14:04** | **Centralisation in cancer care: Who benefits, who gets left behind?** |
| 13:43 - 13:50 | **Setting the scene: Centralise or decentralise care in genitourinary malignancies?**<br>J. Oldenburg, Oslo (NO) |
| 13:50 - 13:57 | **Challenges of centralisation in middle-income regions**<br>P. Nyirády, Budapest (HU) |
| 13:57 - 14:04 | **Quality measures in urologic oncological care: Why should we follow up on patients and treatment outcomes?**<br>R. Nicoletti, Florence (IT) |
| **14:04 - 14:17** | Case-based panel discussion **Referral dilemmas and oncology patient pathways: How do we do it in our countries?** |

14:04 - 14:07 **Case presentation** **mHSPC**
T. Ložar, Ljubljana (SI)

14:07 - 14:17 **Panel discussion** **Country perspectives**
M. Hora, Plzen (CZ)
R. Nicoletti, Florence (IT)
P. Nyirády, Budapest (HU)
J. Oldenburg, Oslo (NO)
I. Tomašković, Zagreb (HR)

**14:17 - 14:22** **How EAU mobility programmes and fellowships can transform your clinical practice and research**
P. Rajwa, Warsaw (PL)

**14:22 - 14:30** **Baltic25 Young urologist competition winner** **When PSMA doesn't light up: Challenges in prostate cancer diagnosis and treatment**
A. Rautio, Tallinn (EE)

## Shared decision-making in kidney cancer: Insights from global patient data & clinical practice

Patient Advocacy Roundtable

**Friday 13 March**
**13:00 - 14:00**

**Location** Red Area, Room 17

**Chair** C. Ungarelli, Forest (BE)

**Learning objectives**
In this session, participants will explore shared decision-making (SDM) in kidney cancer through insights from global patient survey data, clinician perspectives, and lived patient experiences. The discussion will examine how SDM currently functions across different care settings, highlighting disparities across Europe and identifying ways to promote more consistent patient engagement in treatment choices.

The session will also delve into the differences between patient-reported and clinician-reported barriers to SDM, shedding light on where perceptions diverge and how these can be better aligned to improve communication and trust. Participants will gain an understanding of practical tools and frameworks that can help clinicians and patients work together more effectively, ensuring that every treatment decision reflects both medical evidence and individual patient values.

By the end of the session, attendees will be equipped with a clearer view of how SDM can be strengthened in kidney cancer care - from improving conversations in the clinic to embedding shared decision-making principles across the broader healthcare system.

**13:00 - 13:05** **Welcome & introduction**
C. Ungarelli, Forest (BE)

**13:58 - 14:00** **Closing**
C. Ungarelli, Forest (BE)

# Female urology: Changing landscapes

Abstract Session 02

**Friday 13 March**
**13:00 - 14:30**

**Location** Red Area, Room 14

**Chairs**
R. Barratt, London (GB)
E. Costantini, Perugia (IT)
To be confirmed

**13:00 - 13:35** **Periurethal injection, artificial sphincter and more in the mesh controversy era**

A0019 **Transurethral Injection of Autologous Muscle Precursor Cells in Collagen Solution for the Treatment of Female Stress Urinary Incontinence – Results from a Blinded, Prospective and Randomised Phase II Clinical Trial (SUISSE MPC2 Study)**
T.S. Schmidli, Zurich (CH)

A0020 **Ultrasound-Based Predictors of Polyacrylamide Hydrogel Injection Success in Stress Urinary Incontinence: Longitudinal Study by a Single Experienced Surgeon**
E. Illiano, Terni (IT)

A0021 **Efficacy of Periurethral Platelet-Rich Plasma Therapy in Women with Stress Urinary Incontinence: A Prospective Evaluation Using VAS, Stamey Scale, and King's Health Questionnaire**
A. Petca, Bucharest (RO)

A0022 **10-year evolution of the number of surgeries for female urinary incontinence in France (2015-2024)**
PL.D. Dequirez, LILLE (FR)

A0023 **1-year outcomes of female artificial urinary sphincter implantation in Europe: the VENUS registry[CC1]**
B. Peyronnet, Rennes (FR)

A0024 **Implantation of an AMS-800 artificial urinary sphincter in women with severe stress urinary incontinence: comparison between open and robot-assisted approaches in a single-center retrospective study**
S. Duboys Fresney, (FR)

**13:35 - 13:50** **Mesh removal: What then?**

A0026 **Sexual morbidity pre and post mesh removal in a New Zealand population**
H. Stewart, Christchurch (NZ)

A0027 **The Natural History of Continence and Patient Satisfaction after Mesh Removal: a Tertiary-Centre Experience**
I. Loufopoulos, London (GB)

A0028 **SUSTeR study : Sub-Urethral Sling Treatment Removal, a retrospective multicentric cohort about mid and long term mid-urethral sling complications between 2010-2024 : Symptomatic recovery is it possible ?**
A. Boileau, Toulouse (FR)

**13:50 - 14:05** **Pelvic organ prolapse: Is robotic sacrocolpopexy evidence based?**

A0029 **Extended Follow-Up of a Randomized Study Comparing Robotic and Laparoscopic Sacrocolpopexy: Results at 9 Years**
E. Illiano, Terni (IT)

A0030 **Biomechanical modeling and finite element analysis of pelvic floor reconstruction for pelvic organ prolapse**
D. Tian, Kunming (CN)

A0031 **Laparoscopic versus Robot-Assisted Laparoscopic Sacrocolpopexy: A Randomized Controlled Trial (ROBOLAPS Study)**
S. Kutchukian, Poitiers Cedex (FR)

**14:05 - 14:20** **Overactive bladder**

A0032 **A double-blind randomized controlled trial of low intensity extracorporeal shock wave therapy for overactive bladder in women with metabolic syndrome**
M. Leong, Kaohsiung (TW)

A0034 **Ambulatory Posterior Tibial Nerve Stimulation Using the TENSI+ Device: A Prospective Clinical Study in Detrusor Overactivity**
J.F. Monzon Falconi, Barcelona (ES)

**14:20 - 14:30** **Pelvic pain**

A0035 **Multi-omics profiling reveals divergent pathogenic mechanisms between Hunner-type and non-Hunner-type interstitial cystitis**
H. Ke, Chengdu (CN)

## Late-breaking and high-impact abstracts

Abstract session

**Friday 13 March**
**13:00 - 15:00**

**Location** Orange Area, Room 3

**Chairs**
J. Boormans, Rotterdam (NL)
K.A.O. Tikkinen, Helsinki (FI)
D. Tilki, Hamburg (DE)

**13:00 - 13:30** **Prostate cancer: Screening, diagnosis and treatment planning**

LB002 **Closing the knowledge gap to inform policy decision-making: health-related quality of life and health anxiety in men undergoing screening for prostate cancer**
S. Hao, Stockholm (SE)

LB003 **Genomic Prostate Score predicts adverse oncological outcomes in patients with prostate cancer undergoing active surveillance, surgery, or radiotherapy in the ProMPT study**
F.C. Hamdy, Oxford (GB)

LB004 **Progression-free survival following primary staging with [$^{18}$F]PSMA-1007-PET/ceCT versus Na[$^{18}$F]F-PET/ceCT in prostate cancer: Results from the PRISMA-PET randomized controlled trial**
K.M. Buch-Olsen, Odense C (DK)

**13:30 - 13:50** **Prostate Cancer: Optimizing radical prostatectomy outcomes & focal therapy**

LB005 **Randomized controlled trial evaluating MRI-guided transurethral ultrasound ablation (TULSA) versus robotic prostatectomy: Initial perioperative outcomes**
L.H. Klotz, Toronto (CA)

LB006 **Phase III results of the RoboSling randomised controlled trial - continence outcomes with autologous vascularised bladder neck sling during robotic radical prostatectomy**
D. Ashrafi, (AU)

**13:50 - 14:20** **NMIBC**

LB008 **Final analysis of the phase 1 first-in-human study of erda-iDRS, an erdafitinib intravesical drug-releasing system, in patients with non–muscle-invasive bladder cancer harboring select FGFR alterations**
A. Vilaseca, Barcelona (ES)

LB009 **Fluorescence cystoscopy and adjuvant optimized mitomycin-C in non-muscle invasive bladder cancer with high risk of recurrence – results from the prospective randomized FinnBladder 9 trial**
V. Sell, Turku (FI)

**Study Group**
FinnBladder Research group(Helsinki, Finland)

LB010 **Holmium Laser En-Bloc Resection Versus Conventional TURBT for Large Non-Muscle Invasive Bladder Tumors: Safety and Mid-term Oncological Outcomes from a Prospective Randomized Trial**
M. Pereira, Sao Paulo (BR)

**14:20 - 14:50** **Peri-operative management & kidney transplantation**

LB011 **Open versus robot-assisted kidney transplantation in adults with end-stage kidney disease (ORAKTx): a randomised open-label trial**
M. Ortved, Copenhagen (DK)

P0874 **Perioperative Management of Direct Oral Anticoagulants in Urological Surgery – The prospective PAUSE-URO Trial**
N. Carl, Mannheim (DE)

A0875 **KEYNOTE-905 study of neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: assessment of surgical outcomes**
N. Shore, Myrtle Beach (US)

## Guided precision: AR, novel imaging and advanced robotics in partial nephrectomy

Video Session 02

**Friday 13 March**
**13:00 - 14:30**

**Location** Blue Area, George 3

**Chairs**
R. Barod, London (GB)
O. Tayara, Otwock (PL)
To be confirmed

V008 (▢: 7 min.) **Single-Port Robot-assisted Partial Nephrectomy: Early Spanish Experience**
V. Hevia Palacios, Madrid (ES)

V009 (▢: 7 min.) **Robot-Assisted Partial Nephrectomy Using Four Different Robotic Platforms: Institutional Experience and Feasibility**
C. Cámara Martínez, Ourense (ES)

V010 (⊡: 8 min.)
**Hyperspectral Imaging Enables Selective Clamping During Robot-Assisted Partial Nephrectomy**
A. Studier-Fischer, Mannheim (DE)

V012 (⊡: 8 min.)
**Exploring the Feasibility of 3D Augmented Reality in Image-Guided Robot-Assisted Partial Nephrectomy: Initial prospective Clinical Experience and Outcomes of 3D AR-IGRAPN (UroCCR 112)**
A. Pitout, Nancy (FR)

V013 (⊡: 7 min.)
**Minimally invasive partial nephrectomy under the guidance of augmented reality dynamic real-time navigation based on the deep-learning multi-structural tridimensional kidney model**
S. Zhang, Nanjing (CN)

V014 (⊡: 7 min.)
**Prone position "Three-Port" retroperitoneal laparoscopic partial nephrectomy for complete dorsal T1a renal tumors**
Q. Cao, Nanjing (CN)

V011 (⊡: 8 min.)
**3D-Image Guided Robot Assisted Partial Nephrectomy for non-oncological reasons**
G. Margue, Bordeaux (FR)

## Challenges in African urology

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Pan-African Urological Surgeons Association (PAUSA)

**Friday 13 March**
**13:00 - 15:00**

**Location** Blue Area, Victoria 6

**Chairs** J. N'Dow, Aberdeen (GB)
A.S. Zribi, Tunis (TN)

**Learning objectives**

**Master the Transition to Minimally Invasive Surgery (MIS)**
Compare and contrast the current roles of traditional open surgery versus laparoscopic surgery in various African settings. Analyze and manage the risks associated with conversion from laparoscopy to open surgery (laparotomy). Understand the continuing necessity for African urologists to maintain and teach open surgical skills.

**Initiate and Develop Robotic Surgery Programs**
Outline the essential steps for launching a robotic surgery program, including logistical, technical, and training requirements. Evaluate initial feedback and lessons learned from recent robotic surgery experiences in African countries.

**Manage Complex Reconstructive Challenges**
Review alternative management strategies for complex vesico-vaginal fistulas, including the presentation of a novel continent cystoplasty technique from a major reference center. Discuss prevention and treatment strategies for high-risk complications, such as buccal mucosa graft contracture in urethroplasty. Detail the specific surgical techniques required for redo repairs of pelvic fracture urethral injuries.

**13:00 - 13:05** **Introduction**

**13:05 - 13:50** **Open surgery in the era of minimally invasive surgery**

*Moderators*
A. Cheriyan, Aberdeen (GB)
R. Veeratterapillay, Newcastle Upon Tyne (GB)

13:05 - 13:15 **Open surgery, initial choice: When and why**
A. Cheriyan, Aberdeen (GB)

13:15 - 13:30 **Laparoscopy to laparotomy: The decision and management of conversion**
M. Benatta, Oran (DZ)

**The enduring relevance of laparoscopy in the robotic era**

13:30 - 13:37 **In Africa**
M. Bouassida, Sfax (TN)

13:37 - 13:44 **In Europe**
I. Minčík, Presov (SK)

13:44 - 13:50 **Discussion**

---

**13:50 - 14:25** **Robotic surgery**

*Moderators*
A. Mottrie, Aalst (BE)
P. Ngwu, Umuahia (NG)
B. Njinou Ngninkeu, Le Havre (FR)

13:50 - 14:05 **Building a robotic surgery program: Step-by-step roadmap**
A. Mottrie, Aalst (BE)

14:15 - 14:25 **Discussion**

---

**14:25 - 15:00** **Reconstructive surgery**

*Moderators*
A.D. Dangi, Aberdeen (GB)
H. Kibansha, Kampla (UG)
A.A. Mbassi, Yaounde (CM)

14:25 - 14:35 **Complex pelvic fracture urethral injuries re-do**
E. Moshokoa, Midrand (ZA)

14:35 - 14:45 **Buccal mucosa graft contracture in African countries**
A. Bouker, Tunis (TN)

14:45 - 14:55 **The new continent augmentation cystoplasty**
I. Vaz, Maputo (MZ)

14:55 - 15:00 **Discussion**

# Controversies in uro-oncology: Case based discussions

Urology Beyond Europe: Joint session between the European Association of Urology (EAU), the SAARC Association of Urological Surgeons (SAUS) and Pakistan Association of Urological Surgeons (PAUS)

**Friday 13 March**
**13:00 - 15:30**

**Location** Red Area, Room 7

**Chairs**
M.S. Agrawal, Agra (IN)
H. Ather, Karachi (PK)
M. Babjuk, Prague (CZ)
Rajeev Thekumpadam Puthenveetil, Guwahati (IN)

**Learning objectives**
This UBE session is divided into two sections. The first section, case-based learning, enhances clinical reasoning, problem-solving, and decision-making skills by having urologists analyse real scenarios in general urology, thereby integrating theory with practice and developing critical thinking abilities. Section 2 addresses some contemporary issues in uro-oncology, focusing on three primary urological cancers: bladder, prostate, and kidney. There is ample opportunity for interactive discussion during the session.

| | |
|---|---|
| **13:00 - 13:05** | **Opening by president of SAUS and PAUS**<br>H. Ather, Karachi (PK) |
| **13:05 - 14:10** | **Case based discussions: Benign urological conditions** |
| 13:05 - 13:08 | Case presentation **Moderate burden staghorn stone in a 30-year-old male, first-time stone former**<br>*Case presenter* S.K. Chandrasekera, Sri Jayewardenepura (LK) |
| 13:08 - 13:14 | **PCNL is still the treatment of choice**<br>B. Somani, Southampton (GB) |
| 13:14 - 13:20 | **RIRS with FANS is the new gold standard**<br>M.A. Salam, Dhaka (BD) |
| 13:20 - 13:25 | **Discussion and voting** |
| 13:25 - 13:28 | **Case discussion: 57-year-old male with medical treatment-refractory BPH**<br>*Case presenter* H. Mithani, Karachi (PK) |
| 13:28 - 13:34 | **MIST is the standard of care now**<br>M. Rieken, Zürich (CH) |
| 13:34 - 13:40 | **TURP/laser enucleation is still the gold standard**<br>P. Maheshwari, Mumbai (IN) |
| 13:40 - 13:45 | **Discussion and voting** |
| 13:45 - 13:48 | Case presentation **2 cm bulbar urethral stricture in a 32-year-old male**<br>*Case presenter* I. Memon, Hyderabad (PK) |
| 13:48 - 13:54 | **Dorsal onlay urethroplasty**<br>*Case presenter* A. Abdullah, Karachi (PK) |
| 13:54 - 14:00 | **Ventral onlay urethroplasty**<br>K. Dimitropoulos, Larissa (GR) |

14:00 - 14:05 **Discussion and voting**

14:05 - 14:10 **Session wrap-up**
A.P. Malalasekera, Colombo (LK)

**14:10 - 15:30** **Uro oncology**

*Moderators*
M. Babjuk, Prague (CZ)
N. Bin Nusrat, Galway (IE)
Rajeev Thekumpadam Puthenveetil, Guwahati (IN)

14:10 - 14:20 **Evolving role of PSMA PET CT in diagnosis and staging**
G. Gandaglia, Milan (IT)

14:20 - 14:30 **Balancing toxicity and cancer control in metastatic prostate cancer**
M.J. Kabir, Dhaka (BD)

14:30 - 14:35 **Discussion**

14:35 - 14:45 **Management of complex renal masses in a solitary kidney**
T. Klatte, Bad Saarow (DE)

14:45 - 14:55 **Modern imaging modalities in staging and diagnosis of RCC**
Z. Aslam, Aberdeen (GB)

14:55 - 15:00 **Discussion**

15:00 - 15:10 **Management dilemma in pT0 bladder cancer following NAC**
H. Ather, Karachi (PK)

15:10 - 15:20 **De-escalations in the follow-up of NMI bladder cancer - pros and cons**
A.H. Qureshi, Karachi (PK)

15:20 - 15:25 **Discussion**

15:25 - 15:30 **Session wrap-up**
F. Mumtaz, London (GB)

## Hidden challenges: Diagnosis and management of rare GU tumours

Urology Beyond Europe: Joint session of the European Association of Urology (EAU) and the Canadian Urological Association (CUA)

**Friday 13 March**
**13:00 - 15:00**

**Location** Blue Area, George 1

**Chairs**
W. Kassouf, Montreal (CA)
J.L. Vásquez, Copenhagen (DK)

**Learning objectives**
1. Recognize the burden of rare genitourinary cancers and understand their impact on patients and healthcare systems. 2. Review advances in penile cancer, including HPV-related disease and management of node-positive disease. 3. Identify clinical and pathological precursors of penile, bladder and testicular cancer and their implications for diagnosis, surveillance, and intervention. 5. Discuss complex management challenges in postchemotherapy germ cell tumors.

**13:00 - 13:05** **Introduction**

| | | |
|---|---|---|
| **13:05 - 13:15** | State-of-the-art lecture **The burden of rare genitourinary cancers**<br>A. Necchi, Milan (IT) | |
| **13:15 - 13:20** | **Discussion** | |
| **13:20 - 13:35** | **Penile cancer** | |
| 13:20 - 13:30 | State-of-the-art lecture **Penile intraepithelial neoplasia and HPV**<br>A. Thomas, Mainz (DE) | |
| 13:30 - 13:35 | **Discussion** | |
| **13:35 - 14:10** | **Node-positive penile carcinoma - a case-based discussion** | |
| | *Case presenter* | M. Lodde, Québec (CA) |
| | *Panel* | B.E. Ayres, London (GB)<br>J.M. Crook, Kelowna (CA)<br>L. Elst, Leuven (BE)<br>S. Sridhar, Toronto (CA) |
| **14:10 - 14:25** | **Bladder cancer** | |
| 14:10 - 14:20 | State-of-the-art lecture **Premalignant bladder cancer lesions**<br>M.P. St-Laurent, Vancouver (CA) | |
| 14:20 - 14:25 | **Discussion** | |
| **14:25 - 14:55** | **Testicular cancer** | |
| 14:25 - 14:35 | State-of-the-art lecture **Clinical and pathologic precursors of testicular cancer**<br>C. Tholomier, Montréal (CA) | |
| 14:35 - 14:40 | **Discussion** | |
| 14:40 - 14:50 | State-of-the-art lecture **Challenging postchemotherapy germ cell tumors: growing teratoma and malignant transformation**<br>R. Hamilton, Toronto (CA) | |
| 14:50 - 14:55 | **Discussion** | |
| **14:55 - 15:00** | **Wrap up** | |

# Current topics of urology: Prostate cancer and urolithiasis

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Japanese Urological Association (JUA)

**Friday 13 March**
**13:00 - 15:30**

**Location** Blue Area, Victoria 1

**Chairs**
A.S. Merseburger, Lübeck (DE)
M. Sugimoto, Kagawa (JP)

**Learning objectives**
The topic of this session is prostate cancer and urolithiasis, two of the most common conditions in urology. A wide range of treatment options is available for prostate cancer, and pharmacotherapy is becoming increasingly complex. In addition to hormonal therapy, personalized treatments based on genetic testing are being developed. Theranostics using PSMA is also becoming widespread, while significant advancements are being made in both particle beam radiation therapy and surgical techniques. In the field of urolithiasis, progress is being made not only in molecular-level understanding but also in the rapid evolution of endoscopic surgery. Moreover, preventive strategies are gaining more attention alongside therapeutic approaches.

**13:00 - 13:05** **Opening**

**13:05 - 13:50** **Prostate cancer**

*Moderators*
G. Kramer, Vienna (AT)
H. Miyake, Kobe (JP)

13:05 - 13:15 **Comprehensive genomic profiling tests in prostate cancer: How to translate basic research knowledge into real-world clinical practice?**
T. Sasaki, Tsu (JP)

13:15 - 13:25 **From mHSPC to mCRPC**
A.S. Bjartell, Malmö (SE)

13:25 - 13:50 **Case presentation: Prostate cancer**

*Case presenter*
N. Gunge, Fukuoka (JP)

**Panel discussion**

*Panel*
G. Gandaglia, Milan (IT)
N. Gunge, Fukuoka (JP)
K. Morozumi, Sendai (JP)

**13:50 - 14:35** **JUA abstract presentations**

*Moderators*
A.S. Merseburger, Lübeck (DE)
M. Sugimoto, Kagawa (JP)

13:50 - 13:55 **Initial dose-reduced apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): comparative outcomes versus full dose**
T. Yanagisawa, Tokyo (JP)

13:55 - 14:00 **A Retrospective Analysis of Errors with the Hugo RAS System in Urological surgery**
A. Yamamoto, Yonago-shi, Tottori-ken (JP)

14:00 - 14:05 **Efficacy, safety, and cost-effectiveness of reduced vs. full initial dose androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer**
N. Fujita, Hirosaki (JP)

14:05 - 14:10 **Clinical characteristics and predictive factors of symptomatic skeletal events in patients with metastatic castration-resistant prostate cancer treated with denosumab**
M. Nakata, Tokyo (JP)

14:10 - 14:15 **Targeting EphA2 reverses immunotherapy resistance by promoting CCL5-dependent T-cell infiltration in basal/squamous bladder cancer**
E. Tomiyama, Osaka (JP)

14:15 - 14:20 **Association of serum kidney injury molecule-1 with treatment response and survival in metastatic renal cell carcinoma**
A. Kumono, Tokyo (JP)

14:20 - 14:25 **Cross-resistance in sequential androgen receptor signaling inhibitor use for non-metastatic castration-resistant prostate cancer**
N. Fujita, Hirosaki (JP)

14:25 - 14:30 **An external validation study of peritoneal closure and the processus vaginalis transection method to prevent inguinal hernia after robot-assisted radical prostatectomy**
T. Soma, Tokyo (JP)

**14:35 - 14:40** **Break**

**14:40 - 15:25** **Stones**

*Moderators*
O. Angerri Feu, Barcelona (ES)
T. Yasui, Nagoya (JP)

14:40 - 14:50 **Discovery of a novel biomarker for urolithiasis using crystal engineering techniques**
Y. Tanaka, Nagoya (JP)

14:50 - 15:00 **How to crack the stones?**
O. Angerri Feu, Barcelona (ES)

15:00 - 15:25 **Case presentation: Stones**

*Case presenter*
S. Kayano, Oshima-cho, Ota-shi, Gunma (JP)

**Panel discussion**

*Panel*
S. Kayano, Oshima-cho, Ota-shi, Gunma (JP)
Y. Nagata, Kitakyushu (JP)
T. Tailly, Ghent (BE)
L. Tzelves, Athens (GR)

**15:25 - 15:30** **Closing**
H. Kume, Tokyo (JP)

# Facing the grey zones: Urological debates

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Arab Association of Urology (AAU)

**Friday 13 March**
**13:00 - 15:00**

**Location** Blue Area, Victoria 5

**Chairs**
W. Kamal, Jeddah (SA)
T. Knoll, Sindelfingen (DE)
S. Mourad, Heliopolis (EG)

**Learning objectives**
Participants should learn to make evidence-based decisions in challenging urological grey zones. They should understand how to balance early cystectomy versus intravesical escalation in high-risk NMIBC, how to choose between urethroplasty and endoscopic approaches for a recurrent 2-cm stricture, and how to manage refractory storage dysfunction in high-risk neuro-urological patients. In addition, they should be able to compare multi-tract PCNL with ECIRS for multi-calyceal stones, evaluate treatment options after BCG failure, and determine when residual fragments ≥4 mm should be observed or actively treated.

**Welcome and introduction**
W. Kamal, Jeddah (SA)

**13:00 - 13:20** Debate **High-risk NMIBC**

13:00 - 13:10 **Early cystectomy**
M. Moussa, Beirut (LB)

13:10 - 13:20 **Intravesical therapy escalation**
L. Afferi, Aarau (CH)

**13:20 - 13:40** Debate **Recurrent 2 cm urethral stricture**

13:20 - 13:30 **Urethroplasty**
S.C. Morgenstern, Frankfurt am Main (DE)

13:30 - 13:40 **Endoscopic management**
Y. Farahat, Umm Al Quwain (AE)

**13:40 - 14:00** Debate **Refractory storage dysfunction in the high-risk neurology patient**

13:40 - 13:50 **Botolunium toxin injection**
M. Bulbul, Riad El Solh - Beirut (LB)

13:50 - 14:00 **Augmented cystoplasty**
T. Antunes Lopes, Porto (PT)

**14:00 - 14:20** Debate **Multiple stones in different calyces**

14:00 - 14:10 **PCNL with multiple tracks**
T. Knoll, Sindelfingen (DE)

14:10 - 14:20 **ECIRS**
W. Kamal, Jeddah (SA)

**14:20 - 14:40** Debate **High-risk NMIBC post BCG failure**

14:20 - 14:30 **Radical cystectomy**
P. Sountoulides, Panorama - Thessaloniki (GR)

14:30 - 14:40 **Newer agents**
W.A. Hassen, Abu Dhabi (AE)

**14:40 - 15:00** Debate **Residual fragments 4 mm or more after some stone surgery**

14:40 - 14:50 **Leave it**
R. Al-Okour, Cambridge (GB)

14:50 - 15:00 **Chase it**
A. Pietropaolo, Southampton (GB)

**Closing remarks**
W. Kamal, Jeddah (SA)

## Transforming urologic practice through innovation and technology

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Korean Urological Association (KUA)

**Friday 13 March**
**13:00 - 15:00**

**Location** Blue Area, Victoria 2

**Chairs** F.K-H. Chun, (DE)
S.I. Jung, Gwangju (KR)

**Learning objectives**
This joint session will bring together specialists and key opinion leaders from South Korea and Europe to address cutting-edge topics in uro-oncology, robotic surgery, and andrology/LUTS. Delegates can expect detailed and up-to-date coverage of specific topics including the treatment of urothelial carcinoma, new platforms in robotic surgery, and the management of post-prostatectomy urinary symptoms. The session will feature lectures from both European and Korean speakers, followed by discussion panels composed of members from both associations.

**13:00 - 13:05** **Welcome and introduction**
F.K-H. Chun, (DE)
S.I. Seo, Seoul (KR)

**13:05 - 13:45** **Advances in the management of urothelial carcinoma**

*Moderators* A. Masson-Lecomte, Paris (FR)
S.I. Seo, Seoul (KR)

13:05 - 13:15 **En-bloc TURB: A new standard for NMIBC?**
J.H. Kim, Seoul (KR)

13:15 - 13:25 **Updates on the treatment of BCG-refractory NMIBC**
H.K. Seo, Goyang-si, (KR)

13:25 - 13:35 **Cytoreductive cystectomy: Where are we now?**
E.N. Xylinas, Paris (FR)

13:35 - 13:45 **Panel discussion**

*Panel*
J.S. Chung, Busan (KR)
Y.H. Ko, Daegu (KR)
J.Y. Ku, Busan (KR)
E.N. Xylinas, Paris (FR)

---

**13:45 - 14:22** **Revolutionizing urologic surgery through emerging technologies**

*Moderators*
S.K. Hong, Seongnam (KR)
S. Secco, Milan (IT)

13:45 - 13:55 **Urological applications of a robotic surgical system**
B.M.C. Rocco, Rome (IT)

13:55 - 14:05 **Urologic surgery with a robotic assisted system**
C.W. Jeong, Seoul (KR)

14:05 - 14:15 **Telesurgery: Technical challenges and prospects**
B. Somani, Southampton (GB)

14:15 - 14:22 **Panel discussion**

*Panel*
B.M.C. Rocco, Rome (IT)
B. Somani, Southampton (GB)
S.H. Song, Seoul (KR)

---

**14:22 - 14:59** **Emerging therapeutic paradigms in andrology and LUTS**

*Moderators*
S.I. Jung, Gwangju (KR)
V. Phé, Paris (FR)

14:22 - 14:32 **Androgen replacement therapy for prostate cancer survivors with hypogonadism**
H. Han, Seoul (KR)

14:32 - 14:42 **Changes and management of urinary symptom after radical prostatectomy**
S. Bang, Seoul (KR)

14:42 - 14:52 **Current status of neuromodulation for urinary disease**
M. Tutolo, Milan (IT)

14:52 - 14:59 **Panel discussion**

*Panel*
K.J. Oh, Gwangju (KR)
H.J. Park, Busan (KR)
M. Tutolo, Milan (IT)

---

**14:59 - 15:00** **Wrap-up and closing**

*Speaker*
S.I. Jung, Gwangju (KR)

# Navigating the future of urologic care: Trials in progress

EGPT 08

**Friday 13 March**
**13:00 - 14:30**

**Location** Orange Area, EGPT 1

**Chairs** To be confirmed
A. Røder, Gentofte (DK)
T. Seibert, San Diego (US)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**13:00 - 13:25** **Benign urological disease**

P0128 **Cord blood platelet-rich plasma (CB-PRP) plus penile traction therapy versus penile traction alone in patients with Peyronie's disease: a randomized clinical trial (CB-PRP-TRAC1)**
F. Gadda, Cernusco Sul Naviglio (IT)

P0129 **Epidural spinal cord stimulation to restore bladder and bowel function after spinal cord injury: the ImPRESS Project**
S.L. Knight, London (GB)

P0130 **A multicenter, randomized, placebo-controlled trial to compare sacral neuromodulation versus placebo in patients with multiple sclerosis with neurogenic lower urinary tract, bowel and sexual dysfunction**
H. Kobberø, Odense V (DK)

P0131 **PRescription exercise for Older men with Urinary Disease (PROUD) trial**
S. Bauer, San Francisco (US)

**13:25 - 13:30** **Prostate cancer**

P0132 **Penile vibratory stimulation in the prevention of sexual dysfunction and urinary incontinence after radical prostatectomy (ProVibrate)**
H.R. Andersen, Lillerød (DK)

**13:30 - 13:40** **Penile cancer**

P0133 **DEPECA-1 (DEfeating PEnile CAncer 1) – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for advanced and metastatic penile carcinoma**
I. Tsaur, Tuebingen (DE)

P0134 **DEPECA-2 (DEfeating PEnile CAncer 2) – Robot-assisted vs. open inguinal lymphadenectomy for penile cancer – a prospective randomized trial with a supporting translational program**
I. Tsaur, Tuebingen (DE)

**13:40 - 14:10** **Bladder cancer**

P0135 **Prospective multicenter real-time Lund Taxonomy bladder cancer classification**
F. Liedberg, Malmö (SE)

| | |
|---|---|
| P0136 | **COOKER-Bladder Trial- modifiCatiOn of fOod intaKe to influence the Equilibrium of the uRinary BLADDER – a trial in progress**<br>S. Manser, Biel (CH) |
| P0137 | **Artificial Intelligence (AI) CystoSmartTM Software for Papillary and Flat Lesions during Bladder Endoscopy: A Pilot, Non-interventional, Prospective Observational Protocol Proposal for Video Analysis and AI Generating Models**<br>R. Corvino, Roma (IT) |
| P0138 | **A Phase II randomized trial of bicalutamide in patients receiving intravesical BCG for non-muscle invasive bladder cancer (BicaBCa)**<br>P. Toren, Québec (CA) |
| P0139 | **A classic test, a new concept: Development of a prognostic model based on dynamic urine cytology and Decision Support System (DSS) in NMIBC patients treated with BCG- Study Design**<br>G. Papavasileiou, Athens (GR) |
| P0140 | **SPICE: Supporting Sexual Health in Bladder Cancer Patients - A Sequential Mixed-Methods Intervention Study**<br>J. Krieger, Aarhus N (DK) |
| **14:10 - 14:20** | **UTUC** |
| P0141 | **A Phase 2A/B, Multi center, Open Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)**<br>S. Matin, Houston (US) |
| P0142 | **Single bladder instillation with chemotherapy following endoscopic management for upper tract urothelial carcinoma to reduce bladder recurrence**<br>S. Khoury, Haifa (IL) |
| **14:20 - 14:30** | **Kidney cancer** |
| P0143 | **Real-Time Image-Guided Robot-Assisted Partial Nephrectomy: Design and Methodology of the BISTOURY-CLINICAL Prospective Trial**<br>F. Prata, Rome (IT) |
| P0144 | **Clinical outcomes for Caval Thrombus involved Renal Cancer (IR1 – CAVALThromb): a prospective, multicentre, international registry**<br>M.J. Connor, London (GB)<br>**Study Group**<br>IR1-CAVALThromb Study Investigators(London, United Kingdom) |

# Navigating the complexities of penile health: Innovations, challenges, and insights

EGPT 11

**Friday 13 March**
**13:00 - 14:30**

**Location** Blue Area, EGPT 4

**Chairs**
W.G. Lee, London (GB)
A. Morgado, Porto (PT)
To be confirmed

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**13:00 - 13:35** **Erectile dysfunction**

P0182 **A contemporary series of treatment outcomes and satisfaction following insertion of penile prosthesis for psychogenic erectile dysfunction in men aged ≤ 40 years**
J.S.L. Lindsay, London (GB)

P0184 **A more accurate evaluation of erectile function using the IIEF in men who do not engage in sexual intercourse after radical prostatectomy**
F. Kirchhoff, München (DE)

P0185 **Beyond testosterone: the role of dehydroepiandrosterone sulfate and estradiol in erectile dysfunction in men without hypoandrogenism**
N. Fujita, Hirosaki (JP)

P0186 **Corporal Flow Reserve Assessed via Dynamic Penile Color Doppler Duplex Ultrasound: Translating a Cardiological Paradigm to Evaluate Arteriogenic Erectile Dysfunction**
E. Pozzi, Milan (IT)

P0187 **Association Between Erectile Dysfunction and Frailty in Elderly Male Patients With Urological Diseases**
O. Soma, Hirosaki (JP)

P0183 **Clinical implications of systematic ASCVD score assessment in men with suspected vasculogenic erectile dysfunction: Results from a tertiary referral center**
A. Bertini, Detroit (US)

**13:35 - 14:05** **Peyronie's disease**

P0188 **Validated Simulator for Training Penile Reconstructive Procedures in Peyronie's Disease and Congenital Curvature**
Z. Wang, London (GB)

P0190 **Operation for penile deviation and risk of depression. A nationwide 25-year cohort study**
L. Lund, Odense (DK)

P0191 **Exploring depression among men with Peyronie's Disease: A binational cohort from Australia and Denmark**
M. Juul-Haslund, Frederiksberg C (DK)

P0193 **3D DOCUMENTATION OF COMPLEX PENILE DEFORMITIES IN PEYRONIE'S DISEASE – AN EXPERTIMENTAL ANALYSIS OF 2 DEVICES.**
M. Ruggeri, São Paulo (BR)

| | |
|---|---|
| **14:05 - 14:20** | **Transgender** |
| P0194 | **Impact of Gender-Affirming Surgery on Sexual Quality of Life and Sexual Satisfaction in Transgender Women**<br>A. Vural, Istanbul (TR) |
| P0195 | **First of its kind: A Multicentre Retrospective Cohort Analysis of ZSI 475 FTM Penile Implants Following Phalloplasty**<br>M. Levy, Amsterdam (NL) |
| P0196 | **A long learning curve demonstrates the complexity of Gender-affirming inflatable penile prosthesis insertion**<br>A. Gobbo, London (GB) |
| **14:20 - 14:30** | **Vasectomy** |
| P0197 | **Feasibility Study: Use of the SymaniTM microsurgical robot with a 4K 3D Video-Exoscope to perform vaso-vasostomy using fresh human tissues**<br>M. Garcia, Los angeles (US) |
| P0198 | **Post-vasectomy pain syndrome and vasectomy complications: real-life data from a single tertiary referral center**<br>M. Raffo, Milan (IT) |

# Navigating prognostic terrain: Prediction models and surgical outcomes in renal tumour management

EGPT 10

**Friday 13 March**
**13:00 - 14:30**

**Location** Orange Area, EGPT 3

**Chairs** To be confirmed
H. Tanaka, Tokyo (JP)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**13:00 - 13:30** **Surgical outcomes**

P0163 **Barriers to Care and Individual Expenditures Among Patients with Von Hippel–Lindau Syndrome: Insights from a Patient-Reported Outcomes Study in a Large Comprehensive Care Center**
A. Barretta, Cava de Tirreni (IT)

P0164 **Positive Surgical Margins After Partial Nephrectomy: Still a Real Concern or a Fading Threat?**
A. Bertini, Detroit (US)

P0165 **Prognostic Impact and Predictors of Indeterminate Surgical Margins after Nephrectomy for Renal Cell Carcinoma: Analysis from the NCDB**
I. Derweesh, La Jolla (US)

P0166 **Predictors of Recurrence Following Robot-Assisted Partial Nephrectomy for Primary Renal Cancer**
M. Kyono, Kobe (JP)

P0167 **Surgery- and patient-specific determinants of renal function decline after partial nephrectomy in solitary-kidney patients**
L. Salerno, Milan (IT)

P0168 **Proton pump inhibitors and renal vulnerability: hidden risks in patients undergoing unilateral nephrectomy or nephroureterectomy**
T.W. Hsu, Taipei (TW)

**13:30 - 13:55** **Subsequent systemic therapies**

P0169 **BRCA2 Expression Predicts Immune Infiltration and Tumor Progression in Kidney Chromophobe and Renal Papillary Cell Carcinoma**
Y. Wu, GuangZhou (CN)

P0170 **Development and Internal Validation of a Novel Prognostic Score for Real-World Renal Cell Carcinoma Patients Eligible for Adjuvant therapy**
R.S. Flammia, Rome (IT)

P0171 **Real-World Data of Patients Eligible for Adjuvant Pembrolizumab Prior to its National Reimbursement in Italy: Results from an Italian National Cancer Institute Registry**
R.S. Flammia, Rome (IT)

P0172 **Dynamic and Reversible Drug Tolerance to Cabozantinib in Renal Cell Carcinoma**
A. Zaccagnino, Homburg/Saar (DE)

P0173 **An International Multidisciplinary Delphi Consensus Statement on Definition, Classification, and Characterization of Oligometastatic Renal Cell Carcinoma to Guide Treatment Decisions**
Z. Wu, Shanghai (CN)

**Study Group**
International Oligometastatic Renal Cell Carcinoma Collaborative Group(Multi-centre, Hong Kong)

**13:55 - 14:30** **Models to predict survival**

P0175 **Prognostic Indicators in pT3a Renal Cell Carcinoma**
L. Rosmaninho, Porto (PT)

P0177 **Renal Epithelioid Angiomyolipoma: Clinicopathological Predictors in a Rare Entity**
A. Pecoraro, Peschiera del garda VR (IT)

**Study Group**
YAU WORKING GROUP RENAL CELL CARCINOMA(Arnhem, The Netherlands)

P0180 **Cancer-specific survival in renal cell carcinoma: histological subtype-specific analysis of a single high-volume center with 15 years of follow-up**
L. Nocera, Milan (IT)

## Hormone-Sensitive Prostate Cancer: From Epidemiology to Therapeutic Frontiers

EGPT 09

**Friday 13 March**
**13:00 - 14:30**

**Location** Orange Area, EGPT 2

**Chairs**
E.A. Hernandez Mendez, Mexico City (MX)
M. Wenzel, Frankfurt (DE)
T. Zilli, Bellinzona (CH)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**13:00 - 13:40** **Systemic treatment choice in mHSPC**

P0145 **Longitudinal Real-World Comparison of Triplet and Doublet Therapies in Metastatic Hormone-Sensitive Prostate Cancer: A Propensity-Matched Analysis at 6 and 36 Months**
J.Y. Hsu, Taichung (TW)

P0146 **Epidemiology and treatment patterns of metastatic hormone-sensitive prostate cancer in France (EPICAP): Insights from a retrospective claims database study**
L. Inchboard, Bordeaux (FR)

P0147 **Comparative efficacy of prostate radiotherapy and androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: an integrated network and reconstructed patient-level analysis**
W. Chen, Tokyo (JP)

P0148 **Drug-drug interaction between ARPI and statin via CYP3A4 induction: the first real-world report of worsened lipid control**
A.Q. Liu, Hong Kong (HK)

P0149 **Potential for Drug-Drug Interactions with novel ARTAs and concomitant medications: analysis based on the Metastatic Hormone Sensitive Prostate Cancer (MHSPC) patients in the Real-World Evidence (RWE) RECOMMEND study**
A. Bahl, Bristol (GB)

P0150 **Regret After Treatment Decisions in Advanced Prostate Cancer: What Do We Know - a Systematic Review**
R. Birch, London (GB)

P0155 **Results of a prospective, single-center phase-II study on modern androgen deprivation therapy followed by cytoreductive radical prostatectomy in men with de novo metastatic hormone-sensitive prostate cancer (mHSPC)**
A. Heidenreich, Cologne (DE)

P0151 **Implementing the EAU Guidelines Bot in urological tumor boards: a real-world analysis of impact and lessons learned**
A. Romero Crespo, Malaga (ES)

---

**13:40 - 14:15** **Cytoreductive treatment in mHSPC**

P0152 **Evaluation of the feasibility and safety of darolutamide-based triplet therapy combined with cytoreductive prostatectomy in the treatment of metastatic hormone-sensitive prostate cancer**
S. Wang, Nanjing (CN)

P0156 **Effect of cytoreductive radical prostatectomy combined with hormonal therapy in patients with oligometastatic prostate cancer a multicentered prospective non-randomized control study**
L. Xu, Shanghai (CN)

P0157 **Do cytoreductive treatments improve symptomatic adverse local events and urinary patients reported outcome measures in de novo metastatic prostate cancer? Analysis from a phase II randomised study (IP2-ATLANTA)**
S.J. Morris, London (GB)

**Study Group**
IP2-ATLANTA Trial Investigators(London, United Kingdom)

P0158 **Oncological outcomes of high-and low-volume metastatic prostate cancer treated with cytoreductive prostatectomy in a multidisciplinary setting**
G. Reitano, Acireale (IT)

P0159 **Health-Related Quality of Life (HRQOL) following cytoreductive radical prostatectomy in patients with nonregional lymph node metastases**
E. Berg, München (DE)

---

**14:15 - 14:30** **Metastasis-directed radiotherapy in mHSPC**

P0162 **Oncological Outcomes Following Prostate Specific Membrane Antigen PET/CT-Guided Salvage Whole-Pelvis Radiotherapy for Recurrent Prostate Cancer**
A. Jansen, Amsterdam (NL)

# Refining risk stratification in non–muscle-invasive bladder cancer

EGPT 12

**Friday 13 March**
**13:00 - 14:30**

**Location** Blue Area, EGPT 5

**Chairs**
L.S. Mertens, Amsterdam (NL)
J. Rautiola, Solna (SE)
J.Y.C. Teoh, Hong Kong (HK)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**13:00 - 13:25** **Predisposition to bladder cancer and active surveillance for low-risk non-muscle invasive bladder cancer**

P0199 **Air pollutants, genetic susceptibility, and bladder cancer risk: a prospective study**
L. Jianyong, Shenzhen (CN)

P0200 **Life's Essential 8, genetic susceptibility, and risk of bladder cancer: A prospective cohort study**
W. Liu, Beijing (CN)

P0201 **Guideline Adherence for Hematuria Evaluation in the Real World: Evidence from 1.9 million Patients in Epic COSMOS**
C. Silvani, Milan (IT)

P0202 **Update from the bladder cancer Italian active surveillance (BIAS) project for low-grade bladder tumors: long-term oncological outcomes of patients under active surveillance**
A. Finocchiaro, Catania (IT)

P0203 **Active Surveillance in Recurrent Low-Grade Non–Muscle-Invasive Bladder Cancer: Experience from Our Center**
C. Pujol Sanjuan, Barcelona (ES)

**13:25 - 13:55** **The risk of recurrence in non-muscle invasive bladder cancer**

P0204 **Clinical validation of the International Bladder Cancer Group's intermediate-risk non-muscle-invasive bladder cancer stratification model**
JS Siva, Cleveland (US)

P0205 **Recurrence-free survival after Checklist adoption in non-muscle invasive bladder cancer: insights from a single-center experience**
A. Occhi, (IT)

P0206 **Homogeneity of EAU Intermediate Risk group : a multicenter external validation. Retrospective multicentric analysis on behalf of Young Academic Urologist : Urothelial Cancer Working Group**
F. Colucci, Torino (IT)

P0207 **RECURxNCE-BCa, an artificial intelligence-based tool to predict recurrence in non-muscle invasive bladder cancer using the WHO 2004/2022 grading system**
J. Kwong, Toronto (CA)

P0208 **Multi-Institutional External Validation of the European Risk Classification for High-Grade Ta Non–Muscle-Invasive Bladder Cancer**
M. Cournède, Amiens (FR)

P0209 **Predictors of Disease Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer Following En Bloc Resection of Bladder Tumour: Insights from The Global ERBT Registry.**
A.L. Pastore, Rome (IT)

**Study Group**
The Global ERBT Registry Working Group(Hong Kong, Hong Kong)

**13:55 - 14:30** **Risk of progression and BCG failure in non-muscle invasive bladder cancer**

P0210 **EAU21 Risk stratification misclassifies prognosis in BCG-treated bladder carcinoma in situ: a multicenter analysis integrating cure fractions and conditional survival estimates**
S. Garach Fernandez, Madrid (ES)

P0211 **Performance of the EAU Risk Classification in Predicting Progression in Primary vs. Recurrent Non-Muscle-Invasive Bladder Cancer: Do We Need New Tools**
M. Longoni, Milan (IT)

P0212 **Refining the Classification of BCG Failure in Non-Muscle-Invasive Bladder Cancer: An Exploration of the IBCG Definitions within an International Multicenter Cohort**
A. Ślusarczyk, Warsaw (PL)

P0213 **Predicting Cancer-Specific Mortality in Non-Muscle-Invasive Bladder Cancer: Comparative Performance of AUA vs EAU Risk Classifications**
A. Santangelo, Milan (IT)

P0214 **Translational Insights from CORE-008 Cohort A- Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk BCG-Naïve Non-Muscle Invasive Bladder Cancer**
T. Bivalacqua, Philadelphia (US)

P0215 **Optimizing Candidates for Repeated TURBT in Non-Muscle-Invasive Bladder Cancer Using Urinary Low-Depth Sequencing: A Prospective Multicenter Study**
X. Yang, Nanjing (CN)

P0216 **Nomogram for Predicting Tumor Persistence at Second-Look TURBT in Non–Muscle-Invasive Bladder Cancer**
M. De Angelis, Milan (IT)

## Policy Office - UK and Ireland's men's health strategy as examples of what can be achieved in other EU countries

Special Session

**Friday 13 March**
**13:15 - 13:45**

**Location** EAU Square

**Chair** H. Van Poppel, Leuven (BE)

**Why a men's health strategy is important, and how urologists can work to achieve that in their own countries or regions**

*Discussants*
P. Baker, Brighton (GB)
E. Rogers, Roscommon (IE)
H. Van Poppel, Leuven (BE)

# Laparoscopy for beginners: From theory to practice

ESU Course 14

**Friday 13 March**
**13:30 - 15:30**

**Location** Red Area, Room 3

**Chair** D. Veneziano, New York (US)

Voting will be available via the EAU26 App or via www.qna.at/eau

**Learning objectives**

Over the past decades laparoscopy has played a major role in the therapeutic options of most urological conditions. Nevertheless, the steep learning curve associated with laparoscopic surgery makes it a challenging technique to master.

The aim of this ESU course is to provide you not only the basics of laparoscopic surgery, but also the tips and tricks to develop your laparoscopic skills.

- Peritoneal access and pneumoperitoneum
- How to choose and use the best laparoscopic instruments
- Indications and contraindications of the laparoscopic approach
- How to prevent and manage complications

Video and lively discussions will aid beginners shortening their learning curve and optimizing the success of their laparoscopic procedures.

**Laparoscopy: Historical perspective**
D. Veneziano, New York (US)

**Basic principles of laparoscopic surgery and pneumoperitoneum**
T.M. Ribeiro De Oliveira, Lisbon (PT)

**Laparoscopic equipment and trocar placement**
D. Veneziano, New York (US)

**Indications for laparoscopic surgery in urology**
T.M. Ribeiro De Oliveira, Lisbon (PT)

**Managing complications in laparoscopic surgery**
D. Veneziano, New York (US)

# Andrological emergencies for the general urologist

ESU Course 13

**Friday 13 March**
**13:30 - 15:30**

**Location** Red Area, Room 12

**Chair** K. Pang, London (GB)

**Learning objectives**

This is a state of the art course focused on the management of andrological emergencies. The faculty consists of experienced international experts from high volume centres which manage andrological emergencies. The primary learning objectives include understanding the diagnostic approaches and both medical and surgical management of common andrological emergencies, with a particular emphasis on step-by-step surgical techniques.

The delegate will gain an understanding of:
• The presentation, assessment and investigation of common andrological emergencies (priapism, testis and penile injury, Fournier's gangrene and prosthetic infections)
• The medical and step-by-step operative techniques

**Introduction**
K. Pang, London (GB)

**Priapism**
K. Pang, London (GB)

**Testicular torsion and trauma**
K. Pang, London (GB)

**Iatrogenic penile injuries including fracture, avulsion and amputation**
G. Fallara, Milan (IT)

**Fournier's gangrene**
K. Pang, London (GB)

**Prosthetic infections**
G. Fallara, Milan (IT)

**Closing remarks, feedback and discussion**
G. Fallara, Milan (IT)
K. Pang, London (GB)

# Kidney stones made simple: A comprehensive update for all urologists

ESU Course 12

**Friday 13 March**
**13:30 - 15:30**

**Location** Red Area, Room 11

**Chair** T.E. Şener, Istanbul (TR)

**Learning objectives**

The aims and objectives of this course is to provide a complete overview of kidney stone treatment to urologists. At the end the participants will be able to learn all the current concepts of kidney stone management. It is targeted to all urologists who commonly deal with kidney stones in their practice. It is a more practice based real life clinical management with more emphasis on common clinical scenarios.

**Welcome and introduction**
T.E. Şener, Istanbul (TR)

**Diagnosis and imaging**
T.E. Şener, Istanbul (TR)

**Medical management made simple**
T.E. Şener, Istanbul (TR)

**Best clinical practice and preventing complications: SWL**
B. Ballesta Martinez, Alicante (ES)

**Best clinical practice ureteroscopy (including scopes, suction, pressure)**
M.A. Corrales Acosta, Clemont Ferrand (FR)

**Lasers (types, pulse modulation, temperature)**
M.A. Corrales Acosta, Clemont Ferrand (FR)

**Best clinical practice puncture/disintegration/exiting and preventing complications: PCNL**
B. Ballesta Martinez, Alicante (ES)

Case discussion **Case discussion and management of index cases**
B. Ballesta Martinez, Alicante (ES)
M.A. Corrales Acosta, Clemont Ferrand (FR)
T.E. Şener, Istanbul (TR)

# 2026 EAU Guidelines update – Trauma, paediatric urology and urethral strictures: What has changed

ESU Course 15

**Friday 13 March**
**13:30 - 16:30**

**Location** Red Area, Room 13

**Chair** M. Waterloos, Ghent (BE)

Voting will be available via the EAU26 App or via www.qna.at/eau

**Learning objectives**

This course highlights some updates in the guidelines on urological trauma, pediatric urology, and urethral strictures.

- Understand how the management of urological trauma is evolving toward increasingly minimally invasive approaches.
- Recognize when, and more importantly when not, to use drug-coated balloon dilatation for urethral strictures.
- Learn practical strategies for managing enuresis, a frequently encountered issue in everyday clinical practice.
- Enhance your knowledge of duplication pathologies in children.

**Welcome and introduction**
M. Waterloos, Ghent (BE)

**Managing urological trauma: Focus on urinary drainage and antibiotic prophylaxis**
C. Ochoa Vargas, Bristol (GB)

**Urological trauma: Can we get even more minimally invasive?**
C. Ochoa Vargas, Bristol (GB)

**Enuresis: Current guidelines and updates**
A. Van Uitert, Nijmegen (NL)

**Duplication pathologies with special focus on ureterocele and ectopic ureter**
A. Van Uitert, Nijmegen (NL)

**Drug-coated balloon dilatation: Current guidelines and expanding indications**
M. Waterloos, Ghent (BE)

**Standard of care in male urethroplasty**
M. Waterloos, Ghent (BE)

# Hands-on Training in PSMA/PET image reading for urologists

HOT PSMA/PET

**Friday 13 March**
**13:30 - 16:30**

**Location** Red Area, Room 2

**Chairs**
V. Kasivisvanathan, London (GB)
F. Sanguedolce, Barcelona (ES)

**Tutors**
D. Köhler, Hamburg (DE)
R. Mei, Bologna (IT)

**Learning objectives**

This course provides training in PSMA-PET imaging for prostate cancer. The unique aspect of this course is that attendees will actually learn to look through the imaging themselves on workstations provided to them. The course aims to help participants understand the role PSMA-PET imaging plays in the management of patients with prostate cancer and how to interpret the images. In particular, the training addresses how prostate PSMA-PET imaging works in the most prevalent clinical scenarios it is indicated, like initial staging and re-staging at recurrence, and the implications that PSMA imaging has in the clinical practice (i.e. in clinical decision making or modifying management of patients). The current limitations and pitfalls of PET imaging will be critically assessed and discussed.

| | |
|---|---|
| **13:30 - 13:35** | **Importance of PSMA-PET imaging to the Urologist and introduction to the course**<br>V. Kasivisvanathan, London (GB) |
| **13:35 - 13:45** | **Overview of PET tracers and radioligands**<br>R. Mei, Bologna (IT) |
| **13:45 - 14:00** | **Principles, limitations and pitfalls of PSMA-PET in Prostate Cancer**<br>D. Köhler, Hamburg (DE) |
| **14:00 - 14:10** | **Current data on PSMA-PET imaging in newly diagnosed prostate cancer**<br>V. Kasivisvanathan, London (GB) |
| **14:10 - 14:20** | **Explanation of PSMA workstation for imaging reading and interpretation**<br>D. Köhler, Hamburg (DE) |
| **14:20 - 15:20** | **View of PSMA/PET images for initial prostate cancer staging & discussion** |
| **15:20 - 15:30** | **Current data on PET imaging in recurrent prostate cancer**<br>F. Sanguedolce, Barcelona (ES) |
| **15:30 - 16:25** | **View of PSMA/PET images for recurrent prostate cancer staging** |
| **16:25 - 16:30** | **Summary and close**<br>F. Sanguedolce, Barcelona (ES) |

# Hands-on Training in Urological Ultrasound

HOT Ultrasound - 1.1

**Friday 13 March**
**13:30 - 16:30**

**Location** Red Area, Room 4

**Chairs**
P. Martino, Bari (IT)
V. Scattoni, Milan (IT)

**Learning objectives**

The Hands-on Training in Urological ultrasound is designed to provide healthcare professionals with a thorough understanding of urology diagnostics. The course blends expert presentations and practical hands-on sessions, offering participants a solid foundation in urological ultrasound examinations.

By the end of this course, participants will be equipped with the necessary baseline training to implement abdominal ultrasound as well as transrectal ultrasound of the prostate as a routine diagnostic tool in daily practice. The training covers urological ultrasound examinations following standardised procedures, accurately identify normal and pathological findings, and confidently conduct assessments of the urinary tract and genital organs, as well as valuable insights and skills that can be immediately applied to enhance patient care and diagnostic accuracy.

| | |
|---|---|
| **13:30 - 13:35** | **Introduction**<br>F. Sanguedolce, Barcelona (ES) |
| **13:35 - 13:40** | **Standard operating procedure for ultrasound examination urinary tract: Kidney and bladder**<br>C.B. Maccagnano, Milan (IT) |
| **13:40 - 13:45** | **Ultrasound of the kidney and bladder: tip and tricks**<br>K.F. Stock, Munich (DE) |
| **13:45 - 13:50** | **Standard operating procedure for ultrasound examination genital organs: Prostate and testis**<br>R. Hubbard, Sheffield (GB) |
| **13:50 - 13:55** | **Ultrasound of prostate and testis: Tips and tricks**<br>T. Loch, Flensburg (DE) |
| **13:55 - 16:25** | **Hands-on Training: Kidney and bladder / Prostate & testis Tutors:**<br>*Tutors*<br>C.L. Dickinson, Surrey (GB)<br>R. Hubbard, Sheffield (GB)<br>T. Loch, Flensburg (DE)<br>C.B. Maccagnano, Milan (IT)<br>P. Martino, Bari (IT)<br>V. Scattoni, Milan (IT)<br>K.F. Stock, Munich (DE) |

**16:25 - 16:30** **Conclusions**
V. Scattoni, Milan (IT)

## Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 1.2

**Friday 13 March**
**13:45 - 14:35**

**Location** Red Area, Room 1

**Coordinator** L.B. Dragoş, Cambridge (GB)

**Tutors** V. Novak, Praha (CZ)
O. Stakhovskyi, Kyiv (UA)

**Learning objectives**
This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

## Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 1.2

**Friday 13 March**
**13:45 - 14:35**

**Location** Red Area, Room 1

**Tutors** A.C. Bouma - Houwert, Amsterdam (NL)
M. Talso, Milan (IT)
S. Yuen, Hong Kong (HK)

**Learning objectives**
This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

# Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 1.2

**Friday 13 March**
**13:45 - 14:35**

**Location** Red Area, Room 1

**Tutors** S. García Barreras, Madrid (ES)
M. Jarzemski, Bydgoszcz (PL)

**Learning objectives**

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 1.2

**Friday 13 March**
**13:45 - 14:35**

**Location** Red Area, Room 1

**Tutor** F. Al Jaafari, Kirkcaldy (GB)

**Learning objectives**

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

# Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 1.2

**Friday 13 March**
**13:45 - 14:35**

**Location** Red Area, Room 1

**Tutors**
M. Goossens, Aalst (BE)
M.C. Klitsch, Vienna (AT)

**Learning objectives**

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 1.2

**Friday 13 March**
**13:45 - 14:35**

**Location** Red Area, Room 1

**Tutors**
I. Kartalas Goumas, Vigevano (IT)
D. Perri, Como (IT)
B.M. Schoensee, Berlin (DE)

**Learning objectives**
This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

# Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 1.2

**Friday 13 March**
**13:45 - 14:35**

**Location** Red Area, Room 1

**Tutors**
M. Paciotti, Rozzano, Milan (IT)
M.E. Rodríguez Socarrás, Madrid (ES)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# UroEvidenceHub ProReg - Getting started with the real-world prostate cancer registry

Special Session

**Friday 13 March**
**14:00 - 15:00**

**Location** EAU Square

**Learning objectives**
Come and find out what is involved in joining the prospective prostate cancer registry. The EAU UroEvidenceHub Team will be on hand to answer questions about how your clinic can contribute to driving new real world evidence to improve outcomes.

**14:00 - 15:00** **Advancing prostate cancer research through prospective data collection**

*Experts*

B. De Meulder, Larajasse (FR)
S. Evans Axelsson, Ystad (SE)
E. Moyse, Brussels (BE)
M.J. Roobol, Rotterdam (NL)

# Sleep deprivation in urology patients

Patient Advocacy Roundtable

**Friday 13 March**
**14:15 - 15:15**

**Location** Red Area, Room 17

**Chair** A. De Santis, Rome (IT)

**Learning objectives**
In this session, participants will examine the often-overlooked connection between urological conditions and sleep deprivation, raising awareness of how nocturia, incontinence, and other urological symptoms can significantly disrupt rest and recovery.

The discussion will explore both the physical and psychological consequences of poor sleep, including its impact on mental health, quality of life, and treatment outcomes. Through shared patient stories and lived experiences, participants will gain valuable insight into how sleep disruption affects daily functioning and emotional wellbeing.

The session will also highlight practical strategies and recommendations to help improve sleep quality among urology patients—ranging from clinical interventions to behavioural and lifestyle approaches—fostering a more holistic and patient-centred model of care.

**14:15 - 14:20** **Welcome & introduction**
A. De Santis, Rome (IT)

**14:20 - 14:30** **Sleep science and practical framework**
H. Selsick, London (GB)

**14:30 - 14:40** **Clinical perspectives: Symptom assessment and management**
T. Kelly, Galway (IE)

| | |
|---|---|
| **14:40 - 14:50** | **Patient perspective: Nocturia, incontinence, and night-time reality**<br>L. Brett, London (GB) |
| **14:50 - 15:00** | **Patient perspective: Overactive bladder and family impact**<br>W. Gough, (GB) |
| **15:00 - 15:15** | **Q&A and closing**<br>A. De Santis, Rome (IT) |

## Infections 2: Predictors of urological infections and outcomes

Abstract Session 04

**Friday 13 March**
**14:45 - 16:15**

**Location** Red Area, Room 14

**Chairs**
G. Bonkat, Basel (CH)
M. Chen, Taipei (TW)
To be confirmed

| | |
|---|---|
| **14:45 - 15:00** | **Genital Infections** |
| A0057 | **Transurethral vs. Suprapubic Catheterization in Acute Bacterial Prostatitis: Clinical Predictors and Outcomes**<br>A.E. Handke, Herne (DE) |
| **15:00 - 15:10** | **Controversies in treatment of infections** |
| A0058 | **Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Nitrofurantoin) for the Treatment of Localised Urinary Tract Infections in Women: A Retrospective, Real-World, Parallel-Group, Multicentre Study**<br>M. Kadihasanoglu, Istanbul (TR) |
| A0059 | **To Treat or Not to Treat? A Systematic Review and Updated Meta-Analysis on the Management of Asymptomatic Bacteriuria**<br>J.A. Shiomi da Cruz, Sao Paulo (BR) |
| **15:10 - 15:20** | **Recurrent UTI's** |
| A0060 | **Recurrent UTI Care in the Real World: Low Guideline Adherence, High Investigation Burden, and Suboptimal Outcomes**<br>V. Bodean, London (GB) |
| A0061 | **A randomized placebo-controlled trial of combined medical treatment A randomized placebo-controlled trial of combined medical treatment for recurrent UTI prevention**<br>L. Spivak, Moscow (RU) |
| **15:20 - 15:30** | **Interstitial Cystitis** |
| A0062 | **Urinary Inflammatory and Oxidative Stress Biomarkers Changes After Intravesical Platelet-Rich Plasma or Botulinum Toxin A Injection in Interstitial Cystitis**<br>Y-H. Jiang, Hualien (TW) |

| | |
|---|---|
| A0063 | **Comparison of Therapeutic Efficacy among Different Bladder Monotherapy and Multimodal Therapy for Patients with Interstitial Cystitis/ Bladder Pain Syndrome**<br>T.H. Huang, Hualien (TW) |
| **15:30 - 16:00** | **Procedure-related infections** |
| A0064 | **Outcomes of single-dose/day vs extended prophylactic antibiotics for endourological surgeries: a randomized controlled study**<br>R. Nayyar, New Delhi (IN) |
| A0065 | **Out- patient cystoscopy and risk of urinary tract infection. A nationwide 5-year cohort study.**<br>L. Lund, Odense (DK) |
| A0066 | **REPLACE or RETAIN? A global look at catheter management in CAUTI**<br>E.C. Schippers, Leiden (NL) |
| A0067 | **Risk factors and adverse outcomes following ureteroscopy for urolithiasis: A nationwide analysis of 90,807 procedures in the English NHS**<br>B. Somani, Southampton (GB) |
| A0068 | **Post-operative complications and morbidity following Ureteroscopy – 12 years of cases from a university teaching hospital**<br>S. Fernandes, Southampton (GB) |
| A0069 | **Saving money while preventing infections: Economic analysis of nurse-led preoperative asymptomatic bacteriuria screening in endourology**<br>A. Affentranger, Luzern (CH) |
| **16:00 - 16:15** | **TRUS biopsy** |
| A0070 | **Ciprofloxacin versus Fosfomycin for Prophylaxis Before Transrectal Prostate Biopsy: A Prospective Comparative Study of Clinical and Microbiological Outcomes**<br>E. Buržinskis, Kaunas (LT) |
| A0071 | **Perioperative antibiotic prophylaxis and infection rates after transperineal prostate biopsy**<br>M. Sandberg, winston-salem (US) |
| A0072 | **Rectal Swab-Based Targeted Prophylactic Antibiotics Reduces Infectious Complications after Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials**<br>I. Tsuboi, Okayama (JP) |

## Renal cell carcinoma: From detection to prediction through novel imaging and biomarkers

Abstract Session 03

**Friday 13 March**
**14:45 - 16:15**

**Location** Blue Area, Victoria 4

**Chairs**
T. Kuusk, London (GB)
E. Roussel, Leuven (BE)
T.T-C. Wei, Taipei City (TW)

| | |
|---|---|
| **14:45 - 15:00** | **Screening** |

A0037 **Trends and Regional Burden of Kidney Cancer in Europe, 1990–2040: An Analysis Based on the Global Burden of Disease Study 2023**
Y. Huang, Wuhan (CN)

A0038 **Prevalence of kidney cancer in attendees for combined lung and kidney cancer screening by CT scanning**
S. Rossi, Cambridge (GB)

A0039 **Cardiovascular Health Scores Predict Incidence and Mortality of Renal cell carcinoma: A Large Cohort Prospective Study**
S. Luo, Beijing (CN)

**15:00 - 15:25** **Risk stratification**

A0040 **A Step Forward in RCC Staging: External Validation of the EAU-Proposed M staging**
A. Bertini, Detroit (US)

A0041 **KURADS (Kidney URologic Assessment Data Score): Leveling Up Prediction of High-Risk RCC in Solid Renal Masses**
G. Musso, Milan (IT)

A0042 **Comparative analysis of EAU-refined staging criteria, 8th Edition AJCC and a novel 5 tier classification of Localized (pT1/pT2) Renal Cell Carcinoma. An International Multicenter Analysis**
C. Saitta, Pieve Emanuele (IT)

A0043 **Radiomics signatures of intratumoral and perirenal adipose regions predict immune microenvironment heterogeneity and prognosis in renal cell carcinoma**
W. Xiao-Hui, Fuzhou (CN)

A0044 **Comprehensive Pathological Analysis of 1,369 Renal Cell Carcinoma Patients Reveals Novel Biomarkers and Establishes a Predictive Model for Clinical Outcomes**
J Qiu, Beijing (CN)

**15:25 - 15:55** **Imaging**

A0045 **Comprehensive evaluation of 68Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear cell renal cell carcinoma patients**
J. Gao, Nanjing (CN)

A0046 **[89Zr]Zr-girentuximab PET/CT in the non-invasive characterization of indeterminate renal lesions: Initial real-world clinical experience**
I. Hübner-Resch, Wien (AT)

A0047 **First-in-human phase I evaluation of [$^{68}$Ga]Ga-OncoCAIX PET/CT in clear cell renal cell carcinoma: Preliminary diagnostic performance, safety and biodistribution**
F. Gelardi, Milan (IT)

A0048 **Impact of 89Zr-girentuximab PET versus conventional imaging on clinical decision-making in patients with indeterminate renal masses (ZIRCON-X)**
K. Goffin, Leuven (BE)

A0049 **Malignancy risk of complex renal cystic masses: Subclassification and histopathologic correlation of Bosniak III cysts**
H.O. Kazan, istanbul (TR)

A0050 **Bosniak IIF Renal Cysts: Natural History and Impact of Lesion Size on Progression**
A. Fernandez-Mardomingo Diaz, Madrid (ES)

**15:55 - 16:15** **Hereditary syndromes**

A0051 **Common VHL mutations and the genotype-phenotype correlation: a retrospective study of 1172 patients with von Hippel-Lindau syndrome in China**
C. Wang, Beijing (CN)

A0052 **Analysis of High-Frequency Mutations and Protein Stability of the VHL Gene in Patients with von Hippel-Lindau Syndrome**
T. Liu, Beijing (CN)

A0053 **Evaluation of Renal Imaging in patients with Birt-Hogg-Dubé Syndrome**
A. Angel, Odense C (DK)

A0054 **Integrated Genomic and Metabolomic Profiling of 60 Patients with Von Hippel–Lindau Syndrome Reveals Key Metabolic Alterations and Predictive Biomarkers of Disease Progression**
Z. Song, Beijing (CN)

## Robotic urinary diversion: Neobladder, ileal conduit and precision techniques in female cystectomy

Video Session 03

**Friday 13 March**
**14:45 - 16:15**

**Location** Blue Area, George 3

**Chairs** To be confirmed
B. Pradère, Toulouse (FR)
O. Rodriguez Faba, Barcelona (ES)

V015 (▢1: 7 min.) **Robotic Partial Cystectomy for Urachal Carcinoma: surgical steps and case series**
M. Ferriero, Rome (IT)

V016 (▢1: 5 min.) **Radical nerve-sparing cystectomy in women: surgical technique preservation of sexual and urinary function**
S. Maggiorelli, Modena (IT)

V017 (▢1: 7 min.) **Female Genital-Sparing Robotic Radical Cystectomy with Robotic Intracorporeal Karolinska Orthotopic Neobladder Reconstruction: Technique and Early Outcomes**
T.B. Yuvaraja, Mumbai (IN)

V018 (▢1: 4 min.) **First Experience with the Hugo™ RAS Robotic LigaSure™ Device During Female Radical Cystectomy: Technical Feasibility and Early Outcomes**
D. Fettucciari, Rome (IT)

V019 (▢1: 7 min.) **Simplifying stoma creation in intracorporeal ileal conduit diversion**
K. Fukuta, tokushima (JP)

V020 (▢1: 6 min.) **Robotic Ileal Conduit Reconstruction: a 10-Step Guide**
S. Maggiorelli, Modena (IT)

V021 (▢1: 8 min.) **Robotic Intracorporeal Urinary Diversion: Technical Insights and Head-to-Head Comparison between Ileal Conduit and Orthotopic Neobladder**
R. Mastroianni, Rome (IT)

V022 (7 min.) **Stentless Totally Intracorporeal “Delta” Neobladder: Perioperative Outcomes and 12-months Urodynamic Evaluation**
F. Tedesco, Rome (IT)

## Redefining urology: Prostate cancer challenges and endourology innovations

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Confederación Americana de Urología (CAU)

**Friday 13 March**
**14:45 - 16:45**

**Location** Orange Area, eURO Auditorium 2

**Chairs** M.J. Ribal Caparros, Barcelona (ES)
H. Zampolli, São Paulo (BR)

**Learning objectives**
This joint EAU–CAU session will provide delegates with up-to-date insights into two challenging fields of urology: prostate cancer and endourology. Participants will explore how biomarkers are shaping precision diagnosis and treatment in localised prostate cancer, review surgical strategies for complex anastomotic strictures, and examine salvage options after radiotherapy failure. The session will also address controversial issues in endourology, including en bloc resection, bilateral RIRS, and complex ureteral stricture management, highlighting innovative solutions and global perspectives.

**14:45 - 14:47** **Welcome and introduction**
H. Zampolli, São Paulo (BR)

**14:47 - 15:41** **Prostate cancer challenges: Precision tools and surgical solutions**

14:47 - 14:57 **Unlocking the future: Biomarkers in localised prostate cancer**
C. Moore, London (GB)

**Surgical challenges: How to tackle anastomotic strictures**

14:57 - 15:05 **Robotic soloution**
R. Cadillo-Chavez, Bayamon (PR)

15:05 - 15:13 **Open approach**
D.E. Andrich, London (GB)

15:13 - 15:19 **Panel discussion**

**When radiotherapy fails: Salvage options that work**

15:19 - 15:24 **HIFU**
M. Emberton, London (GB)

15:24 - 15:29 **Cryotherapy**
E. Barret, Paris (FR)

15:29 - 15:34 **Robotic surgery**
R. Coelho, Sao Paulo (BR)

15:34 - 15:41 **Panel discussion**

**15:41 - 16:41** **Endourology 360°: Resection, RIRS and reconstruction**

**En bloc resection: Always the best choice?**

15:41 - 15:51 **Yes**
A. Breda, Barcelona (ES)

15:51 - 16:01 **No**
M. Pichardo, santo domingo (DO)

**Bilateral RIRS: Double benefit or double trouble?**

16:01 - 16:11 **Yes**
P.N. Contreras, Buenos Aires (AR)

16:11 - 16:21 **No**
A. Sierra Del Rio, Barcelona (ES)

**Complex ureteral strictures: Endo vs. robotic battle**

16:21 - 16:31 **Endourological approach**
E. Liatsikos, Patras (GR)

16:31 - 16:41 **Robotic-assisted reconstruction**
L. Ruiz, Panama (PA)

**16:41 - 16:45** **Take home messages and closing remarks**

*Speaker* M.J. Ribal Caparros, Barcelona (ES)

## Oligometastatic prostate cancer

ESU Course 05

**Friday 13 March**
**14:45 - 16:45**

**Location** Red Area, Room 9

**Chair** T. Maurer, Hamburg (DE)

Voting will be available via the EAU26 App or via www.qna.at/eau

**Learning objectives**

- Provide an introduction to working definition(s), background, and biology of oligometastatic prostate cancer.
- Update the current molecular imaging to provide such a diagnosis.
- Review the potential roles of surgery and/or radiation as metastasis-directed therapy.
- Understand opportunities and challenges in individualising care of the oligometastatic prostate cancer patient.

**Introduction: Oligometastatic prostate cancer as a diagnosis**
T. Maurer, Hamburg (DE)

**Surgery of primary oligometastatic prostate cancer (N1/M1)**
G. Gandaglia, Milan (IT)

**Surgery for recurrent nodal metastasis with updates on molecular/PET imaging**
T. Maurer, Hamburg (DE)

**Radiation in oligometastatic prostate cancer (primary and recurrent) and clinical trial updates**
T. Zilli, Bellinzona (CH)

**Further cases (case illustrations throughout)**

G. Gandaglia, Milan (IT)

T. Maurer, Hamburg (DE)

T. Zilli, Bellinzona (CH)

**Discussion and conclusion**

T. Maurer, Hamburg (DE)

## Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 1.3

**Friday 13 March**
**14:45 - 15:35**

**Location** Red Area, Room 1

**Coordinator** L.B. Dragoş, Cambridge (GB)

**Tutors** To be confirmed

B. Petrut, Cluj Napoca (RO)

**Learning objectives**

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

## Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 1.3

**Friday 13 March**
**14:45 - 15:35**

**Location** Red Area, Room 1

**Tutors** K. Dilen, Heusden-Zolder (BE)

L.M. Vendrell, Ciudad - Mendoza (AR)

**Learning objectives**

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 1.3

**Friday 13 March**
**14:45 - 15:35**

**Location** Red Area, Room 1

**Tutor** I. Schwartzmann, Barcelona (ES)

**Learning objectives**

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

# Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 1.3

**Friday 13 March**
**14:45 - 15:35**

**Location** Red Area, Room 1

**Tutors** L.B. Dragoş, Cambridge (GB)
I. Mykoniatis, Thessaloniki (GR)
M. Talso, Milan (IT)

**Learning objectives**

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

# Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 1.3

**Friday 13 March**
**14:45 - 15:35**

**Location** Red Area, Room 1

**Tutors**
M. Goossens, Aalst (BE)
S.M. Haensel, Rotterdam (NL)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 1.3

**Friday 13 March**
**14:45 - 15:35**

**Location** Red Area, Room 1

**Tutors**
I. Kartalas Goumas, Vigevano (IT)
J.B. Roche, Bordeaux (FR)
B.M. Schoensee, Berlin (DE)

**Learning objectives**
This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

# Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 1.3

**Friday 13 March**
**14:45 - 15:35**

**Location** Red Area, Room 1

**Tutors**
M. Paciotti, Rozzano, Milan (IT)
A. Tuncel, Ankara (TR)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# Urolithiasis: Research - Science for the future

EGPT 17

**Friday 13 March**
**14:45 - 16:15**

**Location** Blue Area, EGPT 5

**Chairs**
S. Howles, High Wycombe (GB)
P. Kallidonis, Patras (GR)
G.H. Zeng, Guangzhou (CN)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**14:45 - 15:20** **Novel therapeutics and targets**

P0291 **Caffeine and its metabolites inhibit calcium oxalate stone formation through the NRF2/HO-1 pathway**
K. Dang, Beijing (CN)

P0292 **Novel marine-derived peptide FWEK prevents calcium oxalate stone formation via Keap1-Nrf2 activation: From computational discovery to in vivo validation**
H. Xu, Suzhou (CN)

P0293 **Finerenone-associated nephrolithiasis risk compared to spironolactone, SGLT2 inhibitors, and ACEi/ARB: Insights from a large TriNetX cohort study**
Z-J. Zhu, Tainan (TW)

P0294 **The Hippo-YAP1/TEAD1-SLC7A5 axis: Uncovering a novel therapeutic target for oxalate-induced renal tubular ferroptosis**
Y. Junyi, Wuhan (CN)

| | |
|---|---|
| P0295 | **Targeting Ferroptosis and Macrophage-to-Myofibroblast Transition in Renal Fibrosis Induced by Urinary Obstruction: Deciphering the Multitarget Therapeutic Effects of A Modified Carbon Dots**<br>W. Wu, Xi'an (CN) |
| P0296 | **High-fat diet exacerbates calcium oxalate crystal-induced kidney injury via inhibiting Echs1-mediated fatty acid metabolism**<br>Y. Chen, Tianjin (CN) |
| P0297 | **Iteratively Designed Multifunctional Carbon Dots Nanoplatform for Targeted Celastrol Delivery and Combination Therapy of Kidney Stones**<br>X. Zhu, Wuhan (CN) |
| **15:20 - 15:55** | **Immunity, inflammation and microenvironment** |
| P0299 | **Temporal Dynamics of Calcium Oxalate Nephrolithiasis and Molecular Responses in a Glyoxylate-Induced Mouse Model**<br>P-H. Lee, Tainan (TW) |
| P0300 | **Mechanism of obesity induced ACSM5 deficiency promoting calcium oxalate induced renal tubular epithelial cell injury**<br>Y. Xiangyang, Shen Zhen (CN) |
| P0302 | **A Bifidobacterium metabolite inhibits kidney stone formation by dampening T cell activation**<br>Y. Yang, Wuhan (CN) |
| P0303 | **The role and mechanism of alternative splicing of PKM2 by RNA binding protein LGALS3 in metabolic reprogramming of renal tubular epithelial cells in renal injury induced by calcium oxalate crystals**<br>F. Cheng, Wuhan (CN) |
| **15:55 - 16:15** | **Biomarkers and risk prediction** |
| P0305 | **Machine learning analysis of plasma proteomics identifies CALCA and STC1 as early biomarkers for urolithiasis**<br>R. Tang, Beijing (CN) |
| P0306 | **A Multi-Omics-Based Predictive Model for Kidney Stone Formation: Integrating Gut Microbial and Metabolic Features with Clinical Parameters**<br>K. Dang, Beijing (CN) |
| P0308 | **Development and Validation of a Predictive Model for Kidney Stone Recurrence: Integrating Gut Multi-Omics and Clinical Profiles**<br>K. Dang, Beijing (CN) |

# Urolithiasis: Stents, strictures and shockwaves

EGPT 14

**Friday 13 March**
**14:45 - 16:15**

**Location** Orange Area, EGPT 2

**Chairs**
K.L.S. Stern, Phoenix (US)
J. Veser, Vienna (AT)
C. Waked, hadat (LB)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**14:45 - 15:10** **Different stent types**

P0235 **Enhancing patient safety through digitalisation: A two-cycle audit of ureteric stent documentation before and after implementation of an online ureteric stent database system**
A. Elmadani, Leicester (GB)

P0236 **Magnetic versus conventional ureteral stents: preliminary evidence of improved patient tolerance and cost efficiency from a randomized trial in an Eastern European tertiary center**
C. Calinoiu Petrino, Bucharest (RO)

P0238 **Prospective, multicenter, non-randomized trial clinical study to evaluate the Uriprene® degradable stent**
K.L.S. Stern, Phoenix (US)

**15:10 - 15:20** **Stent encrustation**

P0240 **The Association of Urinary Metabolites and Indwelling Time with Double J Stent Encrustation**
S. Tekgül, Ankara (TR)

P0241 **Phytotherapeutic prophylaxis to limit biofilm and encrustation on ureteral stents: early results from a randomized, placebo-controlled study**
G.S. Ferrante, San Giuseppe Jato (IT)

**15:20 - 15:45** **Stent symptoms**

P0244 **A prospective randomized controlled trial on comparison of 5 Fr and 6 Fr ureteral stents on stent-related symptoms following ureterorenoscopy**
N. Puliyath, Calicut (IN)

P0245 **Is There a Relationship Between Bladder Neck–Meatus Distance, Intravesical Double-J Stent Length, and Stent-Related Symptoms?**
H. Ben Hadj Alouane, Ariana (TN)

P0246 **Do stent durometer and diameter affect patient outcomes in long-term stented patients?**
B.H. Chew, Vancouver (CA)

**15:45 - 16:00** **Strictures**

P0247 **Ureteral Strictures after Ureteral stones treatment: Insights from a Decade of Real-World Data in EpicCosmos**
F. Tamborino, Chieti (IT)

P0248 **Preoperative prediction of factors associated with impacted ureteral stones and construction of a nomogram model**
S. Xinyu, Zhengzhou (CN)

P0249 **Endoscopic Management of Iatrogenic Ureteral Strictures: Risk Factors for Treatment Failure**
S. Moretto, Paris (FR)

**16:00 - 16:15** **Shockwave Lithotripsy**

P0250 **Risk factors for urinary tract infection after shock wave lithotripsy for urolithiasis: A secondary analysis of the international APPEAL trial**
F. Tondroanamag, Helsinki (FI)

P0251 **Exploring the impact of virtual reality to improve the consent process and provide counselling for patients undergoing shock wave lithotripsy**
S. Bracey, Southampton (GB)

## Robot-assisted Radical Prostatectomy: Outcomes across platforms

EGPT 13

**Friday 13 March**
**14:45 - 16:15**

**Location** Orange Area, EGPT 1

**Chairs** To be confirmed
A.E. Canda, Istanbul (TR)
E. Mazzone, Milan (IT)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**14:45 - 15:10** **HUGO RAS**

P0217 **Multicentre Outcomes of Robot-Assisted Radical Prostatectomy Using the Hugo™ RAS System: Results from a Large Italian Experience**
F. Prata, Rome (IT)

P0218 **Perioperative outcomes in the First Worldwide Obese Cohort Undergoing RARP with the Hugo™ RAS: A Multicenter Series**
A. De Giuseppe, Rome (IT)

P0219 **Robotic Radical Prostatectomy Using the HUGO™ RAS Robotic Surgical System: The First Clinical Experience in Turkiye**
B. Esen, Istanbul (TR)

P0220 **Extraperitoneal robot-assisted radical prostatectomy with the Hugo™ RAS system: 100 consecutive cases 1 year outcomes and learning-curve analysis**
P. Russo, Roma (IT)

P0221 **First Comparative Evidence of Oncological and Functional Outcomes of Retzius-sparing Versus Anterior RARP using Hugo-RAS**
E. Mazzone, Milan (IT)

| | |
|---|---|
| **15:10 - 15:35** | **Single port** |
| P0222 | **Single Port Italian Network (SPIN) RARP: assessing feasibility, safety and early functional outcomes with different reconstructive techniques**<br>D. Amparore, Orbassano (Turin) (IT) |
| P0223 | **Preoperative Predictors of Immediate Urine Continence Following Single Port Transvesical Robotic Radical Prostatectomy**<br>N. Soputro, Cleveland (US) |
| P0224 | **The Impact of Prostate Size on Single Port Robot-Assisted Radical Prostatectomy Surgical Outcomes.**<br>A. Finocchiaro, Catania (IT) |
| P0225 | **Assessing the impact of learning curve on perioperative and pathologic outcomes of single port robotic radical prostatectomy in a center with established multiport robotic program**<br>G. Tuderti, Roma (IT) |
| P0226 | **Early discharge after Robot-assisted Radical Prostatectomy: the impact of Single Port surgery**<br>A. Biasatti, Trieste (IT) |
| **15:35 - 15:50** | **Toumai** |
| P0228 | **Feasibility and safety of robot-assisted radical prostatectomy with the Toumai system: Initial experience from a European robotic referral center**<br>C. Brancelli, Sant'Egidio del Monte Albino (IT) |
| P0229 | **Robotic-Assisted Radical Prostatectomy (RARP) using the Medbot Toumai System : First African experience**<br>A. Ouzzane, Casablanca (MA) |
| **15:50 - 16:00** | **hinotori** |
| P0230 | **Evaluating learning curves and robotic skill transfer from da Vinci® to hinotori™: CUSUM analysis of multi-surgeon learning curves after a complete platform conversion in radical prostatectomy**<br>L. Yu, Singapore (SG) |
| P0231 | **hinotori vs. da Vinci: A Multi-Institutional Study on RARP Outcomes**<br>K. Takahashi, Kobe (JP) |
| **16:00 - 16:15** | **Comparison of different platforms** |
| P0232 | **Single-Boom or Multi-Cart? Surgical times Comparison in Robot-Assisted Radical Prostatectomy: Toumai MT-1000 versus Hugo RAS First Twenty Cases**<br>S.K. Moosavi, Rome (IT) |
| P0233 | **Cost-minimization of Hugo RAS vs Da Vinci Xi in robot-assisted radical prostatectomy: a detailed micro-costing analysis**<br>P. Piazza, Bologna (IT) |
| P0234 | **Comparative experience with three robotic platforms for radical prostatectomy: Da Vinci Xi, Medtronic Hugo™ RAS and Da Vinci Single Port**<br>R. Brime Menendez, Madrid (ES) |

# Advancements in female pelvic medicine and reconstructive surgery

EGPT 16

**Friday 13 March**
**14:45 - 16:15**

**Location** Blue Area, EGPT 4

**Chairs**
E. Fong, Auckland (NZ)
E. Illiano, Terni (IT)
M-A. Perrouin Verbe, Nantes (FR)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**14:45 - 15:15** **Pelvic organ prolapse**

P0271 **Robotic fascia lata sacrocolpopexy : a single center study**
M. Chommeloux, Rennes (FR)

P0272 **Efficacy and safety of robot-assisted sacrocolpopexy for cystocele**
J. Lee, Changwon (KR)

P0273 **Analysis of the Impact of Robot-Assisted Sacrocolpopexy on Lower Urinary Tract Symptoms**
Y. Kimura, Yonago (JP)

P0274 **Can colpocleisis with continuous innovative barbed suture decrease urinary complications after masculinizing genital gender affirmation surgery?**
S. Pusica, Belgrade (RS)

**15:15 - 15:30** **Chronic pelvic pain**

P0277 **Accuracy, readability, and understandability of EAU guidelines bot for female LUTS.**
G. Malavasi, Roma (IT)

**15:30 - 15:40** **Urodynamics**

P0280 **Sympathetic–parasympathetic interactions and urodynamic patterns in women with OAB**
M. Ivanov, Chisinau (MD)

P0281 **Are urodynamic parameters associated with pain during outpatient intravesical botulinum toxin instillation in women with overactive bladder?**
M. Alonso Grandes, Fuenlabrada (ES)

**15:40 - 16:00** **Basic science in female LUTs**

P0282 **Sex differences in cardiovascular and metabolic correlates of nocturnal polyuria: Insights from the EpiNP study**
L. Van de Steen, Sint-Andries (BE)

P0285 **Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treating Overactive Bladder: A Prospective Mechanistic Study Integrating Advanced Neuroimaging and Clinical Assessments**
X. Yang, Guangzhou (CN)

**16:00 - 16:15** **Surgical treatments**

P0286 **Cumulative Social Disadvantage and Risk of Overactive Bladder: A National Cross-Sectional Study with Machine Learning and Mediation Analysis**
W. Lin, Guangzhou (CN)

P0287 **Functional outcomes of robot-assisted artificial urinary sphincter (rAUS) implantation in women**
M. Moriconi, Rome (IT)

P0288 **Factors Affecting Success in Laparoscopic Transperitoneal Vesicovaginal Fistula Repair: A Retrospective Study from a Tertiary care centre from Eastern India.**
S. Singh, Patna (IN)

## Minimally-invasive surgery in localised renal tumour

EGPT 15

**Friday 13 March**
**14:45 - 16:15**

**Location** Orange Area, EGPT 3

**Chairs**
J-C. Bernhard, Bordeaux (FR)
M. Tran, London (GB)
A. Tursunkulov, Tashkent (UZ)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**14:45 - 15:00** **Predictors of surgical complexity & quality of life**

P0253 **Correlation between Mayo Adhesive Probability score (MAP) and surgical outcomes in robot-assisted partial nephrectomy.**
M. Nicolazzini, Novara (IT)

P0254 **The negligible role of Mayo Adhesive Probability (MAP) Score on Surgical Outcomes of off-clamp Robotic Partial Nephrectomy**
E. Bologna, Rome (IT)

P0255 **Longitudinal assessment of health-related quality of life after renal tumour surgery: Combined impact of surgical technique and access**
I. Kuliniec, Lublin (PL)

**15:00 - 15:25** **Surgical nuances in minimally invasive treatment**

P0256 **Three-Dimensional Laparoscopic Partial Nephrectomy for Hilar versus Non-Hilar Tumors: Outcomes from a Large Contemporary Series**
M. Karavitakis, Pagkrati - Athens (GR)

P0257 **Transperitoneal versus retroperitoneal approach does not alter arterial clamping strategy during robot-assisted partial nephrectomy: interim results from the PODRACING trial**
J. Vangeneugden, Ghent (BE)

P0258 **Feasibility, Perioperative and Pain Outcomes of Low-Pressure Robot-Assisted Partial Nephrectomy: Results from the Randomized P-NeLoP Trial (UroCCR 85)**
G. Margue, Bordeaux (FR)

| | |
|---|---|
| P0260 | **Robot-Assisted Partial Nephrectomy for Polar Renal Masses Using the Hugo™ RAS System: Comparative Outcomes and Technical Insights from a Novel Upper-Pole Configuration**<br>F. Prata, Rome (IT) |
| **15:25 - 15:55** | **New surgical approaches** |
| P0261 | **Impact of 3D Virtual Models on trifecta rates during Laparoscopic Partial Nephrectomy for Complex Renal Masses (PADUA ≥9)**<br>A. Pecoraro, Peschiera del garda VR (IT) |
| P0262 | **Virtual Reality–Derived Anatomical Intelligence: A paradigm shift in enhancing Predictive Precision and Operative Outcomes in Partial Nephrectomy**<br>T. Sriskandaraja, Chennai (IN) |
| P0263 | **Feedback on the implementation of image-guided robot-assisted partial nephrectomy (3D-IGRAPN) over a 7-year period (UroCCR-186)**<br>A. Pitout, Nancy (FR) |
| P0264 | **Transabdominal lumbar approach (TALA) shows advantages over the retroperitoneal approach in robot-assisted renal surgery: First randomised controlled trial (PIONEER-OPTICS)**<br>L. Hefermehl, Baden (CH) |
| P0266 | **Robot-Assisted Partial Nephrectomy with the Hugo™ RAS System versus the Da Vinci® Platform: Updated Propensity Score-Matched Comparison after Learning Curve Consolidation**<br>F. Prata, Rome (IT) |
| **15:55 - 16:10** | **Suture vs sutureless RAPN** |
| P0268 | **Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy**<br>A.Y. Lazarovich, Edmonton (CA) |
| P0269 | **Cost comparison between sutureless and renorrhaphy off-clamp robotic partial nephrectomy: results from a single-center randomized controlled trial**<br>A. Brassetti, Rome (IT) |
| P0270 | **Single-port retroperitoneal lower anterior Robotic partial nephrectomy: impact of surgical access on intraoperative anesthesiologic parameters**<br>G. Tuderti, Roma (IT) |

## APCCC meets EAU

Thematic Session

**Friday 13 March**
**15:15 - 16:45**

**Location** Orange Area, Room 3

**Chairs**
S. Gillessen Sommer, Bellinzona (CH)
B. Tombal, Brussels (BE)

**Learning objectives**
Learn about the new options/data in high risk non metastatic disease. Learn about the new data in the metastatic hormone sensitive disease setting. Understand the factors to take into account for chosing the optimal treatment for an individual patient.

| | |
|---|---|
| **15:15 - 15:20** | **Introduction**<br>S. Gillessen Sommer, Bellinzona (CH) |
| **15:20 - 15:25** | Case presentation & voting **Patient with high-risk nmHSPC**<br>D. Cannoletta, Milan (IT) |
| **15:25 - 15:35** | **Presentation of APCCC 2024/2025 results on high-risk nmHSPC & Voting**<br>A. Omlin, Zürich (CH) |
| **15:35 - 15:43** | **Update on high-risk nmHSPC**<br>I. Heidegger, Innsbruck (AT) |
| **15:43 - 15:51** | **Macroscopic local relapse after RP in the context of high-risk nmHSPC**<br>C. Parker, London (GB) |
| **15:51 - 16:01** | Panel discussion & voting **What is the best treatment for patients with high-risk biochemical relapse**<br>*Panel*<br>D. Cannoletta, Milan (IT)<br>I. Heidegger, Innsbruck (AT)<br>A. Omlin, Zürich (CH)<br>C. Parker, London (GB) |
| **16:01 - 16:06** | Case presentation & voting **Patient with synchronous high-volume mHSPC**<br>B. Tombal, Brussels (BE) |
| **16:06 - 16:16** | **Presentation of APCCC 2024/2025 results on synchronous high-volume mHSPC & Voting**<br>F. Turco, Bellinzona (CH) |
| **16:16 - 16:24** | **News in the mHSPC setting, PARP inhibitors and more**<br>K. Fizazi, Villejuif (FR) |
| **16:24 - 16:32** | **What do you need for decision making in mHSPC in 2026?**<br>B. Tombal, Brussels (BE) |
| **16:32 - 16:42** | Panel discussion & voting **Which triplet therapy to give to whom in 2026?**<br>*Panel*<br>K. Fizazi, Villejuif (FR)<br>B. Tombal, Brussels (BE)<br>F. Turco, Bellinzona (CH) |
| **16:42 - 16:45** | **Closing remarks**<br>S. Gillessen Sommer, Bellinzona (CH) |

# Surgery in Motion: Urethral stricture unplugged - Innovative surgical options

Thematic Session

**Friday 13 March**
**15:15 - 16:15**

**Location** Blue Area, Victoria 2

**Chairs**
R. De Groote, Aalst (BE)
M. Fisch, Hamburg (DE)

**Learning objectives**
Learn how to deal with urethral strictures on different levels, of different lengths and in different kind of patients. Experts will guide you through the options of diagnostic work-up and therapeutic management.

| | |
|---|---|
| **15:23 - 15:27** | **Discussion** |
| **15:27 - 15:35** | Semi-live video **Ventral vs. dorsal approach in buccal mucosa graft urethroplasty**<br>E.M.F. Palminteri, Arezzo (IT) |
| **15:35 - 15:39** | **Discussion** |
| **15:39 - 15:47** | Semi-live video **Posterior urethral stricture management**<br>F.E. Martins, Lisbon (PT) |
| **15:47 - 15:51** | **Discussion** |
| **15:51 - 15:59** | Semi-live video **Urethroplasty in females**<br>D.E. Andrich, London (GB) |
| **15:59 - 16:03** | **Discussion** |
| **16:03 - 16:11** | **Urethral stricture repair in transgender patients**<br>W. Verla, Ghent (BE) |
| **16:11 - 16:15** | **Discussion** |

# Urolithiasis: Laser technology, pressure and temperature

Abstract Session 06

**Friday 13 March**
**15:15 - 16:45**

**Location** Blue Area, Victoria 5

**Chairs**
A. Budía Alba, Valencia (ES)
O.R. Durutovic, Belgrade (RS)
A. Tsaturyan, Yerevan (AM)

| | |
|---|---|
| **15:15 - 15:30** | **Laser efficiency** |
| A0091 | **Energy Efficiency Index (EEI) predicts stone-free outcome after ureteroscopy: pilot analysis of a prospective cohort**<br>V. Tzikoulis, Thessaloniki (GR) |

| | |
|---|---|
| A0092 | **High-peak TFL enables sustained conical cavitation with lower retropulsion in stone lithotripsy: ex vivo ultra-high-speed imaging versus baseline TFL and long-pulse/low-peak Ho:YAG**<br>M.C. Kanne, Berlin (DE) |
| A0093 | **Laser settings: how do they impact on visibility during ureteroscopic laser lithotripsy? A YAU Endourology and PEARLS study**<br>P. Kachlik, Olten (CH) |
| **15:30 - 15:45** | **Lasers - AI** |
| A0094 | **Ex-Vivo and In-Vivo Evaluation of an Automated Target Recognition System for Thulium Fiber Laser Lithotripsy**<br>O. Traxer, Paris (FR) |
| A0095 | **AI-assisted in-vitro assessment of dusting performance with Ho:YAG laser with Magneto technology and direct in-scope suction**<br>A. Cretì, Rome (IT) |
| A0096 | **Initial physician experience with MOSES Raydar™: A bench test to discover the potential of fiber-stone proximity approximation**<br>B. Turney, Oxford (GB) |
| **15:45 - 15:55** | **Laser - Outcomes** |
| A0097 | **Outcomes of utilization of Magneto Ho:YAG in flexible ureterorenoscopy with flexible and navigable suction access sheath (FANS) from Global FLEXOR-F Registry: An EAU- Endourology initiative**<br>S. Yuen, Hong Kong (HK) |
| A0098 | **Flexible Ureteroscopy and Lithotripsy with Pulsed Thulium:YAG Laser: A Multicenter Retrospective Study**<br>C. Gonzalez Gonzalez, Paris (FR) |
| **15:55 - 16:15** | **Lasers - Comparative trials** |
| A0099 | **Comparative Performance of Virtual Basket + Magneto Pulse Modulations Versus Standard Pulse Holmium Laser Lithotripsy for Urinary Stones: A Multicenter Study**<br>M.E. Rodríguez Socarrás, Madrid (ES) |
| A0100 | **High- vs Low-Power Thulium Fiber Laser Ureteroscopic lithotripsy: Results from a Randomised Clinical Trial**<br>M.S.R. Asoy, Bergen (NO) |
| A0101 | **Dual Laser Showdown: Holmium vs. Thulium in Ureterorenolithotripsy: Efficacy and Safety Unveiled**<br>A. Minore, Rome (IT) |
| A0102 | **Laser Analysis for Stone Treatment (LAST): An Ex-Vivo Comparative Study of Magneto Holmium:YAG and Fiber Dust Thulium Fiber Lasers – Primary Effects on Ablation, Retropulsion, Fragmentation, and Heat Generation Using Phantom Urologic Stones**<br>A.V. Luna, Mandaluyong (PH) |
| **16:15 - 16:30** | **Temperature** |
| A0103 | **Preliminary application of intelligent temperature-and pressure-controlled flexible ureteroscope combined with negative pressure suction sheath in holmium laser lithotripsy for upper urinary tract calculi**<br>S. Xinyu, Zhengzhou (CN) |

A0104 **Balancing Heat and Efficiency in Robot-assisted laser lithotripsy: Preliminary Validation of the Laser:Stop Ratio (LS ratio)**
H.Y. Lee, Kaohsiung (TW)

A0105 **Intrarenal temperature during retrograde intrarenal surgery using flexible ureteroscopes with integrated direct in-scope suction: An experimental in-vitro study**
B. Ballesta Martinez, Alicante (ES)

**Study Group**
Young Academic Urologists and EAU Section of Endourology(Arnhem, The Netherlands)

**16:30 - 16:45** **Pressure**

A0106 **Influence of Ureteral Access Sheaths and Irrigation Techniques on Intrarenal Pressure in a Porcine Model**
V. Gauhar, Singapore (SG)

A0107 **A physics-based simulation of intrarenal fluid pressure and flow during suction ureteroscopy**
T. Li, Toronto (CA)

A0108 **Real-Time Intrarenal Pressure (IRP) Monitoring and Intelligent Autoregulation during Flexible Ureterorenoscopy Using an IRP-monitoring Flexible and Navigable Suction Ureteral Access Sheath (FANS) with iMimer™: A Pilot Study**
S. Yuen, Hong Kong (HK)

## High-risk NMIBC: Evolving BCG–immunotherapy strategies and technical advances in TURB

Abstract Session 05

**Friday 13 March**
**15:15 - 16:45**

**Location** Blue Area, George 1

**Chairs**
L. Izquierdo Reyes, Barcelona (ES)
P. Nyirády, Budapest (HU)
R. Seiler-Blarer, Biel (CH)

**15:15 - 15:50** **Novel therapies for BCG unresponsive non-muscle invasive bladder cancer**

A0077 **Building a Synthetic Benchmark for Efficacy Evaluation in BCG-Unresponsive Carcinoma in Situ Trials**
D. Robesti, Milan (IT)

A0073 **Development and Validation of a Model to Predict BCG-Unresponsiveness in High-Grade Non-Muscle-Invasive Bladder Cancer: An International Multicenter Study**
A. Ślusarczyk, Warsaw (PL)

A0074 **Phase 1/2 study of an anti-PD-L1/IL-15 variant fusion protein (SIM0237) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC)**
D-W. Ye, Shanghai (CN)

A0076 **Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ**
G. Kulkarni, Toronto (CA)

A0078 **Omitting Pelvic Lymph Node Dissection during Radical Cystectomy for NMIBC: An Interim Analysis of a Prospective, Multicenter, Randomized Trial**
Q. Lyu, Nanjing (CN)

A0079 **Comparative effectiveness of nogapendekin alfa inbakicept (NAI) +BCG versus other bladder-sparing therapies in BCG-unresponsive NMIBC with CIS ± Ta/T1 papillary disease: an external control arm study (d-uo, Germany)**
C. Doehn, Lübeck (DE)

**Study Group**
d-uo(Berlin, Germany)

A0080 **Durvalumab (D) in combination with bacillus Calmette-Guérin (BCG) induction (I) and maintenance (M) therapy for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): outcomes for patients (pts) aged ≥65 years from POTOMAC**
J. Palou, Barcelona (ES)

---

**15:50 - 16:15** **Technical developments in transurethral resection of the bladder**

A0081 **The Global En Bloc Resection of Bladder Tumour Registry – First Descriptive Analysis on Safety and Technical Feasibility Outcomes.**
T. Yanagisawa, Tokyo (JP)

**Study Group**
The Global ERBT Registry Working Group(Hong Kong, Hong Kong)

A0082 **Translating Visual Benefit to Oncologic Benefit: Blue-Light TURBT Reduces Recurrence in T1 and High-Risk NMIBC**
S. Binti Mohd Rizal, London (GB)

A0083 **The feasibility of treating NMIBC in an outpatient-based setting with local anaesthetic TULA in a TURBT naïve population; an EORTC risk-matched 1 & 5 year recurrence & progression analysis**
K. Yamada, Woking (GB)

A0085 **Single-Center Prospective Study of Transurethral Cystoscopic Bladder Tumor Resection with Ultrasonic Scalpel Under $CO_2$ Pneumovesicum: Report on Technical Feasibility and Preliminary Efficacy**
S. Yang, Beijing (CN)

---

**16:15 - 16:40** **Local and systemic immunotherapy in the treatment of non-muscle invasive bladder cancer**

A0086 **BCG plus mitomycin (BCG+MM) versus BCG-alone as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer (NMIBC): effects on urinary symptoms and other aspects of health-related quality of life (HRQL) in a randomised trial (BCGMM, ANZUP 1301)**
D. Hayne, East Fremantle (AU)

**Study Group**
Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group(Sydney, Australia)

A0087 **Side Effects of Bacillus Calmette-Guérin (BCG) in Intermediate- and High-Risk NMIBC: One-Year Results from the Randomised Controlled NORTH-REG Dwell Time Study**
L. Munk, Aarhus (DK)

A0088 **Bacillus Calmette-Guérin (BCG) with or without Immune Checkpoint Inhibitors in BCG-Naive High-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-Analysis**
M.A. Saad, Rabat (MA)

A0089 **Paradigm 1 - A multi-center Phase 1 Study evaluating the safety and clinical effect of a novel microbial immunotherapeutic (ZH9) in patients with relapsed NMIBC – A first Interim Review**
I. Mahmood, London (GB)

A0090 **Disitamab Vedotin Alone or Combined with PD-1 Inhibitors in High-Risk Non–Muscle-Invasive Bladder Cancer: A Multicenter Real-World Study**
X. Guo, Beijing (CN)

**16:40 - 16:45** **Late-breaking abstract presentation**

LB013 **Extended clinical outcomes of neoadjuvant intravesical mitomycin-c therapy administered immediately prior to transurethral resection of bladder tumor in non-muscle invasive bladder cancer: over 3 years of follow-up data from a randomized phase II trial**
H.K. Seo, Goyang-si, (KR)

## Modern solutions for upper ureteral strictures: Robotic repair, graft substitution and ileal ureter reconstruction

Video Session 04

**Friday 13 March**
**15:15 - 16:45**

**Location** Blue Area, Victoria 6

**Chairs**
J. Heinzelbecker, Marburg (DE)
B. Peyronnet, Rennes (FR)
F. Van Der Aa, Leuven (BE)

V023 (⧉: 8 min.) **Beyond buccal - alternative tissue transfer techniques in upper tract reconstruction**
R.A. Keenan, Dublin 14 (IE)

V024 (⧉: 8 min.) **Upper urinary tract reconstruction for the treatment of ureteral stricture in a duplex collecting system: Our experience**
Y. Huang, Beijing (CN)

V025 (⧉: 8 min.) **Robotic assisted laparoscopic management of upper ureteric strictures**
C. Mallikarjuna, Hyderabad (IN)

V026 (⧉: 5 min.) **Description of surgical techniques for ileal ureter replacement and ileocystoplasty in the treatment of bilateral ureteral stenosis**
Y. Gu, Beijing (CN)

V027 (⧉: 8 min.) **Robot-Assisted Ileal Ureteroplasty for the Treatment of Ureteral Avulsion Caused by Ureteroscopy**
P. Song, Beijing (CN)

V028 (⧉: 6 min.) **Robot-Assisted Buccal Mucosal Graft Ureteroplasty and Pyeloplasty: A Single-Port Series**
L. Santodirocco, Monte Sant'Angelo (IT)

V029 (8 min.)

**Intraoperative Diuretic Drainage Test to Guide Laparoscopic Vascular Hitch vs. Laparoscopic Dismembered Pyeloplasty in UPJO with Crossing Vessels**
P. Kwok, Scarborough (CA)

# Penile cancer: The impact on mental health and intimacy

Patient Advocacy Roundtable

**Friday 13 March**
**15:30 - 16:30**

**Location** Red Area, Room 17

**Chair** R. Cornes, London (GB)

**Learning objectives**
This session will explore the often-overlooked psychological and emotional challenges faced by men with penile cancer throughout diagnosis, treatment, and survivorship. Faculty members will discuss the effects of isolation, changes in body image, and emotional distress, drawing attention to the profound impact these issues have on quality of life.

The discussion will also address the role of intimacy and partner relationships, recognising the shared psychosocial burden experienced by both patients and their partners.

Participants will gain insights into opportunities for improving psychological and psychosexual support pathways in clinical practice and learn how patient and partner perspectives can guide the development of more personalised, holistic models of care.

**15:30 - 15:35**

**Welcome & introduction**
R. Cornes, London (GB)

**15:35 - 15:50**

**Addressing the psychological impact of penile cancer for patients and their partners, from diagnosis through survivorship**

*Panel*

M. Albersen, Leuven (BE)
R. Jackson, (GB)
R. Lagden, BRussels (BE)
P. Meehan, (GB)
J. Osborne, Nottingham (GB)
C. Roumieux, Etterbeek (BE)

**15:50 - 16:05**

**Exploring the psychosexual impact of penile cancer treatment on intimacy and relationships**

*Panel*

M. Albersen, Leuven (BE)
R. Jackson, (GB)
R. Lagden, BRussels (BE)
P. Meehan, (GB)
J. Osborne, Nottingham (GB)
C. Roumieux, Etterbeek (BE)

| | | |
|---|---|---|
| **16:05 - 16:20** | **Embedding psychological and psychosexual support as a core part of penile cancer care and follow-up** | |
| | *Panel* | M. Albersen, Leuven (BE)<br>R. Jackson, (GB)<br>R. Lagden, BRussels (BE)<br>P. Meehan, (GB)<br>J. Osborne, Nottingham (GB)<br>C. Roumieux, Etterbeek (BE) |
| **16:20 - 16:30** | **Q&A and closing**<br>R. Cornes, London (GB) | |

## Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 1.4

**Friday 13 March**
**15:45 - 16:35**

**Location** Red Area, Room 1

**Coordinator** L.B. Dragoş, Cambridge (GB)

**Tutors** G. Bozzini, Como (IT)
B. Petrut, Cluj Napoca (RO)

**Learning objectives**
This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

## Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 1.4

**Friday 13 March**
**15:45 - 16:35**

**Location** Red Area, Room 1

**Tutors**
E.X. Keller, Zürich (CH)
I. Mykoniatis, Thessaloniki (GR)
M. Talso, Milan (IT)

**Learning objectives**
This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

## Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 1.4

**Friday 13 March**
**15:45 - 16:35**

**Location** Red Area, Room 1

**Tutors**
K. Dilen, Heusden-Zolder (BE)
D. Veneziano, New York (US)

**Learning objectives**
The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 1.4

**Friday 13 March**
**15:45 - 16:35**

**Location** Red Area, Room 1

**Tutor** I. Schwartzmann, Barcelona (ES)

**Learning objectives**

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

# Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 1.4

**Friday 13 March**
**15:45 - 16:35**

**Location** Red Area, Room 1

**Tutors** M. Goossens, Aalst (BE)
S.M. Haensel, Rotterdam (NL)

**Learning objectives**

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 1.4

**Friday 13 March**
**15:45 - 16:35**

**Location** Red Area, Room 1

**Tutors**
I. Kartalas Goumas, Vigevano (IT)
J.B. Roche, Bordeaux (FR)
B.M. Schoensee, Berlin (DE)

**Learning objectives**
This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

## Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 1.4

**Friday 13 March**
**15:45 - 16:35**

**Location** Red Area, Room 1

**Tutors**
M. Paciotti, Rozzano, Milan (IT)
A. Tuncel, Ankara (TR)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## EAU Opening Ceremony

Special Session

**Friday 13 March**
**18:00 - 19:30**

**Location** Orange Area, eURO Auditorium 1

| | |
|---|---|
| | **Opening performance** |
| | **Opening address** |
| | **Announcement of the new EAU Honorary Members** |
| | **Presentation of the EAU Willy Gregoir Medal 2026** |
| | **Presentation of the EAU Frans Debruyne Life Time Achievement Award 2026** |
| | **Presentation of the EAU Crystal Matula Award 2026** |
| | **Presentation of the EAU Hans Marberger Award 2026** |
| | **Presentation of the EAU Innovators in Urology Award 2026** |
| | **Presentation of the EAU Ernest Desnos Prize 2026** |
| | **Presentation of the EAU Prostate Cancer Research Award 2026** |
| | **Presentation of the EAU Patient Advocacy Medal of Excellence 2026** |
| | **Closing performance** |

## Lights on urinary retention and underactive bladder in BPO patients

Plenary Session

**Saturday 14 March**
**08:00 - 09:45**

**Location** Orange Area, eURO Auditorium 1

**Chairs** C. De Nunzio, Rome (IT)
K.A.O. Tikkinen, Helsinki (FI)

**Learning objectives**
This session will address the current understanding of underactive bladder (UAB) and acute (AUR) and chronic urinary retention (CUR) in male. Despite the significant impact of UAB and CUR on patients' quality of life, many aspects require further investigation and deeper understanding. The discussion will focus in detail on: pathophysiology; appropriate diagnosis (kidney function evaluation, US, MRI, urodynamics) and the initial management of acute and chronic urinary retention (indwelling catheter vs cystostomy vs intermittent catheterization). Management of patients with UAB and BPO will be evaluated. Experts will engage in debates over paradigmatic clinical cases throughout the session.

| | |
|---|---|
| **08:00 - 08:02** | **Introduction** |
| **08:02 - 08:10** | CAU lecture **The natural history of benign prostatic obstruction**<br>M.S. Gonzalez, Buenos Aires (AR) |
| **08:10 - 08:25** | **Urinary retention - Diagnosis** |
| 08:10 - 08:12 | **Case presentation**<br>M. Creta, Naples (IT) |

08:12 - 08:22 **Panel discussion and voting**

*Moderator* M.A. Averbeck, Porto Alegre (BR)

*Panel* S. Arlandis, Valencia (ES)
S. Biers, Cambridge (GB)
C. Persu, Bucharest (RO)
S. Sinha, Hyderabad (IN)

08:22 - 08:25 Live interview **Take away messages**

*Interviewer* V. Parry, Carterton (GB)

*Speaker* J. Heesakkers, Maastricht (NL)

---

**08:25 - 08:49** Debate **Urinary retention: Initial management**

08:25 - 08:27 **Continuation case: What is most beneficial for the patient?**
M. Creta, Naples (IT)

08:27 - 08:30 **Indwelling catheter**
S. Musco, Florence (IT)

08:30 - 08:33 **Suprapubic catheter**
B.Y. Padilla Fernandez, Zamora (ES)

08:33 - 08:36 **Aseptic intermittent catheterisation**
M-A. Perrouin Verbe, Nantes (FR)

08:36 - 08:46 **Discussion**

08:46 - 08:49 Live interview **Take away messages**

*Interviewer* V. Parry, Carterton (GB)

*Speaker* J. Heesakkers, Maastricht (NL)

---

**08:49 - 08:57** State-of-the-art lecture **Detrusor underactivity and underactive bladder: Definition and clinical implication**
T. Tarcan, Istanbul (TR)

---

**08:57 - 09:13** **How to manage detrusor underactivity before and after BPO surgery**

08:57 - 09:00 **Case presentation**
M. Creta, Naples (IT)

09:00 - 09:10 **Panel discussion and voting**

*Moderator* M. Rieken, Zürich (CH)

*Panel* T. Antunes Lopes, Porto (PT)
M. Drake, London (GB)
S. Gravas, Larissa (GR)

09:10 - 09:13 Live interview **Take away messages**

*Interviewer* V. Parry, Carterton (GB)

*Speaker* J. Heesakkers, Maastricht (NL)

---

**09:13 - 09:35** Debate **BPO surgery: Remove, cook or compress?**

09:13 - 09:18 Video-based presentation **Enucleation or resection**
T.R.W. Herrmann, Frauenfeld (CH)

09:18 - 09:23 Video-based presentation **Ablative MISTs**
S. Secco, Milan (IT)

09:23 - 09:28 Video-based presentation **Temporary stents**
D. Elterman, Toronto (CA)

09:28 - 09:35 **Discussion**

**09:35 - 09:43** State-of-the-art lecture **Should you operate every patient with retention?**
E. Finazzi Agrò, Rome (IT)

**09:43 - 09:45** **Closure**

## Urothelial cancer: Towards integrated therapeutic strategies

Plenary Session

**Saturday 14 March**
**08:00 - 10:00**

**Location** Orange Area, eURO Auditorium 2

**Chairs** L.S. Mertens, Amsterdam (NL)
M. Rouprêt, Paris (FR)

**Learning objectives**
This plenary session will explore the evolving landscape of bladder cancer management, from novel strategies in BCG-naïve and BCG-unresponsive NMIBC to real-world approaches for bladder-sparing in MIBC. Faculty will highlight how de-intensification, new systemic and intravesical combinations, and biomarker-driven decisions such as ctDNA can optimize outcomes. Finally, the session will address emerging standards and sequencing in metastatic UC, with a focus on integrating innovation while preserving patient-centered care.

**08:00 - 08:01** **Welcome and introduction**

**08:01 - 08:14** **Minimally invasive, maximally effective: The new era of NMIBC therapy**

08:01 - 08:09 State-of-the-art lecture **BCG-Naïve NMIBC in 2025: Are we moving beyond BCG alone?**
E.N. Xylinas, Paris (FR)

08:09 - 08:14 State-of-the-art lecture **Treatment de-intensification in NMIBC**
R. Contieri, Naples (IT)

**08:14 - 08:57** Case-based panel discussion **High-risk NMIBC post-BCG failure: Spare the bladder?**

*Moderator* S. Psutka, Seattle (US)

08:14 - 08:17 **Case presentation and voting**
Y. Abu Ghanem, London (GB)

08:17 - 08:22 **Bladder sparing: Trial overview immune checkpoint blockade (combinations)**
T. Bivalacqua, Philadelphia (US)

08:22 - 08:27 **Bladder sparing: Trial overview intravesical gene therapy (combinations)**
Y. Loriot, Villejuif (FR)

08:27 - 08:32 **Bladder sparing: Trial overview other intravesical options**
J.W.F. Catto, Sheffield (GB)

08:32 - 08:37 **Cystectomy is still relevant**
A. Van Der Heijden, Nijmegen (NL)

08:37 - 08:42 **How do cystectomy and bladder sparing compare when we ask patients?**
K. Gessner, Chapel Hill (US)

08:42 - 08:52 **Panel discussion**

*Panel*
Y. Abu Ghanem, London (GB)
T. Bivalacqua, Philadelphia (US)
J.W.F. Catto, Sheffield (GB)
K. Gessner, Chapel Hill (US)
Y. Loriot, Villejuif (FR)
A. Van Der Heijden, Nijmegen (NL)

08:52 - 08:57 **Take-away messages**
S. Psutka, Seattle (US)

---

**08:57 - 09:15** Debate **Beyond the muscle: Redefining MIBC management**

08:57 - 09:00 **Case presenation and voting: Measurable ctDNA after radical cystectomy**
E. Grobet-Jeandin, Geneva (CH)

09:00 - 09:05 **Pro: ctDNA should guide adjuvant decisions**
J. Bjerggaard Jensen, Aarhus (DK)

09:05 - 09:10 **Con: Evidence still lacking for clinical use**
A. Masson-Lecomte, Paris (FR)

09:10 - 09:15 **Rebuttals**

---

**09:15 - 09:23** State-of-the-art lecture **Bladder-sparing in MIBC: The real-world evidence**
J.Y.C. Teoh, Hong Kong (HK)

---

**09:23 - 09:31** State-of-the-art lecture **Who really needs surgery after neo-adjuvant chemotherapy?**
A.R. Zlotta, Toronto (CA)

---

**09:31 - 09:58** Case-based panel discussion **Beyond platinum: Evolving frontlines in mUC**

09:31 - 09:34 **Case presentation and voting: Metastatic UC – patient unfit for platinum**
A. Ślusarczyk, Warsaw (PL)

09:34 - 09:42 **What should be the standard treatment in 2026?**
T. Powles, London (GB)

09:42 - 09:50 **Where do ADCs fit in the sequencing?**
M. Galsky, New York (US)

09:50 - 09:58 **Panel discussion**

*Panel*
M. Galsky, New York (US)
T. Powles, London (GB)
A. Ślusarczyk, Warsaw (PL)

| | |
|---|---|
| **09:58 - 10:00** | **Closure** |

## Artificial Intelligence 1 - Basic

ESU Course 16

**Saturday 14 March**
**08:30 - 10:30**

**Location** Red Area, Room 7

**Chair** P. De Backer, Ghent (BE)

**Learning objectives**

This introductory course provides a clear and practical overview of Artificial Intelligence in urology. Participants will learn key terminology (AI, ML, Deep Learning, GAI, agentic AI, Foundation Models, LLMs) and discover available tools and how to use them effectively — and responsibly — in clinical and research contexts. Through hands-on examples, prompting exercises, and practical cheat sheets, the course encourages participants to explore how AI can be applied in daily work.

**Welcome and session framing**
P. De Backer, Ghent (BE)

**Computer vision applications**
S. Rodler, Kiel (DE)

**LLM applications**
S. Rodler, Kiel (DE)

**Basics of computer vision and LLMs**
P. De Backer, Ghent (BE)

**Practical AI applications today**
S. Rodler, Kiel (DE)

**Vision-language models**
P. De Backer, Ghent (BE)

**Foundation models**
S. Rodler, Kiel (DE)

**Clinical implementation: How AI impacts everyday urology practice**
S. Rodler, Kiel (DE)

**Discussion and wrap-up**
P. De Backer, Ghent (BE)
S. Rodler, Kiel (DE)

# Treatment of localised renal masses: Tips and tricks

ESU Course 21

**Saturday 14 March**
**08:30 - 11:30**

**Location** Red Area, Room 12

**Chair** A. Minervini, Florence (IT)

**Learning objectives**

- Learn tips and tricks for successfully managing challenging cases of localised renal tumours through interactive case discussion
- Become familiar with the current standards of minimally-invasive surgical techniques and ablative therapies for localized renal tumours
- Understand the benefits of robotics and 3D reconstruction for surgical conservative treatment in challenging scenarios through interactive cases and surgical videos
- Review and analyse the patterns and predictors of recurrence in localized RCC through analysis of clinical trial evidence

**Partial nephrectomy: Indications and surgical steps**
M.J. Ribal Caparros, Barcelona (ES)

**Radical Nephrectomy: Indications and surgical steps**
A. Minervini, Florence (IT)

**Ablative treatment: Technologies, indications and results**
M.G. Pitoni, Milan (IT)

**Discussion**

**Surgical treatment in challenging cases and bilateral renal tumours**
A. Minervini, Florence (IT)

**Ablative treatment in challenging cases: Tips and tricks**
M.G. Pitoni, Milan (IT)

**Adjuvant therapy in localised RCC: Patterns and predictors of recurrence and evidences from clinical trials**
M.J. Ribal Caparros, Barcelona (ES)

**Interactive case reports discussion**
A. Minervini, Florence (IT)
M.G. Pitoni, Milan (IT)
M.J. Ribal Caparros, Barcelona (ES)

# Tips and tricks in cystectomy

ESU Course 20

**Saturday 14 March**
**08:30 - 11:30**

**Location** Red Area, Room 11

**Chair** J. Palou, Barcelona (ES)

Voting will be available via the EAU26 App or via www.qna.at/eau

**Learning objectives**

The aim of this course is to describe the surgical technique of radical cystectomy.

There are different approaches for radical surgery depending on the expertise and economical possibilities of the centers, and even there are some differences on the results, it is important to follow some basic principles.

The main differences according to the surgical approach will be described (open, laparoscopic and robotic).

Tips and tricks of each approach will be presented in order to show the most important steps of each procedure, and also according to execute a nerve sparing or and organ spring procedure.

Finally the most common complications will be analysed in order prevent and improve their management.

Objectives:
• Describe the rational to choose an specific urinary diversions
• Describe the main details of the different approaches and treatment anatomy related to nerve sparing, organ sparing, intracorporeal diversion
• Provide tips and tricks to improve the efficacy and results of the operation
• Explain the complications including their prevention and management

**Introduction**
J. Palou, Barcelona (ES)

**Which diversion for which patient?**
J. Palou, Barcelona (ES)

**Open cystectomy in male (nerve and no nerve sparing)**
B. Ali-El-Dein, Mansoura (EG)

**Laparoscopic female cystectomy (organ and non- organ sparing)**
M. Karavitakis, Pagkrati - Athens (GR)

**Robotic intracorporeal ileal conduit and neobladder diversion**
B. Pradère, Toulouse (FR)

**Global tricks to decrease complications**
J. Palou, Barcelona (ES)

# Post surgical infections in urology – prevention and management

ESU Course 17

**Saturday 14 March**
**08:30 - 10:30**

**Location** Red Area, Room 8

**Chair** J. Kranz, Aachen (DE)

**Learning objectives**

This ESU course on post-surgical infections in urology provides a concise, practice-oriented overview of one of the most relevant peri-operative challenges in modern urology. Increasing surgical complexity, ageing patients and antimicrobial resistance all contribute to a rising burden of infections after urological procedures. The course will review current evidence and guideline recommendations on prevention bundles, rational peri-operative antibiotic use and early recognition of complications. Practical case discussions will focus on typical problem scenarios and severe infections such as urosepsis after endourological, prosthetic and reconstructive surgery.

- Risk factors and classification of post-surgical infections after common urological procedures as a basis for prevention
- Evidence-based strategies for peri-operative prophylaxis, infection-prevention bundles and optimisation of high-risk patients
- Diagnostic work-up and stepwise management of post-operative infections, including source control and antimicrobial therapy
- Management of complex situations: prosthetic material, multidrug-resistant pathogens and severe complications such as urosepsis

| | |
|---|---|
| **08:30 - 10:30** | **Welcome and course objectives**<br>J. Kranz, Aachen (DE) |
| **08:30 - 10:30** | **Epidemiology, risk factors and classification of post-surgical infections in urology**<br>J. Kranz, Aachen (DE) |
| **08:30 - 10:30** | **Antibiotic prophylaxis in urological surgery: Guidelines, timing and duration**<br>J. Kranz, Aachen (DE) |
| **08:30 - 10:30** | **Management of early post-operative infections and surgical site infections after common urological procedures**<br>M. Vallée, Poitiers (FR) |
| **08:30 - 10:30** | **Case-based discussion: Severe complications and urosepsis after urological surgery (stones, endourology, prosthetic and reconstructive surgery)**<br>M. Vallée, Poitiers (FR) |
| **08:30 - 10:30** | **Take-home messages and final Q&A**<br>J. Kranz, Aachen (DE)<br>M. Vallée, Poitiers (FR) |

# Enhanced recovery after surgery (ERAS) in urological surgery

ESU Course 18

**Saturday 14 March**
**08:30 - 11:30**

**Location** Red Area, Room 9

**Chair** J. Walz, Marseille (FR)

**Learning objectives**

Enhanced recovery after surgery (ERAS) has become a mainstay in modern surgical management. The aim of this concept is to optimize and standardize perioperative management to reduce the risk of complications, and promote faster recovery and shorter hospital stays. Key elements of ERAS include increasing the use of minimally invasive surgical approaches and standardized clinical pathways starting before surgery and continuing through recovery, as well as a proactive approach to increasing patient mobilization and return to oral nutrition. ERAS is grounded in a multidisciplinary approach to proactively facilitating recovery. The course provides a detailed overview of the current standard ERAS protocols and pathways as well as practical tips on how to get started with an ERAS programme.

**The concept of ERAS**
J. Walz, Marseille (FR)

**The surgical tools**
J.W.F. Catto, Sheffield (GB)

**The organizational tools**
S. Psutka, Seattle (US)

**The anesthesia tools**
J. Walz, Marseille (FR)

**Protocols for endoscopy**
J.W.F. Catto, Sheffield (GB)

**Protocols for nephrectomy**
S. Psutka, Seattle (US)

**Protocols for radical prostatectomy**
J. Walz, Marseille (FR)

**Protocols for cystectomy**
J.W.F. Catto, Sheffield (GB)

**Personalized risk stratification**
S. Psutka, Seattle (US)

**How to get started with ERAS?**
J. Walz, Marseille (FR)

**Questions and answers**

# 2026 EAU Guidelines update - Renal, bladder and prostate cancer: What has changed?

ESU Course 22

**Saturday 14 March**
**08:30 - 11:30**

**Location** Red Area, Room 13

**Chair** J.L. Domínguez Escrig, Valencia (ES)

**Learning objectives**

During the course, recent practice changing alterations in the EAU Guidelines will be discussed. Based on the clinical recommendations, the highlights of the guidelines on prostate, renal and bladder cancer changed in the 2022 updates, will be presented and illustrated by clinical cases. A basic knowledge of the guidelines information is assumed for participating trainees.

**Welcome and introduction**
J.L. Domínguez Escrig, Valencia (ES)

**Update renal cancer: Localised**
A. Bex, London (GB)

**Discussion**

**Update renal cancer: Metastasised**
A. Bex, London (GB)

**Discussion**

**Update bladder cancer: Non-muscle invasive**
J.L. Domínguez Escrig, Valencia (ES)

**Discussion**

**Update bladder cancer: Muscle invasive**
J.L. Domínguez Escrig, Valencia (ES)

**Discussion**

**Update prostate cancer: Localised**
D. Tilki, Hamburg (DE)

**Discussion**

**Update prostate cancer: Metastasised**
D. Tilki, Hamburg (DE)

**Discussion**

# Advanced course on urethral stricture surgery

ESU Course 19

**Saturday 14 March**
**08:30 - 11:30**

**Location** Red Area, Room 10

**Chair** F. Campos Juanatey, Santander (ES)

Voting will be available via the EAU26 App or via www.qna.at/eau

**Learning objectives**

The advanced urethral stricture course will cover the assessment and surgical treatment of strictures of the penile, bulbar and posterior urethra. General principles of assessment and follow-up, oral mucosa harvest and complications will be reviewed with evidence. Techniques of penile, bulbar and full length urethroplasty will be discussed and compared and cases reviewed with audience participation encouraged.

Pelvic fracture urethral injuries will also be discussed together with management techniques. Female urethroplasty will also be discussed and assessed.

Prior knowledge of relevant anatomy and basic endoscopic techniques will be helpful to those attending the course.

**General principles in urethral stricture surgery. Preoperative workup and follow-up. Indications of endourological treatments.**
M.W. Vetterlein, Hamburg (DE)

**Penile urethroplasty. Lichen sclerosus.**
M.W. Vetterlein, Hamburg (DE)

**Bulbar urethroplasty. Grafts, anastomotic and combined techniques, Perineal urethrostomy.**
F. Campos Juanatey, Santander (ES)

**Posterior urethroplasty (pelvic fracture distraction injuries, bladder neck contractures).**
V. Kojovic, Belgrade (RS)

**Female urethroplasty**
F. Campos Juanatey, Santander (ES)

**Discussion / Cases**
F. Campos Juanatey, Santander (ES)
V. Kojovic, Belgrade (RS)
M.W. Vetterlein, Hamburg (DE)

# Paediatric Urology 3: Challenges in diagnosis and treatment

EGPT 19

**Saturday 14 March**
**08:30 - 10:00**

**Location** Orange Area, EGPT 2

**Chairs**
B. Bañuelos Marco, Madrid (ES)
G. Bogaert, Leuven (BE)
S. Tekgül, Ankara (TR)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**08:30 - 08:55** **Hypospadias**

P0330 **Distal urethral plate augmentation with preputial skin graft in long tubularized incised plate urethroplasty for proximal hypospadias repair**
M. Bencic, Belgrade (RS)

P0331 **Integrated Histology and Transcriptomics Identify Novel Fibrotic Targets in Hypospadias**
M. Yu, Shanghai (CN)

**08:55 - 09:15** **Testis**

P0332 **Prospective evaluation of the TWIST score in pediatric testicular torsion**
M.J. Salö, Lund (SE)

P0333 **Diagnostic value of contrast-enhanced MRI in acute scrotum: real-world clinical experience for 20 years at a single institution**
K. Murakami, Kyoto City (JP)

P0334 **WHAT ARE THE IDEAL FETAL PARAMETERS FOR THE TESTICULAR MIGRATION PROCESS TO BE COMPLETED?**
L.A. Favorito, Rio de Janeiro (BR)

P0335 **A Cross-Sectional Study on Gonadal Hormone Levels in Pediatric and Adolescent Patients with Varicocele**
S. Teraoka, Yonago (JP)

**09:15 - 09:40** **DIAGNOSIS**

P0336 **Clinical relevance of postoperative biomarkers in pediatric endourology: Is procalcitonin telling the truth?**
O.C. Ozkan, Istanbul (TR)

P0337 **Analysis of the Association of Pediatric Urinary Stone Composition with Clinical Features and Laboratory Indicators: A 15-Year, Single-Center, Propensity Score-Matched Retrospective Study**
C. Yuan, Chengdu (CN)

P0338 **Immobilisation Hypercalciuria causing calcium phosphate stones is a significant contributor to stone burden in the paediatric population**
E. Edison, London (GB)

P0339 **Prognostic Value of Cystatin C for Chronic Kidney Disease in Pediatric Urologic Malformations**
Y-H. Yang, Taipei (TW)

| | |
|---|---|
| P0340 | **Alteration of microbiome in boys with phimosis with histological proof of Lichen sclerosus – A prospective study**<br>M. Promm, Regensburg (DE) |
| **09:40 - 09:50** | **Social** |
| P0341 | **The impact of socioeconomic deprivation on non-attendance at paediatric urology outpatient clinics**<br>A. Ansari, Birmingham (GB) |
| P0342 | **Multi-center survey on gender preference in pediatric urology: who do parents want when choosing a specialist?**<br>B. Ebner, Zürich (CH) |
| **09:50 - 10:00** | **URETER** |
| P0343 | **Continent vesicostomy with distal ureter in children: Technique and outcomes**<br>M. Bencic, Belgrade (RS) |
| P0344 | **Ureteral dilation is a clinically significant risk factor for urinary tract infections in children with prenatal hydronephrosis**<br>A. Khondker, Toronto (CA) |

# Kidney transplantation: From basics to surgery

EGPT 18

**Saturday 14 March**
**08:30 - 10:00**

**Location** Orange Area, EGPT 1

**Chairs** R. Boissier, Marseille (FR)
To be confirmed
V. Gomez Dos Santos, Madrid (ES)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**08:30 - 08:45** **Basic & translational research**

P0309 **C1q+ Macrophages Drive CD8+ T Cell Exhaustion via the Cr1l/NF-κB/Tox Axis to Promote Kidney Allotransplant Tolerance**
J. Ge, Shanghai (CN)

P0310 **Visceral-to-Subcutaneous Fat Ratio as a Predictor of Chronic Kidney Disease in Living Kidney Donors**
G. Trujillo Martinez, Mexico City (MX)

**08:45 - 09:00** **Oncology & kidney transplantation**

P0312 **Viral infections and tumour-specific mortality after kidney transplantation: distinct CMV and EBV patterns across tumour types and stages**
A. Lopez Abad, Murcia (ES)

P0313 **Distinct Clinicopathological Aggressiveness of Upper Tract Urothelial Carcinoma Compared to Bladder Cancer in Renal Transplant Recipients: A Case-Control Study**
X. Li, Beijing (CN)

P0314 **Renal Cell Carcinoma of the Transplanted Kidney: From Treatment to Origin**
T. Isaev, Moscow (RU)

**09:00 - 09:30** **Outcomes in kidney transplantation**

P0315 **Global Comparison of Kidney Transplantation and Dialysis Outcomes: Mortality and Major Cardiovascular Events from the TriNetX Network**
J.Y. Hsu, Taichung (TW)

P0316 **Risk Factors for Incisional Hernia Following Open Kidney Transplantation: A 10-Year Retrospective Case–Control Study**
J. De la Mata, Bilbao (ES)

P0317 **Outcomes of total extraperitoneal technique on pediatric kidney transplantation**
L.S. Bong, Singapore (SG)

P0318 **Tadalafil Improves Cardiovascular and Renal Outcomes in Kidney Transplant Recipients with Benigh Prostate Hyperplasia or Erectile Dysfunction**
J. Hsu, Taichung (TW)

P0319 **Association of Ureteric Stent Dwell Time and Bladder Catheterization with Post-Transplant Urinary Tract Infections**
O. Boiko, Castro Urdiales (ES)

P0320 **Nomogram for Predicting Graft Outcomes in Deceased Donor Kidney Transplantation from Acute Kidney Injury Donors: Analysis of the Japanese National Registry**
S. Hori, Kashihara (JP)

**09:30 - 09:55** **Ultimate techniques in transplantation**

P0323 **Robot-assisted lumboscopic radical nephrectomy in patients with polycystic kidney disease: a single-center observational study**
S. Duboys Fresney, (FR)

P0324 **RECONSTRUCTIVE SURGERY FOR URETERAL STRICTURES IN RENAL TRANSPLANT PATIENTS: A COMPARATIVE ANALYSIS BETWEEN ROBOTIC AND OPEN SURGERY**
C. Bardella Altarriba, Barcelona (ES)

P0325 **An Evaluation of YouTube Videos on Kidney Xenotransplantation: Educational Content and Quality Assessment**
K. Karimzada, Ankara (TR)

P0326 **A deep learning-based model for multiphase CT image segmentation and single-kidney renal function estimation: A multi-disease multicenter retrospective cohort study**
L. Bao, Guangdong (CN)

## Patient advocacy plaza - The underprivileged patient, shared decision making, and the CLEAR-PC project

Special Session

**Saturday 14 March**
**09:00 - 09:30**

**Location** Patient Advocacy Plaza

**Chairs**
E. Briers, Hasselt (BE)
B. Lumbreras, Alicante (ES)

**Organisation 'Europa UOMO'**
E. Briers, Hasselt (BE)

**CLEAR-PC**
B. Lumbreras, Alicante (ES)

## Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.1

**Saturday 14 March**
**09:00 - 09:50**

**Location** Red Area, Room 1

**Tutors**
M.F. Frascheri, Southampton (GB)
C. Netsch, Hamburg (DE)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.1

**Saturday 14 March**
**09:00 - 09:50**

**Location** Red Area, Room 1

**Tutors**
B. Ballesta Martinez, Alicante (ES)
F. Esperto, Rome (IT)
H. Ismail, Cottbus (DE)

**Learning objectives**
This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

# Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.1

**Saturday 14 March**
**09:00 - 09:50**

**Location** Red Area, Room 1

**Tutors**
S. Erdem, Istanbul (TR)
O. Příman, Prague (CZ)

**Learning objectives**
This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

# Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.1

**Saturday 14 March**
**09:00 - 09:50**

**Location** Red Area, Room 1

**Tutors**
M. Jarzemski, Bydgoszcz (PL)
G. Pini, Como (IT)

**Learning objectives**
The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.1

**Saturday 14 March**
**09:00 - 09:50**

**Location** Red Area, Room 1

**Tutor** N. Barber, Camberley (GB)

**Learning objectives**

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.1

**Saturday 14 March**
**09:00 - 09:50**

**Location** Red Area, Room 1

**Tutors** M.I. Gökce, Ankara (TR)
D. Perri, Como (IT)
T.E. Şener, Istanbul (TR)

**Learning objectives**

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

# Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.1

**Saturday 14 March**
**09:00 - 09:50**

**Location** Red Area, Room 1

**Tutors** A. Papatsoris, Athens (GR)
A. Sousa Castro, Lisboa (PT)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# Hands-on Training in Urodynamics

HOT UDS - 2.1

**Saturday 14 March**
**09:30 - 12:30**

**Location** Red Area, Room 3

**Chair** H. Hashim, Bristol (GB)

**Learning objectives**
This hands-on training course is designed to help participants enhance their knowledge and technical skills in urodynamics, with a strong emphasis on practical, real-world application. Through guided instruction and supervised practice, participants will gain experience in each step of the urodynamic study (UDS) process, including equipment setup, test execution, troubleshooting common technical and clinical issues, and accurate data interpretation. The course aims to build confidence and competence in performing and analyzing urodynamic studies in a clinical setting.

**09:30 - 09:45** **Introducution**
H. Hashim, Bristol (GB)

**09:45 - 11:05** **Hands-on Training: Rotation 1**

09:45 - 11:05 **Setting up**

*Tutor* A. Gammie, Bristol (GB)

09:45 - 11:05 **Running a test**

*Tutor* D.A.W. Janssen, Nijmegen (NL)

**11:05 - 12:25** **Hands-on Training: Rotation 2**

11:05 - 12:25 **Troubleshooting**

*Tutor* L. Thomas, Bristol (GB)

11:05 - 12:25 **Interpretation**

*Tutor* A.A. Sharaf, Scarborough (GB)

**12:25 - 12:30** **Questions and conclusions**
H. Hashim, Bristol (GB)

## Patient advocacy plaza - Engaging patients in research.

Special Session

**Saturday 14 March**
**09:45 - 10:15**

**Location** Patient Advocacy Plaza

**Chair** C. Moore, London (GB)

**EAU guidelines office**
R. Hanly, London (GB)
C. Moore, London (GB)

## Game Changer Session

**Saturday 14 March**
**10:00 - 10:30**

**Location** Orange Area, eURO Auditorium 2

**Chairs** L.S. Mertens, Amsterdam (NL)
M. Rouprêt, Paris (FR)

**Learning objectives**
Contrast perioperative strategies in bladder and kidney cancer. Discuss acceptable toxicity thresholds in curative-intent disease. Identify key unanswered questions shaping next-generation GU oncology trials. Compare combination therapy with prior adjuvant immunotherapy standards. Identify patient populations most likely to benefit from treatment intensification.

**10:00 - 10:15** **Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Pathological and surgical outcomes in KEYNOTE-B15**

*Speaker* Y. Loriot, Villejuif (FR)

*Discussant* A.M. Kamat, Houston (US)

**10:15 - 10:30**

**Adjuvant pembrolizumab (pembro) plus belzutifan (bel) for clear cell renal cell carcinoma (ccRCC): primary and exploratory efficacy outcomes from the phase 3 LITESPARK-022 study**

*Speaker* T. Powles, London (GB)

*Discussant* E. Roussel, Leuven (BE)

## Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.2

**Saturday 14 March**
**10:00 - 10:50**

**Location** Red Area, Room 1

**Tutors**
M.F. Frascheri, Southampton (GB)
C. Netsch, Hamburg (DE)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.2

**Saturday 14 March**
**10:00 - 10:50**

**Location** Red Area, Room 1

**Tutors**
B. Ballesta Martinez, Alicante (ES)
F. Esperto, Rome (IT)
H. Ismail, Cottbus (DE)

**Learning objectives**
This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

# Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.2

**Saturday 14 March**
**10:00 - 10:50**

**Location** Red Area, Room 1

**Tutors**
S. Erdem, Istanbul (TR)
O. Příman, Prague (CZ)

**Learning objectives**

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

# Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.2

**Saturday 14 March**
**10:00 - 10:50**

**Location** Red Area, Room 1

**Tutors** M. Jarzemski, Bydgoszcz (PL)
G. Pini, Como (IT)

**Learning objectives**
The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.2

**Saturday 14 March**
**10:00 - 10:50**

**Location** Red Area, Room 1

**Tutor** N. Barber, Camberley (GB)

**Learning objectives**
The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

## Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.2

**Saturday 14 March**
**10:00 - 10:50**

**Location** Red Area, Room 1

**Tutors**
E.D. Demirkiran, Zonguldak (TR)
M.I. Gökce, Ankara (TR)
D. Perri, Como (IT)

**Learning objectives**
This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

## Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.2

**Saturday 14 March**
**10:00 - 10:50**

**Location** Red Area, Room 1

**Tutors**
A. Papatsoris, Athens (GR)
A. Sousa Castro, Lisboa (PT)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## EAU26 Live Surgery

Special Session

**Saturday 14 March**
**10:15 - 17:45**

**Location** Orange Area, eURO Auditorium 1

**Live Surgery Hospitals**

**University College Hospital at Westmoreland Street**

*Coordinator* R.D. Smith, London (GB)

**Guy's and St Thomas' NHS Foundation Trust**

*Coordinator* B.J. Challacombe, London (GB)

**Royal Free Hospital**

*Coordinator* L. Ajayi, London (GB)

10:15 - 10:15 **London Bridge Hospital, HCA Healthcare UK**

*Coordinator* B.J. Challacombe, London (GB)

---

**10:15 - 10:45** **Part 1**

Channel 1 **Retrograde intrarenal surgery (RIRS)**

*Moderators* A. Sierra Del Rio, Barcelona (ES)
J. Veser, Vienna (AT)

*Surgeon* L.B. Dragoş, Cambridge (GB)

Channel 2 **Semi-live: ECIRS with DualView**

*Moderators* H.U. Jung, Vejle (DK)
V.M. Moreira Guerra Dos Santos Cavadas, Porto (PT)

*Semi-live presenter* O. Angerri Feu, Barcelona (ES)
A.S.K. Kanashiro Azabache, Barcelona (ES)

Channel 3 **En-Bloc EEP**

*Moderators* S. Kutchukian, Poitiers Cedex (FR)
R. Miano, Rome (IT)

*Surgeon* C.M. Scoffone, Turin (IT)

Channel 4 **Radical Prostatectomy with Elipse trial**

*Moderators* C. Berquin, Gent (BE)
R. De Groote, Aalst (BE)

*Surgeon* B.J. Challacombe, London (GB)

---

**10:45 - 11:15** **Part 2**

Channel 1 **T-incisional assisted Early apical release with V-dissection technique for enbloc enucleation (TEV technique)**

*Moderators* A. Madden, Cork (IE)
R. Mallet, Périgueux (FR)

*Surgeon* T. Aho, Cambridge (GB)

**Channel 2** **Semi-live: Flexible Ureteroscopy with pressure-sensor ureteroscope and Smart High-Power Holmium Laser**

| | |
|---|---|
| *Moderators* | E.K. Bres-Niewada, Pruszkow (PL)<br>T.E. Şener, Istanbul (TR) |
| *Semi-live presenter* | O. Wiseman, Cambridge (GB) |

**Channel 3** **Photoselective Vaporisation of the Prostate: A Versatile Approach to Prostate Tissue Reduction**

| | |
|---|---|
| *Moderators* | L.M.I. Jannello, Milan (IT)<br>G. Kamphuis, Amsterdam (NL) |
| *Surgeon* | A. Emara, Basinsgtoke (GB) |

**Channel 4** **Radical Prostatectomy with Elipse trial**

| | |
|---|---|
| *Moderators* | C. Berquin, Gent (BE)<br>R. De Groote, Aalst (BE) |
| *Surgeon* | B.J. Challacombe, London (GB) |

**11:15 - 11:45** **Part 3**

**Channel 1** **ECIRS with thulium fiber laser**

| | |
|---|---|
| *Moderators* | A.C. Bravo Balado, Barcelona (ES)<br>G. Giusti, Milan (IT) |
| *Surgeons* | M.M. Popiolek, Örebro (SE)<br>Ø. Ulvik, Bergen (NO) |

**Channel 2** **Semi-live: Reshaping BPH treatment**

| | |
|---|---|
| *Moderators* | B. Ballesta Martinez, Alicante (ES)<br>S. Doizi, Paris (FR) |
| *Semi-live presenter* | S. Secco, Milan (IT) |

**Channel 3** **Thulium Fiber Laser Enucleation of Prostate**

| | |
|---|---|
| *Moderators* | G. Kamphuis, Amsterdam (NL)<br>F. Zorzi, Trieste (IT) |
| *Surgeon* | J. Romero-Otero, Madrid (ES) |

**Channel 4** **Semi-live: Transcontinental surgery**

| | |
|---|---|
| *Moderators* | S. Nathan, London (GB)<br>P.J. Zondervan, Amsterdam (NL) |
| *Semi-live presenter* | S. Aldousari, Kuwait City (KW) |

**11:45 - 12:15** **Part 4**

**Channel 1** **Semi-live: Flexible ureteroscopy**

| | |
|---|---|
| *Moderators* | S. Ferretti, Modena (IT)<br>W. Gamal, Sohag (EG) |
| *Semi-live presenter* | F. Al Jaafari, Kirkcaldy (GB) |

**Channel 2** **Semi-live: Robotic RIRS with pulse modulation**

*Moderators*
A. Bosio, Torino (IT)
S. Yuen, Hong Kong (HK)

*Semi-live presenter*
S.Y. Cho, Seoul (KR)

**Channel 3** **RIRS with pulse modulation and suction access sheath**

*Moderators*
D. Pérez Fuentes, Sevilla (ES)
L. Villa, Milan (IT)

*Surgeon*
T. Tailly, Ghent (BE)

**Channel 4** **RARP - Telesurgery from London Clinic to St Bernard hospital - Gibraltar**

*Moderators*
S. Nathan, London (GB)
P.J. Zondervan, Amsterdam (NL)

*Surgeon*
P. Dasgupta, London (GB)

**12:15 - 12:45** **Part 5**

**Channel 1** **Semi-live: UTUC endoscopic ablation**

*Moderators*
V. Gauhar, Singapore (SG)
S. Proietti, Milan (IT)

*Semi-live presenter*
J. Baard, Amsterdam (NL)

**Channel 2** **Semi-live: Conservative management of UTUC using pulse modulation technology**

*Moderators*
A. Bosio, Torino (IT)
A. Masson-Lecomte, Paris (FR)

*Semi-live presenter*
A. Territo, Barcelona (ES)

**Channel 2** **Semi-live: En-bloc TURBT with pulse modulation technology**

*Moderators*
E. Altobelli, Groningen (NL)
J.L. Vásquez, Copenhagen (DK)

*Semi-live presenter*
C.M. Cracco, Torino (IT)

**Channel 3** **To dust or to bust? - Pulse modulation does it all!**

*Moderators*
M. Chicaud, Dax (FR)
L. Villa, Milan (IT)

*Surgeon*
L. Ajayi, London (GB)

**Channel 4** **Partial Nephrectomy: Telesurgery from Excel London to ROC Clinic Madrid**

*Moderators*
S. Nathan, London (GB)
P.J. Zondervan, Amsterdam (NL)

*Surgeons*
R. Brime Menendez, Madrid (ES)
G. De Naeyer, Aalst (BE)

**12:45 - 13:15** **Part 6**

**Channel 1** **Part I: The new Kid is EnBloc (HoLEP)**

*Moderators*
G. Bozzini, Como (IT)
C. Persu, Bucharest (RO)

*Surgeon*
F. Gomez Sancha, Madrid (ES)

**Channel 2** **Semi-live: Tm:YAG - the ideal laser for FANS**

*Moderators*
R. Cansino, Madrid (ES)
M.A. Corrales Acosta, Clemont Ferrand (FR)

*Semi-live presenter*
B. Turney, Oxford (GB)

**Channel 2** **Semi-live: Pulsed Tm: YAG - the ideal laser for Mini-PCNL?**

*Moderators*
V.M.J. De Coninck, Brasschaat (BE)
T. Tefik, Istanbul (TR)

*Semi-live presenter*
G. Giusti, Milan (IT)

**Channel 3** **Anatomical Endoscopic Enucleation of the Prostate (AEEP)**

*Moderators*
A. Miernik, Freiburg (DE)
S. Moretto, Paris (FR)

*Surgeon*
T. Nitkunan, Sutton (GB)

**Channel 4** **Semi-live: En-Bloc TUR-BT using photo-dynamic diagnosis**

*Moderators*
L. Candela, Paris (FR)
P. Kallidonis, Patras (GR)

*Semi-live presenter*
L. Lusuardi, Salzburg (AT)

**Channel 4** **Semi-live: BipolEP**

*Moderators*
L.B. Dragoş, Cambridge (GB)
K. Lehrich, Berlin (DE)

*Semi-live presenter*
T.R.W. Herrmann, Frauenfeld (CH)

**13:15 - 13:45** **Part 7**

**Channel 1** **Part II: The new Kid is EnBloc (HoLEP)**

*Moderators*
G. Bozzini, Como (IT)
C. Persu, Bucharest (RO)

*Surgeon*
F. Gomez Sancha, Madrid (ES)

**Channel 1** **Semi-live: RIRS with pulse modulation technology**

*Moderators*
C. Nedbal, Milan (IT)
A. Skolarikos, Athens (GR)

*Semi-live presenter*
B. Somani, Southampton (GB)

**Channel 2** **Semi-live: RIRS with suction and hydrogel clot controlled fragment extraction (Dust-Clot-Aspirate-Clean)**

| | |
|---|---|
| *Moderators* | M.L. Letouche, Tours (FR)<br>J. Veser, Vienna (AT) |
| *Semi-live presenter* | T. Amiel, Munich (DE) |

**Channel 3** **Part I: ECIRS with pulse modulation - Team Work makes the Dream Work**

| | |
|---|---|
| *Moderators* | C.M. Cracco, Torino (IT)<br>M. Talso, Milan (IT) |
| *Surgeons* | O. Angerri Feu, Barcelona (ES)<br>A. Pietropaolo, Southampton (GB) |

**Channel 4** **Semi-live: RIRS assisted with DISS, through a 5.1 Fr working channel**

| | |
|---|---|
| *Moderators* | A. Abdel Karim, Alexandria (EG)<br>C. Netsch, Hamburg (DE) |
| *Semi-live presenter* | B. Ballesta Martinez, Alicante (ES) |

**13:45 - 14:15** **Part 8**

**Channel 1** **Semi-live: Penile Implant Surgery via Peno-scrotal approach**

| | |
|---|---|
| *Moderators* | A. Budía Alba, Valencia (ES)<br>C. Nedbal, Milan (IT) |
| *Semi-live presenter* | M. Hamdan, Amman (JO) |

**Channel 2** **Semi-live: PPD and NBI - When does it add value for your TIRBTs?**

| | |
|---|---|
| *Moderators* | B. Geavlete, Bucharest (RO)<br>M.L. Letouche, Tours (FR) |
| *Semi-live presenter* | H. Burden, Bristol (GB) |

**Channel 3** **Part II: ECIRS with pulse modulation - Team Work makes the Dream Work**

| | |
|---|---|
| *Moderators* | C.M. Cracco, Torino (IT)<br>M. Talso, Milan (IT) |
| *Surgeons* | O. Angerri Feu, Barcelona (ES)<br>A. Pietropaolo, Southampton (GB) |

**Channel 4** **Semi-live: Pulsed Tm: YAG - the ideal laser for organ sparing UTUC treatment?**

| | |
|---|---|
| *Moderators* | A. Abdel Karim, Alexandria (EG)<br>C. Netsch, Hamburg (DE) |
| *Semi-live presenter* | M. Brehmer, Stockholm (SE) |

**Channel 4** **Semi-live: Pulsed Tm: YAG - the ideal laser for enucleation?**

| | |
|---|---|
| *Moderators* | E. Barret, Paris (FR)<br>M. Bultitude, London (GB) |
| *Semi-live presenter* | I. Kartalas Goumas, Vigevano (IT) |

**15:15 - 16:15** **Part 9**

**Channel 1** **Robotic-assisted radical prostatectomy**

| | |
|---|---|
| *Moderators* | G. Basile, London (GB)<br>V. Phé, Paris (FR) |
| *Surgeon* | C. Wagner, Gronau (DE) |

**Channel 2** **Semi-live: Advanced Robotic Y-V Ureteroplasty for Proximal Ureteral Stricture: Integrating Force Feedback, 3D Modeling, and Predictive Analytics**

| | |
|---|---|
| *Moderators* | A. Gallioli, Barcelona (ES)<br>P. Kallidonis, Patras (GR) |
| *Semi-live presenter* | M. Stifelman, Hackensack (US) |

**Channel 3** **Low anterior approach Single Port partial nephroectomy**

| | |
|---|---|
| *Moderators* | J-C. Bernhard, Bordeaux (FR)<br>N.N. Harke, Hannover (DE) |
| *Surgeons* | K. Decaestecker, Gent (BE)<br>R. Nair, London (GB) |

**Channel 4** **Single Port Prostate case**

| | |
|---|---|
| *Moderators* | B.M.C. Rocco, Rome (IT)<br>S. Secco, Milan (IT) |
| *Surgeon* | C. Schwentner, Stuttgart (DE) |

**16:15 - 16:45** **Part 10**

**Channel 1** **Semi-live: First telesurgery programme in Spain**

| | |
|---|---|
| *Moderators* | P. Juárez Del Dago Anaya, Las Palmas de G.C. (ES)<br>G. Shaw, London (GB) |
| *Semi-live presenter* | A. Breda, Barcelona (ES) |

**Channel 2** **Semi-live: Cystectomy**

| | |
|---|---|
| *Moderators* | R. Barod, London (GB)<br>A. Minervini, Florence (IT) |
| *Semi-live presenter* | R. Papalia, Rome (IT) |

**Channel 3** **Nerve sparing radical prostatectomy**

| | |
|---|---|
| *Moderators* | I. Andras, Cluj (RO)<br>J.M. Gaya Sopena, Barcelona (ES) |
| *Surgeon* | A. Haese, Hamburg (DE) |

**Channel 4** **Semi-live: Robotic-assisted radical prostatectomy**

| | |
|---|---|
| *Moderators* | E. Beatrici, Rozzano (IT)<br>A. Noya Mourullo, Las Palmas de Gran Canaria (ES) |
| *Semi-live presenter* | M. Montesi, Roma (IT) |

**16:45 - 17:15** **Part 11**

**Channel 1** **Robotic-assisted radical prostatectomy**

| | |
|---|---|
| *Moderators* | P. Juárez Del Dago Anaya, Las Palmas de G.C. (ES)<br>G. Shaw, London (GB) |
| *Surgeon* | P. Wisz, Warsaw (PL) |

**Channel 2** **Nerve sparing radical prostatectomy RARP**

| | |
|---|---|
| *Moderators* | R. Barod, London (GB)<br>A. Minervini, Florence (IT) |
| *Surgeon* | F. Porpiglia, Turin (IT) |

**Channel 4** **Semi-live: Aquablation Therapy: Advancing a Complete BPH Solution**

| | |
|---|---|
| *Moderators* | E. Beatrici, Rozzano (IT)<br>A. Noya Mourullo, Las Palmas de Gran Canaria (ES) |
| *Semi-live presenter* | N. Barber, Camberley (GB) |

**17:15 - 17:45** **Part 12**

**Channel 1** **Robotic-assisted radical prostatectomy**

| | |
|---|---|
| *Moderators* | P. Juárez Del Dago Anaya, Las Palmas de G.C. (ES)<br>G. Shaw, London (GB) |
| *Surgeon* | P. Wisz, Warsaw (PL) |

**Channel 2** **Nerve sparing radical prostatectomy RARP**

| | |
|---|---|
| *Moderators* | R. Barod, London (GB)<br>A. Minervini, Florence (IT) |
| *Surgeon* | F. Porpiglia, Turin (IT) |

# Urology to the rescue: Reconstruction and diversion beyond boundaries

Thematic Session

**Saturday 14 March**
**10:30 - 12:00**

**Location** Orange Area, Room 3

**Chairs** E.J. Redmond, Cork (IE)
F. Van Der Aa, Leuven (BE)

**Learning objectives**
Discover how to prevent and manage ureteral injuries with real-world cases and expert video demonstrations. Learn when to choose immediate versus delayed repair and what the EAU guidelines recommend. Explore cutting-edge management of urosymphyseal fistulae and osteitis pubis, from conservative to surgical options. See robotic techniques for urinary diversion in benign disease, including ileal conduit, Indiana pouch, and Mitrofanoff. Engage with leading experts in dynamic discussions designed to sharpen your reconstructive skills.

**10:30 - 10:32** **Welcome and introduction**

**10:32 - 11:01** Case-based discussion **Ureteral injury during a gynecological surgical procedure**

10:32 - 10:35 **Case presentation**
A. Bourillon, Rennes (FR)

10:35 - 10:41 Video-based presentation **Immediate repair and how**
N.R. Bhatt, Dublin (IE)

10:41 - 10:47 Video-based presentation **Delayed repair and how**
B. McGuire, Dublin (IE)

10:47 - 10:53 **Prevention, repair, MDT: What do the EAU guidelines say?**
M. Waterloos, Ghent (BE)

10:53 - 11:01 **Panel discussion**

**11:01 - 11:35** Case-based discussion **Management of urosymphyseal fistulae and osteitis pubis**

11:01 - 11:04 **Case presentation**
R. Barratt, London (GB)

11:04 - 11:11 **Non-surgical management**
M. Vallée, Poitiers (FR)

11:11 - 11:18 **Bladder sparing surgical treatment**
B.R. Viers, Rochester (US)

11:18 - 11:28 **Non conservative surgical treatment/urinary diversion**

*Speakers* M. Herteleer, (BE)
S. Joniau, Leuven (BE)

11:28 - 11:35 **Panel discussion**

**11:35 - 11:53** **How I do it: Robotic urinary diversion for benign condition**

11:35 - 11:41 **Robotic ileal conduit**
M-A. Perrouin Verbe, Nantes (FR)

| | |
|---|---|
| 11:41 - 11:47 | **Robotic Indiana pouch**<br>L. Zhao, New York (US) |
| 11:47 - 11:53 | **Robotic Mitrofanoff**<br>B. Peyronnet, Rennes (FR) |
| **11:53 - 12:00** | **Summary and conclusion** |

## EAU Data initiatives

Thematic Session

**Saturday 14 March**
**10:30 - 12:00**

**Location** Blue Area, Victoria 6

**Chairs** P. Cornford, Cork (IE)
J. N'Dow, Aberdeen (GB)

| | |
|---|---|
| **10:30 - 10:38** | **Adapting to innovation: EAU's engagement with big data and real-world evidence**<br>J. N'Dow, Aberdeen (GB) |
| **10:38 - 10:48** | **UroEvidenceHub: Building the evidence ecosystem for smarter urological care**<br>S. Evans Axelsson, Ystad (SE) |
| **10:48 - 10:58** | **Complementing tradition: The role of real-world evidence in modern guideline development**<br>A. Golozar, New York (US) |
| **10:58 - 11:08** | **PIONEER in practice: Changing care through collaboration and data**<br>R. Nicoletti, Florence (IT) |
| **11:08 - 11:18** | **Transforming clinical practice: Bridging rule-based systems and empiric models**<br>P. Cornford, Cork (IE) |
| **11:18 - 11:28** | **Harnessing AI to transform systematic reviews: Faster, smarter, scalable**<br>S. Canfield, Houston (US) |
| **11:28 - 11:38** | **Enhancing guideline dissemination with Chatbots: A digital companion for clinical practice**<br>M.J. Ribal Caparros, Barcelona (ES) |
| **11:38 - 11:48** | **Driving adherence, improving outcomes: The role of IMAGINE in urological care**<br>N.M. Pereira Azevedo, Porto (PT) |
| **11:48 - 11:58** | **How EHDS will support the use of RWE for clinical research and evidence-based decision making**<br>F. Raffaelli, (BE) |
| **11:58 - 12:00** | **Closing remarks**<br>P. Cornford, Cork (IE) |

# Paediatric urology 1: Robotic surgery, technology and treatment of stone disease in children

Abstract Session 07

**Saturday 14 March**
**10:30 - 12:00**

**Location** Blue Area, George 4

**Chairs**
A. Bujons Tur, Barcelona (ES)
M.I Dönmez, Istanbul (TR)
W. Gamal, Sohag (EG)

**10:30 - 11:20** **Stones**

A0109 **Flexible ureterorenoscopy and laser lithotripsy using direct-in-scope-suction (DISS) in the paediatric population – first worldwide pilot study from a tertiary paediatric endourology referral centre**
S. Dassanayake, Reading (GB)

A0110 **Impact of lower pole stone location on outcomes of paediatric flexible ureteroscopy: Results from EAU Endourology multicentre cohort study**
D. Fuligni, Ancona (IT)

A0111 **Efficacy and safety of ureteroscopy in children with lower pole renal stones – a machine learning predictive model from the EAU section of Endourology**
C. Nedbal, Milan (IT)

A0113 **Comparative Effectiveness of Thulium-Fiber and Holmium:YAG Lasers in Pediatric Retrograde Intrarenal Surgery: A Multicenter Study**
A. Bujons Tur, Barcelona (ES)

A0114 **Utilization of Explainable Machine Learning Models in predicting Stone-Free outcome in Pediatric Laser Lithotripsy**
M. Chua, Toronto (CA)

A0116 **Supine Mini Tubeless Percutaneous Nephrolithotomy for management of renal stones in paediatric population: A prospective single-centre experience**
N. Kumar, Patna (IN)

A0117 **Step-by-Step Endoscopic Management of Pediatric Endogenous Simple Renal Cysts with fURS and Needle-Perc PCN**
Q. Hu, Hangzhou (CN)

A0118 **Comparative Outcomes of Vacuum-Assisted Versus Conventional Access Sheaths in Single-Tract Pediatric Supine Mini-PCNL**
A. Sezer, Istanbul (TR)

**11:20 - 12:00** **Laparoscopy & robotic surgery in children**

A0119 **Robotic-assisted laparoscopic oral mucosal graft ureteroplasty for the treatment of long-segment ureteral defects**
Y. Yang, Beijing (CN)

A0121 **Comparative outcomes of laparoscopic and pneumovesicoscopic politano-leadbetter ureteral reimplantation for pediatric vesicoureteral reflux**
Y.M. Shen, Changhua City (TW)

A0122 **Outcomes of infant versus older pediatric robot-assisted laparoscopic pyeloplasty: A single-surgeon experience**
J. Arias, Chicago, Illinois (US)

A0123 **Pediatric robotic-assisted ureteral reconstruction for long-segment strictures associated with UPJO: outcomes from a single-center cohort**
H. Jia, Beijing (CN)

A0124 **Applications and Outcomes of Indocyanine Green-Guided Near-Infrared Fluorescence in Paediatric Urological Surgery: A Systematic Review**
P. Nikolinakos, London (GB)

A0125 **Defining the learning curve for pediatric robotic-assisted laparoscopic ureteral reimplantation**
D. Fu, Chicago, Illinois (US)

A0126 **Trifecta-Based Comparison of Mini-Laparoscopic and Standard Pyeloplasty in the Pediatric Population**
M.N. Mercimek, Samsun (TR)

## Infections 1: From bench to bedside

Abstract Session 09

**Saturday 14 March**
**10:30 - 12:00**

**Location** Blue Area, Victoria 5

**Chairs**
K. Bausch, Basel (CH)
J. Medina Polo, Madrid (ES)
E. Moshokoa, Midrand (ZA)

**10:30 - 10:50** **Antibiotic prophylaxis before urological procedures**

A0133 **Evaluating the Rapid Uropathogen Identifier Lodestar Dx against Standard Culture and Dipstick for Pre-operative screening.**
C. Musabyimana, reading (GB)

A0134 **Adherence to EAU Recommendations Against Antibiotic Prophylaxis Before Cystoscopy: Results from the Impact Assessment of Guidelines Implementation and Education (IMAGINE) Audit of 12,037 Patients Across 29 European Countries**
N.M. Pereira Azevedo, Porto (PT)

A0135 **Optimizing antibiotic stewardship in urodynamic studies through a standardized risk-based prophylaxis protocol**
J.N.J. Azuero Perdomo, Bogotá (CO)

A0136 **UROPRIME (UROlogical Prosthetic Infection Model Evaluation): Development of a European Multicenter Nomogram Predicting Perioperative Infectious Risk in Urological Prosthetic Surgery**
B. Bucca, Rome (IT)

**10:50 - 10:55** **Screening**

A0137 **Urological Exposomics Analysis Platform: Quantifying the Influence of Dynamic Exposomic Profiles Across Life Stages on Urological Health**
S. Qiu, Chengdu (CN)

**10:55 - 11:05** **Urosepsis**

A0139 **Construction and validation of a machine learning-based prediction model for urosepsis**
W. Ke, Shanghai (CN)

| | |
|---|---|
| **11:05 - 11:35** | **Diagnosis** |
| A0140 | **When mpMRI Falls Short: Diagnostic Insights from a LATP Biopsy Cohort**<br>N. Kanwal, Dudley (GB) |
| A0141 | **tNGS is a rapid and accurate detection method for diagnosing urinary tract infections.**<br>G. Wenzhi, beijing (CN) |
| A0143 | **Impact of Sysmex PA-100 AST System for rapid antibiotic susceptibility test in the management of localised cystitis in a Primary Care setting**<br>J. Medina Polo, Madrid (ES) |
| A0145 | **External validation of a mortality prediction score in emphysematous pyelonephritis: A multicentric study from tertiary care centers**<br>A. Sakly, Monastir (TN) |
| **11:35 - 12:00** | **Complicated UTI's** |
| A0146 | **Randomized controlled trials (RCTs) on complicated urinary tract infection (cUTI) show low adherence to the FDA research guidance, high heterogeneity and poor comparability**<br>T.E. Bjerklund Johansen, Oslo (NO) |
| A0147 | **Accurate and rapid turnaround of four hours for the diagnosis of complicated UTIs using metagenomics**<br>R. Ahmad, Hamar (NO) |
| A0148 | **Bringing Metagenomics to the Bedside: Personalized Management of cUTIs for Patient Care**<br>R. Ahmad, Hamar (NO) |
| A0149 | **Efficacy of Vaginal Laser Therapy for Recurrent Cystitis in Postmenopausal Women: First Real-World Clinical Evidence**<br>E. Kasuya, Tokyo (JP) |
| A0150 | **Heterogeneity causes unacceptable risks of bias in studies on new antibiotics and requires abandonment of the concept of complicated urinary tract infection (cUTI)**<br>T.E. Bjerklund Johansen, Oslo (NO) |

## EAU Lab extended abstract presentations: Tumour microenvironment and immune regulation

EAU26 Lab

Abstract session 08

**Saturday 14 March**
**10:30 - 12:00**

**Location** Blue Area, Victoria 4

**Chairs**
L. Bukavina, Cleveland (US)
L. Dyrskjøt, Aarhus (DK)
E.A. Gibb, Vancouver (CA)

| | |
|---|---|
| **10:30 - 11:20** | **Tumour microenvironment and immune regulation** |
| A0128 | **Microbiome Immunogenicity in Bladder Cancer - Associations of Systemic Antibody Repertoires with Treatment Response**<br>A. Suleja, Katowice (PL) |

A0129 **Tumour Microenvironment Analysis by Spatial Transcriptomics in Muscle-Invasive Bladder Cancer to Delineate Therapy Response Biology: Results from the TOMBOLA Trial**
J. Kohler, Kiel (DE)

A0130 **A universal molecular map of bladder cancer: from cell lines in vitro to tumors and back using co-regulatory networks**
G. Marcq, Lille (FR)

A0132 **Cancer-associated fibroblast niche drives tumor growth in non-muscle-invasive bladder cancer**
M. Olislagers, Rotterdam (NL)

A0386 **Transcriptomic subtyping of metastases in renal cell carcinoma reveals distinct tissue-specific molecular niches with differential immunotherapy response: Moving beyond one-size-fits-all molecular tumor classifications**
C. Kalogirou, Würzburg (DE)

**11:20 - 11:27** State-of-the-art lecture **Tumor microenvironment and immune regulation**
*Case presenter* R. Seiler-Blarer, Biel (CH)

**11:27 - 11:30** **Discussion**

## Reconstructive penile and distal urethral surgery: From Peyronie's repair to organ-preserving cancer techniques

Video Session 05

**Saturday 14 March**
**10:30 - 12:00**

**Location** Blue Area, Victoria 1

**Chairs**
P. Anderson, Dudley (GB)
W.G. Lee, London (GB)
I. Mykoniatis, Thessaloniki (GR)

V030 (▢1: 8 min.) **Inflatable Penile Prosthesis Placement & modified Egydio Tunica Expansion Procedure (TEP) for the treatment of severe curvature in Peyronie's disease with concomitant Erectile Dysfunction**
L. Karapanos, Leverkusen (DE)

V031 (▢1: 7 min.) **Outcomes of adult acquired buried penis reconstruction: a multicentre cohort study**
E. Zupo, Turin (IT)

V032 (▢1: 6 min.) **Diode LASER for the management of PeIN in the outpatient setting - a single centre experience**
A.J. Bochinski, Leicester City (GB)

V033 (▢1: 6 min.) **Glansectomy and Neoglans Reconstruction Using a Free Skin Graft**
M.C. Conde Redondo, Valladolid (ES)

V034 (▢1: 8 min.) **Urethroplasty using double-face buccal mucosa grafts for obliterative penile urethral strictures involving the fossa navicularis**
L. Karapanos, Leverkusen (DE)

V035 (5 min.) **Dorso-lateral preputial graft augmentation in panurethral stricture by penile invagination**
F. Chierigo, Milan (IT)

V037 (6 min.) **Organ-preserving surgery and intraoperative lymphoscintigraphy in urethral cancer management.**
D. Yagudaev, RISHON LEZION (IL)

## Frontiers in functional urology: Emerging challenges and innovations

EAU Section of Functional Urology

**Saturday 14 March**
**10:30 - 12:00**

**Location** Blue Area, Victoria 2

**Chairs** S. Arlandis, Valencia (ES)
E. Finazzi Agrò, Rome (IT)

**Learning objectives**
The session will explore some hot topics in functional urology: The role of surgery in this subspecialty and new devices for male incontinence; how to manage voiding dysfunction in female patients and in patients with multiple sclerosis. The aim of this session is to increase the knowledge of the urologists on new technical possibilities and old problems in this subspecialty.

**10:30 - 10:33** **Introduction**
E. Finazzi Agrò, Rome (IT)

**10:33 - 10:43** **Is functional urologist a surgeon? - Differences and sometimes underestimated surgical indications in our subspecialty.**
T.J. Greenwell, London (GB)
J. Ockrim, London (GB)

**10:43 - 10:48** **Discussion**

**10:48 - 11:18** Debate **Female urology: Voiding dysfunction in women**

*Moderators* E. Costantini, Perugia (IT)
S. Mourad, Heliopolis (EG)

10:48 - 10:51 **Clinical case**
N.I. Osman, Sheffield (GB)

10:51 - 10:54 **Is there a role for disobstruction in women?**
B.Y. Padilla Fernandez, Zamora (ES)

10:54 - 10:57 **The role of urodynamics**
T. Tarcan, Istanbul (TR)

10:57 - 11:00 **Which are the good candidates for neuromodulation?**
M.A. Averbeck, Porto Alegre (BR)

11:00 - 11:15 **Debate**
T. Antunes Lopes, Porto (PT)
E. Illiano, Terni (IT)
M.R. Van Balken, Arnhem (NL)

11:15 - 11:18 **Clinical Case: How it ended**
N.I. Osman, Sheffield (GB)

**11:18 - 11:23** **New devices for male incontinence**
E. Chartier-Kastler, Paris (FR)

**11:23 - 11:28** **Discussion**

**11:28 - 11:58** Debate **Neurourology: Challenges in multiple sclerosis patients**

*Moderators* C. Konstantinidis, Athens (GR)
C. Persu, Bucharest (RO)

11:28 - 11:31 **Clinical case**
V. Birkhäuser, Zürich (CH)

11:31 - 11:34 **Coexisting detrusor under and overactivity in multiple sclerosis patients**
N. Mangir Bolat, Ankara (TR)

11:34 - 11:37 **How to manage BPO in MS patients**
T.M. Kessler, Zurich (CH)

11:37 - 11:40 **Sacral or tibial neuromodulation - or..?**
J. Krhut, Ostrava (CZ)

11:40 - 11:55 **Debate**
F. Cruz, Porto (PT)
S. Musco, Florence (IT)
M. Przydacz, Krakow (PL)
K-D. Sievert, Detmold (DE)

11:55 - 11:58 **Clinical case: How it ended…**
V. Birkhäuser, Zürich (CH)

**11:58 - 12:00** **Closing remarks**
E. Finazzi Agrò, Rome (IT)

# Mastering modern urology: Precision, innovation & advanced techniques - A scientific video session

EAU Section of Outpatient and Office Urology

**Saturday 14 March**
**10:30 - 12:00**

**Location** Blue Area, George 3

**Chairs**
M. Benyó, Debrecen (HU)
F. Dimitriadis, Thessaloniki (GR)
Ł. Zapala, Warsaw (PL)

**Learning objectives**
Step into the forefront of urological innovation with ESUO's scientific video session. Experts delve into cutting-edge advancements and refined surgical techniques. Attendees will explore the cultural and medical dimensions of circumcision, the precision of HOLEP for prostate health, and the transformative role of sperm extraction in fertility treatments. The session covers varicocelectomy's impact on vascular health, ureteroscopic lithotripsy's efficiency in stone management, and neuromodulation's effectiveness in treating urinary urgency. Also, attendees will gain insight into vasovasostomy's meticulous approach to restoring fertility post-vasectomy. Elevate your expertise with comprehensive videos and expert insights in modern urology.

| | |
|---|---|
| **10:30 - 10:31** | **Welcome and introduction**<br>F. Dimitriadis, Thessaloniki (GR) |
| **10:31 - 10:40** | **TURED - technique and tips**<br>P. Sangster, London (GB) |
| **10:40 - 10:43** | **Questions, comments and discussion** |
| **10:43 - 10:52** | **HOLEP: Laser enucleation of the prostate**<br>W. Krajewski, Wrocław (PL) |
| **10:52 - 10:55** | **Questions, comments and discussion** |
| **10:55 - 11:19** | **Helmut Haas Session** |
| 10:55 - 11:04 | **Beyond the barrier: Sperm extraction from the vas deferens**<br>N. Sofikitis, Ioannina (GR) |
| 11:04 - 11:07 | **Questions, comments and discussion** |
| 11:07 - 11:16 | **Breaking stones: Ureteroscopic lithotripsy in action**<br>T.H. Kuru, Köln (DE) |
| 11:16 - 11:19 | **Questions, comments and discussion** |
| | **Returning to the general session** |
| **11:19 - 11:28** | **Varicocelectomy: Restoring vascular health for fertility**<br>G. Semini, Tirane (AL) |
| **11:28 - 11:31** | **Questions, comments and discussion** |

| | |
|---|---|
| **11:31 - 11:40** | **Neuromodulation unveiled: Managing urinary urgency with sacral stimulation**<br>T. Piecha, Warsaw (PL) |
| **11:40 - 11:43** | **Questions, comments and discussion** |
| **11:43 - 11:52** | **Vasovasostomy: Reversing vasectomy with precision surgery**<br>M. Benyó, Debrecen (HU)<br>Z. Kopa, Budapest (HU) |
| **11:52 - 11:55** | **Questions, comments and discussion** |
| **11:55 - 12:00** | **Helmut Haas Award** |
| 11:55 - 11:57 | **In memoriam Helmut Haas and presentation of the Helmut Haas award 2026 winner**<br>S.M. Haensel, Rotterdam (NL) |
| 11:57 - 12:00 | **Winner**<br>*Winner* S.T. De Cillis, Turin (IT) |
| **12:00 - 12:00** | **Closing remarks**<br>M. Benyó, Debrecen (HU) |

## From guidelines to grey zones: Hot topics in GU cancers

EAU Section of Oncological Urology

**Saturday 14 March**
**10:30 - 12:00**

**Location** Blue Area, George 1

**Chairs**
G. Giannarini, Udine (IT)
M-O. Grimm, Jena (DE)
A. Volpe, Novara (IT)

**Learning objectives**
This session led by the EAU Oncology Section aims to enhance participants' understanding of complex decision-making in prostate, bladder and penile cancers. Through expert debates and case-based discussions, attendees will explore multidisciplinary approaches, ethical dilemmas, and emerging strategies in imaging, biomarkers and treatment planning. The program emphasizes bridging clinical trials with real-world practice, reducing surgical morbidity, and evaluating bladder-preserving techniques versus radical interventions - all to improve patient-centered care in oncological urology.

| | |
|---|---|
| **10:30 - 10:32** | **Introduction** |
| **10:32 - 10:52** | **Hot topics in prostate cancer** |
| 10:32 - 10:35 | **Nightmare case discussion: How NOT to treat a young man with a locally advanced prostate cancer in the PSMA PET era**<br>G. Marvaso, Milan (IT) |
| 10:35 - 10:39 | **What I would have done: Urologist**<br>G. Ploussard, Toulouse (FR) |

| | |
|---|---|
| 10:39 - 10:43 | **What I would have done: Radiation oncologist**<br>N. Sanmamed, Madrid (ES) |
| 10:43 - 10:47 | **What I would have done: Medical oncologist**<br>C. Mercinelli, Milan (IT) |
| 10:47 - 10:52 | **Discussion and take home messages** |
| **10:52 - 11:12** | **Building bridges between trials and practice in advanced prostate cancer** |
| 10:52 - 11:02 | **Current controversies in mHSPC treatment**<br>E. Castro, Madrid (ES) |
| 11:02 - 11:12 | **Legal and ethical dilemmas: When guidelines clash with real world**<br>J. Gómez Rivas, Madrid (ES) |
| **11:12 - 11:27** | **Hot topics in penile cancer** |
| 11:12 - 11:24 | **Decreasing morbidity of inguinal lymphadenectomy: Where are we?**<br>A. Muneer, London (GB) |
| 11:24 - 11:27 | **Discussion** |
| **11:27 - 11:57** | **Hot topics in muscle invasive bladder cancer** |
| 11:27 - 11:30 | **Case: I want to keep my bladder**<br>E. Mensah, London (GB) |
| | **Radical treatment is still the standard (RC or TMT)** |
| 11:30 - 11:35 | **Con: Let's save the bladder**<br>S. Gupta, Minneapolis (US) |
| 11:35 - 11:40 | **Pro**<br>S. Psutka, Seattle (US) |
| 11:40 - 11:45 | **Discussion - Strategies to safely avoid cystectomy in MIBC** |
| 11:45 - 11:49 | **Role of biomarkers**<br>L. Dyrskjøt, Aarhus (DK) |
| 11:49 - 11:53 | **Role of MRI/imaging**<br>T. Barrett, Cambridge (GB) |
| 11:53 - 11:57 | **Role of endoscopic evaluation**<br>M.C. Mir Maresma, New York (US) |
| **11:57 - 12:00** | **Closing remarks** |

## Patient advocacy plaza - Information on prostate cancer in non-specialized books, periodical publications and newspapers

Special Session

**Saturday 14 March**
**10:30 - 11:00**

**Location** Patient Advocacy Plaza

**Chair** R. Montironi, Ancona (IT)

**Polytechnic University of the Marche Region Italy**
R. Montironi, Ancona (IT)

# Hands-on Training in prostate MRI reading for urologists

HOT MRI - 2.1

**Saturday 14 March**
**10:30 - 14:00**

**Location** Red Area, Room 6

**Learning objectives**

This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on a provided computer using realistic software, followed by a reference reading provided by expert radiologists and pathological verification.

| | |
|---|---|
| **10:30 - 10:35** | **Course overview**<br>V. Kasivisvanathan, London (GB) |
| **10:35 - 10:45** | **Lecture: The importance of prostate MRI to the urologist**<br>L. Budäus, Hamburg (DE) |
| **10:45 - 11:15** | **Lecture: Introduction to MRI sequences, scoring systems, PI-RADS**<br>J.A. Hernández Mancera, Barcelona (ES) |
| **11:15 - 11:45** | **Lecture: Interactive case discussion – reporting MRI using PI-RADS**<br>M. Pecoraro, Rome (IT) |
| **11:45 - 11:50** | **Introduction to the software for MRI interpretation**<br>V. Kasivisvanathan, London (GB) |
| **11:50 - 12:20** | **Diagnosis I: Practical MRI diagnosis** |
| **12:20 - 12:50** | **Review of the findings I**<br>J.A. Hernández Mancera, Barcelona (ES) |
| **12:50 - 13:20** | **Diagnosis II: Practical MRI diagnosis** |
| **13:20 - 13:50** | **Review of the findings II**<br>M. Pecoraro, Rome (IT) |
| **13:50 - 14:00** | **Discussion, feedback & closure**<br>L. Budäus, Hamburg (DE) |

# Hands-on Training in Urological Ultrasound

HOT Ultrasound - 2.1

**Saturday 14 March**
**10:30 - 13:30**

**Location** Red Area, Room 4

**Chairs**
P. Martino, Bari (IT)
V. Scattoni, Milan (IT)

**Learning objectives**

The Hands-on Training in Urological ultrasound is designed to provide healthcare professionals with a thorough understanding of urology diagnostics. The course blends expert presentations and practical hands-on sessions, offering participants a solid foundation in urological ultrasound examinations.

By the end of this course, participants will be equipped with the necessary baseline training to implement abdominal ultrasound as well as transrectal ultrasound of the prostate as a routine diagnostic tool in daily practice. The training covers urological ultrasound examinations following standardised procedures, accurately identify normal and pathological findings, and confidently conduct assessments of the urinary tract and genital organs, as well as valuable insights and skills that can be immediately applied to enhance patient care and diagnostic accuracy.

| | |
|---|---|
| **10:30 - 10:35** | **Introduction**<br>P. Martino, Bari (IT) |
| **10:35 - 10:40** | **Standard operating procedure for ultrasound examination urinary tract: Kidney and bladder**<br>C.B. Maccagnano, Milan (IT) |
| **10:40 - 10:45** | **Ultrasound of the kidney and bladder: tip and tricks**<br>K.F. Stock, Munich (DE) |
| **10:45 - 10:50** | **Standard operating procedure for ultrasound examination genital organs: Prostate and testis**<br>R. Hubbard, Sheffield (GB) |
| **10:50 - 10:55** | **Ultrasound of prostate and testis: Tips and tricks**<br>T. Loch, Flensburg (DE) |
| **10:55 - 13:25** | **Hands-on Training: Kidney and bladder / Prostate & testis**<br>*Tutors*<br>C.L. Dickinson, Surrey (GB)<br>R. Hubbard, Sheffield (GB)<br>T. Loch, Flensburg (DE)<br>C.B. Maccagnano, Milan (IT)<br>P. Martino, Bari (IT)<br>V. Scattoni, Milan (IT)<br>K.F. Stock, Munich (DE) |
| **13:25 - 13:30** | **Conclusions**<br>V. Scattoni, Milan (IT) |

# Setting standards for localised & locally-advanced renal tumour treatment

EGPT 22

**Saturday 14 March**
**10:30 - 12:00**

**Location** Orange Area, EGPT 3

**Chairs** M. Hora, Plzen (CZ)
G. Margue, Bordeaux (FR)
To be confirmed

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**10:30 - 10:55** **Local treatment outcomes**

P0381 **The impact of Area Deprivation Index on treatment selection for Small Renal Masses. A state-wide analysis**
A. Santangelo, Milan (IT)

P0382 **16 years of DISSRM experience elucidate the relationship in using both tumor size and growth rate for clinical decisions in patients with small renal masses**
K. Alkhatib, Philadelphia (US)

P0383 **Aggressive pathologic features and recurrence risk in small renal masses up to 2 centimetres**
L. Salerno, Milan (IT)

P0384 **The current landscape of robotic surgery in patients with cT1 renal masses: a collaborative analysis from the EAU-YAU RCC and US-KIDNET collaborative**
L. Lambertini, Florence (IT)

P0385 **Simple nephrectomy is not always simple – comparing outcomes of simple versus radical nephrectomy**
T. Ng, Singapore (SG)

**10:55 - 11:20** **Learning curve in robotic surgery**

P0386 **Beyond the Learning Curve: Continuous Improvement in Surgical Precision and Functional Outcomes during Robot-Assisted Partial Nephrectomy with the Hugo™ RAS System**
F. Prata, Rome (IT)

P0388 **MASTERING SINGLE PORT ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY WITH THE LOW ANTERIOR ACCESS: A LEARNING CURVE ANALYSIS WITH COMPARISON OF PERIOPERATIVE OUTCOMES**
V. Santarelli, Roma (IT)

P0389 **Quantifying surgical experience and performance improvement in Robot-Assisted Partial Nephrectomy using intraoperative analytics**
F. Prata, Rome (IT)

P0390 **Learning curve and perioperative outcomes of single-port vs. multi-port robot-assisted partial nephrectomy: First European comparative analysis**
A. Affentranger, Luzern (CH)

**11:20 - 11:35** **Standard definitions**

P0391 **Decision-making discordance between multidisciplinary tumor board (MDT), EAU Guidelines artificial intelligence (AI) Chatbot, and ChatGPT for patients with renal cancer: a single-Centre prospective cohort study**
S. Granata, Acireale (IT)

P0392 **Defining Standards for Retroperitoneal Single-Port Robotic Surgery: the ARISE International Delphi Consensus**
G. Spena, Naples (IT)

P0393 **Multi-center real-world evidence on preoperative systemic therapy for clear cell renal cell carcinoma patients with inferior vena cava tumor thrombus**
G. Liangyou, Beijing (CN)

**11:35 - 12:00** **Peri-operative treatment**

P0395 **A Phase II Study of Neoadjuvant Lenvatinib and Cadonilimab in High-Risk Localized and Locally Advanced Renal Cell Carcinoma (POST-RCC-01): Achieving Primary Endpoint in Simon's First Stage**
W. Dong, Guangzhou (CN)

P0396 **Adjuvant Pembrolizumab for Surgically Treated Clear Cell Renal Cell Carcinoma: the first experience of high-volume referral centers**
G. Basile, London (GB)

P0398 **Eligibility for Adjuvant Pembrolizumab and Real-World Survival Outcomes in Portuguese Clear Cell Renal Cell Carcinoma: A Multicenter National Study**
B. Oliveira, Vila Nova de Gaia (PT)

## Urolithiasis: Non-surgical management and follow-up

EGPT 24

**Saturday 14 March**
**10:30 - 12:00**

**Location** Blue Area, EGPT 5

**Chairs**
A. Abdel Karim, Alexandria (EG)
B. Dybowski, Pruszkow (PL)
M. Fernández, Santiago (CL)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**10:30 - 10:40** **Predicting success**

P0417 **Residual Stone Volume, Rather Than Stone-Free Status, Predicts Downstream Healthcare Utilization After Ureteroscopy: Secondary Analysis of the ASPIRE Trial**
B. Johnson, Dallas, Texas (US)

P0418 **Gout is Associated with Increased Risk for Surgical Recurrence in Calcium Oxalate Stone Formers: A Propensity-Score Matched Cohort Study**
H.B. Tamir, Karmei Yosef (IL)

**10:40 - 10:45** **Stone passage**

P0419 **Double versus Triple Drug Regimen for Ureteric Stone Medical Expulsion Therapy - A Prospective Study from Central India.**
D. Kaushal, Bhopal (IN)

| | |
|---|---|
| **10:45 - 11:10** | **Follow-up** |
| P0420 | **Characterizing Pain Interference after Ureteroscopy: Who Does It Affect and for How Long?**<br>MU Uy, Ann Arbor (US) |
| P0421 | **Patient Quality of Life and Caregiver Strain after Ureteroscopy for Stone Disease**<br>J. Ziemba, Cherry Hill (US) |
| P0422 | **Assessing financial toxicity in Cystinuria: The impact on healthcare utilization and out-of-pocket spending**<br>E. Edison, London (GB) |
| P0423 | **Modelling the Health Economic Impact of the EAU Urolithiasis Follow-Up Algorithm**<br>R. Geraghty, Newcastle upon Tyne (GB) |
| **11:10 - 11:25** | **Urine and serum monitoring** |
| P0425 | **A home device measuring urine quality for preventing recurrent urolithiasis**<br>V.F.S. Tsai, Taoyuan County (TW) |
| P0426 | **Chemiluminescence of urine as a predictor of recurrent stone formation**<br>S.V. Kotov, Moscow (RU) |
| P0427 | **Serum cystatin C and globulin as independent risk factors for recurrence of calcium oxalate stones: A retrospective cohort study**<br>K. Xia, Hefei (CN) |
| **11:25 - 11:30** | **Radiological Detection** |
| P0428 | **Leveraging high-resolution 3D micro-CT imaging to predict calcium oxalate and uric acid compositions in kidney stones**<br>M.B. Berjaoui, Toronto (CA) |
| **11:30 - 11:55** | **Stone prevention** |
| P0429 | **Urinary supersaturation in a Randomized trial among Individuals with Nephrolithiasis comparing Empiric versus selective therapy (URINE)**<br>R. Hsi, Newport Beach (US) |
| P0430 | **Impact of a Multidisciplinary Clinic on Patient Adherence to Preventive Treatment for Kidney Stones – A Prospective Study**<br>D. Golomb, Ramat Gan (IL) |
| P0431 | **Economic and clinical impact of Potassium Citrate in kidney stone disease: a systematic review and economic evidence synthesis**<br>B. Somani, Southampton (GB) |
| P0432 | **Role of SGLT2 inhibitors in urinary stone prevention**<br>H. Razvi, London, Ontario (CA) |
| P0433 | **Balancing renal risk and stone prevention: real-world outcomes of febuxostat versus allopurinol**<br>S-C. Su, Taichung (TW) |
| **11:55 - 12:00** | **Late-breaking abstract presentation** |
| LB016 | **Health-Economic Implications of the SURE procedure in Kidney Stone Removal: A Claims Data Analysis based on Two-Year Results of the ASPIRE Study**<br>B. Johnson, Dallas, Texas (US) |

# Tailoring bladder cancer care: Emerging insights in detection, treatment, and economic implications

EGPT 21

**Saturday 14 March**
**10:30 - 12:00**

**Location** Orange Area, EGPT 2

**Chairs**
C. Cano Garcia, Frankfurt am Main (DE)
P. Mariappan, Edinburgh (GB)
I. Minčík, Presov (SK)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**10:30 - 11:00** **Response to neoadjuvant chemotherapy in muscle-invasive bladder cancer**

P0363 **How far are we from bladder sparing after complete response to neoadjuvant chemotherapy?**
D. Robesti, Milan (IT)

P0364 **Contemporary Trends and Predictors of pT0 at Radical Cystectomy Specimens among Non-Muscle or Muscle Invasive Bladder Cancer Patients: A Propensity Score-Matched Analysis from a Single Tertiary Centre in the United Kingdom**
V. Asero, Rome (IT)

P0365 **Short-Term Impact of Neoadjuvant Chemotherapy on Urinary Complications After Radical Cystectomy and Ileal Neobladder**
Y. Yoon, Seoul (KR)

P0367 **Machine learning analysis for predicting pathological complete response after chemoradiotherapy in patients with muscle-invasive bladder cancer**
H. Tanaka, Tokyo (JP)

P0368 **Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Improves Long-Term Oncological Control Over Gemcitabine–Cisplatin in Muscle-Invasive Bladder Cancer: A Real-World Emulation of the VESPER Trial Using a Cure Modeling Approach**
J.D. Subiela Henriquez, Madrid (ES)

**11:00 - 11:35** **Care pathway of localised muscle-invasive bladder cancer**

P0370 **Introducing MRI into the diagnostic pathway for bladder masses: a health economic analysis**
N. Sathianathen, Melbourne (AU)

P0373 **Predicting Gene Expression and Patient Outcomes in Muscle-Invasive Bladder Cancer using Integrated Foundation Model Ensemble**
F.J. Koll, Graz (AT)

P0374 **Component and Total Healthcare-Related Costs of Bladder Cancer in a Universal Healthcare System**
D. Cheung, Toronto (CA)

P0375 **Intervention strategy selection for bladder preservation maintenance therapy in MIBC patients: a multi-center retrospective study**
Z. Ou, Changsha (CN)

| | |
|---|---|
| **11:35 - 12:00** | **Risk of metastatic disease in localised muscle-invasive bladder cancer** |
| P0376 | **Prognostic Value of Perioperative ctDNA Dynamics in Patients Undergoing Radical Cystectomy for Bladder Cancer**<br>A. Zhu, New York (US) |
| P0377 | **Utilization of Perioperative Systemic Therapy in Muscle-Invasive Bladder Cancer: A Real-World Survey-based Analysis of 323 Patients in Germany**<br>S. Rausch, Tübingen (DE) |
| P0378 | **Ex vivo culture to evaluate dynamic changes in the tumor microenvironment following durvalumab treatment.**<br>P. Toren, Québec (CA) |
| P0379 | **Surgical Bladder Preservation in Muscle-Invasive Bladder Cancer: Early oncological and safety results in a contemporary series**<br>D.A. González-Padilla, Madrid (ES) |
| P0380 | **Peptides translation of lncLRRTM4 sustains the lymphatic metastasis of bladder cancer**<br>C. Chen, Guangzhou (CN) |

## High-risk and locally-advanced Prostate Cancer: Neoadjuvant Strategies and Radical Prostatectomy Outcomes

EGPT 20

**Saturday 14 March**
**10:30 - 12:00**

**Location** Orange Area, EGPT 1

**Chairs**
T. Esen, Istanbul (TR)
N. Fossati, Lugano (CH)
S.T. Pang, Taipei (TW)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

| | |
|---|---|
| **10:30 - 11:15** | **Neoadjuvant treatment before radical prostatectomy** |
| P0345 | **Impact of Neoadjuvant Hormonal Therapy Duration on PSA Response and Pathological Outcomes in High-Risk Prostate Cancer: A Retrospective Analysis**<br>Y. Huang, Guangzhou (CN) |
| P0346 | **Response-Adapted Neoadjuvant Intensification with Abiraterone and LHRH Agonist ± Docetaxel Before Radical Prostatectomy in High-Risk Localized Prostate Cancer: A Prospective Cohort Study Emulating a Target Trial**<br>X. Wang, Beijing (CN) |
| P0347 | **INDUCTive Apalutamide therapy combined with radical prostatectomy in patients with locally inoperable T4 high risk prostate cancer - first results of the prospective Phase II INDUCTA trial**<br>J. Linxweiler, Homburg/saar (DE) |
| P0348 | **Treatment Transformation in Very High-Risk Prostate Cancer: Impact of Neoadjuvant Chemohormonal Therapy Before Robot-Assisted Radical Prostatectomy**<br>N. Yamaguchi, Yonago (JP) |

P0350 **Biochemical recurrence and safety in patients with high-risk localised prostate cancer treated with [177Lu] Lu-PSMA-617 prior to prostatectomy: Follow-up of the LuTectomy trial**
D. Hennes, Melbourne (AU)

P0351 **Impact of PSA Response to Neoadjuvant Androgen Deprivation Therapy on Outcomes After Robot-Assisted Radical Prostatectomy**
M. Todaka, Yufu (JP)

P0352 **The Impact of Neoadjuvant Therapy on Early Postoperative Continence Recovery after Radical Prostatectomy**
S. Chen, Jinan (CN)

---

**11:15 - 12:00** **Outcomes after radical prostatectomy**

P0354 **Oncological outcomes after radical prostatectomy for high-risk prostate cancer: A systematic review and meta-analysis**
A. Giesen, Leuven (BE)

P0355 **Feasibility and Outcomes of Robot-Assisted Radical Prostatectomy with the Hugo™ RAS System in Patients with Locally Advanced Prostate Cancer: Insights from a Multicentric Cohort**
A. Barretta, Cava de Tirreni (IT)

P0356 **Oncological outcomes of robot-assisted radical prostatectomy in International Society of Urological Pathology Grade 5 prostate cancer: 10-years follow up**
A. Govorov, Moscow (RU)

P0357 **Radical Prostatectomy in STAMPEDE-Defined High-Risk Prostate Cancer: Long-Term Oncologic and Perioperative Outcomes from a Large Single-Center Cohort**
S.L.A. Scuderi, Stockholm (SE)

P0358 **Robot-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Oncological Potential and Limitations as the Primary Treatment**
N. Miura, Toon (JP)

P0359 **PSMA Imaging-Based Stratification of Men with High-Risk Prostate Cancer Candidates for Radical Prostatectomy: Beyond Clinical Risk Factors**
M. Brancaccio, Milan (IT)

P0361 **Preoperative Surgical Planning for High-Risk Prostate Cancer: Maximising Continence While Maintaining Oncological Safety of Nerve-Sparing Robotic Prostatectomy**
A. Bilé Silva, London (GB)

P0362 **Oncological Outcomes of Patients Undergoing Radical Prostatectomy with Extended versus Indocyanine-Guided Lymphadenectomy: Mid-Term Follow-Up of PersonalymPCa Clinical Trial**
J.F. Anagua Melendres, Barcelona (ES)

# Advancements in male fertility: From global burden to innovative treatments

EGPT 23

**Saturday 14 March**
**10:30 - 11:45**

**Location** Blue Area, EGPT 4

**Chairs**
P. Capogrosso, Varese (IT)
L. Elst, Leuven (BE)
N. Sofikitis, Ioannina (GR)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**10:30 - 10:50** **Sperm decline and risk factors**

P0399 **Male Infertility: Global Burden and Spatiotemporal Trends from 1990–2021 and Projected Trajectories to 2050**
X. Zhou, Chengdu (CN)

P0400 **Pathomorphological changes in spermatozoa following SARS-CoV-2 infection (COVID-19)**
R.S. Ismailov, Rostov-on-Don (RU)

P0401 **Finasteride 1 mg: Silent Impacts on Male Fertility Despite Preserved Hormonal Balance**
M. Ruggeri, São Paulo (BR)

P0402 **Testosterone levels and sperm quality improve in men treated with GLP1 inhibitors**
C. Persu, Bucharest (RO)

**10:50 - 11:00** **Varicocele management**

P0403 **The Effect of Varicocele Embolization on Sperm DNA Fragmentation and Assisted Reproductive Outcomes**
C. Clark, Harpenden (GB)

P0404 **Can a novel ultrasound protocol improve the diagnosis of varicocele?**
T.H. Reid, London (GB)

**11:00 - 11:10** **Translational studies**

P0406 **Coenzyme Q2 Enhances Heat Stress-Induced Anti-Proliferative and Pro-Apoptotic Effects via AMPK Pathway Inactivation in Mouse Testicular Cell Lines**
Y. Wu, GuangZhou (CN)

**11:10 - 11:30** **Male infertility**

P0411 **Impact of Early versus Late Colchicine Therapy on Male Fertility in Patients with Familial Mediterranean Fever**
D. Tonoyan, Yerevan (AM)

P0414 **Association between preoperative body mass index (BMI) and postoperative hypogonadism after microdissection testicular sperm extraction (micro- TESE)**
S. Khoury, Haifa (IL)

| | |
|---|---|
| P0415 | **Missed karyotype abnormalities and Y-chromosome microdeletions in male infertility: trial simulation challenges current European Association of Urology guidelines genetic testing thresholds**<br>E. Pozzi, Milan (IT) |
| **11:30 - 11:40** | **Late-breaking abstracts** |
| LB015 | **Autotransplanted human testicular tissue shows germ cell survival despite extensive structural degeneration**<br>E. von Rohden, Copenhagen (DK) |
| LB014 | **Predictors of Penile Prosthesis Length: Results from the PHOENIX Registry**<br>A. Gomez Villanueva, Madrid (ES)<br>**Study Group**<br>EAU Research Foundation PHOENIX Study Group(Arnhem, The Netherlands) |
| **11:40 - 11:45** | **Closing remarks** |

## Talkshow: Physicians' well-being and sustainable performance – joint session with the Young Urologists Office

Thematic Session

**Saturday 14 March**
**10:45 - 12:00**

**Location** Orange Area, eURO Auditorium 2

**Chairs** M.C. Mir Maresma, New York (US)
P.M. Pierorazio, Philadelphia (US)

**Sidekick** J.L. Vásquez, Copenhagen (DK)

**Learning objectives**
- To understand the importance of aligning career choices with personal values, and recognise common pitfalls in goal-setting for high-performing professionals.
- To Understand how sleep, light exposure and exercise influence cognitive performance and mental health.
- Provide science-backed, time-efficient strategies to improve well-being.
- To recognise the emotional impact of complications on physicians (the "second victim" phenomenon), and discuss strategies for emotional regulation and professional recovery after adverse events.

| | |
|---|---|
| **10:45 - 10:50** | **Welcome** |
| **10:50 - 11:30** | **Living your core values for physical and mental well-being**<br>*Speakers* S. Brookman-May, Munich (DE); J. Howlett, Rødovre (DK)<br>**Opening question and voting**<br>**The concept of core values**<br>**Common pitfalls in goal-setting**<br>**Case example**<br>**Strategies for alignment** |

| | |
|---|---|
| | **Final take-home messages** |
| **11:30 - 12:10** | **Beyond the OR: Emotional management of surgical and non-surgical complications** |
| | *Speakers* P.M. Pierorazio, Philadelphia (US)<br>K.J. Turner, Bournemouth, Dorset (GB) |
| | **Introduction** |
| | **Understanding the emotional impact** |
| | **Case study: Emotional journey through a complication** |
| | **Framework for emotional management** |
| | **Final takeaways and audience reflection** |
| **12:10 - 12:15** | **Closing remarks** |

## Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.3

**Saturday 14 March**
**11:00 - 11:50**

**Location** Red Area, Room 1

**Tutors**
M.F. Frascheri, Southampton (GB)
C. Netsch, Hamburg (DE)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.3

**Saturday 14 March**
**11:00 - 11:50**

**Location** Red Area, Room 1

**Tutors**
O.R. Durutovic, Belgrade (RS)
F. Esperto, Rome (IT)
M. Henderickx, Wilrijk (BE)

**Learning objectives**
This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

## Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.3

**Saturday 14 March**
**11:00 - 11:50**

**Location** Red Area, Room 1

**Tutors**
C. Marialva, Algés (PT)
P. Umari, London (GB)

**Learning objectives**
This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

# Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.3

**Saturday 14 March**
**11:00 - 11:50**

**Location** Red Area, Room 1

**Tutors** M. Jarzemski, Bydgoszcz (PL)
G. Pini, Como (IT)

**Learning objectives**
The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.3

**Saturday 14 March**
**11:00 - 11:50**

**Location** Red Area, Room 1

**Tutor** N. Barber, Camberley (GB)

**Learning objectives**
The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.3

**Saturday 14 March**
**11:00 - 11:50**

**Location** Red Area, Room 1

**Tutors**
E.D. Demirkiran, Zonguldak (TR)
M.I. Gökce, Ankara (TR)
D. Perri, Como (IT)

**Learning objectives**
This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

# Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.3

**Saturday 14 March**
**11:00 - 11:50**

**Location** Red Area, Room 1

**Tutors**
A. Papatsoris, Athens (GR)
A. Sousa Castro, Lisboa (PT)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# Non-Technical Skills for Surgical Excellence: Immersive Simulation

HOT NTS - 2.1 VR Sim

**Saturday 14 March**
**11:00 - 12:00**

**Location** EAU Square

**Tutors**

C.S. Biyani, Leeds (GB)

M. Pears, Barnsley (GB)

K. Wadhwa, Wickham Bishops (GB)

**Learning objectives**

Participants will be assigned to one of two simulation-based activities: a simulated operating room session or a computer-based virtual patient interaction. Both formats are designed to enhance non-technical skills, including communication, teamwork, and clinical decision-making.

# Patient advocacy plaza - Update on the PROCON project about continence care in nursing homes

Special Session

**Saturday 14 March**
**11:15 - 11:45**

**Location** Patient Advocacy Plaza

**Chairs**

E.R Romano, The Hague (NL)

A. Wagg, Edmonton (CA)

**University of Alberta, Dept. of Medicine**

E.R Romano, The Hague (NL)

A. Wagg, Edmonton (CA)

## Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.4

**Saturday 14 March**
**12:00 - 12:50**

**Location** Red Area, Room 1

**Tutors**
N.C. Grossmann, Lucerne (CH)
A. Olivero, Milan (IT)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.4

**Saturday 14 March**
**12:00 - 12:50**

**Location** Red Area, Room 1

**Tutors**
O.R. Durutovic, Belgrade (RS)
M. Henderickx, Wilrijk (BE)
G. Kamphuis, Amsterdam (NL)

**Learning objectives**
This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

# Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.4

**Saturday 14 March**
**12:00 - 12:50**

**Location** Red Area, Room 1

**Coordinator** D. Oliveira Reis, Lisboa (PT)

**Tutors** C. Marialva, Algés (PT)
P. Umari, London (GB)

**Learning objectives**
This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

# Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.4

**Saturday 14 March**
**12:00 - 12:50**

**Location** Red Area, Room 1

**Tutors** S. García Barreras, Madrid (ES)
D. Veneziano, New York (US)

**Learning objectives**
The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.4

**Saturday 14 March**
**12:00 - 12:50**

**Location** Red Area, Room 1

**Tutor** D. Elterman, Toronto (CA)

**Learning objectives**

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.4

**Saturday 14 March**
**12:00 - 12:50**

**Location** Red Area, Room 1

**Tutors** M. Arslan, Istanbul (TR)
E.D. Demirkiran, Zonguldak (TR)
B.M. Schoensee, Berlin (DE)

**Learning objectives**

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

# Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.4

**Saturday 14 March**
**12:00 - 12:50**

**Location** Red Area, Room 1

**Tutors**
M. Paciotti, Rozzano, Milan (IT)
A. Tuncel, Ankara (TR)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# How far have we come with PCa screening in the EU?

Thematic Session

**Saturday 14 March**
**12:15 - 13:45**

**Location** Orange Area, eURO Auditorium 2

**Chairs**
P. Albers, Düsseldorf (DE)
E. Briers, Hasselt (BE)
H. Van Poppel, Leuven (BE)

**Learning objectives**
This session will provide an update on current prostate cancer screening trials within the EU-funded PRAISE-U initiative and other screening pilots which have been initiated throughout Europe. The trial results will be discussed in the context of the European Health Initiatives.

**12:15 - 12:22** **Highlight achievements of PRAISE U so far**
M.J. van Harten, Rotterdam (NL)

**12:22 - 12:59** **The good, the bad, and the ugly: Results from PRAISE U pilots**

12:22 - 12:28 **Galicia**
R.M.F. Montero Fabuena, Ferrol (ES)

12:28 - 12:34 **Ireland**
D.J. Galvin, Dublin (IE)

12:34 - 12:40 **Poland**
K. Tupikowski, Wroclaw (PL)

12:40 - 12:46 **Manresa**
J. Vilaseca, Barcelona (ES)

12:46 - 12:52 **Lithuania**
A. Patasius, Vilnius (LT)

| | |
|---|---|
| 12:52 - 12:59 | **Discussion** |
| **12:59 - 13:06** | **OPT programme in Sweden - lessons learned after 4 years of piloting**<br>O. Bratt, Gothenburg (SE) |
| **13:06 - 13:13** | **Czech Republic experience of quality control of its PCa pilot**<br>O. Majek, Brno (CZ) |
| **13:13 - 13:20** | **How cost effective is PCa screening?**<br>P. Vynckier, Ghent (BE) |
| **13:20 - 13:27** | **What psycho-social impact does screening have on men?**<br>P. Kirkegaard, (DK) |
| **13:27 - 13:34** | **GU cancer and comprehensive cancer centres**<br>T. Albreht, Ljubljana (SI) |
| **13:34 - 13:39** | **An update on the PRAISE U knowledge hub**<br>M.J. Roobol, Rotterdam (NL) |
| **13:39 - 13:45** | **Questions and answers** |

## EAU Lab: Immuno-oncology in urology - a primer for urologists

EAU26 Lab

Thematic Session

**Saturday 14 March**
**12:15 - 13:35**

**Location** Blue Area, Victoria 4

**Chairs** L. Dyrskjøt, Aarhus (DK)
J. Paramio, Madrid (ES)

**Learning objectives**
* To provide urologists with a structured understanding of tumour immunology and mechanisms of immune resistance in urological cancers, including prostate and testicular malignancies. * To outline the biological rationale for emerging immune checkpoints, combinatorial strategies, and perioperative immunotherapy approaches. * To strengthen the conceptual framework needed to interpret and contextualise immune-based treatments in contemporary urological oncology.

| | |
|---|---|
| **12:15 - 12:20** | **Introduction**<br>L. Dyrskjøt, Aarhus (DK) |
| **12:20 - 12:30** | **Introduction to tumour immunity for urologists**<br>L. Bukavina, Cleveland (US) |
| **12:30 - 12:40** | State-of-the-art lecture **Mechanisms of immune resistance in prostate cancer and opportunities for modulation**<br>G. von Amsberg, Hamburg (DE) |
| **12:40 - 12:50** | State-of-the-art lecture **Immune privilege in testicular germ cell tumours: Biology, resistance, and translational insights**<br>L. Looijenga, Utrecht (NL) |

**12:50 - 13:00** State-of-the-art lecture **Emerging immune checkpoints and rationale for combinatorial strategies**
M.S. Van Der Heijden, Amsterdam (NL)

**13:00 - 13:10** State-of-the-art lecture **Neoadjuvant vs. adjuvant immunotherapy: A comparative perspective on biology**
A. Bex, London (GB)

**13:10 - 13:30** Panel discussion **Translating immune mechanisms into therapeutic strategies**

*Panel*
A. Bex, London (GB)
L. Bukavina, Cleveland (US)
L. Looijenga, Utrecht (NL)
M.S. Van Der Heijden, Amsterdam (NL)
G. von Amsberg, Hamburg (DE)

**13:30 - 13:35** **Wrap-up: Immune modulation and therapeutic opportunity in urological cancer**
L. Dyrskjøt, Aarhus (DK)

## LUTS/BPO surgery: Master in disaster

Thematic Session

**Saturday 14 March**
**12:15 - 13:45**

**Location** Orange Area, Room 3

**Chairs**
R. Autorino, Cleveland (US)
C. De Nunzio, Rome (IT)

**Learning objectives**
This session provides a practical approach to managing complications of BPO surgery, including bleeding, incontinence, strictures, and ejaculatory dysfunction. Through real-world cases and expert insights, participants will learn to recognize, prevent, and treat complications across various techniques such as TURP, HoLEP as well as after minimally invasive treatments. Emphasis will be placed on perioperative decision-making and tailored strategies for complex patients. The goal is to enhance surgical safety, reduce reintervention rates, and improve patient outcomes in everyday urological practice.

**12:15 - 12:16** **Introduction**

**12:16 - 12:25** **How we define success and failure in LUTS/BPO surgery?**
R. Autorino, Cleveland (US)

**12:25 - 12:45** Video case presentation **Perioperative pitfalls in TURP, laser and simple prostatectomy**

*Presenter* I. Kartalas Goumas, Vigevano (IT)

*Discussants*
S. Ahyai, Graz (AT)
B. Geavlete, Bucharest (RO)
K. Lehrich, Berlin (DE)

| | | |
|---|---|---|
| **12:45 - 13:05** | Video case presentation **Perioperative pitfalls in new BPO treatments** | |
| | *Presenter* | L. Cindolo, Salerno (IT) |
| | *Discussants* | E. García Rojo, Madrid (ES)<br>J.H. Kim, Seoul (KR)<br>K.C. Zorn, Montreal (CA) |
| **13:05 - 13:25** | Case-based discussion **Complicated BPO cases** | |
| | *Presenter* | C. De Nunzio, Rome (IT) |
| | *Discussants* | N.R. Bhatt, Dublin (IE)<br>M. Gacci, Florence (IT)<br>N.I. Osman, Sheffield (GB) |
| **13:25 - 13:34** | **Present and future of BPO surgery**<br>J-N.L. Cornu, Rouen (FR) | |
| **13:34 - 13:43** | **Patient decision aids in BPO surgery**<br>S. Malde, London (GB) | |
| **13:43 - 13:45** | **Summary** | |

## History of Urology

Abstract Session 13

**Saturday 14 March**
**12:15 - 13:45**

| | |
|---|---|
| **Location** | Red Area, Room 7 |
| **Chairs** | J. Angulo Cuesta, Getafe (ES)<br>J.C. Goddard, Leicester (GB)<br>D. Schultheiss, Giessen (DE) |

| | |
|---|---|
| A0205 | **LHRH in Prostate Cancer Treatment: From Breakthrough Discovery to Modern Therapeutic Approaches**<br>S. Benisti, Montreal (CA) |
| A0206 | **Votes for Women!**<br>O. Olaitan, Leicester (GB) |
| A0207 | **The principles of Sir Pendrill Varrier-Jones: Blueprints for future generations or just 'old hat'?**<br>J.K. Badawi, Luzern (CH) |
| A0209 | **Urethral Sub-incision and Circumcision – Historical Urogenital Initiation Rituals in Aboriginal Australian Communities**<br>K. Keane, Perth (AU) |
| A0210 | **Angioneurectomy: A Pre-endocrine Concept in the Early Medical Treatment of Prostatic Disease (Albarrán & Motz, 1897)**<br>J.J. Szczesniewski, Getafe (ES) |

A0211 **From Steinach to Survivor: The Urological and Endocrine Legacy of Conversion Therapy Targeting Homosexuality**
M. Agrawal, LONDON (GB)

A0213 **“Cure without danger, pain and bloodshed” - Docteur Bazénerie and his electrical treatment methods for urological diseases**
J.K. Badawi, Luzern (CH)

A0214 **Alessandri Massariae Praelectiones de morbis mulierum, conceptus et partus: Massaria’s Contribution to Urogynecology in Seventeenth-Century Italy between Tradition and Innovation**
G. Mazzucato, Bolzano (IT)

A0215 **From General Surgery to Specialized Practice: The Historical Journey of Urology in Ecuador**
R. Arevalo, Madrid (ES)

A0216 **The genius Joaquín Albarran was once a kid, and a poet!**
J. Angulo Cuesta, Getafe (ES)

A0217 **Viennese urology – a mirror of science and medicine that is participating in the building and maintaining of empires**
F. Moll, Cologne (DE)

A0218 **History of the Urology Service in the Central Lisbon Hospital University Centre**
P.G. Silva, Almada (PT)

A0219 **Even His Majesty's doctors were censured by the Inquisition: The case of Andres Laguna and his Dioscorides translation.**
J. Angulo Cuesta, Getafe (ES)

## Urolithiasis: Suction Technology

Abstract Session 10

**Saturday 14 March**
**12:15 - 13:45**

**Location** Blue Area, George 1

**Chairs**
B. Ballesta Martinez, Alicante (ES)
B.H. Chew, Vancouver (CA)
To be confirmed

**12:15 - 12:30** **FANS vs. conventional access sheaths**

A0153 **COMPARISON OF FLEXIBLE VACUUM-ASSISTED VERSUS CONVENTIONAL URETERAL ACCESS IN RETROGRADE INTRARENAL SURGERY: A RANDOMIZED CONTROLLED PROSPECTIVE RIRSEARCH GROUP STUDY**
M.F. Simsekoglu, London (GB)

**Study Group**
Rirsearch(İstanbul, Turkey)

| | |
|---|---|
| A0151 | **Conventional versus Flexible and Navigable Suction Ureteral Access Sheaths: An In Vitro Evaluation on Ureteral Temperature Modulation during high power Holmium YAG Laser Lithotripsy**<br>S. Yuen, Hong Kong (HK) |
| **12:30 - 12:45** | **Suction ureteroscopy vs PCNL** |
| A0154 | **Flexible ureteroscopy with a flexible vacuum-assisted ureteral access sheath versus mini-percutaneous nephrolithotomy in patients with 2-3 cm upper urinary tract stones: a multicenter randomized clinical trial**<br>X. Linguo, Tianjin (CN) |
| A0155 | **Utility and Challenges of Flexible and Navigable Suction Ureteral Access Sheath (FANS) vs. Suction Mini-PCNL in Children: A Comparative Analysis**<br>R.Z.S. Teng, Singapore (SG) |
| A0156 | **CVAC 2.0 vs Mini PCNL: a Real-world Comparison for Moderate Size Stones**<br>A. Gonzalez, Dallas (US) |
| **12:45 - 13:10** | **Comparative studies** |
| A0158 | **Simulated Kidney Study of CVAC 2.0 vs FANS: Fragment Clearance and Surgeon Workload**<br>J. Winoker, New York (US) |
| A0159 | **Multicenter Comparison of Stone Clearance with CVAC Aspiration Ureteroscope and Flexible and Navigable Ureteral Access Sheaths**<br>A. Amenyogbe, Phoenix (US) |
| A0160 | **Comparing the Efficacy, Safety and Pressure Dynamics of FANS versus DISS-Assisted RIRS for Renal Stones less than 1.5 cm: A Prospective Randomised Study.**<br>V Palanisamy, TIRUPPUR (IN) |
| A0161 | **Real-time monitoring with DISS and FANS systems to assure safe and effective stone treatment: Insights from ex-vivo experimental study.**<br>A. Tsaturyan, Yerevan (AM) |
| **13:10 - 13:25** | **Direct in-scope suction** |
| A0162 | **Fragment Size Distribution in a Clinical Study of a Novel Integrated System Combining Flexible DISS and Thulium Fiber Laser Lithotripsy**<br>F. Zorzi, Trieste (IT) |
| A0163 | **Outcomes of direct in-scope suction for renal and/or ureteric stones: The DISS-Global database**<br>K.Y. Fong, Singapore (SG) |
| A0164 | **Reproducible Stone Evacuation with CVAC Technology: Pooled Analyses of the ASPIRE and CLEARANCE Trials**<br>N. Pathak, Nadiad (IN) |
| **13:25 - 13:45** | **Flexible and navigable access sheaths** |
| A0165 | **The Global Flexible and Navigable Suction Ureteral Access Sheaths (FANS) Survey on Utility, Practices and Future Needs in Flexible Ureteroscopy - An EAU, YAU Endourology and IAU collaboration**<br>S. Yuen, Hong Kong (HK) |
| A0166 | **Optimal Pressure and Sheath Setting for Safe and Efficient Stone Removal with Flexible and Navigable Suction Ureteral Access Sheath**<br>S.W. So, seoul (KR) |

A0167 **How do we choose the optimal length of a Flexible and Navigable Suction Ureteral Access Sheaths (FANS): An EAU Endourology and AUSET prospective analysis**
S. Yuen, Hong Kong (HK)

A0168 **The safety and effectiveness analysis of Vacuum-assisted Dedusting Lithotripsy using flexible and navigable suction ureteral access sheath under local anesthesia with monitored anesthesia care：a prospective, randomized controlled clinical trial**
H. Xie, Tianjin (CN)

## Paediatric urology 2: Congenital abnormalities and voiding dysfunction

Abstract Session 12

**Saturday 14 March**
**12:15 - 13:45**

**Location** Blue Area, Victoria 6

**Chairs**
J.M. Chung, Yangsan-si (KR)
C. Gernhold, Linz (AT)
T.M. Oktar, Istanbul (TR)

**12:15 - 12:50** **Bladder-bowel dysfunction**

A0187 **The impact of transurethral catheterisation on urodynamic results in paediatric patients**
S. Tseng, New Taipei City (TW)

A0188 **Transcutaneous posterior tibial nerve stimulation (TPTNS) for refractory overactive bladder symptoms in pediatric patients: A subgroup analysis in the philippine setting**
J.C. Timkang, Manila (PH)

A0190 **Factors affecting the clinical response to desmopressin treatment for primary monosymptomatic nocturnal enuresis in children**
I. Selvi, Diyarbakir (TR)

A0191 **Efficacy and Safety of Mirabegron Versus Solifenacin in the Treatment of Overactive Bladder in Children: A Systematic Review and Meta-Analysis**
A. Badr, Liverpool (GB)

A0193 **The Effectiveness of Different Therapy Modalities in Refractory Monosymptomatic Enuresis in Children: A Systematic Review by The EAU-YAU Paediatric Urology Working Group**
I. Selvi, Diyarbakir (TR)

**12:50 - 13:15** **Transition**

A0194 **Associations and Moderation by Baseline Knowledge on Effects of a Structured Urologic Transition Program on Transition Readiness and Emergency Department Use**
M. Chua, Toronto (CA)

A0195 **STREAMWAY – Perceptions and Barriers to Transition in Urological Care among Adolescents – Intermediate analysis**
M. Van den Ende, Gent (BE)

A0196 **Bridging the Gap: Implementing a Structured Transition Pathway for Young Adults with Complex Neurourological Disorders**
P.G. Silva, Almada (PT)

| | |
|---|---|
| **13:15 - 13:45** | **Congenital and genital** |
| A0199 | **Hot vs cold knife for endoscopic ablation of posterior urethral valves: A systematic review by the EAU-YAU Paediatric Urology Working Group**<br>L.A. 't Hoen, Rotterdam (NL) |
| A0200 | **"To circ or not to circ" – that is the question for patients with posterior urethral valves**<br>S. Kim, Vancouver (CA) |
| A0202 | **CDKN2B inhibits Vascular Smooth Muscle Phenotypic Switching in Corpus Spongiosum surrounding the urethral plate in hypospadias**<br>M. Yu, Shanghai (CN) |
| A0203 | **A clinical pathway incorporating the TWIST score and ultrasound for low risk cases safely decreases the negative exploration rate and time to theatre in testicular torsion**<br>S. Folkard, London (GB) |
| A0204 | **Obesity and testicular function in children with micropenis**<br>J.M. Chung, Yangsan-si (KR) |

# Training, gender disparities & perioperative challenges of urologists

Abstract Session 17

**Saturday 14 March**
**12:15 - 13:45**

**Location** Red Area, Room 11

**Chairs** M.G.R. Asmundo, Catania (IT)
To be confirmed
G.K. Çalik, Istanbul (TR)

**12:15 - 12:40** **Gender**

A0276 **Gender-specific ergonomic challenges in endourology: a Dutch national survey**
E. Altobelli, Groningen (NL)

A0274 **Gender distribution of invited speakers at major international, pan-surgical conferences: A retrospective open cohort study**
A. Asif, London (GB)

A0275 **Career Paths in Urology and Gender Structure: Persistent Glass Ceilings**
B. Bañuelos Marco, Madrid (ES)

**Study Group**
YAU PAEDIATRIC UROLOGY - EAU(Arnhem, The Netherlands)

A0277 **Pregnancy and parenthood during urology residency across Europe: Opinions do not differ between childbearing and non-childbearing urologists**
L. Afferi, Aarau (CH)

A0278 **Gender Disparities in Academic Authorship, Leadership, and Compensation in Urology: A Systematic Review of Quantitative Evidence**
P.G. Silva, Almada (PT)

**12:40 - 13:10** **Training**

A0279 **Anatomical training using Anatomage Table® 3D reconstruction for novice learners: a randomized controlled trial**
G. Rossin, Trieste (IT)

A0280 **Robotic Surgery Across Surgical Specialties in Italy: A Nationwide Survey on Implementation, Training, and Satisfaction Levels Among Residents and Young Attendings - on behalf of the Italian Polyspecialistic Society of Young Surgeons (SPIGC)**
V. Santarelli, Roma (IT)

A0281 **Advancing laparoscopic training in Urology: Establishing the LUSs3 cadaveric model within the European School of Urology (ESU) curriculum**
T.M. Ribeiro De Oliveira, Lisbon (PT)

A0283 **The European School of Urology (ESU) Urology Boot Camp (ESU-UBC) program for first-year residents: Results from flagship European Association of Urology (EAU) program**
T.M. Ribeiro De Oliveira, Lisbon (PT)

A0284 **Validation and Benchmarking of Intermediate Laparoscopic Simulation Modules: An ESU Laparoscopic Working Initiative**
A. Pischetola, Rome (IT)

| | |
|---|---|
| **13:10 - 13:20** | **Challenges for surgeons** |
| A0285 | **Supporting surgeons after adverse events: our experience of implementing a multi-centre peer support programme**<br>G. Scrimgeour, Salisbury (GB) |
| A0286 | **Surgeons inhale what they cauterize: Quantitative assessment of VOC exposure during TURBT**<br>W.K. Hwang, Seoul (KR) |
| **13:20 - 13:35** | **Artificial Intelligence** |
| A0287 | **Development and validation of an AI-assisted scoring system for abstract evaluation in urology: comparison with human reviewers at a national meeting**<br>J.F. Lopez Joannon, Santiago (CL) |
| A0288 | **Evaluating Interactions of Patients with Large Language Models for Medical Information**<br>N. Carl, Mannheim (DE) |
| A0289 | **Development of a ChatGPT-Based Assistant in Multidisciplinary Team Discussions in Oncological Urology: The UroMDT Advisor Study**<br>R. Lombardo, Rome (IT) |
| **13:35 - 13:45** | **Controversies** |
| A0290 | **Quantifying the Environmental Impact of Robotic Urological Surgery by Calculating Greenhouse Gas**<br>Y. Kimura, Yonago (JP) |
| A0291 | **Bike-saddle and LUTS, bad surpises?**<br>A. Alberti, Florence (IT) |

## Kidney cancer conundrums: Assessing function, prognosis, and patient perspectives

Abstract Session 16

**Saturday 14 March**
**12:15 - 13:45**

**Location** Red Area, Room 10

**Chairs**
R.G. Bertolo, Verona (IT)
H-P. Marti, Bergen (NO)
Z. Wu, Shanghai (CN)

| | |
|---|---|
| **12:15 - 12:45** | **Surgical outcomes** |
| A0256 | **Comparison of patients with and without tumor pseudocapsule rupture during robot-assisted partial nephrectomy at a High-Volume Tertiary Care Referral Center**<br>L. Bianchi, Bologna (IT) |
| A0257 | **When Complications Strike: The Role of Age in Failure-to-Rescue After Partial Nephrectomy**<br>D. Chahrour, Riad El Solh - Beirut (LB) |
| A0258 | **In Partial Nephrectomy Time Matters only when there are comorbidities**<br>C. Piccolo, Milan (IT) |

A0259 **Robotic vs. Open Partial Nephrectomy in Complex Cases: Real-World Benchmarking of the OpeRa Trial**
C. Piccolo, Milan (IT)

A0260 **Risk factors of prolonged hospitalization after radical nephrectomy and thrombectomy: Based on 656 patients with renal cell carcinoma and tumor thrombus**
S. Yu, Beijing (CN)

A0261 **Functional Status at Admission Predicts Prolonged Hospital Stay After Renal Surgery: The Hidden Value of Nursing Assessments**
C. Piccolo, Milan (IT)

---

**12:45 - 13:15** **Renal function after nephrectomy**

A0262 **Computed Tomography Radiomics-Derived Nomogram for Predicting Early Renal Function Decline after Partial Nephrectomy in Renal Cell Carcinoma: A Multicenter Development/Validation Study**
S. Chen, Fuzhou (CN)

A0263 **Evaluating the role of measured eGFR in the post-operative management of single kidney patients after radical nephrectomy for kidney cancer.**
F. Trevisani, Milan (IT)

A0264 **External Validation of the RENSAFE Model for Predicting Acute and Chronic Kidney Failure in Patients Undergoing Nephrectomy**
B. Kaptzan, Be'erotaim (IL)

A0265 **When the Thrombus Rises: Inferior Vena Cava Involvement Impairs Preoperative Renal Function in Renal Cell Carcinoma**
G. Musso, Milan (IT)

A0266 **Renal Functional Following Angioembolization After Partial Nephrectomy**
F. Cei, Segrate (IT)

A0267 **Beyond creatinine: Early biomarkers of AKI and impact on medium-term CKD following robotic renal surgery**
R. La Mura, Perugia (IT)

---

**13:15 - 13:30** **Prognosis and recurrence**

A0268 **Reassessing Prognosis in RCC with Venous Tumor Thrombus: Prospective Cohort Study from 46 Cases**
V. Meyyappan, Hyderabad (IN)

A0269 **Development and validation of a multimodal predictive recurrence score (MPRS) integrating clinical, radiological, and histopathological information for multicenter patients with clear cell renal cell carcinoma (ccRCC)**
J. Zheng

A0270 **DaRenCa risk score: a prognostic tool to assess risk of recurrence in patients with clear cell renal cell carcinoma**
P. Hedegaard, Roskilde (DK)

---

**13:30 - 13:40** **Patient and clinician perspective on RCC**

A0273 **Awareness and Perspectives on Hereditary Renal Cell Carcinoma and Genetic Testing in Clinical Practice: A Multi-National Survey**
C. Re, Milan (IT)

A0271 **Kidney function (KF) issues and related emotional concerns among patients with kidney cancer (KC) in Europe: Findings from the International Kidney Cancer Coalition (IKCC) global patient survey (GPS)**
O. Exertier, Utrecht (NL)

**13:40 - 13:45** **Late-breaking abstract presentation**

LB018 **Exploring The Role Of Carbonic Anhydrase IX As Diagnostic Target In Von-Hippel Lindau Disease: A Phase 2 Clinical Trial (CAT-VHL - PRR-POC-2023-12377493 - Cohort A)**
A. Larcher, Milan (IT)

## The evolving management of metastatic renal cell carcinoma

Abstract Session 18

**Saturday 14 March**
**12:15 - 13:45**

**Location** Red Area, Room 12

**Chairs** To be confirmed
S. Erdem, Istanbul (TR)
X. Ma, Beijing (CN)

**12:15 - 12:25** **New treatment strategies in metastatic kidney cancer**

A0292 **Fruquintinib Plus Serplulimab as First-Line Therapy in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (nccRCC): Updated Efficacy and Safety Data from a Multicenter, Single-Arm, Phase II Trial**
Y. Ding, Shanghai (CN)

A0293 **Prognostic significance of time-of-day administration (ToDA) of immune checkpoint inhibitor (ICI) in patients with metastatic renal cell carcinoma (mRCC) treated with first-line therapies**
K. Takemura, Tokyo (JP)

**12:25 - 12:40** **Staging and treatment of advanced renal cancer in clinical practice**

A0295 **A majority of patients with high grade renal cell carcinoma and early lung recurrence are initially miss-staged**
P-O. Lundgren, Stockholm (SE)

A0296 **Real-world incidence and clinical impact of grade 3–4 adverse events in patients with metastatic renal cell carcinoma treated with first-line immune combinations: ARON-1 study**
B.A. Maiorano, Milan (IT)

**12:40 - 13:10** **Role of nephrectomy in the current metastatic kidney cancer scenario**

A0297 **SCREENing smarter: outperforming IMDC in predicting first-year mortality among patients undergoing cytoreductive nephrectomy**
L. Yu, Singapore (SG)

A0298 **Efficacy and Safety of deferred nephrectomy following targeted therapy combined with immunotherapy in patients with unresectable/advanced renal cell carcinoma: A prospective, single-arm trial**
G. Liangyou, Beijing (CN)

A0299 **Feasibility and Outcomes of Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Therapy in Metastatic Clear Cell Renal Cell Carcinoma**
C.H. Hsu, Taipei (TW)

A0300 **Cytoreductive Nephrectomy with Venous Tumor Thrombectomy: Comparing Outcomes of Historical Upfront vs Modern Deferred Treatment A single center experience**
R. Packham, San Antonio (US)

A0301 **Impact of Nephrectomy in the Era of Combined Immunotherapy for Intermediate-Poor Risk Metastatic Renal Cell Carcinoma**
Y. Mita, Kobe (JP)

A0302 **The Impact of Local Therapy on the Prognosis of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma**
X. Wei, Chengdu (CN)

**13:10 - 13:40** **Prognostic factors in metastatic kidney cancer**

A0303 **Effect of prior nephrectomy and bone metastases on real-world efficacy of Ipilimumab/Nivolumab and Pembrolizumab with TKI in metastatic clear-cell RCC**
I. Surovtsova, Stuttgart (DE)

A0304 **Cancer-Specific Survival After Synchronous or Metachronous Metastasis Following Surgery for Renal Tumors: A 10-Year Comparative Analysis**
I. Donnini, Varano de' melagari (IT)

A0305 **Landmark Complete Metabolic Response on FDG-PET/CT at One Year: A Powerful Surrogate for Survival Benefit in Metastatic Renal Cell Carcinoma Treated with Immunotherapy**
C. Lei, Nanjing (CN)

A0306 **Ultra-Early PIV Kinetics Predict Survival in Metastatic Renal Cell Carcinoma: Identification of the "PIV Boost" Phenomenon**
T. Inoue, Yufu City (JP)

A0308 **Serum IgG: A novel biomarker for efficacy and prognosis in metastatic clear cell renal cell carcinoma patients receiving first-line immunotherapy combined with tyrosine kinase inhibitors.**
T. Han, Beijing (CN)

## Testicular cancer: From diagnosis to survivorship

Abstract Session 19

**Saturday 14 March**
**12:15 - 13:45**

**Location** Red Area, Room 13

**Chairs**
T.L. Cha, Taipei (TW)
R. Hamilton, Toronto (CA)
R. Matulewicz, New York (US)

**12:15 - 12:30** **Indeterminate lesions and primary diagnosis**

A0309 **How reliable are serum tumor markers in the diagnosis of small testicular masses? A multicentric analysis from the Milan Testis Cancer Alliance**
C. Corsini, Milan (IT)

| | |
|---|---|
| A0310 | **Role of Elastography in the Evaluation of Testicular Neoplasms: Correlation Between Tissue Stiffness (kPa) and Histological Type**<br>F. Di Pippa, Castellaneta (IT) |
| A0311 | **Chest CT in Testicular Mass Evaluation: A Stepwise Approach to Minimize Radiation Exposure**<br>E. Eigner, Haifa (IL) |
| **12:30 - 12:45** | **Relapse risk & adjuvant therapy decisions** |
| A0313 | **Establishment of a miRNA signature for individual prognostic evaluation of seminoma patients**<br>K. Junker, Homburg (DE) |
| A0314 | **Pure testicular seminomas that relapse with nonseminomatous elements: clinical patterns and management**<br>P. Kraft, Zurich (CH) |
| **12:45 - 13:05** | **RPLND: Outcomes and complications** |
| A0315 | **Quantifying the Spectrum of Perioperative Morbidity in 444 Retroperitoneal Lymph Node Dissection for Testicular Cancer Using the ClassIntra and Clavien-Dindo Classification Systems**<br>N. Thimiri Mallikarjun, Chennai (IN) |
| A0316 | **Primary retroperitoneal lymph node dissection (RPLND) for clinical stage IIA/IIB seminoma – updated population-based results from The Swedish and Norwegian testicular cancer group (SWENOTECA)**<br>A. Thor, Stockholm (SE) |
| A0317 | **Cure without consolidation: long-term outcomes of a surveillance-based approach after post-chemotherapy RPLND in metastatic nonseminomatous germ cell tumors**<br>A. Mousa, Toronto (CA) |
| A0318 | **Propensity Score-Matched Comparison of Laparoscopic and Open Post-Chemotherapy Retroperitoneal Lymph Node Dissection (RPLND) in Nonseminomatous Germ Cell Tumors (NSGCT)**<br>C. Saitta, Pieve Emanuele (IT) |
| **13:05 - 13:30** | **RPLND: Can we predict histology?** |
| A0319 | **Clinical evaluation of the role of miRNA 371 in early stage II germ-cell tumors (GCT) of the testis in histology prediction and relapse monitoring. Results of the "Internal" Trial**<br>S. Nazzani, Milan (IT) |
| A0321 | **Evaluation of miRNA-371a-3p (miR371a) assay to predict final pathohistology in patients undergoing primary nerve-sparing retroperitoneal lymphadenectomy (nsRPLND) for stage IIA/B seminomas and non-seminomas (NSGCT)**<br>J. Heidenreich, Cologne (DE) |
| A0322 | **Three-Dimensional CT-Based Volumetric Shrinkage as an Independent Predictor of Residual Pathology in Post-Chemotherapy Non-Seminomatous Germ Cell Tumors**<br>F. Irmak, Istanbul (TR) |
| A0323 | **Screening for circulating biomarkers in therapy-resistant subtypes of testicular germ cell tumors**<br>P. Pongratanakul, Düsseldorf (DE) |
| **13:30 - 13:45** | **QOL and follow-up** |

A0324 **Incidence of ototoxicity in testicular cancer survivors: A nationwide retrospective cohort study**
G. Musso, Milan (IT)

A0325 **A qualitative study of health-related quality of life and supportive care needs of testicular cancer survivors after 1 year post-treatment**
L. Fox, London (GB)

## Oncologic, surgical & functional outcomes in localised renal tumour

Abstract Session 11

**Saturday 14 March**
**12:15 - 13:45**

**Location** Blue Area, George 4

**Chairs**
C.K. Bensalah, Rennes (FR)
C. Palumbo, Novara (IT)
T. Takagi, Tokyo (JP)

**12:15 - 12:45** **Oncologic outcomes**

A0169 **The impact of time to local tumor destruction on cancer-specific mortality in pT1a renal cell carcinoma**
N. Lee, Montreal (CA)

A0170 **Partial Nephrectomy for cT1 RCC: Reassuring Oncological Outcomes Despite Pathological Upstaging**
D.K-W. Leung, hong kong (HK)

**Study Group**
EAU YAU RCC Working Group(Hong Kong, Italy)

A0171 **Two-year follow-up on oncological, functional und quality of life outcomes of the randomized ROBOt-assisted versus Conventional Open Partial nephrectomy (ROBOCOP) II trial**
C.M. Haney, Heidelberg (DE)

A0172 **sPaRT2 - Partial versus Radical Nephrectomy for cT2 Renal Cell Carcinoma: A National Matched-Pair Analysis (UroCCR 235)**
R. Et-Touzani, Dijon (FR)

A0173 **Competing Risk Regression Analysis of Cancer-Specific and Other-Cause Mortality After Partial vs. Radical Nephrectomy in T3aN0M0 Rencal Cell Carcinoma**
X. Li, Chengdu (CN)

A0174 **Prognostic Implications of Nodal Status in Localized and Locally-Advanced Renal Cell Carcinoma: Analysis from the NCDB**
G. Musso, Milan (IT)

**12:45 - 13:15** **Surgical outcomes**

A0184 **Optimization of Postoperative Care for Nephrectomy Patients Using the UroConnect Telemonitoring Tool (UroCCR n°129)**
G. Margue, Bordeaux (FR)

A0185 **Three-Dimensional Image-Guided Robot-Assisted Partial Nephrectomy for Tumors in Horseshoe Kidneys: A European Multicentre Case Series (YAU RCC – UroCCR)**
G. Margue, Bordeaux (FR)

**Study Group**
EAU - YAU Renal cancer working group(Amsterdam, The Netherlands)

A0181 **CORE-Renal: A fully automated, data-driven comprehensive scoring system for the precise prediction of perioperative risks in renal tumor surgery**
Z. Zhao, Jinan (CN)

A0182 **Predicting Surgical Outcomes in Single-Port Robot-Assisted Partial Nephrectomy: External Validation and comparative analysis of PADUA, RENAL, and SPARE Scores**
F. Tamborino, Chieti (IT)

A0183 **Surgical Quality Metrics Predict Clinically Meaningful Outcomes in Nephrectomy for Renal Cell Carcinoma (RCC): Lessons from 10,991 Nephrectomies**
D.K-W. Leung, hong kong (HK)

**Study Group**
EAU YAU RCC Working Group(Hong Kong, Italy)

A0186 **Robotic Surgery of Wilms Tumour: Time to expand the frontiers of minimally invasive surgery? Preliminary results from a tertiary center**
U.M. Pierucci, Milano (IT)

**13:15 - 13:45** **Functional outcomes**

A0175 **Investigation of the effects of mannitol and mirabegron in terms of hypoxia-triggered mechanisms and angiogenesis in renal ischemia reperfusion injury**
N. Karabacak, Ankara (TR)

A0176 **Personalized Predictors Of Renal Recovery After Partial Nephrectomy**
A. Campugiani, Milan (IT)

A0177 **Baseline renal function predicts survival in patients undergoing small renal mass ablation**
B. Golijanin, providence (US)

A0178 **Sutureless Off-Clamp Robot-Assisted Partial Nephrectomy: Adoption, Learning Curve, and Propensity-Score Matched Outcomes in a Large Single-Center Cohort**
R.S. Flammia, Rome (IT)

A0179 **Sutureless Purely Off-Clamp Robotic Partial Nephrectomy: evidence from a randomized controlled non-inferiority trial**
A. Brassetti, Rome (IT)

## Kidney transplantation: Expanding indications through new technologies

Abstract Session 15

**Saturday 14 March**
**12:15 - 13:45**

**Location** Red Area, Room 9

**Chairs**
A. Gallioli, Barcelona (ES)
M. Musquera Felip, Barcelona (ES)

**12:15 - 12:40** **Basic & translational research**

A0238 **XBP1s-GAS1 mediates the formation of tertiary lymphoid structures after kidney transplantation in elderly donors through the Hedgehog signaling pathway**
J. Ruan, Beijing (CN)

A0239 **Dynamic Donor-Derived cfDNA Normalization After Kidney Transplantation: Preliminary Results from a Personalized NGS and AI-Based Monitoring Platform**
M.E. Polat, Ankara (TR)

A0240 **TGF-β Drives Memory-like NK Cell Formation and Transplant Rejection through AP-1-mediated Epigenetic Reprogramming**
Z. Xu, Shanghai (CN)

A0241 **Normothermic machine perfusion of murine kidneys leads to intragraft ferroptosis and cellular stress**
F. Friedersdorff, Berlin (DE)

A0242 **An ex-vivo normothermic perfusion model to study metabolic interplay between liver and kidney: a proof-of-concept study.**
A. Panis, Paris (FR)

---

**12:40 - 13:05** **Robotic-assisted kidney transplantation & simulation**

A0243 **Trifecta in Robot-Assisted Kidney Transplantation (RAKT) from living donors: Insights from 8-years ERUS-RAKT experience**
A. Gallioli, Barcelona (ES)

A0244 **Robot assisted kidney transplantation with double artery allografts: perioperative and graft survival outcome comparison of different anastomotic techniques from a tertiary centre**
A.K. Pal, Kolkata (IN)

A0245 **Single-Port Robotic Retroperitoneal Living Donor Nephrectomy using the supine anterior retroperitoneal approach (SARA): Toward a New Standard in Minimally Invasive Kidney Transplantation**
T-H. Yen, Taichung (TW)

A0247 **Design and Implementation of a High-Fidelity 3D-Printed Kidney Transplantation Simulator**
J. Kassir, Lyons (FR)

---

**13:05 - 13:25** **Robotic vs open surgery**

A0248 **Open versus robotic-assisted orthotopic kidney transplantation: a comparative retrospective cohort study**
C. Bardella Altarriba, Barcelona (ES)

A0250 **Age-stratified length of stay benefit of robotic versus open approach in deceased-donor kidney transplantation: evidence from a European multicenter registry**
A. Belarmino, Barcelona (ES)

**Study Group**
ERUS-RAKT Working Group(Barcelona, Spain)

A0251 **Body-mass index and postoperative recovery after robotic versus open deceased-donor kidney transplantation: a European multicenter registry analysis**
A. Belarmino, Barcelona (ES)

**Study Group**
ERUS-RAKT Working Group(Barcelona, Spain)

---

**13:25 - 13:45** **Expanding the donors' pool**

A0252 **Outcomes of simultaneous liver-kidney transplantation using graft from controlled donors after circulatory death**
E. Maicas Aran, Barcelona (ES)

A0253 **Mobile Surgical Unit for Organ Retrieval in Controlled DCD Donors**
E. Seizilles de Mazancourt, LYON (FR)

A0254 **Expanding the donor pool: Multicentric outcomes of kidney transplantation from donors with small renal tumors**
G. A. Payet walsh, Barcelona (ES)

A0255 **External validation of the Kidney Transplantation Outcome Predictions models**
A. González Serrano, Palma (ES)

## Genitourinary reconstruction

Abstract Session 14

**Saturday 14 March**
**12:15 - 13:45**

**Location** Red Area, Room 8

**Chairs**
X-S. Li, Beijing (CN)
P. Neuville, LYON (FR)
A-F. Spinoit, Ghent (BE)

**12:15 - 13:00** **Upper urinary tract reconstruction**

A0227 **Predictors of adverse outcomes after ureteral reconstructive surgery: insights from an international multicenter study**
S. Moretto, Paris (FR)

A0221 **Real-Time Intraluminal Optical Coherence Tomography Predicts Ureteral Stricture Formation in a Bama Minipig Model**
Y. Zhu, Nanjing (CN)

A0222 **Robotic-assisted Gonadal Vein Transposition for Nutcracker Syndrome: Surgical Technique and Results**
E. Seizilles de Mazancourt, LYON (FR)

A0223 **Clinical and Functional Outcomes of Robotic-Assisted Buccal Mucosal Graft Ureteroplasty (RU-BMG) for Complex Recurrent Ureteric Strictures: A Multicentre Experience**
C. Clark, Harpenden (GB)

A0224 **Robotic vs. open ureteral reimplantation: a retrospective comparative single-center series**
A. Bourillon, Rennes (FR)

A0225 **Ten years of robot-assisted laparoscopic ureterolysis (RALU): the solution to problematic ureteric obstruction caused by Retroperitoneal Fibrosis**
A. Fernando, London (GB)

A0226 **Comparative Analysis of 30-Day Postoperative Outcomes Between Robotic and Laparoscopic Pyeloplasty in Adults: Evidence from a Large National Prospective Database from 2022 and 2023**
R. Touma Sawaya, Beirut (LB)

A0228 **Robot-assisted bilateral ileal ureter replacement for the treatment of bilateral long ureteral strictures: technique and outcomes form multi-institutional database**
J. Yang, Beijing (CN)

**13:00 - 13:25** **Gender affirming surgery**

A0229 **Long-term patient-reported outcomes of salvage ileocecal vaginoplasty after failed penile inversion in trans women**
R.J. Schulz, Hamburg (DE)

A0230 **International Delphi Consensus on Indications, Contraindications, and Complication Management in Masculinizing Genital Surgery for Assigned-Female-at-Birth Individuals**
M. Lo Re, Florence (IT)

A0231 **Mechanical failure rates are high following inflatable penile prosthesis insertion in transgender patients**
A. Gobbo, London (GB)

A0232 **International Delphi Consensus on Indications and Management for Feminizing Genital Surgery in Assigned-Male-at-Birth Individuals**
M. Pezzoli, Florence (IT)

A0233 **A multi-institutional analysis of outcomes after vaginal sparing metoidioplasty**
D. Callahan, Austin (US)

**13:25 - 13:45** **Fistulas genitourinary reconstruction**

A0234 **Laparoscopic Transvesical vs Extravesical Repair for Supratrigonal VVF: A Randomized Trial**
P. Chowdhury, BHUBANESWAR (IN)

A0235 **York Mason repair of rectourethral fistula: 10 year experience**
M.Y. Hu, Durham (US)

A0237 **Transvaginal Fascial Patch Repair for Circumferential Urethral Diverticulum: Five-Year Experience in 68 Cases**
S.H. Shen, Chengdu (CN)

## Into the vein: Innovations in robotic kidney cancer surgery

Video Session 06

**Saturday 14 March**
**12:15 - 13:45**

**Location** Blue Area, Victoria 1

**Chairs** P. Dell'Oglio, Milan (IT)
To be confirmed
A. Mottrie, Aalst (BE)

V043 (▢1: 8 min.) **Kidney cancer with segmental venous invasion : tips and tricks for 3D Image-Guided Robotic Assisted Partial Nephrectomy (3D IGRAPN)**
G. Margue, Bordeaux (FR)

V038 (▢1: 7 min.) **Renal tumor with Level IV thrombus: Comparing the transdiaphragmatic and sternotomy approaches**
C.H. Yee, Hong Kong (HK)

V039 (: 8 min.)
**Robot-assisted IVC Thrombectomy: Insights from over a Decade of Experience**
L. Misuraca, Rome (IT)

V040 (: 8 min.)
**Robot-assisted Partial Nephrectomy and Thrombectomy in a Patient with Angiomyolipoma and Renal Venous Thrombus under Hypothermia Perfusion**
Z. Wu, Shanghai (CN)

V041 (: 7 min.)
**Superior Mesenteric Artery (SMA) injury during robot-assisted thrombectomy, always a nightmare?**
F. Piramide, Turin (IT)

V042 (: 8 min.)
**3D Image guided robot-assisted heminephrectomy with IVC thrombectomy on a single kidney**
M. Odin, (FR)

V044 (: 7 min.)
**Robot-Assisted Nephron-Sparing Surgery and Tumor Thrombectomy in Patient with Renal Angiomyolipoma and Inferior Vena Cava Tumor Thrombus: Step-by-Step Technique Description and Preliminary Results**
C. Xu, Beijing (CN)

## Urological infections in the era of AMR: Rethinking prevention, management and surgical strategy

eau Infections

EAU Section of Infections in Urology

**Saturday 14 March**
**12:15 - 13:45**

**Location** Blue Area, Victoria 2

**Chairs**
J. Kranz, Aachen (DE)
Z. Tandoğdu, London (GB)

**Learning objectives**
By the end of this session, participants will be able to critically evaluate perioperative antibiotic prophylaxis strategies and their impact on infection prevention in urological surgery. The session will address real-world challenges related to antimicrobial resistance (AMR), including surgical complications and difficult infections. Participants will learn how principles of surgical stewardship can reduce infection risk and support AMR control. Finally, emerging therapeutic approaches, including novel antibiotics and non-antibiotic strategies, will be discussed to highlight future directions in infection management in urology.

**12:15 - 12:17**
**Introduction**
Z. Tandoğdu, London (GB)

**12:17 - 12:57**
**Safe surgery and sepsis in the AMR era**

12:17 - 12:27
**Prophylaxis and practice: Game-changing studies that shift the needle (APPEAL, DEEP URO, updated periop protocols)**
K.A.O. Tikkinen, Helsinki (FI)

12:27 - 12:37
**AMR in the real world: Post-surgical infections and long-term impact**
L. Tzelves, Athens (GR)

Debate **Should the transperitoneal route be phased out in favour of retro-/extraperitoneal when infection risk is high?**

12:37 - 12:42 **Pro: Surgical safety and infection avoidance**
T.E. Bjerklund Johansen, Oslo (NO)

12:42 - 12:47 **Con: Oncologic access, learning curve, patient anatomy**
K. Touijer, New York (US)

12:47 - 12:57 **Discussion and Q&A**

*Panel*
T.E. Bjerklund Johansen, Oslo (NO)
K.A.O. Tikkinen, Helsinki (FI)
K. Touijer, New York (US)
L. Tzelves, Athens (GR)

---

**12:57 - 13:27** **Future-proofing urology against AMR**

12:57 - 13:07 **Antibiotic resistance and urology: From passive to proactive**
J. Medina Polo, Madrid (ES)

13:07 - 13:17 **What's coming? New antibiotics and non-antibiotic tools for urology (including bacteriophages, vaccines, microbiome therapies)**
F.M.E. Wagenlehner, Giessen (DE)

13:17 - 13:27 **Surgical stewardship in action: How urologists can lead the next phase of AMR control**
T. Cai, Trento (IT)

---

**13:27 - 13:45** Debate **New antibiotics or no antibiotics: What should urologists bet on to beat AMR?**

*Moderator*
Z. Tandoğdu, London (GB)

13:27 - 13:30 **Introduction**
Z. Tandoğdu, London (GB)

13:30 - 13:33 **Side A: Invest in new antibiotics**
J. Kranz, Aachen (DE)

13:33 - 13:36 **Side B: Prioritise non-antibiotic strategies**
C. Harding, Newcastle upon Tyne (GB)

13:36 - 13:38 **Audience Vote**

13:38 - 13:40 **Rebuttal: Side A**

13:40 - 13:42 **Rebuttal: Side B**

13:42 - 13:45 **Final votes and closing remarks**

# How imaging is shaping prostate cancer management

EAU Section of Urological Imaging in collaboration with European Society of Urologenital Radiology (ESUR) and European Association of Nuclear Medicine (EANM)

**Saturday 14 March**
**12:15 - 13:45**

**Location** Blue Area, George 3

**Chair** F. Sanguedolce, Barcelona (ES)

**Learning objectives**

Imaging in prostate cancer is revolutionising patients' management, from screening and early diagnosis, to local treatment planning and systemic therapy. In order to better understand how and which imaging modalities play a major role in the decision making or in the treatment guidance, the session involves experts from different disciplines including representatives from the European Society of the Urogenital Radiology and from the European Association of Nuclear Medicine.

Key topics will be:

- The current role of AI and new imaging modalities in diagnosis
- How the prostate biopsy strategies may influence local treatment management
- Everything the urologists should know about theranostics in prostate cancer

**12:15 - 12:16** **Welcome and introduction**
F. Sanguedolce, Barcelona (ES)

**12:16 - 12:42** **Screening and early detection**

*Moderators* F. Giganti, London (GB); G. Lughezzani, Rozzano (IT)

12:16 - 12:22 **MRI and artificial Intelligence in prostate cancer detection**
I.G. Schoots, Rotterdam (NL)

Rapid-fire debate **New ultrasound technologies in Pca detection: A contender to MRI?**

12:22 - 12:27 **The trend is promising**
L.H. Klotz, Toronto (CA)

12:27 - 12:32 **Too soon to tell**
R. Girometti, Udine (IT)

12:32 - 12:35 **Q&A**

12:35 - 12:42 **Does PSMA PET/CT have a role in early detection?**
D. Murphy, Melbourne (AU)

**12:42 - 13:11** **Biopsy and surgical planning**

*Moderators* D. Murphy, Melbourne (AU); V. Panebianco, Rome (IT)

12:42 - 12:48 Challenging the guidelines **What is the evidence in support of target and perilesional biopsy?**
P. Cornford, Cork (IE)

**...and what next? Perilesional biopsy is enough to undertake my surgeries?**

12:48 - 12:53 **Yes indeed!**
F. Sanguedolce, Barcelona (ES)

12:53 - 12:58 **No way… I need what's in the contralateral lobe!**
E. Barret, Paris (FR)

12:58 - 13:01 **Q&A**

Rapid-fire debate **The cN1 PSMA positive and CT negative**

13:01 - 13:06 **A case for radiotherapy + abiraterone**
B.A. Jereczek-Fossa, Milan (IT)

13:06 - 13:11 **A case for prostatectomy + lymphadenectomy**
G. Giannarini, Udine (IT)

---

**13:11 - 13:42** **All urologists needs to know on theranostics in prostate cancer**

*Moderators* D. Oprea-Lager, Nijmegen (NL)
F. Sanguedolce, Barcelona (ES)

13:11 - 13:16 **Theranostics in hormone-sensitive PCa: Evidence and ongoing trials**
D. Oprea-Lager, Nijmegen (NL)

13:16 - 13:17 **Introducing the debate**
F. Sanguedolce, Barcelona (ES)

Rapid-fire debate **Oligometastatic recurrent PCa on PSMA PET**

13:17 - 13:22 **Perfect scenario for theranostics**
K. Goffin, Leuven (BE)

13:22 - 13:27 **Perfect scenario for SBRT (+/- ARSI)**
B.A. Jereczek-Fossa, Milan (IT)

13:27 - 13:32 **...and what about surgery role?**
L. Budäus, Hamburg (DE)

13:32 - 13:35 **Q&A**

13:35 - 13:42 **Alpha, beta emitters and future development**
W. Fendler, Essen (DE)

---

**13:42 - 13:45** **EAU Imaging Vision Award 2026**

*Winner* A. Kinnaird, Edmonton (CA)

---

**13:45 - 13:45** **Closing remarks**
F. Sanguedolce, Barcelona (ES)

# YUORDay26 - EAU Young Urologists Office (YUO) & European Society of Residents in Urology (ESRU) - Part I

Special Session

**Saturday 14 March**
**12:15 - 14:15**

**Location** Blue Area, Victoria 5

**Chairs** L.C. Baekelandt, Leuven (BE)
C. Cerrato, Nottingham (GB)

**Learning objectives**
This session introduces the European Urology Scholarship Programme (EUSP) and highlights opportunities for residents and young urologists to engage in international fellowships, research, and academic collaboration. Participants will learn how to apply for EUSP scholarships, explore available endourology fellowship pathways, and hear practical insights from experienced tutors and former scholars. Award-winning research projects will be presented to showcase the programme's scientific impact. The session will also address key aspects of professional development, including research initiation, leadership within the EAU, sustainability in urology, and basic principles of health economics relevant to clinical decision-making.

**12:15 - 12:25** **Welcome and introduction**
L.C. Baekelandt, Leuven (BE)

**12:25 - 13:15** **European urology scholarship programme (EUSP)**

12:25 - 12:40 **Updates on EUSP programme and how to apply**
A.S. Merseburger, Lübeck (DE)

12:40 - 12:55 **Introducing the endourology fellowships**
B. Somani, Southampton (GB)

12:55 - 13:10 **My experience being a tutor and what I have advised**
Y. Abu Ghanem, London (GB)

13:10 - 13:13 Best scholar winner: Clinical research **Diagnostic accuracy of MRI-guided transperineal prostate biopsy using a low-field, portable, office-based, open MRI device vs traditional MRI/ultrasound fusion-guided prostate biopsy: A prospective, multicenter, single-arm, open-label pilot study**

*Winner* L. Afferi, Aarau (CH)

13:13 - 13:15 Best scholar winner: Basic research **Stimulated Raman histopathology for intraoperative tissue margin assessment during robot assisted radical prostatectomy and robot assisted partial nephrectomy**

*Winner* A. Özkan, Freiburg (DE)

**13:15 - 14:15** **Development as a young urologist**

*Moderators* A. Jin Ye, Lisbon (PT)
G. Margue, Bordeaux (FR)
M. Özalevli, Artvin (TR)

13:15 - 13:30 **Climbing the ladder within the EAU: From resident to leadership**
J.L. Vásquez, Copenhagen (DK)

13:30 - 13:45 **Go green as urologist?**
B. Pradère, Toulouse (FR)

13:45 - 14:00 **Starting your first research project: What should you know?**
N.R. Bhatt, Dublin (IE)

14:00 - 14:15 **Health economics for urologists: Understanding costs, value and decision-making**
B. Somani, Southampton (GB)

## Policy Office - Living with urinary incontinence as a comorbidity

Special Session

**Saturday 14 March**
**12:15 - 12:45**

**Location** EAU Square

**Chair** P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

**Learning objectives**
Representatives of four patient organisations dealing with different medical conditions will discuss how is living for patients with their initial health problem and urinary incontinence as a comorbidity. Additionally a new document will be presented "COEXISTING CONDITIONS. Urinary incontinence as a NCD comorbidity" as part of the "Urge to Act" campaign of the EAU Policy Office. This session will involve a conversation between patient representatives and will focus on how it is living with urinary incontinence as a comorbidity of another disease and the impact it has on quality of life. Clinicians will be informed about the relevance of the patients perspective for their daily practice.

**Living with urinary incontinence as a comorbidity: patient perspectives and the launch of the Urge to Act campaign document**

*Discussants*
M. Daly, Roscommon (IE)
A. De Santis, Rome (IT)
A. Filicevas, Brussels (BE)
P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)
M.L. Van Poelgeest-Pomfret, Bari (IT)

## Fine tuning prostate cancer diagnostics

EGPT 25

**Saturday 14 March**
**12:15 - 13:45**

**Location** Orange Area, EGPT 1

**Chairs** C.L. Dickinson, Surrey (GB)
To be confirmed
A. Stabile, Milan (IT)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

12:15 - 12:40 **Biopsy strategy**

| | |
|---|---|
| P0435 | **One plane or two? A randomized comparison of biplanar versus monoplanar prostate biopsy strategies**<br>Z. Zeng, Guangzhou (CN) |
| P0436 | **Diagnostic Value of Combined Transperineal MRI-Targeted and Systematic Mapping Biopsies: Diagnostic Contribution of Secondary and Tertiary Lesions**<br>N.E. Paesano, Madrid (ES) |
| P0437 | **Can we drop systematic cores? Predictors supporting cognitive TP biopsy as a stand-alone strategy**<br>T. Uzel, Ankara (TR) |
| P0438 | **Diagnostic Value of Perilesional Sampling to the Detection of Clinically Significant Prostate Cancer in Software-Based Multiparametric MRI-Targeted Biopsies: Early Results of a Prospective Study**<br>N. Karabacak, Ankara (TR) |
| **12:40 - 13:00** | **Basic science** |
| P0442 | **Development and clinical validation of a urine-based DNA methylation assay for noninvasive detection of prostate cancer: a prospective study**<br>N.Z. Xing, Beijing (CN) |
| P0443 | **Comprehensive single-cell spatial profiling of prostate cancer reveals ecosystem dynamics in 23.5 million cells**<br>J-H. Pan, Shanghai (CN) |
| **13:00 - 13:05** | **Complications post biopsy** |
| P0444 | **The SETABA Trial: Tadalafil plus Serenoa repens Combination Improves Post-Biopsy Functional Recovery After Transperineal Prostate Biopsy**<br>F. Proietti, Rome (IT) |
| **13:05 - 13:20** | **Race, genetics and socio-economic status** |
| P0445 | **The impact of Area Deprivation Index on receiving appropriate work-up on patients presenting with an elevated PSA**<br>A. Santangelo, Milan (IT) |
| P0446 | **The impact of Race on oncological outcomes in patients with an initial negative prostate biopsy: results from a contemporary North America cohort**<br>A. Bertini, Detroit (US) |
| P0447 | **The prevalence of BRCA1 and BRCA2 gene deleterious alterations in advanced prostate cancer: Analysis of the nationwide cancer genomic database in Japan.**<br>H. Tsumura, Sagamihara (JP) |
| **13:20 - 13:35** | **PSA and other biomarkers** |
| P0449 | **Evidence-based PSA Reference Ranges:  Results from the Norwegian Prostate Cancer Consortium (NPCC)**<br>J. Oldenburg, Oslo (NO) |
| P0450 | **Validation of Stockholm3 for Prostate Cancer Detection in a Swiss Non-Referral Cohort: Balancing Biopsy Reduction and Diagnostic Performance**<br>B. Benjamin, Berne (CH) |
| **13:35 - 13:45** | **Additional imaging beyond MRI** |

P0451 **Coupling MRI Voxel-wise Spatial Heterogeneity with TRUS Dynamic Deep Features Endows High Discernability for Clinically Significant Prostate Cancer**
S.K. Lam, Kowloon Hong Kong (HK)

P0452 **Second-line PSMA PET/MRI-guided prostate biopsies after MRI-first in men assessed for prostate cancer - clinical testing against systematic biopsies**
M.R. Jochumsen, Aarhus (DK)

## Advancements in male sexual health: Surgical techniques, clinical trials, and digital health applications

EGPT 28

**Saturday 14 March**
**12:15 - 13:45**

**Location** Blue Area, EGPT 4

**Chairs**
P. Egydio, Sao Paulo (BR)
M. Gül, Konya (TR)
M. Skrodzka, London (GB)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**12:15 - 13:00** **Erectile dysfunction**

P0487 **Phase I clinical trial: Pilot study of somatic-autonomic nerve grafting technique to restore erectile function in patients with persistent erectile dysfunction post radical prostatectomy**
L. Delli Colli, Montreal (CA)

P0488 **Classic versus stapler circumcision: effects on penile length, sensitivity and sexual function**
M. Czajkowski, Gdansk (PL)

P0489 **The Presence Of A Dose Response Relationship Between Obstructive Sleep Apnoea And Erectile Dysfunction: A Systematic Review**
M. Eldaneen, Tanta (EG)

P0491 **Increased Risk of Erectile and Testicular Dysfunction among Young Men with Type 2 Diabetes Treated with Semaglutide: A Global TriNetX Cohort Analysis**
J.Y. Hsu, Taichung (TW)

P0494 **Superselective Angioplasty of Pudendal Arteries with Sirolimus-Coated Balloon: Percutaneous Intervention for Arteriogenic Erectile Dysfunction**
S.T. De Cillis, Turin (IT)

P0495 **Living with loss: the impact of testicular prosthesis on sexual function, self-esteem, and postoperative well-being after orchifunicolectomy**
M. Menozzi, (IT)

**13:00 - 13:25** **Penile prosthesis**

P0496 **The Effect of Closed Suction Drain Usage on Postoperative Outcomes After Three-Piece Inflatable Penile Prosthesis Surgery: A Retrospective Comparative Study**
M.F. Özervarli, (TR)

P0497 **International Multicenter Validated Tool Assessment of Patient Satisfaction after Inflatable Penile Prosthesis (IPP)**
A. Al-Mitwalli, London (GB)

P0498 **Postoperative complication severity prediction in penile prosthesis implantation: a machine learning-based predictive modeling study**
M. Gül, Konya (TR)

P0499 **Twelve-Week Outcomes and Complications Following Penile Prosthesis Implantation: Data From the EAU Research Foundation PHOENIX Registry**
H. De Bruyn, Leuven (BE)

**Study Group**
EAU RF Phoenix Registry group(Arnhem, The Netherlands)

P0500 **Comparative outcomes of early versus delayed penile prosthesis insertion in patients with ischaemic priapism**
M. Eldaneen, Tanta (EG)

**13:25 - 13:45** **Premature ejaculation**

P0503 **A digital health application to reduce premature ejaculation symptoms: Final results of the German CLIMACS study.**
C. Groeben, Heidelberg (DE)

P0504 **Early Postoperative Erectile Fullness as a Predictor of Orgasmic Function After Robotic-Assisted Radical Prostatectomy with the Hood Technique**
J. Wang, San Jose (US)

## Upper tract urothelial carcinoma: Navigating diagnostics, treatment, and recurrence

EGPT 27

**Saturday 14 March**
**12:15 - 13:45**

**Location** Orange Area, EGPT 3

**Chairs** T.A. Drewa, Bydgoszcz (PL)
M.T. Grabbert, Freiburg (DE)
O. Čapoun, Prague (CZ)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**12:15 - 12:40** **UTUC staging**

P0469 **A novel AI system for preoperative depth prediction in UTUC**
K. Fukuta, tokushima (JP)

P0470 **Diagnostic yield and clinical significance of ureteroscopy in patients with CT scan suggesting upper tract urothelial carcinoma.**
S. Bille, Leeds (GB)

P0471 **Diagnostic Value and Clinical Impact of Staging [$^{18}$F]FDG-PET/CT for Upper Tract Urothelial Carcinoma**
R. Lijnen, Amsterdam (NL)

P0472 **Artificial Intelligence vs clinicians in Upper Tract Urothelial Cancer Management: accuracy and decision-making**
C. Fernandes, Porto (PT)

P0473 **Development and internal validation of machine-learning models to predict adverse pathological features in upper tract urothelial carcinoma using data from the ROBUUST 3.0 collaborative**
P. Korn, Munich (DE)

**12:40 - 13:05** **Endoscopical treatments for UTUC**

P0478 **Kidney-sparing surgery versus radical nephroureterectomy for high-grade organ-confined upper tract urothelial carcinoma: Analysis of the ROBUUST Registry**
F. Proietti, Rome (IT)

**Study Group**
ROBUUST Registry(Cleveland, United States of America)

P0474 **Conditional survival and bladder cancer free survival of upper tract urothelial carcinoma treated with endoscopic kidney-sparing surgery: a YAU Urothelial group perspective**
G. Avesani, Milan (IT)

P0475 **Endoscopic Management of Upper Tract Urothelial Carcinoma: A Multicenter Study on the Efficacy and Safery of Holmium laser with Vapor Tunnel, Holmium laser with Magneto technology and Thulium Fiber Laser**
D. Perri, Como (IT)

P0476 **Other-cause mortality in upper tract urothelial cancer patients receiving second-look ureteroscopy: multicenter EAU-YAU Urothelial study**
F. Di Bello, Napoli (IT)

**Study Group**
EAU-YAU Urothelial Working Group and Ureteroscopic Treatment of upper tract Urothelial Carcinoma (UTUC) registry(Barcelona, Spain)

**13:05 - 13:15** **Minimaly invasive techniques**

P0480 **Single-Port Versus Multi-Port Robotic Nephroureterectomy: A Multi-Institutional Contemporary Comparison of Perioperative Outcomes and Tetrafecta Achievement from the ROBUUST & SPARC Collaborative Groups**
G. Spena, Naples (IT)

**13:15 - 13:45** **Recurrence and adjuvant therapies**

P0482 **Bladder Cuff Excision and Intravesical Recurrence After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Cohort Study**
N. Rössler, Hamburg (DE)

P0483 **The Worse Impact of Diagnostic Ureteroscopy with Biopsy Prior to Radical Nephroureterectomy on Intravesical Recurrence-Free Survival in Patients with Upper Tract Urothelial Carcinoma**
T. Matsumoto, Fukuoka (JP)

P0484 **Contralateral Recurrence after Surgery for Upper Tract Urothelial Carcinoma: Risk Factors, Timing, and Treatment Patterns from the ROBUUST 3.0 International Registry**
F. Ditonno, Verona (IT)

P0481 **Do We Need to Redefine Recurrence-Free Survival in Patients with Localized Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy?**
C.H. Hsu, Taipei (TW)

P0486 **Impact of adjuvant intracavitary therapy on recurrence of upper tract urothelial carcinoma following endoscopic management**
P. Korn, Munich (DE)

# Advanced RCC management: Real-world data and prognostic indicators

EGPT 26

**Saturday 14 March**
**12:15 - 13:45**

**Location** Orange Area, EGPT 2

**Chairs** To be confirmed
L. Marandino, London (GB)
V. Mollica, Bologna (IT)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**12:15 - 12:25** **Role of radiotherapy in advanced renal cancer**

P0453 **Radiotherapy without regimen switch preserved survival in RCC immunotherapy**
S. Naito, Yamagata (JP)

**Study Group**
IMPACT8(Sapporo, Japan)

P0454 **Efficacy and Safety of Targeted-Immunotherapy With or Without Stereotactic Radiotherapy for Recurrent/Metastatic Renal Cell Carcinoma: Interim Analysis of a Multicenter Ambidirectional Cohort Study**
K. Hu, Beijing (CN)

**12:25 - 12:50** **Improving patient stratification in advanced renal cancer**

P0455 **Prognostic Impact of Metastatic Organ Burden and Site in Patients Treated with Nivolumab plus Ipilimumab for Metastatic Renal Cell Carcinoma: A Multi-institutional Study**
M. Oki, Nagasaki (JP)

P0456 **Lung Immune Prognostic Index and Subcutaneous Fat Index were prognostic factors for combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma**
N. Yamaguchi, Yonago (JP)

P0457 **IMPACT8 Criteria: IO-Specific Risk Models for Locally Advanced Metastatic RCC Across IO–IO and IO–TKI Therapies**
H. Naito, Kagawa (JP)

P0458 **Impact of Histological Subtype and Metastatic Burden on Overall Survival After Cytoreductive Nephrectomy for Metastatic RCC in the Immunotherapy Era: Insights from the National Cancer Database**
G. Garofano, Pieve Emanuele (IT)

P0459 **Prediction of immune-related adverse events in urological cancer during checkpoint inhibitor immunotherapy through immunohistochemical analysis of tumorous LCP1/ADPGK**
L. Xu, Beijing (CN)

**12:50 - 13:35** **Outcomes of metastatic renal cancer in the real world**

P0460 **Impact of metastatectomy on survival in metastatic clear cell renal carcinoma: In the era of systemic and targeted therapy**
A. Pon Avudaiappan, Miami (US)

P0461 **Real-World Outcomes of Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study**
M. Däuwel, Würzburg (DE)

P0462 **First-line treatment outcomes in metastatic renal cell carcinoma (mRCC) patients with pancreatic and/or thyroid metastases (PM/TM): results from the IMDC**
M. Zarba, Calgary (CA)

P0463 **Real-world Comparison of Nivolumab–Ipilimumab and Nivolumab–Cabozantinib in Metastatic RCC**
YT Lan, Taichung (TW)

P0464 **Impact of Age on Outcomes in Metastatic Non–Clear Cell Renal Cell Carcinoma (mnccRCC): A Real-World TriNetX Analysis**
A. Cigliola, Milan (IT)

P0465 **Are Real-World Patients with mRCC Receiving Sequential Therapies as in Trials? A Comparative Study**
H. Sato, Hirosaki (JP)

P0466 **Characteristics and first-line treatment of patients with advanced renal cell carcinoma (aRCC) in the UK**
D. Poonam, London (GB)

P0467 **First-line ICI+ICI versus ICI+TKI for metastatic renal cell carcinoma: Results from the Immune-checkpoint inhibitor Multi-institutional Project for Advanced Renal Cancer Therapy (IMPACT-8)**
K. Ohba, Nagasaki (JP)

P0468 **Occurrence, number of organs, and grade of irAEs in combination therapy of nivolumab plus ipilimumab predict the prognosis: A retrospective, multi-institutional study**
M. Oki, Nagasaki (JP)

**13:35 - 13:40** **Late-breaking abstract presentation**

LB017 **Data Accuracy and Its Impact on Evidence Validity for Evidence synthesis practice: A Reproducibility Study in Urology**
W. Xiaolong, Philadelphia (US)

## Innovations and insights in urinary incontinence management

EGPT 29

**Saturday 14 March**
**12:15 - 13:45**

**Location** Blue Area, EGPT 5

**Chairs** G. Bou Kheir, Gent (BE)
N. Sihra, London (GB)
To be confirmed

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**12:15 - 13:00** **Female incontinence**

P0505 **Fractional $CO_2$ Laser versus Biofeedback Therapy in Mild to Moderate Female Stress Urinary Incontinence: A Prospective Randomized Controlled Trial**
J. Ke, Guangzhou (CN)

P0506 **Vaginal microbiota in women before and after surgical treatment of SUI**
L. Sevastyanov, Karaganda (KZ)

P0507 **Autologous Fascia Lata Sling in Patients with Stress Urinary Incontinence: A decade of institutional experience**
L. Witlox, Schoten (BE)

P0508 **Effect of Diabetes on Quality-of-Life Improvement After Platelet-Rich Plasma Therapy for Women with Stress Urinary Incontinence**
A. Petca, Bucharest (RO)

P0509 **Predicting Persistent SUI After Weight-Loss Surgery: A Clinical Risk Score**
A.F. Rodrigues, Goiania (BR)

P0512 **Complications and Causes of Readmission Following Midurethral Sling Surgery for Stress Urinary Incontinence in 88,880 Patients**
A. Blondeau, Vandoeuvre Les Nancy (FR)

P0513 **The Australasian pelvic floor procedure registry: a maturing SUI registry cohort**
R. Whale, Melbourne (AU)

---

**13:00 - 13:45** **male incontinence**

P0514 **Single-center experience in the surgical treatment of cuff-related urethral erosion in men with artificial urinary sphincters**
L. Mas Grilló, Barcelona (ES)

P0515 **Barriers to Post-Prostatectomy Stress Incontinence Care: Knowledge Gaps, Patient Concerns, and Urologist Communication**
V. Menzel, Dresden (DE)

P0516 **Urodynamic risk factors for transient urinary incontinence after endoscopic enucleation of prostate hyperplasia**
O. Nesterova, Moscow (RU)

P0518 **Artificial urinary sphincter in men aged 75 Years and Older: Is it worth implanting? A single-center experience**
M. Henrique Bitar Siqueira, Toronto (CA)

P0519 **Evaluating the Impact of Radiotherapy on the Adjustable Transobturator Male System (ATOMS) Efficacy for Post-Prostatectomy Incontinence**
M. Kidess, München (DE)

P0520 **Early Multicenter Experience with the Adjustable Artificial Urinary Sphincter VICTO™ for the Treatment of Severe Male Stress Urinary Incontinence**
A. Fraile Poblador, Madrid (ES)

P0521 **Prospective PROXIMAL trial: 6-month outcomes after proximal ATOMS implantation in a challenging male incontinence cohort**
F. Queißert, Münster (DE)

P0522 **Impact of Salvage Radiotherapy on Delayed Referral for Artificial Urinary Sphincter Implantation After Radical Prostatectomy**
M. Kobayashi, Tokyo (JP)

# UroEvidenceHub PIONEER+ - Learning through big data

Special Session

**Saturday 14 March**
**13:00 - 14:00**

**Location** EAU Square

**Learning objectives**
Find out what is happening in big data research on PCa - meet the team that is advancing prostate cancer outcomes through the use of real-world evidence. The research team will be on hand to answer your questions.

**13:00 - 14:00**

**Meet the Prostate Cancer Research Team**

*Experts*

K. Beyer, Rotterdam (NL)
S. Evans Axelsson, Ystad (SE)
J. Gómez Rivas, Madrid (ES)
R. Nicoletti, Florence (IT)
P. Rajwa, Warsaw (PL)

# Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.5

**Saturday 14 March**
**13:00 - 13:50**

**Location** Red Area, Room 1

**Tutors**

O.R. Durutovic, Belgrade (RS)
M. Henderickx, Wilrijk (BE)
G. Kamphuis, Amsterdam (NL)

**Learning objectives**
This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

## Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.5

**Saturday 14 March**
**13:00 - 13:50**

**Location** Red Area, Room 1

**Tutor** D. Elterman, Toronto (CA)

**Learning objectives**

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

## Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.5

**Saturday 14 March**
**13:00 - 13:50**

**Location** Red Area, Room 1

**Coordinator** D. Oliveira Reis, Lisboa (PT)

**Tutors** C. Marialva, Algés (PT)
P. Umari, London (GB)

**Learning objectives**

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

## Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.5

**Saturday 14 March**
**13:00 - 13:50**

**Location** Red Area, Room 1

**Tutors**
N.C. Grossmann, Lucerne (CH)
A. Olivero, Milan (IT)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.5

**Saturday 14 March**
**13:00 - 13:50**

**Location** Red Area, Room 1

**Tutors**
S. García Barreras, Madrid (ES)
D. Veneziano, New York (US)

**Learning objectives**
The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

## Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.5

**Saturday 14 March**
**13:00 - 13:50**

**Location** Red Area, Room 1

**Tutors**
M. Arslan, Istanbul (TR)
E.D. Demirkiran, Zonguldak (TR)
B. Dreyer, Kirkcaldy (GB)

**Learning objectives**
This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

## Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.5

**Saturday 14 March**
**13:00 - 13:50**

**Location** Red Area, Room 1

**Tutors**
M. Paciotti, Rozzano, Milan (IT)
A. Tuncel, Ankara (TR)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# Patient advocacy plaza - Faecal incontinence and the impact of shared decision-making from the patient perspective

Special Session

**Saturday 14 March**
**13:30 - 14:00**

**Location** Patient Advocacy Plaza

**Chair** M.L. Van Poelgeest-Pomfret, Bari (IT)

**World Federation of Incontinence and Pelvic Problems (WFIPP)**
M.L. Van Poelgeest-Pomfret, Bari (IT)

# Patient advocacy plaza - The OAB PROMS study entitled 'REVEAL'

Special Session

**Saturday 14 March**
**14:15 - 14:45**

**Location** Patient Advocacy Plaza

**Chair** M.R. Van Balken, Arnhem (NL)

**Learning objectives**
To highlight the SDM-focus of EAU Patient Office To share consensus with patients an nurses on what SDM is To give examples of working together on this with WFIPP To explain that no SDM can excist without good PROMs - input To explain the REVEAL trial as an unique opportunity to collect these PROMs

**EAU Patient Office Vice-chair**
M.R. Van Balken, Arnhem (NL)

# Non-Technical Skills for Surgical Excellence: Immersive Simulation

HOT NTS - 2.2

**Saturday 14 March**
**14:15 - 15:15**

**Location** EAU Square

**Tutors**
A. Aydin, London (GB)
S.M. Haensel, Rotterdam (NL)
N. Raison, London (GB)
G. Zanovello, Verona (IT)

**Learning objectives**
Participants will be assigned to one of two simulation-based activities: a simulated operating room session or a computer-based virtual patient interaction. Both formats are designed to enhance non-technical skills, including communication, teamwork, and clinical decision-making.

**14:15 - 14:25**

**Concept of learning**
S.M. Haensel, Rotterdam (NL)

# Patient advocacy plaza - Recap march for men – UK & Sierre Leone & BALANCE: Embracing diversity in prostate cancer PROMS study.

Special Session

**Saturday 14 March**
**15:00 - 15:30**

**Location** Patient Advocacy Plaza

**Chairs**
T. Davies OBE, Waltham Cross (GB)
E. Rogers, Roscommon (IE)

**Learning objectives**
To hear firsthand about the experiences of Sierra Leone men who are diagnosed with prostate cancer, to identify the challenges in accessing timely treatment and to identify strategies needed to promote awareness of prostate cancer and prompt diagnosis and treatment.

**EAU Patient Office**
E. Rogers, Roscommon (IE)

**Cancer UK-Salone**
T. Davies OBE, Waltham Cross (GB)

# YUORDay26 - EAU Young Urologists Office (YUO) & European Society of Residents in Urology (ESRU) - Part II

Special Session

**Saturday 14 March**
**15:15 - 17:30**

**Location** Blue Area, Victoria 5

**Chairs**
L.C. Baekelandt, Leuven (BE)
J.L. Vásquez, Copenhagen (DK)

**Learning objectives**
This interactive session provides practical insights for residents and young urologists, combining surgical tips, challenging real-life cases, and simplified explanations of complex urological concepts. Participants will learn technical pearls for key procedures such as orchidopexy, nerve-sparing robotic prostatectomy, and mini-PCNL, and explore decision-making in difficult “nightmare” scenarios through expert discussion. The session also aims to simplify essential topics including urodynamics, erectile dysfunction assessment, and the clinical use of AI in urology. It concludes with the Guidelines Cup, reinforcing guideline-based knowledge in a dynamic and engaging format.

**15:15 - 15:36** **Surgery tips and tricks**

*Moderators*
L. Afferi, Aarau (CH)
I.O. Canitez, İstanbul (TR)
A. Giesen, Leuven (BE)

15:15 - 15:22 **Orchidopexy**
A-F. Spinoit, Ghent (BE)

15:22 - 15:29 **Nerve-sparing robotic prostatectomy**
D. Murphy, Melbourne (AU)

15:29 - 15:36 **PCNL & ECIRS**
C. Van Haute, Brussels (BE)

---

**15:36 - 15:57** **Nightmare cases**

*Moderators* A. Gugerli Lazos, Zürich (CH)
C. Toribio-Vazquez, Madrid (ES)
M. Van den Ende, Gent (BE)

15:36 - 15:43 **Case I What begins as a stone surgery unexpectedly turns into a complex oncological journey**

*Case presenter* R. Logli, Ankara (TR)

*Expert* P. Albers, Düsseldorf (DE)

15:43 - 15:50 **Case II When the ureter tears: Salvaging proximal ureteral avulsion during diagnostic URS**

*Expert* A. Skolarikos, Athens (GR)
G. Basso, Cornuda (IT)

15:50 - 15:57 **Case III From recurrent NMIBC to multiorgan exenteration: Lessons from a challenging urothelial carcinoma case**

*Case presenter* D. Carmali, Amadora (PT)

*Expert* P. Gontero, Turin (IT)

---

**15:57 - 16:18** **Urology made simple: Complex topics simplified**

*Moderators* L.C. Baekelandt, Leuven (BE)
C. Siech, Frankfurt Am Main (DE)

15:57 - 16:02 **Urodynamics made simple**
L. Landen, Leuven (BE)

16:02 - 16:04 **Discussion**

16:04 - 16:09 **Erectile dysfunction: Assessment and strategy**
E.C. Şerefoğlu, Istanbul (TR)

16:09 - 16:11 **Discussion**

16:11 - 16:16 **How AI in urology actually works**
E. Checcucci, Candiolo (IT)

16:16 - 16:18 **Discussion**

---

**16:18 - 17:18** **Guidelines cup**

*Moderators* J. Gómez Rivas, Madrid (ES)
J.L. Vásquez, Copenhagen (DK)

16:18 - 17:18 **Guidelines Cup finalists**
O. Alabed Allat, London (GB)
M. Facco, Padua (IT)
P.G. Silva, Almada (PT)

| | | |
|---|---|---|
| **17:18 - 17:24** | **Best abstract by a resident awards** | |
| 17:18 - 17:20 | First prize: Best abstract by a resident - **Diagnostic value and clinical impact of staging [$^{18}$F]FDG-PET/CT for upper tract urothelial carcinoma** | |
| | *Winner* | R. Lijnen, Amsterdam (NL) |
| 17:20 - 17:22 | Second prize: Best abstract by a resident - **Bladder cuff excision and intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: A multicenter cohort study** | |
| | *Winner* | N. Rössler, Hamburg (DE) |
| 17:22 - 17:24 | Third prize: Best abstract by a resident - **Are SGLT2 inhibitors a new risk factor for urinary tract infections after ureteroscopy in diabetic patients?** | |
| | *Presenter* | O. Sadeh, London (GB) |
| | *Winner* | N. Fazaa, Haifa (IL) |
| **17:24 - 17:29** | **Award ceremony guidelines cup** | |
| **17:29 - 17:30** | **Final remarks and closing** | |

# Hands-on Training in Urodynamics

HOT UDS - 2.2

**Saturday 14 March**
**15:15 - 18:15**

**Location** Red Area, Room 3

**Chair** H. Hashim, Bristol (GB)

**Learning objectives**
This hands-on training course is designed to help participants enhance their knowledge and technical skills in urodynamics, with a strong emphasis on practical, real-world application. Through guided instruction and supervised practice, participants will gain experience in each step of the urodynamic study (UDS) process, including equipment setup, test execution, troubleshooting common technical and clinical issues, and accurate data interpretation. The course aims to build confidence and competence in performing and analyzing urodynamic studies in a clinical setting.

| | | |
|---|---|---|
| **15:15 - 15:30** | **Introduction**<br>H. Hashim, Bristol (GB) | |
| **15:30 - 16:50** | **Hands-on Training: Rotation 1** | |
| 15:30 - 16:50 | **Setting up** | |
| | *Tutor* | A. Gammie, Bristol (GB) |
| 15:30 - 16:50 | **Running a test** | |
| | *Tutor* | A. Garcia Mora, Hummelstown (US) |
| **16:50 - 18:10** | **Hands-on Training: Rotation 2** | |
| 16:50 - 18:10 | **Troubleshooting** | |
| | *Tutor* | L. Thomas, Bristol (GB) |
| 16:50 - 18:10 | **Interpretation** | |
| | *Tutor* | C. Ochoa Vargas, Bristol (GB) |
| **18:10 - 18:15** | **Questions and conclusion**<br>H. Hashim, Bristol (GB) | |

# Evolving strategies in active surveillance, focal therapy and lymph node management

Thematic Session

**Saturday 14 March**
**15:30 - 17:00**

**Location** Orange Area, eURO Auditorium 2

**Chairs**
J. Stranne, Göteborg (SE)
D. Tilki, Hamburg (DE)

**Learning objectives**
Delegates will gain an updated understanding of advances in active surveillance, focal therapy, and lymph node management in prostate cancer. The session will highlight evolving evidence and compare differing expert perspectives on active surveillance approaches, focal treatment outcomes, and lymph node dissection.

**15:30 - 15:32** **Introduction**

**15:32 - 16:02** **Active surveillance 2.0**

Debate **Repeat biopsies are necessary in active surveillance**

15:32 - 15:37 **Yes**
R. Van Den Bergh, Rotterdam (NL)

15:37 - 15:42 **No, MRI is sufficient**
M. Emberton, London (GB)

15:42 - 16:02 **Round-table discussion**

*Moderator* M. Emberton, London (GB)

*Speakers*
A. Borkowetz, Rostock (DE)
S. Carlsson, Heidelberg (DE)
P. Sooriakumaran, London (GB)
R. Van Den Bergh, Rotterdam (NL)

**16:02 - 16:30** **Focal therapy in localised prostate cancer**

16:02 - 16:10 State-of-the-art lecture **Evidence base and outcomes of focal treatment**
V. Kasivisvanathan, London (GB)

16:10 - 16:30 **Round-table discussion**

*Moderator* V. Kasivisvanathan, London (GB)

*Speakers*
M. Dall'era, Sacramento (US)
C. Moore, London (GB)
G. Ploussard, Toulouse (FR)
R. Sanchez-Salas, Montreal (CA)

**16:30 - 16:58** **Management of lymph nodes in prostate cancer**

16:30 - 16:38 State-of-the-art lecture **Role of lymph node dissection at the time of RP for localised PCa**
T. Esen, Istanbul (TR)

| | | |
|---|---|---|
| 16:38 - 16:58 | **Round-table discussion** | |
| | *Moderator* | T. Esen, Istanbul (TR) |
| | *Speakers* | G. Gandaglia, Milan (IT)<br>A. Henry, Leeds (GB)<br>N. Lawrentschuk, Melbourne (AU)<br>D. Murphy, Melbourne (AU) |
| **16:58 - 17:00** | **Closing remarks** | |

## Evidence-based medicine made easy for urologists

Thematic Session

**Saturday 14 March**
**15:30 - 17:00**

**Location** Orange Area, Room 3

**Chairs** M.J. Ribal Caparros, Barcelona (ES)
K.A.O. Tikkinen, Helsinki (FI)

**Learning objectives**
Participants will learn a practical framework to judge the trustworthiness of urology evidence across key study types. Participants will recognize i) the essential design features and key measures of diagnostic accuracy, prognostic, and AI/ML studies, ii) interpret randomized trials and meta-analyses (including effect sizes, 95% CIs and p values), and iii) understand how evidence is translated into EAU Guidelines. The keynote is delivered by Gordon Guyatt, who coined the term evidence-based medicine.

| | | |
|---|---|---|
| **15:30 - 15:31** | **Welcome and Introduction** | |
| | M.J. Ribal Caparros, Barcelona (ES) | |
| **15:31 - 15:38** | State-of-the-art lecture | **How to understand a diagnostic accuracy study?** |
| | C. Moore, London (GB) | |
| **15:38 - 15:45** | State-of-the-art lecture | **How to understand a prognostic study?** |
| | G. Guyatt, Hamilton (CA) | |
| **15:45 - 15:52** | State-of-the-art lecture | **What if it's an AI/ML study?** |
| | S. Yuen, Hong Kong (HK) | |
| **15:52 - 16:01** | **Discussion** | |
| | *Panel* | G. Guyatt, Hamilton (CA)<br>C. Moore, London (GB)<br>S. Yuen, Hong Kong (HK) |
| **16:01 - 16:08** | State-of-the-art lecture | **How to understand a randomised trial?** |
| | R. Breau, Ottawa (CA) | |
| **16:08 - 16:15** | State-of-the-art lecture | **How to understand a meta-analysis?** |
| | P. Dahm, Minneapolis (US) | |

| | | |
|---|---|---|
| **16:15 - 16:22** | State-of-the-art lecture **P OR [95% CI] for urologists**<br>R. L. Dunn, Ann Arbor (US) | |
| **16:22 - 16:32** | **Discussion** | |
| | *Panel* | R. Breau, Ottawa (CA)<br>P. Dahm, Minneapolis (US)<br>R. L. Dunn, Ann Arbor (US)<br>To be confirmed |
| **16:32 - 16:39** | State-of-the-art lecture **How data becomes part of EAU Guidelines?**<br>S. Canfield, Houston (US) | |
| **16:39 - 16:51** | Keynote lecture **What is core GRADE?**<br>G. Guyatt, Hamilton (CA) | |
| **16:51 - 16:58** | **Discussion** | |
| | *Panel* | S. Canfield, Houston (US)<br>G. Guyatt, Hamilton (CA) |
| **16:58 - 17:00** | **Closing remarks**<br>K.A.O. Tikkinen, Helsinki (FI) | |

## Innovations in andrology: Fertility insights and hormonal frontiers

Abstract Session 22

**Saturday 14 March**
**15:30 - 17:00**

**Location** Blue Area, Victoria 2

**Chairs**
C.F.S. Jensen, Herlev (DK)
H.J. Park, Busan (KR)
G.I. Russo, Catania (IT)

| | |
|---|---|
| **15:30 - 16:25** | **Sperm quality in male infertility** |
| A0363 | **Age-stratified metabolic, endocrine, and immune profiling in primary male infertility: Insights from a real-world cross-sectional study**<br>E. Pozzi, Milan (IT) |
| A0366 | **Comparative Effects of Finasteride and Dutasteride on Semen Parameters in Young Men with Androgenic Alopecia: A Randomized Controlled Study**<br>H.J. Park, Busan (KR) |
| A0367 | **Inflammatory signatures and sperm concentration in fertile and infertile men: an age-stratified cohort analysis**<br>C. Piccolo, Milan (IT) |
| A0368 | **Phenotyping testicular reserve: What real-life data reveal**<br>A. Salonia, Milan (IT) |
| A0369 | **Seminal Microbiote Shifts After Varicocele Treatment: A Genus-Level Comparative Analysis Before and After Intervention**<br>M.G.R. Asmundo, Catania (IT) |

A0370 **Second semen analysis after first assessment: Challenging the current European Association of Urology guidelines using a trial emulation design study**
M. Oddo, Milan (IT)

A0371 **Flow cytometry sperm apoptosis test can predict sperm DNA fragmentation and can be used as an effective and easy-to-perform screening method for males from infertile couples**
J. Novák, Regensburg (DE)

A0372 **Comparison of demographic and contraceptive patterns in men undergoing vasectomy before and after the COVID-19 pandemic in Barcelona, Spain**
M. Raffo, Milan (IT)

A0373 **Impact of body fat and body fact distribution on testicular function in men with primary infertility**
M. Oddo, Milan (IT)

**16:25 - 16:35** **Traslational biomedicine**

A0374 **Single-Cell Transcriptomic Landscape of Spermatogenic Abnormalities in Diabetes**
Z. Zhang, Shenyang (CN)

A0375 **HIGH-FAT DIET AND RENIN–ANGIOTENSIN SYSTEM INHIBITION CAUSES STRUCTURAL CHANGES IN THE TESTIS STRUCTURE? AN EXPERIMENTAL MODEL**
L.A. Favorito, Rio de Janeiro (BR)

**16:35 - 17:00** **Sperm retrieval in azoospermia**

A0376 **From PI-RADS to Te-RADS: Testicular MRI biomarkers predicting sperm retrieval in non-obstructive azoospermia**
S. Luján Marco, Valencia (ES)

A0378 **AI-Enhanced microdissection testicular sperm extraction: Smart Detection of Spermatogenic Tubules**
Y. Fang, Beijing (CN)

A0379 **Novel Hormonal Spermatogenic Index (HSI) Predicts Micro-TESE Success in Non-Obstructive Azoospermia: A Pilot Study**
I. Uluç, Kocaeli (TR)

A0380 **Sperm retrieval outcomes in men with Y chromosome AZFc microdeletion undergoing testicular sperm extraction: real-world data from a large multicenter cohort**
F. Passarelli, Milano (IT)

## Enucleation is enucleation: Comparing efficacies across technologies

Abstract Session 21

**Saturday 14 March**
**15:30 - 17:00**

**Location** Blue Area, George 4

**Chairs** To be confirmed
J.H. Hong, Taipei (TW)
T. Hüsch, Mainz (DE)

**15:30 - 16:10** **Laser prostatectomy: Setting the standard for the next decade**

A0345 **A Decade of Surgical Trends in BPO Management: Real-World Evidence from a High-Volume LUTS Center Demonstrating the Shift Towards Laser Enucleation over TURP**
L.F. Stadelmeier, München (DE)

A0350 **Holmium:YAG laser enucleation of the prostate using the new Cyber Ho generator with Magneto technology: does it provide any advantages compared to Thulium:YAG prostate enucleation?**
V. Livio, Como (IT)

A0346 **Associated factors for achieving the Trifecta after Holmium Laser Enucleation of the Prostate (HoLEP): Evidence from a Prospective Cohort**
J. Fernandez Siles, Malaga (ES)

A0347 **Impact of Moses technology on HoLEP day-case success rate: a monocentric matched paired cohort study**
C. Klein, Bordeaux CEDEX (FR)

A0348 **Multicenter prospective comparative study to evaluate the safety and efficiency of same day catheter removal after en block holmium laser enucleation of prostate**
A.L. Pastore, Rome (IT)

A0349 **Size Matters: Outcomes and Complications of HoLEP in Large and Very Large Prostates**
J. Herrmann, Berlin (DE)

A0351 **Prospective multicenter real-world study of the Magneto laser in endoscopic enucleation of the prostate: 3-month outcomes**
K.Y. Fong, Singapore (SG)

A0352 **Thulium fiber versus Holmium laser enucleation: 24-months results of a prospective randomized non-inferiority trial**
M. Filzmayer, Frankfurt am Main (DE)

---

**16:10 - 16:35** **Miniaturized enucleation: Outcomes and safety**

A0353 **The MILES trial: Prospective randomized trial of safety and efficacy of minimally-invasive versus standard laser enucleation of the prostate**
A.M. Dymov, Moscow (RU)

A0355 **Comparison instrument miniaturization on surgical efficiency between Holmium Laser (HoLEP) and Slim Holmium (MiLEP) in prostate enucleation**
F. Gomez Regalado, Coahuila (MX)

A0356 **Prospective Multicenter Comparison of Aquablation and Anatomical Endoscopic Enucleation in Patients with Prostate Volumes over 100 ml: A 4-Year Follow-up Analysis**
B. Becker, Hamburg (DE)

---

**16:35 - 17:00** **Robotic assisted simple prostatectomy: An alternative for the large prostate**

A0358 **Multi-Institutional Outcomes of Robot-Assisted Simple Prostatectomy: A Retrospective Study by the ERUS Scientific Reconstructive Working Group**
Y. Heiniger, Winterthur (CH)

**Study Group**
ERUS Scientific Reconstructive Working Group(Winterthur, Switzerland)

A0359 **Comparative Analysis of Functional and Perioperative Outcomes Among HoLEP, RASP, and Aquablation: A Multicenter triple Matched-Pair Study**
M.G.R. Asmundo, Catania (IT)

A0360 **The SPRAMHO trial: single-port robot-assisted madigan resection of the prostate versus holmium laser enucleation of the prostate for large-volume(≥80 mL) benign prostatic hyperplasia — A randomized controlled study with a 1-year follow-up**
Y.B. Chen, Shanghai (CN)

A0362 **Same-Day Discharge Following Multiport Robot-Assisted Simple Prostatectomy: A Prospective Feasibility Study of Outcomes, Costs, and Post-Discharge Healthcare Utilization**
J. Wang, San Jose (US)

## Localised renal tumour treatment: Technology at its best!

Abstract Session 20

**Saturday 14 March**
**15:30 - 17:00**

**Location** Blue Area, George 3

**Chairs**
D. Amparore, Orbassano (Turin) (IT)
I. Gkialas, Athens (GR)
S. Psutka, Seattle (US)

**15:30 - 15:55** **3D model & augmented reality**

A0327 **The Impact of 3D Reconstruction in Preoperative Planning for Partial Nephrectomy: A Prospective Study**
M. Nuthalapati, Kochi (IN)

A0328 **Development of Biomimetic 3D-Printed Models for Training in Robot-Assisted Partial Nephrectomy: Toward Realistic Surgical Simulation of the Human Kidney**
G. Margue, Bordeaux (FR)

A0329 **3D perfusion zone models allow for more accurate and more frequent selective arterial clamping during robot-assisted partial nephrectomy: interim results of the multicentric PODRACING randomized controlled trial**
J. Vangeneugden, Ghent (BE)

A0330 **Three-Dimensional Image-Guided Robot-Assisted Partial Nephrectomy in Ischemia-Sensitive Patients: Surgical and Functional Outcomes from a Large Cohort with Propensity Score Matching (IRC-3D-IGRAPN - UroCCR 238).**
M. Pattou, Bordeaux (FR)

A0331 **Stereoscopic Registration Improves 3D Model Overlay Precision in RAPN with Augmented Reality Compared to Monocular Registration.**
M. Pattou, Bordeaux (FR)

**15:55 - 16:25** **AI**

A0336 **From Image to Insight: Radiomics Accuracy in Predicting Renal Malignancy**
P.G. Silva, Almada (PT)

A0332 **Head-to-Head Challenge: AI Versus the operating surgeon in Real-Time Anatomy Recognition during Single Port Retroperitoneal Surgery**
F. Tamborino, Chieti (IT)

A0333 **Application of Real-time Digital Twin Navigation and Warning System Based on Deep Learning and Augmented Reality Technology Platform (AI+AR) in Robot-assisted and Laparoscopic Partial Nephrectomy (NCT07020169)**
S. Zhang, Nanjing (CN)

| | |
|---|---|
| A0334 | **Artificial intelligence-driven three-dimensional reconstruction and surgical planning optimization for "fan-shaped pre-suturing zero-ischemia resection" in the treatment of renal tumors**<br>N. Yu, Jinan (CN) |
| A0335 | **SRE-RAPN50: A Multi-Task Dataset for Instrument–Anatomy Segmentation, Articulation Prediction, Surgical Action Recognition and Motion Estimation in Robot-Assisted Partial Nephrectomy**<br>Z. Tailai, Beijing (CN) |
| A0337 | **Workflow analysis with computer-vision algorithm to extract information from DaVinci head-up-display: A Proof-of-Concept study using RAPN video data**<br>N. Carl, Mannheim (DE) |
| **16:25 - 16:45** | **New robots on the block** |
| A0338 | **Revo-i versus Da Vinci for Robot-Assisted Partial Nephrectomy: First Clinical Comparison in Human Patients**<br>C.R. Park, Seoul (KR) |
| A0339 | **Outcomes of Single-Port Urologic Procedures Using Low Anterior Access: Outcomes of Single-Port Urologic Procedures Using Low Anterior Access: A Retrospective Multicenter Study**<br>F.M. Valenzi, Latina LT (IT) |
| A0340 | **Evaluating the learning curve of single-port partial nephrectomy: a multi-institutional cohort analysis**<br>A. Santangelo, Milan (IT) |
| A0341 | **Initial Experience with Single-Port Robot-Assisted Partial Nephrectomy Using the Low Anterior Access Technique: Feasibility, Perioperative Outcomes and Learning Curve Analysis in a SP-naive Robotic Referral Center**<br>H. Van Eecke, Ghent (BE) |
| **16:45 - 17:00** | **New technologies** |
| A0342 | **5-Year Outcomes of Stereotactic Radiotherapy for Primary Renal Cell Carcinoma from the Pooled Analysis of the FASTRACK Trials**<br>S. Siva, Melbourne (AU) |
| A0343 | **Spatial and functional analysis of PSMA-positive tumor vessels as predictors of recurrence and potential therapeutic targets in renal cell carcinoma**<br>R. Watanabe, Toon City (JP) |
| A0344 | **Iridium Photosensitizers Drive Pyroptosis–Necroptosis Synergy for Multi-Network Photoimmunotherapy of Renal Cell Carcinoma**<br>X. Qin, Jinan (CN) |

# EAU Lab: Tumour microenvironment, immune evasion & biological mechanisms of cancer progression

EAU26 Lab

Abstract Session 23

**Saturday 14 March**
**15:30 - 17:00**

**Location** Blue Area, Victoria 4

**Chairs**
M. Eckstein, Erlangen (DE)
E.S. Martens-Uzunova, Rotterdam (NL)
T. Strandgaard, Aarhus (DK)

**15:30 - 15:55** **Urothelial cancer**

A0382 **SLBP-mediated remodeling of the immunosuppressive microenvironment as a potential therapeutic target: Insights from multi-omics analyses**
Q. Zhang, guangzhou (CN)

A0383 **Entinostat Overcomes Cisplatin Resistance in Bladder Cancer by Promoting H3K18la-Mediated DHRS2 Expression to Suppress the AKR1C3-Androgen Axis**
G. Xu, Nanjing (CN)

A0384 **TGF-β inhibition upregulates Nectin-4 surface expression and enhances Enfortumab Vedotin efficacy in urothelial carcinoma**
A. Heselich, Bonn (DE)

**15:55 - 16:30** **Renal cancer**

A0385 **Integrative Deep Learning of Histopathology and Immune Microenvironment for Predicting Prognosis and Treatment Response in Renal Cell Carcinoma**
W. Zhai, Shanghai (CN)

A0387 **Genomic alterations in geriatric renal cell carcinoma**
S. Shirzadi, Montreal (CA)

A0389 **High-Throughput Screening of a Human Endogenous Metabolite Library Identifies Vitamin K4 as a Novel Therapeutic Candidate for Attenuating Renal Ischemia-Reperfusion Injury"**
B. Li, Changsha (CN)

A0390 **BIRC3 promotes proliferation of kidney cancer by regulating IFN signaling**
W. Liu, Beijing (CN)

A0391 **Divergent Evolution in Hereditary VHL-Associated and Sporadic Clear Cell Renal Cell Carcinoma**
Z. Zhang, Beijing (CN)

A0392 **Loss-of-function genetic screening identifies IL1RAP as an essential driver for RCC progression under hypoxia**
X. Zhehao, Hangzhou (CN)

**16:30 - 16:55** **Prostate cancer**

A0393 **Subtypes and Treatment Strategies of non-pCR High-Risk /Locally Advanced Prostate Cancer Post-Neoadjuvant Hormonal Therapy**
Y. Cai, Changsha (CN)

A0394 **Molecular Evolution and Resistance Mechanisms after Lu-177-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer**
R. Pe Benito, CAMBRIDGE (US)

A0395 **Epigenetic Profiling Reveals Divergent Methylation Landscapes in MRI-Targeted and Systematic Biopsy Prostate Cancer**
M. Brancaccio, Milan (IT)

A0396 **Tumour cell evolution within patient-derived models of localised hereditary prostate cancer**
R.G. Bristow, Manchester (GB)

A0397 **CGRP-RAMP1 signaling axis mediates sensory nerve-cancer bidirectional interaction and immune suppression to drive prostate cancer progression**
T. Zhuo, Urumqi (CN)

## Urogenital reconstruction: Female continence surgery, fistula repair and robotic pelvic restoration

Video Session 08

**Saturday 14 March**
**15:30 - 17:00**

**Location** Blue Area, Victoria 1

**Chairs**
T.J. Greenwell, London (GB)
H. John, Frauenfeld (CH)
H. Veiby Holm, Oslo (NO)

V053 (▢1: 7 min.) **Modified technique of Robot assisted laparoscopic repair of vesicovaginal fistula**
C. Mallikarjuna, Hyderabad (IN)

V054 (▢1: 6 min.) **Vesicovaginal fistula repair via vNOTES in a patient with a hostile abdomen.**
C. García-Rayo, Madrid (ES)

V055 (▢1: 8 min.) **12 key steps to overcome difficulties in female artificial urinary sphincter implantation**
A. Dubois, Rennes (FR)

V056 (▢1: 8 min.) **Single Port (SP) Robotic Sacrocolopexy and Hysterectomy: Tips and Tricks**
L. Hoang Roberts, Cleveland (US)

V057 (▢1: 7 min.) **Could the 'Urachus-Based Peritoneal Hinge-Flap' be used for Bladder Augmentation? Illustrated Proposed Technique and a Fresh Cadaver-based Surgical Video**
M. Garcia, Los angeles (US)

V058 (▢1: 3 min.) **Robot-assisted buccal mucosa graft ureteroplasty for ureteral stricture: a European multicenter case-series**
A. Bourillon, Rennes (FR)

V059 (▢1: 8 min.) **Victo artificial urinary sphincter implantation and outcomes**
R. Bali Moreira, Sao Paulo (BR)

# Next-gen endourology: AR guidance, intelligent lasers and smarter stone solutions

Video Session 07

**Saturday 14 March**
**15:30 - 17:00**

**Location** Blue Area, George 1

**Chairs**
M. Cepeda Delgado, Valladolid (ES)
W. Krajewski, Wrocław (PL)
S. Kutchukian, Poitiers Cedex (FR)

V045 (▢: 8 min.) **The Fast and the Frictionless: Capabilities of a 6.3Fr Single-Use Digital Flexible Ureteroscope**
MU Uy, Ann Arbor (US)

V046 (▢: 8 min.) **Clinical efficacy of the Automatic Tissue Recognition Function in a Super-pulsed Thulium Fiber Laser: A Multicenter Lithotripsy Study**
A.G. Martov, Moscow (RU)

V047 (▢: 4 min.) **Introducing Augmented Reality Retrograde IntraRenal Surgery (AR-RIRS): First Clinical Implementation of the Surgeree™ Platform**
A. Villano, Gallarate (IT)

V048 (▢: 7 min.) **StoneMetricAI by Medannot - One click, real volume: smarter stone assessment starts here**
C. Slots, Kortrijk (BE)

V049 (▢: 4 min.) **Demonstration of a Simple and Cost-Effective Technique for Non-Cystoscopic Ureteral Stent Removal Using Suture Loop**
H. Donaldson, Chicago (US)

V050 (▢: 8 min.) **Suction sheath in retrograde intrarenal surgery: comparative analysis and five illustrative cases**
J.J. Szczesniewski, Getafe (ES)

V051 (▢: 7 min.) **Laser hits stone – first preliminary study on multi-physics simulation of the laser-stone interaction**
G. Magistro, Hamburg (DE)

V052 (▢: 5 min.) **A Feasibility Study on Clinical Utility and Efficacy of the Novel Vortex Intelligence Stone Optimized Removal (VISOR) System in Retrograde Intrarenal Surgery for Upper Urinary Tract Stones**
B. Wang, hangzhou (CN)

# Paediatric conditions with adult consequences: Managing the long-term sequelae

EAU Working Group on Paediatric Urology

**Saturday 14 March**
**15:30 - 17:00**

**Location** Blue Area, Victoria 6

**Chairs** A. Bujons Tur, Barcelona (ES)
V. Tatanis, Patras (GR)

**Learning objectives**
This session provides a comprehensive overview of the transition of paediatric urological conditions into adulthood and their long-term management. Participants will explore principles for developing effective transitional urology services, including use of patient-reported outcome measures. The programme addresses lifelong sequelae of conditions such as posterior urethral valves and reviews EAU/ESPU guidelines. Case-based discussions focus on managing adult complications of neurogenic bladder surgery, including stoma revision, bladder stones, and issues of sexuality and pregnancy, to support seamless, patient-centred care.

**15:30 - 15:37** **How to establish a transitional urology section?**
G. De Win, Edegem (BE)

**15:37 - 15:44** **Patient reported outcome measures and how to use them during transition period?**
L.A. 't Hoen, Rotterdam (NL)

**15:44 - 15:51** **PUV and lifelong consequences**
J.S.L.T. Quaedackers, Groningen (NL)

**15:51 - 16:01** **ESPU Lecture - Long-term renal transplant outcomes in patients with end-stage renal disease secondary to bladder dysfunction in childhood**
S. Tekgül, Ankara (TR)

**16:01 - 16:04** **Discussion with audience**

**16:04 - 16:21** Clinical Case Discussion **Transition problems and safe solutions: Roundtable discussion based on clinical scenarios**

*Presenter* M.I Dönmez, Istanbul (TR)

*Discussants* R.J.M. Lammers, Groningen (NL)
G. Mosiello, Rome (IT)
A. Zachou, London (GB)

**16:21 - 16:26** **Summary of EAU/ESPU guidelines**
A. Zachou, London (GB)

**16:26 - 16:29** **Discussion with audience**

**16:29 - 16:31** **Managing long-term complications of neurogenic bladder surgery**

*Moderator* G. Bogaert, Leuven (BE)

16:29 - 16:31 **Introduction**
G. Bogaert, Leuven (BE)

| | |
|---|---|
| **16:31 - 16:38** | **Stoma revisions**<br>T.M. Oktar, Istanbul (TR) |
| **16:38 - 16:45** | **Bladder stones**<br>G. Mosiello, Rome (IT) |
| **16:45 - 16:52** | **Sexuality & pregnancy**<br>M. Promm, Regensburg (DE) |
| **16:52 - 16:55** | **Expert summary**<br>G. Bogaert, Leuven (BE) |
| **16:55 - 17:00** | **Discussion with audience** |

## Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.6

**Saturday 14 March**
**15:30 - 16:20**

**Location** Red Area, Room 1

**Tutors**
C. Fiori, Orbassano (IT)
A. Tsaturyan, Yerevan (AM)

**Learning objectives**

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.6

**Saturday 14 March**
**15:30 - 16:20**

**Location** Red Area, Room 1

**Tutors**
A. Freimanis, Riga (LV)
P.M. Kronenberg, Lisbon (PT)
A. Sierra Del Rio, Barcelona (ES)

**Learning objectives**
This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

## Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.6

**Saturday 14 March**
**15:30 - 16:20**

**Location** Red Area, Room 1

**Coordinator** T.M. Ribeiro De Oliveira, Lisbon (PT)

**Tutors**
O. Stakhovskyi, Kyiv (UA)
L.M. Vendrell, Ciudad - Mendoza (AR)

**Learning objectives**
This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

# Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.6

**Saturday 14 March**
**15:30 - 16:20**

**Location** Red Area, Room 1

**Tutors**
S. García Barreras, Madrid (ES)
G. Vitagliano, Buenos Aires (AR)

**Learning objectives**
The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.6

**Saturday 14 March**
**15:30 - 16:20**

**Location** Red Area, Room 1

**Tutor** I. Schwartzmann, Barcelona (ES)

**Learning objectives**
The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

# Hands-on Training in Kidney transplantation surgery

HOT KT - 3.1

**Saturday 14 March**
**15:30 - 18:00**

**Location** Red Area, Room 2

**Chairs**
R. Boissier, Marseille (FR)
M. Musquera Felip, Barcelona (ES)

**Learning objectives**
Kidney transplantation is the treatment of choice for patients with end-stage renal disease (ESRD), providing improved survival and quality of life compared to dialysis. The gold standard procedure for kidney transplantation is the open kidney transplant, which involves several intricate techniques, including vascular anastomoses and graft handling. This hands-on course is designed to introduce the fundamental skills and techniques necessary for performing open kidney transplants, focusing on graft preparation and vascular anastomosis.

| | |
|---|---|
| **15:30 - 15:35** | **Introduction**<br>M. Musquera Felip, Barcelona (ES) |
| **15:35 - 15:45** | **Lecture and explanation of procedure: Kidney graft bench surgery** |
| **15:45 - 16:30** | **Hands-on Training: Kidney graft bench surgery**<br>*Tutors*<br>R. Boissier, Marseille (FR)<br>J. Branchereau, Nantes (FR)<br>B. Da Costa Parada, Coimbra (PT)<br>B.R. Etcheverry Giadrosich, Barcelona (ES)<br>V. Gomez Dos Santos, Madrid (ES)<br>T. Prudhomme, Toulouse (FR)<br>O. Rodriguez Faba, Barcelona (ES) |
| **16:30 - 16:40** | **Lecture and explanation of procedure: Open kidney transplant** |
| **16:40 - 17:25** | **Hands-on Training: Open kidney transplant procedure**<br>*Tutors*<br>R. Boissier, Marseille (FR)<br>J. Branchereau, Nantes (FR)<br>B. Da Costa Parada, Coimbra (PT)<br>B.R. Etcheverry Giadrosich, Barcelona (ES)<br>V. Gomez Dos Santos, Madrid (ES)<br>T. Prudhomme, Toulouse (FR)<br>O. Rodriguez Faba, Barcelona (ES) |
| **17:25 - 17:55** | **Tips and tricks for the placement of kidney in hypothermic perfusion machine** |
| **17:55 - 18:00** | **Q&A and close**<br>M. Musquera Felip, Barcelona (ES) |

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.6

**Saturday 14 March**
**15:30 - 16:20**

**Location** Red Area, Room 1

**Tutors**
G. Bozzini, Como (IT)
I. Kartalas Goumas, Vigevano (IT)
J.B. Roche, Bordeaux (FR)

**Learning objectives**
This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

# Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.6

**Saturday 14 March**
**15:30 - 16:20**

**Location** Red Area, Room 1

**Tutors**
M. Arslan, Istanbul (TR)
A. Papatsoris, Athens (GR)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# Non-Technical Skills for Surgical Excellence: Immersive Simulation

HOT NTS - 2.3

**Saturday 14 March**
**15:30 - 16:30**

**Location** EAU Square

**Tutors**
A. Aydin, London (GB)
S.M. Haensel, Rotterdam (NL)
N. Raison, London (GB)
G. Zanovello, Verona (IT)

**Learning objectives**
Participants will be assigned to one of two simulation-based activities: a simulated operating room session or a computer-based virtual patient interaction. Both formats are designed to enhance non-technical skills, including communication, teamwork, and clinical decision-making.

**15:30 - 15:40** **Concept of learning**
S.M. Haensel, Rotterdam (NL)

# Bladder cancer advancements: From molecular insights to clinical practices

EGPT 31

**Saturday 14 March**
**15:30 - 17:00**

**Location** Orange Area, EGPT 2

**Chairs**
B. Ali-El-Dein, Mansoura (EG)
M. Babjuk, Prague (CZ)
To be confirmed

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**15:30 - 16:00** **Translational and liquid biospsies in urothelial cancer**

P0539 **Mediator complex subunit 8 promotes bladder cancer progression via stearoyl-coA desaturase**
H. Zhang, Shenzhen (CN)

P0542 **Feasibility and interim results from the prospective international LS-URO study: urine tumor DNA-based screening for urothelial cancer in Lynch syndrome carriers (NCT06218433)**
J. Nikkola, Tampere (FI)

P0543 **Improving long-term monitoring in NMIBC: digital Uromonitor® as a complementary tool to cystoscopy for predicting two-year recurrence (EVALUATION-CUETO study)**
J. Rubio Briones, Valencia (ES)

**Study Group**
EVALUATION CUETO investigators(Valencia, Spain)

| | |
|---|---|
| **16:00 - 16:20** | **Staging and prognosis of muscle-invasive bladder cancer** |
| P0546 | **Predicting prognosis of muscle-Invasive bladder cancer patients using an artificial intelligence deep learning model**<br>R. Zhang, Shanghai (CN) |
| P0548 | **Awareness of genetic risk of Bladder Cancer associated to germline variants in DNA-repair genes (gDRGs) in Caucasian ancestry families**<br>M. Tiscione, Pieve Emanuele (IT) |
| **16:20 - 16:45** | **Molecular targets of therapy response and resistance in muscle-invasive bladder cancer** |
| P0549 | **A Multifunctional Patient-Derived Platform for Bladder Cancer: Assessing Chemotherapy Responses and CAR-T Efficacy in Personalized Settings**<br>J. Lu, Guangzhou (CN) |
| P0550 | **Identification of novel therapeutic vulnerabilities in bladder cancer using patient-derived organoids**<br>F. Heuzeroth, Basel (CH) |
| P0551 | **In Vivo Generation of Multiplexed CAR-Immune Cells via Virus-Mimicking Extracellular Vesicles for Bladder Cancer Therapy**<br>H. Zhan, Guangzhou (CN) |
| P0553 | **TMEM11 promotes cisplatin resistance by inhibiting BNIP3-mediated mitophagy in bladder cancer**<br>F. Li, Guangzhou (CN) |
| **16:45 - 17:00** | **Advanced urothelial cancer** |
| P0554 | **Evaluation of the role of pelvic lymph node dissection in urachal carcinoma**<br>A.H. Eldefrawy, Miami (US) |
| P0555 | **Metastatic non-muscle invasive bladder cancer: Insights on metastatic profile and survival outcomes from the National Cancer Database**<br>A.H. Eldefrawy, Miami (US) |
| P0556 | **Re-evaluating First-Line Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysis**<br>H. Tanaka, Tokyo (JP) |
| **17:00 - 17:05** | **Late-breaking abstract presentation** |

# Innovations in Urinary Tract Dysfunction: From Neurogenic Bladders to Novel Therapeutics

EGPT 34

**Saturday 14 March**
**15:30 - 17:00**

**Location** Blue Area, EGPT 5

**Chairs**
M. Madanelo, Lisboa (PT)
C. Mazeaud, Nancy (FR)
S. Mourad, Heliopolis (EG)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**15:30 - 15:55** **neurogenic bladder**

P0594 **Inosine Rebalances Neuroimmune Crosstalk to Restore Bladder Function in Experimental Autoimmune Encephalomyelitis (EAE)**
C. Bahou, Berne (CH)

P0596 **Ambulatory urodynamics for complex neurogenic LUTS: diagnostic value and safety**
IF Ferrari , Pavia (IT)

P0597 **BILATERAL PUDENDAL NERVE BLOCK REDUCES MAXIMUM URETHRAL PRESSURE IN SCI PATIENTS WITH DESD**
C.J.C. Chermansky, Pittsburgh, Pennsylvania (US)

**15:55 - 16:40** **non neurogenic voiding dysfunction**

P0598 **Interobserver agreement of filling cystometry and pressure-flow study parameters**
Y.E. Genc, Istanbul (TR)

P0599 **The Impact of Dynamic Depression Trajectories on Incident Urination and Defecation Disorders: A Nationwide Cohort Study**
To be confirmed

P0602 **Single-nucleus RNA sequencing identifies local stem cell engagement and TGF-β pathway modulation by human umbilical cord mesenchymal stem cells in bladder outlet obstruction–induced detrusor underactivity**
Y-H. Chen, Taipei (TW)

P0603 **Correlation of patient's global impression of improvement and visual analog scale of satisfaction with clinical and urodynamic outcomes of sacral neuromodulation in non-obstructive urinary retention.**
PL.D. Dequirez, LILLE (FR)

P0604 **Resveratrol ameliorates bladder outlet obstruction–induced bladder dysfunction in rats via modulation of TGF-β–associated pathways: Integrative transcriptomic and proteomic evidence**
Y.H. Yeh, Taipei (TW)

P0605 **The Clinical Utility of Urethral Pressure Profilometry in Diagnosing and Guiding Treatment of Men with Voiding Dysfunction**
C. Ng, London (GB)

P0606 **Smooth muscle–derived TGF-β signaling drives extracellular matrix remodeling in bladder outlet obstruction–induced detrusor underactivity: Insights from single-nucleus RNA sequencing**
K. Chen, TAIPEI (TW)

**16:40 - 17:00** **From nocturia to BPO**

P0609 **Nocturnal Bladder Capacity Index Assessment To Improve Nocturia Management In Patients With Lower Urinary Tract Symptoms Related To Benign Prostatic Hyperplasia**
D. Graziani, Latina (IT)

P0610 **Integrative Transcriptomic and Proteomic Analysis Reveals Anti-inflammatory, Metabolic, and Antifibrotic Mechanisms of hUCMSC Therapy in Bladder Outlet Obstruction**
Y.H. Yeh, Taipei (TW)

## Exploring the Frontiers of Prostate Cancer Care: Complications, Technology-Driven Solutions and Patient Experiences

EGPT 30

**Saturday 14 March**
**15:30 - 17:00**

**Location** Orange Area, EGPT 1

**Chairs**
E. Barret, Paris (FR)
G. Palapattu, Ann Arbor (US)
A.S. Zribi, Tunis (TN)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**15:30 - 15:35** **Late-breaking abstract presentation**

LB019 **From co-creation to practice: developing and implementing a stakeholder matrix for prostate cancer and health literacy in the CLEAR-PC framework.**
B. Lumbreras, Alicante (ES)

**15:35 - 15:55** **Optimising outcomes of treatment for prostate cancer**

P0531 **Single-Port Robotic Prostatectomy Under Neuraxial Anesthesia with Virtual Reality Support: A Step Toward Minimal Surgical Impact**
D. Amparore, Orbassano (Turin) (IT)

P0532 **Precision irreversible electroporation for localized prostate cancer guided by a novel system based on artificial intelligence and electromagnetic navigation system**
M. Wang, Beijing (CN)

P0535 **Does Efficiency Equal Surgical Quality? A Multicenter Study of Robotic Vesicourethral Anastomosis**
L. Cella, Milan (IT)

| | |
|---|---|
| P0527 | **Transurethral bladder neck resection combines with intraoperative and postoperative regular injection of triamcinolone acetonide for the treatment of bladder neck contracture after robot-assisted radical prostatectomy**<br>L. Yang, Xian (CN) |
| **15:55 - 16:30** | **Post treatment complications** |
| P0525 | **Patient-reported use and effect of sexual aids for erectile dysfunction within 8 years after radical prostatectomy**<br>A.S. Bjartell, Malmö (SE) |
| P0523 | **Acute genitourinary toxicity predicts late urinary morbidity following prostate radiotherapy: a population-based SEER–Medicare analysis**<br>M. Frankiewicz, Gdańsk (PL) |
| P0524 | **Safety and perioperative outcomes of extraperitoneal and transperitoneal robot-assisted radical prostatectomy: Multi-institutional propensity score analysis**<br>A. Igarashi, Kobe (JP) |
| P0528 | **Rectourinary Fistula After Radical Prostatectomy: Insights Into Etiology and Management**<br>M. De Angelis, Milan (IT) |
| P0529 | **Predictors of De Novo Overactive Bladder After Radical Prostatectomy for Prostate Cancer: Can Retzius-Sparing Robot-Assisted Radical Prostatectomy Reduce Its Incidence?**<br>W. Zheng, fuzhou (CN) |
| P0537 | **Postoperative complications after robot-assisted radical prostatectomy**<br>A. Govorov, Moscow (RU) |
| P0538 | **Improvement in Radical Prostatectomy Surgical Outcomes: A 10-Year Analysis of Complications.**<br>D. Self, Gosford (AU) |
| **16:30 - 16:35** | **Mental health in prostate cancer patients** |
| P0530 | **Suicide Risk in Prostate Cancer Patients: Epidemiological Trends and a Predictive Modeling**<br>Y Yang, Wuhan (CN) |
| **16:35 - 16:50** | **AI in managing prostate cancer patients** |
| P0534 | **Development of Artificial Intelligence-Generated, Explainable Treatment Recommendations for Prostate Cancer Based on 5478 Multidisciplinary Cancer Conferences Cases**<br>G. Duwe, Mainz (DE) |
| P0533 | **Assessing Large Language Models (LLM) for Multi-Disciplinary Team (MDT) decision support in prostate cancer**<br>F. Cianflone, Pavia (IT) |
| P0536 | **The Role of AI in Prostate Cancer Care: Assessing the Role of Chatbots vs Urologists in Patients Communication and Empathy**<br>L. Cacciatore, Palermo (IT) |

# Advancing BPO treatment: From aquablation to enucleation

EGPT 33

**Saturday 14 March**
**15:30 - 17:00**

**Location** Blue Area, EGPT 4

**Chairs**
S.T. De Cillis, Turin (IT)
To be confirmed
B. Geavlete, Bucharest (RO)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**15:30 - 16:00** **New insights aquablation procedures: Outcomes in selected patients and comparative trials**

P0576 **Aquablation Real-World Hemostasis Evolution from 100,000 Patients**
To be confirmed

P0577 **The Impact of Acquablation Treatment in Patients with Concomitant Overactive Bladder Syndorme: functional and patient self-reported outcomes.**
M. Santioni, roma (IT)

P0578 **Six-Month Outcomes of the WATER III Trial: Aquablation versus Transurethral Laser Enucleation (HoLEP/ThuLEP) for Large Prostates (80–180 mL) in Benign Prostatic Hyperplasia**
J. Stein, Bonn (DE)

P0579 **Comparison of Aquablation and Rezūm in the management of patients with medium prostate volume: a propensity score matching analysis**
L.M. Basadonna, Milano (IT)

P0580 **Man versus Robot: comparative urinary and sexual outcomes of Ejaculation-Sparing endoscopic Photoselective Vaporization of the Prostate and Aquablation for the treatment of patients with Benign Prostatic Obstruction.**
M. Sibona, Torino (IT)

**16:00 - 16:30** **New insights laser prostatectomy: Outcomes in selected patients and comparative trials**

P0581 **The optimal hospital caseload to improve perioperative outcomes during Transurethral Resection of the Prostate or Prostate Enucleation: Results from the GRAND study**
N. Pyrgidis, München (DE)

P0582 **Assessment of the Effect of Prostate Volume on Surgical Complications and Outcomes in Antithrombotic-Treated Patients Undergoing Endoscopic Enucleation: Findings from the EAU Endourology Collaborative Study**
C. Giulioni, Jesi (IT)

P0583 **A Randomized, Placebo-Controlled Trial Evaluating Tadalafil 5 mg for Management of Early Storage Symptoms and Erectile Dysfunction After HoLEP**
I. Mansour, Al Mansoura (EG)

P0584 **A Prospective Non-Randomized Trial Comparing the Efficacy and Safety of Pulsed Thulium:YAG Versus Holmium:YAG Lasers for Prostate Enucleation**
H.Y. Sahin, Ankara (TR)

P0586 **Holmium enucleation of the prostate versus robotic aquablation- is there a difference?**
D.T. Reddy, London (GB)

**16:30 - 17:00** **How to improve training: From mentorship to simulators**

P0587 **Face and Content Validation of Laser Enucleation of Prostate Simulation Model: An EAU European School of Urology (ESU) Lower Urinary Tract Endoscopy Working Group Study**
T.E. Şener, Istanbul (TR)

P0588 **Face and Content Validation of TURP and TURB Simulation Models: An EAU European School of Urology (ESU) Lower Urinary Tract Endoscopy Working Group Study**
T.E. Şener, Istanbul (TR)

P0589 **Face and content validation of a novel Aquablation training simulator within the EAU European School of Urology educational framework**
E.D. Demirkiran, Zonguldak (TR)

P0590 **Impact of learning curve on perioperative outcomes of robot assisted simple prostatectomy (RASP); single center comparison of outcomes between trainees versus expert series**
A.M. Bove, Roma (IT)

P0591 **Simulation based training versus mentorship in the initial learning curve of Holmium Laser Enucleation of the Prostate (HoLEP) Surgery. The Effects of Simulation Training on Surgical Success, Complication Rates, and Surgeon Workload: A Prospective Comparative Study**
K. Ceviz, Ankara (TR)

P0592 **Learning Curve of Aquablation: Insights from the First 252 Consecutive Cases in a High-Volume European Centre**
T. Rodrigues, Cascais (PT)

## NMIBC: Surgery, intravesical therapy and follow-up

EGPT 32

**Saturday 14 March**
**15:30 - 17:00**

**Location** Orange Area, EGPT 3

**Chairs**
P. Mariappan, Edinburgh (GB)
A. Masson-Lecomte, Paris (FR)
A. Van Der Heijden, Nijmegen (NL)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**15:30 - 16:00** **TURB, re-staging and risk stratification**

P0557 **Prospective evaluation of ureteral stenting during TURBT for tumors involving the ureteral orifice and its impact on metachronous upper tract carcinoma**
M. Kidess, München (DE)

P0558 **Early BCG Instillation Outweighs Second TURBT Timing for Recurrence-Free Survival in High-Risk NMIBC**
Z. Liu, Guangzhou (CN)

P0559 **Recurrent Papillary (pTa) Non–Muscle-Invasive Bladder Cancer: Identifying Patients Beyond the Reach of Intravesical Therapy**
M. Longoni, Milan (IT)

P0560 **The impact of en-bloc resection of tumor technique on histopathological outcomes, subsequent management, and early recurrence in newly diagnosed bladder cancer: A retrospective analysis of single-institution experience**
S. Erdem, Istanbul (TR)

P0561 **Real-World Data Support Restaging at reTURB for Prognostic Re-Stratification of EAU 2021 Risk Groups in High-Grade T1 Non–Muscle-Invasive Bladder Cancer: A Data-Driven, Risk-Adapted Guide to Timely Radical Cystectomy Decisions**
A. Fernandez-Mardomingo Diaz, Madrid (ES)

P0562 **En-Bloc Resection of Bladder Tumour vs. conventional TURBT: long-term oncological outcomes from a single-center prospective**
G. Avesani, Milan (IT)

**16:00 - 16:30** **Intravesical therapies**

P0563 **BCG-rechallenge after treatment failure: long-term outcomes from a multi-institutional cohort**
P. Zaurito, Milan (IT)

P0565 **IntIntravesical Gemcitabine versus BCG for Intermediate-/High-Risk NMIBC during the BCG Shortage: Safety, Efficacy, and Cost-Effectiveness**
L. R. Fernandes, São Paulo (BR)

P0566 **Gemcitabine-Docetaxel Intravesical Synchronous CO-administration (G-DISCO); A first-in-human evaluation of synchronous gemcitabine-docetaxel**
K. Keane, Perth (AU)

**Study Group**
Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group(Sydney, Australia)

P0567 **Optimizing Mitomycin C Maintenance for Intermediate-Risk Ta NMIBC: A Multicenter Analysis on Instillation Duration**
R. Contieri, Naples (IT)

P0568 **Phase III, single-arm study to evaluate the efficacy and safety of intravesical paclitaxel-hyaluronic acid conjugate in patients with BCG-unresponsive Carcinoma in situ of the bladder +/- Ta-T1 papillary disease (Orion-BC study)**
E.N. Xylinas, Paris (FR)

**16:30 - 17:00** **Decision-making, biomarkers, surveillance and quality of life**

P0569 **Bladder-sparing Therapy versus Upfront Radical Cystectomy for High-risk Non-muscle-invasive Bladder Cancer: A Propensity Score Matching Analysis**
P. Li, Nanjing (CN)

P0570 **Trial Design Drives Outcomes: Harmonizing Efficacy Across BCG-Unresponsive Bladder Carcinoma in Situ Trials**
D. Robesti, Milan (IT)

P0571 **SYMPTOMS, HEALTH-RELATED QUALITY OF LIFE, AND BURDEN AMONG PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER AND CAREGIVERS**
J. Aning, Bristol (GB)

P0572 **Longitudinal assessment of patient-reported quality of life and mental health during active surveillance for low-grade NMIBC**
M. Paciotti, Rozzano, Milan (IT)

P0573 **Randomized trial of urinary tumor DNA (utDNA) testing-guided cystoscopy in high-risk/very high-risk non-muscle-invasive bladder cancer (NMIBC): TRUCE-LB02**
H. Hu, Tianjin (CN)

P0574 **Beyond the guidelines: A real-world assessment of NMIBC surveillance in the Scottish National Health Service and potential cost-effectiveness of the Epicheck biomarker.**
J. Hart-Brooke, Edinburgh (GB)

## Patient advocacy plaza - Patient reported outcomes after chemotherapy and prostate cancer

Special Session

**Saturday 14 March**
**15:45 - 16:15**

**Location** Patient Advocacy Plaza

**Chair** E. Briers, Hasselt (BE)

**Europa Uomo**
E. Briers, Hasselt (BE)

## Artificial Intelligence 2 - Advanced

ESU Course 23

**Saturday 14 March**
**16:00 - 18:00**

**Location** Red Area, Room 7

**Chair** P. De Backer, Ghent (BE)

**Learning objectives**
This advanced session dives deeper into the technical and strategic aspects of AI. It covers Big Data management, AI-ready datasets, data harmonization, and the evolution towards agentic and generalist AI. Participants will explore data harvesting, validation, and training challenges such as imbalance and multimodality (video, imaging, audio, tabular data). The course also offers an overview of emerging trends in AI research — empowering clinicians and researchers to integrate cutting-edge methods into urological practice.

**16:00 - 16:00** **Introduction to the advanced session: Understanding neural networks and the role of big data**
M. Bussmann, Dresden (DE)

**16:00 - 16:00** **TBC**
B. De Meulder, Larajasse (FR)

| | |
|---|---|
| **16:00 - 18:00** | **Understanding neural networks** |
| **16:00 - 18:00** | **How do we teach machines to understand the world?** |
| **16:00 - 18:00** | **The data challenge in AI** |
| **16:00 - 18:00** | **Generative AI** |
| **16:00 - 18:00** | **Multimodal AI, invertible surrogate models** |
| **16:00 - 18:00** | **Big data and federated learning** |
| **16:00 - 18:00** | **Agentic AI** |
| **16:00 - 18:00** | **Why should clinicians understand and design AI?** |
| **16:00 - 18:00** | **A look ahead: World models** |
| **16:00 - 18:00** | **AI in urology practice** |
| **16:00 - 18:00** | **AI in urology research** |
| **16:00 - 18:00** | **How to critically appraise AI** |
| **16:00 - 18:00** | **Demo clinical AI agent** |
| **16:00 - 18:00** | **Q&A** |

## 2026 EAU Guidelines update – Testicular and penile cancer and sexual health: What has changed?

ESU Course 28

**Saturday 14 March**
**16:00 - 18:00**

**Location** Red Area, Room 12

**Chair** O. Brouwer, Amsterdam (NL)

| | |
|---|---|
| | **Welcome and introduction**<br>O. Brouwer, Amsterdam (NL) |
| | **Principles of systemic therapy in testicular cancer across disease stages**<br>A. Patrikidou, Villejuif (FR) |
| | **EAU ASCO Penile Cancer Guidelines: Key recommendations and remaining challenges**<br>O. Brouwer, Amsterdam (NL) |

**Penile size abnormalities and dysmorphophobia – Does size matter? Summary of the EAU Guidelines**
P. Capogrosso, Varese (IT)

## Prostate cancer made simple: A comprehensive update for all urologists

ESU Course 27

**Saturday 14 March**
**16:00 - 18:00**

**Location** Red Area, Room 11

**Chair** D. Eberli, Zürich (CH)

**Learning objectives**
A general update on prostate cancer. Who needs early prostate cancer detection? What is the optimal method of biopsies? What is the best imaging approach? Are surgery and radiotherapy equal options for localised prostate cancer? What is state-of-the-art androgen deprivation therapy for metastasized disease and what are the options at castration resistance. All these topic will be comprehensively discussed during the course.

**Early detection and heredity in prostate cancer**
D. Eberli, Zürich (CH)

**MRI imaging and biopsy strategy for local diagnosis and staging**
P. Rajwa, Warsaw (PL)

**PSMA pet imaging**
C. Surcel, Bucharest (RO)

**Indications for active surveillance and watchfull waiting**
D. Eberli, Zürich (CH)

**Indications for localised treatment (surgery, radiotherapy and focal therapy)**
C. Surcel, Bucharest (RO)

**Androgen deprivation in advanced prostate cancer management**
D. Eberli, Zürich (CH)

**The options for men with castration-resistant prostate cancer**
P. Rajwa, Warsaw (PL)

Case discussion **Case discussion**
D. Eberli, Zürich (CH)
P. Rajwa, Warsaw (PL)
C. Surcel, Bucharest (RO)

# A to Z of recurrent Urinary Tract Infections (UTIs)

ESU Course 24

**Saturday 14 March**
**16:00 - 18:00**

**Location** Red Area, Room 8

**Chair** J. Medina Polo, Madrid (ES)

Voting will be available via the EAU26 App or via www.qna.at/eau

**Learning objectives**

Recurrent urinary tract infections (UTIs) are one of the most common reasons for medical consultation. It is estimated that 2.4% of women will experience recurrent urinary tract infections. The first step in preventing recurrent UTIs is to identify any predisposing factors. The second step involves non-antimicrobial measures, and finally, antimicrobial prophylaxis is recommended. This course will review the available evidence on various non-antibiotic measures, including topical oestrogen treatment, American cranberry extract, D-mannose, probiotics, immunoactive prophylaxis, and intravesical instillations containing hyaluronic acid. Emerging therapies will also be reviewed. The evidence will be presented with a practical approach, encouraging interaction with attendees.

**Introduction and risk factors**
C. Harding, Newcastle upon Tyne (GB)

**Diagnosis work-up**
J. Medina Polo, Madrid (ES)

**Nutraceuticals**
J. Medina Polo, Madrid (ES)

**Non-antibiotic management (Immunoprophylaxis & Methenamine Hippurate)**
C. Harding, Newcastle upon Tyne (GB)

**New emerging tolos**
J. Medina Polo, Madrid (ES)

**Challenging cases: Urinary catheters, neurogenic bladder etc.**
C. Harding, Newcastle upon Tyne (GB)
J. Medina Polo, Madrid (ES)

**Bring your clinical cases**
C. Harding, Newcastle upon Tyne (GB)
J. Medina Polo, Madrid (ES)

# Surgical management of BPO: From resection to ablation of prostate adenoma

ESU Course 25

**Saturday 14 March**
**16:00 - 18:00**

**Location** Red Area, Room 9

**Chair** N. Barber, Camberley (GB)

**Introduction: Why so called standard techniques will prevail despite trends. Sociodemographics, Socioeconomy and skill set spread**
N. Barber, Camberley (GB)

**EAU Guidelines Recommendations on BPO Surgical Treatment: Resection / Ablation**
D. Perri, Como (IT)

**532 nm ("Greenlight") laser vaporisation of the prostate: settings (in house, ambulatory), techniques and outcomes**
N. Barber, Camberley (GB)

**Evidence of Transurethral resection (TURP) and transurethral electrovaporization: Evolution of bipolar technology - When – How what**
D. Perri, Como (IT)

**Challenging TURP – Aquaablation: Settings, techniques (small, medum, large) and outcomes**
N. Barber, Camberley (GB)

**Rezum and Angioembolisation as a challenger of PVP? Settings, techniques (small, medum, large) and outcomes**
N. Barber, Camberley (GB)

Case discussion **Interactive case discussion**
N. Barber, Camberley (GB)
D. Perri, Como (IT)

**Closing remarks**
N. Barber, Camberley (GB)

# Planning, designing and executing randomised clinical trials in urology

ESU Course 29

**Saturday 14 March**
**16:00 - 18:00**

**Location** Red Area, Room 13

**Chair** K. Touijer, New York (US)

Voting will be available via the EAU26 App or via www.qna.at/eau

**Learning objectives**
Describe and apply best practices in clinical trial design.
Identify appropriate inclusion/exclusion criteria and outcome measures for trials.
Discuss statistical models commonly used in clinical trials.
Execute efficient protocol writing and trial activation tasks.

**Competencies developed:**
Ability to formulate research questions and design actionable clinical trials.
Experience in protocol preparation, team-based collaboration, and communication of scientific results.

**Introduction and objectives**
K. Touijer, New York (US)

**Protocol development**
K. Touijer, New York (US)

**Key roles in clinical trials**
A.J. Vickers, New York (US)

**Trial logistics and operations**
A.J. Vickers, New York (US)

**Why do RCTs fail 25 min**
K. Touijer, New York (US)
A.J. Vickers, New York (US)

**Interactive workshop**
K. Touijer, New York (US)
A.J. Vickers, New York (US)

**Q&A & Wrap up**
A.J. Vickers, New York (US)

# Patient advocacy plaza - Discrimination of male patients with incontinence and hot-flushes

Special Session

**Saturday 14 March**
**16:30 - 17:00**

**Location** Patient Advocacy Plaza

**Chair** E. Briers, Hasselt (BE)

**Europa Uomo**
E. Briers, Hasselt (BE)

## Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.7

**Saturday 14 March**
**16:30 - 17:20**

**Location** Red Area, Room 1

**Tutors**
C. Fiori, Orbassano (IT)
A. Tsaturyan, Yerevan (AM)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.7

**Saturday 14 March**
**16:30 - 17:20**

**Location** Red Area, Room 1

**Tutors**
A. Freimanis, Riga (LV)
P.M. Kronenberg, Lisbon (PT)
A. Sierra Del Rio, Barcelona (ES)

**Learning objectives**
This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

# Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.7

**Saturday 14 March**
**16:30 - 17:20**

**Location** Red Area, Room 1

**Coordinator** T.M. Ribeiro De Oliveira, Lisbon (PT)

**Tutors** O. Stakhovskyi, Kyiv (UA)
L.M. Vendrell, Ciudad - Mendoza (AR)

**Learning objectives**
This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

# Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.7

**Saturday 14 March**
**16:30 - 17:20**

**Location** Red Area, Room 1

**Tutors** S. García Barreras, Madrid (ES)
G. Vitagliano, Buenos Aires (AR)

**Learning objectives**
The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

## Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.7

**Saturday 14 March**
**16:30 - 17:20**

**Location** Red Area, Room 1

**Tutor** I. Schwartzmann, Barcelona (ES)

**Learning objectives**

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

## Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.7

**Saturday 14 March**
**16:30 - 17:20**

**Location** Red Area, Room 1

**Tutors** G. Bozzini, Como (IT)
I. Kartalas Goumas, Vigevano (IT)
J.B. Roche, Bordeaux (FR)

**Learning objectives**

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

## Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.7

**Saturday 14 March**
**16:30 - 17:20**

**Location** Red Area, Room 1

**Tutors**
M. Arslan, Istanbul (TR)
A. Papatsoris, Athens (GR)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## Live podcasting session: Challenge the UROmigos

Special Session

**Saturday 14 March**
**17:15 - 18:00**

**Location** Orange Area, eURO Auditorium 2

**Learning objectives**
The Uromigos podcast is a successful urology cancer weekly podcast which has had over half a million listeners worldwide. Prof Brian Rini and Prof Tom Powles lead lively debates with invited speakers on key topics. They have channels in 4 languages including Mandarin and Japanese.

**Latest advances in bladder and kidney cancer**

*Speakers*
T. Powles, London (GB)
B. Rini, Nashville (US)

## EAU General Assembly

Special Session

**Saturday 14 March**
**17:30 - 18:30**

**Location** Blue Area, Victoria 1

**Learning objectives**
Present the work of the EAU History Office

**1. Opening and communications by the Secretary General**

**2. Approval minutes General Assembly of 22 March 2025, Madrid, Spain**

**3. General report by the EAU Secretary General**
A. Stenzl, Stuttgart (DE)

**4.Report by the EAU Treasurer**
J.O.R. Sønksen, Herlev (DK)

**5. Specific reports on the EAU Offices by the EAU Executive**

**6. Report by the Secretary General on the EAU Membership**

**Announcement new EAU members**

**Announcement new Honorary members**

**7. Research & Evidence Generation: vision, mission, goals & activities**
J. N'Dow, Aberdeen (GB)

**8. Other business**

## Making technology work for us in upper tract endourology

Plenary Session

**Sunday 15 March**
**08:00 - 10:00**

**Location** Orange Area, eURO Auditorium 2

**Chairs** M. Bultitude, London (GB)
P.J.S. Osther, Vejle (DK)

**Learning objectives**
Review historical and recent advances in laser technology for upper tract endourology, including Holmium YAG, Thulium Fibre, and Thulium YAG systems. Understand strategies for optimising laser performance in clinical practice through expert discussion and case examples. Learn about innovations in suction technology and features of disposable scopes to enhance endourological outcomes. Evaluate the integration of robotic platforms and AI tools in ureteroscopy and PCNL, focusing on prognostic and surgical applications. Critically compare and debate treatment approaches—shockwave lithotripsy, flexible ureteroscopy, and conservative management—for renal stones, including future techniques like burst wave lithotripsy.

**08:00 - 08:02** **Introduction**

**08:02 - 08:12** Spotlight talk **The history of laser development**
J. Denstedt, London (CA)

**08:12 - 08:32** Round-table discussion **Keeping your finger on the pulse: Optimising my laser**

*Moderator* P.M. Kronenberg, Lisbon (PT)

08:12 - 08:16 **Holmium YAG**
E.K. Bres-Niewada, Pruszkow (PL)

08:16 - 08:20 **Thulium Fibre**
K.L.S. Stern, Phoenix (US)

08:20 - 08:24 **Thulium YAG**
W. Kamal, Jeddah (SA)

08:24 - 08:32 **Discussion**

---

**08:32 - 08:40** State-of-the-art lecture **UTUC: Pushing the boundaries in endoscopic management**
A. Gallioli, Barcelona (ES)

---

**08:40 - 08:48** State-of-the-art lecture **Choosing a disposable scope - features galore!**
A. Pietropaolo, Southampton (GB)

---

**08:48 - 09:08** Panel discussion **How to get the most out of suction technology**

*Moderator* S. Yuen, Hong Kong (HK)

08:48 - 08:53 **In scope suction technology**
V. Gauhar, Singapore (SG)

08:53 - 08:58 **Flexible and navigable suction access sheaths**
D. Castellani, Ancona (IT)

08:58 - 09:03 **PCNL and suction**
L. Tzelves, Athens (GR)

09:03 - 09:08 **Discussion**

---

**09:08 - 09:18** Société Internationale d'Urologie (SIU) lecture **Can robotic platforms become mainstream for ureteroscopy and PCNL?**
S.Y. Cho, Seoul (KR)

---

**09:18 - 09:48** **AI in the upper tract**

09:18 - 09:28 State-of-the-art lecture **AI: Prognostic tools and surgical application**
B. Turney, Oxford (GB)

Rapid fire debate **Back to the future: Treating an incidental 8mm renal stone**

*Moderator* T. Tailly, Ghent (BE)

09:28 - 09:30 **Case presentation**
T. Tailly, Ghent (BE)

09:30 - 09:34 **Shockwave lithotripsy**
R. Dasgupta, London (GB)

09:34 - 09:38 **Flexible ureteroscopy**
S.M. Croghan, Dublin (IE)

09:38 - 09:42 **Watch and wait: Not all stones need treating**
P. Juliebø-Jones, Bergen (NO)

09:42 - 09:48 **Rebuttal and discussion**

---

**09:48 - 09:58** Spotlight talk **Back to the future: Burst wave lithotripsy**
B.H. Chew, Vancouver (CA)

---

**09:58 - 10:00** **Conclusions**

# Evolving landscape in prostate cancer screening and AI-assisted diagnosis

Plenary Session

**Sunday 15 March**
**08:00 - 10:00**

**Location** Orange Area, eURO Auditorium 1

**Chairs** V. Kasivisvanathan, London (GB)
T. Nordström, Stockholm (SE)

**Learning objectives**
This session will review the 2026 EAU guideline updates on prostate cancer early detection and present key findings from the final year of PRAISE-U, including lessons on scaling organised screening across Europe. Participants will explore how screening can be individualised through age, risk stratification, biomarkers and genomic tools, and critically assess screening endpoints and de-escalation strategies. Evidence on MRI, AI-assisted imaging and emerging modalities will be discussed, alongside real-world challenges of quality, access and sustainability, to inform future directions in prostate cancer early detection and screening.

| | |
|---|---|
| **08:00 - 08:01** | **Welcome** |
| **08:01 - 08:08** | Introduction **EAU Guidelines 2026: What's new in early detection?**<br>J. Stranne, Göteborg (SE) |
| **08:08 - 08:21** | **Final year of PRAISE-U** |
| 08:08 - 08:16 | **Screening across Europe: Key findings from the PRAISE-U**<br>M.J. Roobol, Rotterdam (NL) |
| 08:16 - 08:21 | Live interview **Scaling sustainable organised prostate cancer testing**<br>*Interviewer* V. Parry, Carterton (GB)<br>*Speaker* A. Chandran, Lyon (FR) |
| **08:21 - 08:54** | **Individualising screening** |
| 08:21 - 08:27 | **Endpoint of early detection: What are we really screening for?**<br>A.P. Auvinen, Tampere (FI) |
| 08:27 - 08:33 | **Age matters: A guide to risk-adaptive screening**<br>P. Albers, Düsseldorf (DE) |
| 08:33 - 08:39 | **Screening intervals: When and how should we de-escalate?**<br>J. Hugosson, Gothenburg (SE) |
| 08:39 - 08:45 | **What is the role of biomarkers?**<br>M.R. Cooperberg, San Francisco (US) |
| 08:45 - 08:54 | **Discussion** |
| **08:54 - 09:04** | State-of-the-art lecture **Genomic tools in screening: Are we ready for the next step?**<br>V. Hayes, Sydney (AU) |
| **09:04 - 09:48** | **Imaging: Scaling and quality** |

| | |
|---|---|
| 09:04 - 09:11 | **Performance of MRI for screening in 2026**<br>C. Moore, London (GB) |
| 09:11 - 09:18 | **MRI in the Real World: Challenges of quality and access**<br>H.P.S. Schlemmer, Heidelberg (DE) |
| 09:18 - 09:25 | **AI-assisted MRI, ready for prime-time**<br>M. De Rooij, Nijmegen (NL) |
| 09:25 - 09:32 | **AI-assisted MRI, not yet**<br>G. Brembilla, Milan (IT) |
| 09:32 - 09:39 | **Beyond MRI? The case for micro-ultrasound**<br>L.H. Klotz, Toronto (CA) |
| 09:39 - 09:48 | **Discussion** |
| **09:48 - 09:58** | **Early detection and screening — Where should we be heading?**<br>F.C. Hamdy, Oxford (GB) |
| **09:58 - 10:00** | **Closing remarks** |

## Practical approach to paediatric urology

ESU Course 30

**Sunday 15 March**
**08:30 - 11:30**

**Location** Red Area, Room 7

**Chair** R.J.M. Lammers, Groningen (NL)

**Learning objectives**
In this course, we will explore the most common paediatric urological conditions, using interactive case presentations. We will discuss diagnostics, treatment options and follow-up strategies. As many children with congenital anomalies will present to the adult urologist with long-term sequelae, we also discuss transition of care into adulthood. Thus, we give an overview of paediatric urology for the adult urologist.

| | |
|---|---|
| | **Vesico-ureteral reflux (VUR)**<br>A-F. Spinoit, Ghent (BE) |
| | **Bladder- and bowel dysfunction and LUTS**<br>R.J.M. Lammers, Groningen (NL) |
| | **Ureteropelvic junction (UPJ) and uterovesical junction (UVJ) stenosis**<br>B. Burgu, Ankara (TR) |
| | **Neurogenic bladder**<br>R.J.M. Lammers, Groningen (NL) |
| | **Penile anomalies**<br>B. Burgu, Ankara (TR) |
| | **Scrotal anomalies**<br>B. Burgu, Ankara (TR) |

**Transition of care into adulthood**
A-F. Spinoit, Ghent (BE)

# Practical neuro-urology

ESU Course 36

**Sunday 15 March**
**08:30 - 11:30**

**Location** Red Area, Room 13

**Chair** T.M. Kessler, Zurich (CH)

**Learning objectives**

- Learn which nerve centres control the lower urinary tract, and the general principles of how functions change in neurological disease
- Understand key aspects of neuro-urological assessments as described in the EAU guidelines
- Discuss key factors when deciding on therapy

**Introduction: What can go wrong with the lower urinary tract?**
T.M. Kessler, Zurich (CH)

**Neuro-urological assessments**
S.T. De Cillis, Turin (IT)

**Treatment: Key issues**
N. Sihra, London (GB)

**Clinical case discussion**
S.T. De Cillis, Turin (IT)
T.M. Kessler, Zurich (CH)
N. Sihra, London (GB)

**Conclusion**
T.M. Kessler, Zurich (CH)

# Comprehensive management of muscle-invasive bladder cancer

ESU Course 31

**Sunday 15 March**
**08:30 - 11:30**

**Location** Red Area, Room 8

**Chair** A. Van Der Heijden, Nijmegen (NL)

**Learning objectives**

- Gain up-to-date insight into diagnostics and staging of MIBC, including the role of advanced imaging techniques, pathological assessment and subtypes;
- Critically appraise current and emerging treatment strategies, neoadjuvant treatment, surgery, bladder-sparing options, and adjuvant or palliative systemic treatment;
- Apply recent evidence to clinical decision-making in both localized and metastatic settings, including management of oligometastatic disease and follow-up.

**Diagnosis and initial work-up**
A. Van Der Heijden, Nijmegen (NL)

**Perioperative therapy**
R. Cathomas, Chur (CH)

**Surgery**
L.S. Mertens, Amsterdam (NL)

**Bladder preserving treatment**
A. Van Der Heijden, Nijmegen (NL)

**Metastatic disease**
R. Cathomas, Chur (CH)

**Oligometastatic disease and follow-up**
L.S. Mertens, Amsterdam (NL)

# 2026 EAU Guidelines update and controversies – Urolithiasis, female and male LUTS and infections: What has changed?

ESU Course 33

**Sunday 15 March**
**08:30 - 11:30**

**Location** Red Area, Room 10

**Chair** A.K. Nambiar, Newcastle-upon-Tyne (GB)

**Learning objectives**

This course will focus on three non-oncology Guidelines (Non-Neurogenic Female and Male LUTS, and Urolithiasis) and there will be a brief review of the EAU Guidelines methodology and process of guideline development.

The course will then involve an interactive discussion of the main new changes to these guidelines, challenges in development, areas of inconsistency and opportunities for further research.

**Welcome and introduction**
A.K. Nambiar, Newcastle-upon-Tyne (GB)

**Non-neurogenic male LUTS guideline: Updates and controversies**
J-N.L. Cornu, Rouen (FR)

**Urolithiasis guideline: New diagnostic algorithms, best clinical practice in urinary stone intervention, how and how often to follow up and time to discharge urinary stone patients after treatment**
R. Geraghty, Newcastle upon Tyne (GB)

**Female Non-neurogenic LUTS: A re-birth, revamp and re-naming. Changes to expect in 2025**
A.K. Nambiar, Newcastle-upon-Tyne (GB)

**Updates from the EAU Guidelines on infections – Recurrent UTI, ABU and the EMA stance on fluoroquinolones**
G. Bonkat, Basel (CH)

# Surgical genital reconstruction - Step by step video demonstration of common procedures

ESU Course 34

**Sunday 15 March**
**08:30 - 11:30**

**Location** Red Area, Room 11

**Chair** S.C. Morgenstern, Frankfurt am Main (DE)

**Learning objectives**

This new ESU course by the EAU reconstruction section addresses the needs of urologists from first interest in genital reconstruction to those in their early years of reconstructive practise. Based on short surgical step-by-step- videos with a high emphasis on participant-interaction, renown experts share their tips and tricks out of their vast surgical experience on the most common procedures in genio-urethral reconstruction.

### Introduction
S.C. Morgenstern, Frankfurt am Main (DE)

### Penile surgeries

**General pre- and post OP tips and tricks**
S.C. Morgenstern, Frankfurt am Main (DE)

**Complications after circumcision and lichen**
S.C. Morgenstern, Frankfurt am Main (DE)

**Penile Implants**
D.J. Ralph, London (GB)

**Peyronies**
S.C. Morgenstern, Frankfurt am Main (DE)
D.J. Ralph, London (GB)

### Penile emergancies

**Penile fracture**
D.J. Ralph, London (GB)

**Priapism**
S.C. Morgenstern, Frankfurt am Main (DE)
D.J. Ralph, London (GB)

### Basic urethral reconstruction

**Meatus stenosis and anterior urethral stricture**
D. Hernández Hernández, San Cristóbal de La Laguna (ES)
S.C. Morgenstern, Frankfurt am Main (DE)

### Basic male incontinence

**Incontinence**
D. Hernández Hernández, San Cristóbal de La Laguna (ES)

**Evaluation and closure**
S.C. Morgenstern, Frankfurt am Main (DE)
D.J. Ralph, London (GB)

## Robotic-assisted laparoscopic prostatectomy

ESU Course 32

**Sunday 15 March**
**08:30 - 11:30**

**Location** Red Area, Room 9

**Chair** A. De La Taille, Créteil (FR)

**Learning objectives**
The objectives are to explain, using videos and step-by-step explanations, robotic assisted radical prostatectomy with three presenters using three differents approaches: Transperitoneal, preperitoneal and retztius-sparing techniques.

General principles regarding port placement, prostate anatomy and surgical landmarks will be also reminded considering the different possible options and the different types of robotic systems used. Finally, the course will present the possible intraoperative risks of complications and how-to-manage-them strategies.
This course will be interactive including direct and/or multichoice questions to the audience.

**Introduction**
A. De La Taille, Créteil (FR)

**Anatomical remainders**
F. Annino, Arezzo (IT)

**RALP by steps: Anterior transperitoneal**
A. Haese, Hamburg (DE)

**RALP by steps: Retius sparing**
F. Annino, Arezzo (IT)

**Tips and Tricks**

**How to avoid positive margins during nerve-sparing**
A. Haese, Hamburg (DE)

**How to preserve bladder neck**
F. Annino, Arezzo (IT)

**How to avoid and manage urine leakage**
A. De La Taille, Créteil (FR)

**Tricky cases**

**Prostatectomy after TURP/Enucleation**
A. Haese, Hamburg (DE)

**How to manage median lobe and prostate > 100 grms**
F. Annino, Arezzo (IT)

**Salvage prostatectomy**
A. De La Taille, Créteil (FR)

**Beware of complications**

**Bleeding**
A. Haese, Hamburg (DE)

**Ureteral lesion**
F. Annino, Arezzo (IT)

**Manage bladder strictures**
A. De La Taille, Créteil (FR)

**Discussion: Quality control during the learning curve**
A. Haese, Hamburg (DE)

**Conclusion**
A. De La Taille, Créteil (FR)

## Percutaneous nephrolithotripsy (PCNL)

ESU Course 35

**Sunday 15 March**
**08:45 - 11:45**

**Location** Red Area, Room 12

**Chair** A. Skolarikos, Athens (GR)

Voting will be available via the EAU26 App or via www.qna.at/eau

**Learning objectives**
The aim of this course is to describe the surgical techniques of all available treatment options in percutaneous surgery of renal stones in details. In addition to tips and tricks aiming into improving the efficacy of the operation, the most common complications associated with the procedure will be reviewed focusing on prevention and proper management.

Objectives:
• describe the main indications for percutaneous nephrolitotomy and the best clinical practice based on the EAU Guidelines
•Describe the basic percutaneous nephrolithotomy techniques step by step
• Provide tips and tricks to improve the efficacy of the operation
• Identify associate complications including their management

**Guidelines on stone treatment**
E.K. Bres-Niewada, Pruszkow (PL)

**PCNL instrumentation – Suite organisation, wires, dilators and lithotriptors**
E.K. Bres-Niewada, Pruszkow (PL)

**From skin to stone: Step-by-step access using only fluoroscopy (Prone position)**
A. Skolarikos, Athens (GR)

**From skin to stone: Step-by-step access using ultrasonography (US) and fluoroscopy (Supine position)**
O.R. Durutovic, Belgrade (RS)

**MiniPerc- Indications, equipment and technique**
A. Skolarikos, Athens (GR)

**Tips and tricks in PCNL**
O.R. Durutovic, Belgrade (RS)

**Round table: Complications of PCNL: Diagnosis, management, prevention**
E.K. Bres-Niewada, Pruszkow (PL)
O.R. Durutovic, Belgrade (RS)
A. Skolarikos, Athens (GR)

## Hands-on Training in prostate MRI reading for urologists

HOT MRI - 3.1

**Sunday 15 March**
**09:00 - 12:30**

**Location** Red Area, Room 6

**Learning objectives**
This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on a provided computer using realistic software, followed by a reference reading provided by expert radiologists and pathological verification.

**09:00 - 09:05** **Course overview**
J. Walz, Marseille (FR)

**09:05 - 09:15** **Lecture: The importance of prostate MRI to the Urologist**
J.P. Radtke, Düsseldorf (DE)

**09:15 - 09:45** **Lecture: Introduction to MRI sequences, scoring systems, PI-RADS**
F. Giganti, London (GB)

**09:45 - 10:15** **Lecture: Interactive case discussion – reporting MRI using PI-RADS**
T. Barrett, Cambridge (GB)

**10:15 - 10:20** **Introduction to the software for MRI interpretation**
J. Walz, Marseille (FR)

**10:20 - 10:50** **Diagnosis I: Practical MRI diagnosis**

**10:50 - 11:20** **Review of the findings I**
F. Giganti, London (GB)

**11:20 - 11:50** **Diagnosis II: Practical MRI diagnosis**

| | |
|---|---|
| **11:50 - 12:20** | **Review of the findings II**<br>T. Barrett, Cambridge (GB) |
| **12:20 - 12:30** | **Discussion, feedback & closure**<br>J.P. Radtke, Düsseldorf (DE) |

## Hands-on Training in Botulinum Toxin Injection

HOT Botox - 3.1

**Sunday 15 March**
**09:00 - 10:30**

**Location** Red Area, Room 3

**Chairs**
H. Hashim, Bristol (GB)
C. Ochoa Vargas, Bristol (GB)

**Learning objectives**

Botulinum toxin type A has become established in urological practice over the past decades. Onabotulinum-toxin A (BTX-A) is licensed for the treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO) refractory to conservative and medical therapy.

This European Association of Urology (EAU) Hands-on Training (HOT) course is procedure-focused and teaches the practical aspects of intradetrusor onabotulinum-toxin-A administration through hands-on training using bladder models. Participants will learn safe reconstitution, injection techniques, using flexible and rigid cystoscopic equipment.

**09:00 - 09:15** **Introduction**
H. Hashim, Bristol (GB)

Learning objectives of this presentation

- Role of onabotulinumtoxinA (BTX-A) in the OAB and NDO treatment pathway
- Evidence-base and EAU guideline recommendations
- Injection paradigms, dosing, and patient counselling
- Overview of other functional urological applications (off-label)

**09:15 - 10:15** **Hands-on Rotation**

09:15 - 10:15 **Station 1: Onabotulinum-toxin-A reconstitution**

*Tutor* P. Bueno Garcia Reyes, Mexico City (MX)

09:15 - 10:15 **Station 2: Intradetrusor injection using flexible cystoscopy**

*Tutor* A.A. Sharaf, Scarborough (GB)

09:15 - 10:15 **Station 3: Intradetrusor injection using rigid cystoscopy**

*Tutor* M.A. Averbeck, Porto Alegre (BR)

**10:15 - 10:30**

**Wrap-up and Q&A**

C. Ochoa Vargas, Bristol (GB)

Learning objectives of this presentation

- Key learning points
- Discussion of complications and practical considerations

## E-BLUS Exam

HOT EBLUS EXAM - 3.1

**Sunday 15 March**
**09:00 - 09:55**

**Location** Red Area, Room 1

**Coordinator** D. Oliveira Reis, Lisboa (PT)

**Tutors** V. Novak, Praha (CZ)
L.M. Vendrell, Ciudad - Mendoza (AR)

**Learning objectives**

In this exam, your psychomotor skills such as depth perception and bimanual dexterity will be tested and your mastery of basic laparoscopy skills such as instrument handling, pattern cutting and intracorporeal suturing will be assessed by experienced examiners.
The exam is aimed at candidates with intermediate and advanced laparoscopy experience or those who have sufficiently trained to meet the exercises time and quality criteria. Passing the E-BLUS exam will be rewarded with a certificate that serves as a recommendation to continue your laparoscopy training by assisting laparoscopic procedures in the OR.

## Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 3.1

**Sunday 15 March**
**09:00 - 09:50**

**Location** Red Area, Room 1

**Tutors** N.C. Grossmann, Lucerne (CH)
A. Tsaturyan, Yerevan (AM)

**Learning objectives**

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## ESTs1 Exam

HOT EST EXAM 3.1

**Sunday 15 March**
**09:00 - 09:50**

**Location** Red Area, Room 1

**Tutors**
M. Henderickx, Wilrijk (BE)
I. Mykoniatis, Thessaloniki (GR)
A. Papatsoris, Athens (GR)

**Learning objectives**
In this exam, candidates' psychomotor and endoscopic skills are assessed, with a focus on the safe and effective performance of core endourological procedures such as rigid cystoscopy, flexible cystoscopy, semi-rigid ureteroscopy, and flexible ureteroscopy. Candidates are evaluated by experienced examiners on instrument handling, scope control, orientation, and respect for tissue within a simulated setting. The exam is aimed at candidates with basic to intermediate endourology experience or those who have completed sufficient training to meet the required performance standards, and successful completion is rewarded with a certificate recommending progression to supervised endourological procedures in the operating room.

## Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 3.1

**Sunday 15 March**
**09:00 - 09:50**

**Location** Red Area, Room 1

**Tutors**
D. Veneziano, New York (US)
G. Vitagliano, Buenos Aires (AR)

**Learning objectives**
The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 3.1

**Sunday 15 March**
**09:00 - 09:50**

**Location** Red Area, Room 1

**Tutors**
M. Arslan, Istanbul (TR)
G. Bozzini, Como (IT)
D. Perri, Como (IT)

**Learning objectives**
This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

# Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 3.1

**Sunday 15 March**
**09:00 - 09:50**

**Location** Red Area, Room 1

**Tutors**
H. Ismail, Cottbus (DE)
M.E. Rodríguez Socarrás, Madrid (ES)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# Hands-on Training in TP Biopsy and MRI fusion

HOT TPB - MRI - 3.1

**Sunday 15 March**
**09:30 - 12:30**

**Location** Red Area, Room 2

**Chair** L. Budäus, Hamburg (DE)

**Learning objectives**

This course is designed to provide a comprehensive overview of office based transperineal (TP) biopsy techniques in local anaesthesia. It includes the integration of MRI fusion technology into daily clinical practice. Participants will begin with an introduction to the importance of TP biopsy and detailed instructions on performing the procedure by themself..

The hands-on training sessions are the core of the course, where participants will practice:

- Basics of superficial local anesthesia
- Deep periprosthetic block
- Basics of targeting and fusion
- Grid based / free hand / single incision biopsies

**09:30 - 09:35** **Introduction**
L. Budäus, Hamburg (DE)

**09:35 - 09:50** **Why TP biopsy & how to do TP biopsy & different needles**
L. Budäus, Hamburg (DE)

**09:50 - 10:00** **Technical comparison**
C. Kastner, Cambridge (GB)

**10:00 - 11:55** **Hands-on Training**

*Tutors*

H.U. Ahmed, London (GB)
J. Anract, PARIS (FR)
S. Bolomytis, Bristol (GB)
A.K. George, Baltimore (US)
J.L. Hohenhorst, Hamburg (DE)
M. Jahnen, Munich (DE)
C. Kastner, Cambridge (GB)
T. Kuliš, Zagreb (HR)
R. Popert, London (GB)
J.P. Radtke, Düsseldorf (DE)
W.C. Tsang, Singapore (SG)

Learning objectives of this presentation

- Basics of superficial local anesthesia
- Deep periprosthetic block
- Basics of targeting and fusion
- Grid based / free hand / single incision biopsies

**11:55 - 12:25** **Circulate among stations**

**12:25 - 12:30** **Closing remarks**
L. Budäus, Hamburg (DE)

## Game Changer Session

**Sunday 15 March**
**10:00 - 10:15**

**Location** Orange Area, eURO Auditorium 1

**Chairs**
V. Kasivisvanathan, London (GB)
T. Nordström, Stockholm (SE)

**Learning objectives**
Participants will understand how very long-term follow-up from the Gothenburg randomized screening trial within the European Randomised Study of Screening for Prostate Cancer informs the ongoing debate on prostate cancer screening. The session will explore how the balance between mortality benefit and overdiagnosis evolves over decades of follow-up. Attendees will also learn how opportunistic PSA testing in contemporary populations influences the interpretation of screening trials. Finally, the presentation will discuss implications for the design of future screening studies and the need to develop diagnostic pathways that reduce overdiagnosis while preserving the benefits of early detection.

**10:00 - 10:15** **30 years of follow-up in the Gothenburg 1 Randomized Population-based Prostate Cancer Screening Study**

*Speaker* J. Hugosson, Gothenburg (SE)

*Discussant* A.S. Rannikko, Espoo (FI)

# Game Changer Session

**Sunday 15 March**
**10:00 - 10:30**

**Location** Orange Area, eURO Auditorium 2

**Chairs** M. Bultitude, London (GB)
P.J.S. Osther, Vejle (DK)

**Learning objectives**
1. Learn about gamechanging research in urology 2. Understand the role of tranexamic acid in urological surgery 3. Hear latest research using Rezum for male LUTS/ BPO

**10:00 - 10:15**

**Safety and efficacy of tranexamic acid in urologic surgery: results from the international, randomised, placebo-controlled POISE-3 trial**

*Speaker* K.A.O. Tikkinen, Helsinki (FI)

*Discussant* S. Psutka, Seattle (US)

**10:15 - 10:30**

**Water Vapor Thermal Therapy with Rezūm vs. combination therapy for male LUTS/BPO: 1-Year results from a prospective, multicenter randomized controlled trial (VAPEUR-RCT)**

*Speaker* J-N.L. Cornu, Rouen (FR)

*Discussant* C. De Nunzio, Rome (IT)

# Patient advocacy plaza - Update on the BCLEAR project: Health literacy in bladder cancer

Special Session

**Sunday 15 March**
**10:00 - 10:30**

**Location** Patient Advocacy Plaza

**Chair** A. Filicevas, Brussels (BE)

**Learning objectives**
This session will present the BCLEAR project, a European initiative designed to strengthen bladder cancer health literacy and improve public understanding of the disease. Delegates will explore how limited awareness and uneven access to reliable information contribute to disparities in prevention, symptom recognition, and patient engagement in care. The session will also introduce the methodology used to evaluate existing educational materials and develop new evidence-based resources aimed at improving bladder cancer awareness, supporting shared decision-making, and reducing disparities across European healthcare systems.

**World Bladder Cancer Patient Coalition (WBCPC)**
A. Filicevas, Brussels (BE)

## E-BLUS Exam

HOT EBLUS EXAM - 3.2

**Sunday 15 March**
**10:00 - 10:55**

**Location** Red Area, Room 1

**Coordinator** D. Oliveira Reis, Lisboa (PT)

**Tutors** V. Novak, Praha (CZ)
L.M. Vendrell, Ciudad - Mendoza (AR)

**Learning objectives**
In this exam, your psychomotor skills such as depth perception and bimanual dexterity will be tested and your mastery of basic laparoscopy skills such as instrument handling, pattern cutting and intracorporeal suturing will be assessed by experienced examiners.
The exam is aimed at candidates with intermediate and advanced laparoscopy experience or those who have sufficiently trained to meet the exercises time and quality criteria. Passing the E-BLUS exam will be rewarded with a certificate that serves as a recommendation to continue your laparoscopy training by assisting laparoscopic procedures in the OR.

## Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 3.2

**Sunday 15 March**
**10:00 - 10:50**

**Location** Red Area, Room 1

**Tutors** N.C. Grossmann, Lucerne (CH)
A. Tsaturyan, Yerevan (AM)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## ESTs1 Exam

HOT EST EXAM 3.2

**Sunday 15 March**
**10:00 - 10:50**

**Location** Red Area, Room 1

**Tutors**

A.C. Bouma - Houwert, Amsterdam (NL)

M. Henderickx, Wilrijk (BE)

A. Papatsoris, Athens (GR)

**Learning objectives**

In this exam, candidates' psychomotor and endoscopic skills are assessed, with a focus on the safe and effective performance of core endourological procedures such as rigid cystoscopy, flexible cystoscopy, semi-rigid ureteroscopy, and flexible ureteroscopy. Candidates are evaluated by experienced examiners on instrument handling, scope control, orientation, and respect for tissue within a simulated setting. The exam is aimed at candidates with basic to intermediate endourology experience or those who have completed sufficient training to meet the required performance standards, and successful completion is rewarded with a certificate recommending progression to supervised endourological procedures in the operating room.

## Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 3.2

**Sunday 15 March**
**10:00 - 10:50**

**Location** Red Area, Room 1

**Tutors**

M. Jarzemski, Bydgoszcz (PL)

D. Veneziano, New York (US)

**Learning objectives**

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

## Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 3.2

**Sunday 15 March**
**10:00 - 10:50**

**Location** Red Area, Room 1

**Tutors**
M. Arslan, Istanbul (TR)
G. Bozzini, Como (IT)
D. Perri, Como (IT)

**Learning objectives**
This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

## Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 3.2

**Sunday 15 March**
**10:00 - 10:50**

**Location** Red Area, Room 1

**Tutors**
H. Ismail, Cottbus (DE)
M.E. Rodríguez Socarrás, Madrid (ES)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# Policy Office - Kidney cancer: Closing the gap to better outcomes- Scientific briefing and policy recommendations

Special Session

**Sunday 15 March**
**10:15 - 10:45**

**Location** EAU Square

**Chair** H. Van Poppel, Leuven (BE)

**Kidney Cancer White Paper update: Closing the gap to better outcomes- scientific briefing and policy recommendations**

*Discussants*

A. Bex, London (GB)
R. Campi, Florence (IT)
O. Exertier, Utrecht (NL)
L. Marandino, London (GB)
E. Moyse, Brussels (BE)
H. Van Poppel, Leuven (BE)

# Paediatric penile surgeries

Thematic Session

**Sunday 15 March**
**10:30 - 12:00**

**Location** Orange Area, Room 3

**Chairs** C. Gernhold, Linz (AT)
M.S. Silay, Istanbul (TR)

**Learning objectives**
This video-based session will describe the indications, techniques and postoperative management of common pediatric penile surgeries; recognize and prevent potential complications; and apply evidence-based decision making to optimize functional and cosmetic outcomes in children undergoing penile reconstruction.

**10:30 - 10:59** **Most common penile surgeries**

10:30 - 10:37 Semi-live video presentation **Male circumcision**
B. Bañuelos Marco, Madrid (ES)

10:37 - 10:44 Semi-live video presentation **Buried penis**
Y.T. Soygür, Ankara (TR)

10:44 - 10:51 Semi-live video presentation **Webbed penis**
A. Morlacco, Padova (IT)

10:51 - 10:59 **Discussion**

**10:59 - 11:37** **Hypospadias**

10:59 - 11:09 **Distal hypospadias repair techniques**
N. Pakkasjarvi, Turku (FI)

11:09 - 11:19 **Flaps and grafts during distal hypospadias repair: Where to use them?**
R. Subramaniam, Leeds (GB)

| | |
|---|---|
| 11:19 - 11:29 | **Management of most common distal hypospadias repair complications: Fistula, stenosis and glans dehiscence**<br>P. Hoebeke, Ghent (BE) |
| 11:29 - 11:37 | **Discussion** |
| **11:37 - 11:44** | Semi-live video presentation **An unpleasant surprise: Megameatus intact prepuce**<br>B. Burgu, Ankara (TR) |
| **11:44 - 11:51** | Semi-live video presentation **Congenital penile curvature**<br>M. Peycelon, Paris (FR) |
| **11:51 - 11:59** | **Discussion** |
| **11:59 - 12:00** | **Closing remarks** |

## The future of kidney cancer care: Diagnostic innovations and risk assessment

Abstract Session 28

**Sunday 15 March**
**10:30 - 12:00**

**Location** Blue Area, Victoria 5

**Chairs**
B.J. Challacombe, London (GB)
S.D. Pandolfo, Naples (IT)
M. Wroclawski, Sao Paulo (BR)

| | |
|---|---|
| **10:30 - 10:50** | **ctDNA: What's happening in kidney cancer?** |
| A0459 | **Application of Individualized molecular residual disease in risk stratification, recurrence monitoring, and drug efficacy prediction for renal cell carcinoma**<br>M. Chen, Shanghai (CN) |
| A0460 | **Multicenter Establishment and Validation of cM0 (i+) Stage Criteria in Localized Renal Cell Carcinoma Based on Postoperative Circulating Tumor Cell Monitoring**<br>Z.L. Wang, Xi'an (CN) |
| A0461 | **Undetectable ctDNA in patients with localized renal cell carcinoma is associated with improved oncological outcomes and may be amenable to a less intense imaging surveillance protocol**<br>A. Zhu, New York (US) |
| A0462 | **ctDNA-Based MRD Monitoring in Genitourinary Cancers Early Relapse Prediction and Clinical Implications**<br>Y.J. Jiang, Shenyang (CN) |
| **10:50 - 11:25** | **Biomarkers for risk stratification RCC** |
| A0463 | **Diagnostic and Prognostic Role of Prostate-Specific Membrane Antigen Expression in Clear Cell Renal Cell Carcinoma**<br>I. Hamidzada, Istanbul (TR) |
| A0464 | **Radiomics Analysis of CT Imaging for Predicting MIT Family Translocation Renal Cell Carcinoma: A Multicenter Retrospective Clinical Study**<br>S. Chen, Fuzhou (CN) |

A0466 **Endothelial PSMA expression correlates with vascular remodeling, hypoxia and immunosuppressive microenvironment of clear-cell renal cell carcinoma**
J. Gao, Nanjing (CN)

A0467 **Endothelial PSMA expression correlates with EMT, microvascular invasion and metastasis of clear-cell renal cell carcinoma**
J. Gao, Nanjing (CN)

A0468 **From waste to diagnosis: Urinary extracellular vesicle proteomics reveals diagnostic and risk-associated biomarkers in clear-cell renal cell carcinoma**
L.T. de Haan, Amsterdam (NL)

A0469 **First-In-Human Ex-Vivo Validation Of Carbonic Anhydrase IX-Target PET For High-Risk Renal Cancer: Tumor Heterogeneity, Lymph Nodes And Metastases (CAT-VHL - PNRR-POC-2023-12377493 - Cohort B)**
F. Cei, Segrate (IT)

---

**11:25 - 11:50** **Renal biopsy**

A0470 **High versus Low Center Use of Preoperative Renal Biopsy: Oncological Outcomes after Nephrectomy for Small Renal Masses**
J. Sarkis, Meaux (FR)

**Study Group**
UroCCR French Research Network for Kidney Cancer(Bordeaux, France)

A0471 **Biopsy and Identification of Risk Factors for Discordance in Renal Tumor : Results from the BIRD study (UroCCR n°230)**
S. Kutchukian, Poitiers Cedex (FR)

A0472 **Higher harmonic generation microscopy for rapid, label-free imaging of renal cancer tissue: Preliminary results from the INTelligent Imaging RCC (INTIMA) study**
L.T. de Haan, Amsterdam (NL)

A0473 **Breaking The Myth Of Tumor Seeding: Renal Tumor Biopsy Does Not Increase Relapse Or Progression Risk**
F. Belladelli, Milan (IT)

A0474 **Bridging the Diagnostic Gap: A Novel-Invasive Biomarker to Differentiate Chromophobe RCC from Oncocytoma**
F.L. Berg, Cologne (DE)

---

**11:50 - 12:00** **Small renal mass**

A0475 **Refining Surveillance for Small Renal Masses: Predicting Aggressiveness and Oncologic Outcomes Based on Tumour Size and Patient Characteristics**
L. Salerno, Milan (IT)

A0476 **When Silence Speaks Loud: Decoding Symptomatic Presentation in Small Renal Masses**
A. Bertini, Detroit (US)

# Lights and shadows in LUTS/BPO management: From pharmacotherapy to MISTs

Abstract Session 26

**Sunday 15 March**
**10:30 - 12:00**

**Location** Blue Area, Victoria 2

**Chairs**
M.A. Averbeck, Porto Alegre (BR)
S. Secco, Milan (IT)
K.C. Zorn, Montreal (CA)

**10:30 - 10:45** **Medical treatment**

A0435 **Real-world evaluation of clinically meaningful improvement in symptoms and quality of life in Greek patients with benign prostatic hyperplasia after six months of treatment with the fixed dose combination of dutasteride/tamsulosin. Pooled analysis of the PROSPERITY I and II studies.**
G. Tsioumas, Athens (GR)

A0436 **Signal Detection of Depression and Suicidality with the 5-Alpha Reductase Inhibitors: Evidence from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database**
A. Villano, Gallarate (IT)

A0437 **Five-Year Retreatment and Medication Restart Rates Following Benign Prostate Hyperplasia Treatments: A Nationwide Real-World Analysis Using Epic Cosmos**
A. Turcan, Calenzano (IT)

**10:45 - 11:35** **Non-ablative MISTs**

A0438 **Multicenter 24-month outcomes of Rivermark FloStent™: the RAPID-II study**
To be confirmed

A0439 **Interim 24-month outcomes from a randomized, sham controlled study evaluating a novel prostatic urethral stent for the treatment of BPH**
S.A. Kaplan, New York (US)

A0440 **Cost-effectiveness of the prostatic urethral lift compared with endoscopic surgery: interim analysis of the ECOLIFT Study**
G.Y. Robert, Bordeaux (FR)

**Study Group**
ECOLIFT Study group(Bordeaux, France)

A0441 **Predicting Functional Outcomes After Prostatic UroLift: The latest nomogram for prediction of urological outcomes**
A.A. Checchia, San Giovanni Rotondo (IT)

A0442 **A randomized trial comparing iTind versus UroLift (MT-08) - Interim report findings.**
B. Chughtai, Syosset (US)

A0443 **Patient satisfaction and decision regret in patients undergone Temporary Implantable Nitinol Device (iTIND) procedure: an Italian, real life, multicenter study**
L. Cindolo, Salerno (IT)

A0444 **Outcomes of Out-Patient In-Office TURBO OptilumeBPH MIST: Peri-Operative Results, 30-day Patient Recovery Experience and 3-Month Clinical Outcomes**
K.C. Zorn, Montreal (CA)

A0445 **The SUMMIT Study: A real-world, prospective, multi-center study to evaluate the performance of the Optilume® BPH Catheter System in men with symptomatic Benign Prostatic Hyperplasia (BPH)**
To be confirmed

A0446 **Durable Symptom Relief and Functional Preservation: Final 3-Year Results from the PINNACLE Trial of the Optilume® BPH Catheter System**
S.A. Kaplan, New York (US)

**Study Group**
PINNACLE Investigators(-, United States of America)

A0447 **Optilume BPH: A Promising Minimally Invasive Treatment for Benign Prostatic Hyperplasia in Larger Prostates**
K.C. Zorn, Montreal (CA)

**11:35 - 12:00** **Ablative MISTs**

A0448 **Do Patients Rezum Medications? A Real-World Analysis of Medical Retreatment After Water Vapor Thermal Therapy**
V. Nguyen, Seattle (US)

A0449 **Real-World 3-Year Outcomes of Rezūm Water Vapor Therapy in Men with Large (≥80 mL) Prostates: A Multi-Center Study**
M. Henrique Bitar Siqueira, Toronto (CA)

A0450 **Three-Year Reintervention Outcomes After Rezum vs UroLift: A TriNetX Comparative Analysis**
P.C. Chen, Taipei (TW)

A0451 **Risk of death after aquablation and minimally invasive surgical treatment for LUTS/BPH: analysis of the Food and Drug Administration's Manufacturer and User Facility Device Experience Database**
A. Nacchia, Prata Sannita (IT)

A0452 **Functional outcomes of benign prostatic hyperplasia surgery in octogenarians: the role of minimally invasive techniques**
R. Lombardo, Rome (IT)

## Risk stratification, reflex testing, and long-term outcomes in prostate cancer screening

Abstract Session 24

**Sunday 15 March**
**10:30 - 12:00**

**Location** Blue Area, George 1

**Chairs**
O. Bratt, Gothenburg (SE)
S. Carlsson, Heidelberg (DE)
R. Reiter, Los Angeles (US)

**10:30 - 10:45** **Impact of participation and patient characteristics on screening outcomes**

A0399 **Prognostic features in prostate cancers diagnosed in the ProScreen trial**
A.P. Auvinen, Tampere (FI)

A0400 **10-year results of the randomized PROBASE prostate cancer risk-adapted screening trial: comparison of screening outcomes by starting age of 45 years versus 50 years**
P. Albers, Düsseldorf (DE)

**Study Group**
PROBASE Investigators Study Group(Heidelberg, Germany)

A0401 **Does the effect of screening on prostate cancer-specific mortality differ in men with or without comorbidities? Long-term follow-up of ERSPC Rotterdam**
S.F. Westerhout, Rotterdam (NL)

**Study Group**
ERSPC Rotterdam study group(Rotterdam, The Netherlands)

---

**10:45 - 11:05** **Risk-stratification using family history and genetic risk**

A0402 **Does the effect of screening on prostate cancer mortality differ in men with or without a family history? Long-term follow-up of ERSPC Rotterdam**
S.F. Westerhout, Rotterdam (NL)

**Study Group**
ERSPC Rotterdam Study Group(Rotterdam, The Netherlands)

A0403 **Risk stratification of national comprehensive cancer network (NCCN) defined family history and prostate cancer development in the biomarkers of prostate cancer prevention and environment (BIOCaPPE) multicenter observational prospective study**
C. Larose, Laxou (FR)

**Study Group**
BIOCaPPE Network(Québec, Canada)

A0404 **Refining prostate cancer screening with family history: 10-year results from the STHLM3 screening trial**
M. Mariaz, Solna (SE)

A0405 **Targeted prostate cancer screening in BRCA1 or BRCA2 pathogenic germline variant carriers detects clinically relevant disease**
R.A. Eeles, London (GB)

**Study Group**
The IMPACT Study Collaborators and Steering Committee(London, United Kingdom)

---

**11:05 - 11:15** **DRE in screening: Any value?**

A0406 **Is the digital rectal exam (DRE) still relevant in the era of MRI imaging? Results of an international multi-institutional study**
A.R. Zlotta, Toronto (CA)

A0407 **Selective Digital Rectal Examination in the PSA–mpMRI Era: Diagnostic Yield, Rapid Learning Curve, and Educational Implications**
H.E. Lagos Beitz, Ciudad de Mexico (MX)

---

**11:15 - 11:30** **Refining the use of PSA in screening**

A0408 **Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening for Young Men – Data from the PROBASE Trial**
A. Krilaviciute, Heidelberg (DE)

**Study Group**
The PROBASE trial investigators group(Heidelberg, Germany)

A0409 **Assessment of a home capillary PSA test in Population based Prostate Cancer Screening**
D.J. Galvin, Dublin (IE)

A0410 **Age-related PSA-cutoffs on cancer detection: Results from ERSPC Rotterdam**
J.J.L. Meenderink, Rotterdam (NL)

**Study Group**
ERSPC Rotterdam(Rotterdam, The Netherlands)

---

**11:30 - 11:50** **Improving risk-stratification by using reflex blood-tests**

A0411 **Evaluation of the 4Kscore as a reflex test among men with PSA between 1.8 and 3.0 ng/ml in the Göteborg-2 Screening Trial**
F. Möller, Skövde (SE)

A0413 **Stockholm3 Test Performance for Reducing MRI in Organised Prostate Cancer Testing (OPT)**
U.G. Falagario, Bari (IT)

A0412 **Value of Stockholm3 in Men with PSA 1.5–3 ng/mL: Evidence from the Swedish Prostate Cancer Registry**
C. Micoli, Solna (SE)

A0414 **Experience of the Stockholm3-test as a reflex-test in polulation-based organized PSA-screening programme**
M. Waldén, Karlstad (SE)

---

**11:50 - 12:00** **Defining outcomes and putting screening in context**

A0415 **Time to prostate cancer diagnosis and mortality: results from the randomized STHLM3 trial.**
C. Micoli, Solna (SE)

A0416 **Risk-adapted prostate cancer screening achieves mammography-like benefits - Results from the PROBASE trial**
S. Carlsson, Heidelberg (DE)

**Study Group**
on behalf of the PROBASE study group(Heidelberg, Germany)

## Urolithiasis: Robotics, AI and Imaging

Abstract Session 25

**Sunday 15 March**
**10:30 - 12:00**

**Location** Blue Area, George 4

**Chairs**
S.Y. Cho, Seoul (KR)
C.M. Cracco, Torino (IT)
K. Ghani, Ann Arbor (US)

| | |
|---|---|
| **10:30 - 10:50** | **Imaging** |
| A0417 | **Performance of automated and semi-automated methods for measuring kidney stone volumes: Can machine replace man?**<br>A. Amenyogbe, Phoenix (US) |
| A0418 | **Does one-dimensional stone measurement support clinical decision-making? A retrospective cohort analysis of surface area and stone volume.**<br>Y. Yacobi, Zerifin (IL) |
| A0419 | **Ureter wall thickness measurement on computed tomography does not predict pathological ureteral wall thickness.**<br>S. O'Meara, Co. Dublin (IE) |
| A0420 | **Radiation Dose Reduction through the Development of a Novel Pediatric Low-Dose Computed Tomography Protocol for Urolithiasis Assessment**<br>W. MacNevin, Halifax (CA) |
| **10:50 - 11:05** | **AI in stone disease: Diagnosis** |
| A0421 | **UroMAS: A Multi-Agent System for Automated Patient Interview, Clinical Documentation, and Initial Management Planning in Urolithiasis**<br>Y. Chen, Hangzhou (CN) |
| A0422 | **Application of artificial intelligence in computed tomography for the diagnosis of urolithiasis - a single-center study**<br>T. Isaev, Moscow (RU) |
| A0423 | **Assessing the Quality and Readability of Patient Information Available for Ureteroscopy: Human versus Artificial Intelligence Comparison of Resources and Quality Measurement – A Benchmarking Study from EAU Endourology**<br>R. Baskaran, Southampton (GB) |
| **11:05 - 11:35** | **AI in stone disease: Predicting outcomes** |
| A0429 | **Is CHATGPT an expert in endoscopic urinary stone recognition? Results of a preliminary study**<br>S. Kutchukian, Poitiers Cedex (FR) |
| A0424 | **Validation and clinical implementation of a Machine Learning model for predicting sepsis following ureteroscopy: a web-based decision support tool from EAU Urotechnology**<br>C. Nedbal, Milan (IT) |
| A0425 | **Artificial Intelligence-Based Prediction of Postoperative Sepsis in Patients Undergoing Suction Mini-Percutaneous Nephrolithotomy: A Multicenter Analysis from the Global STUMPS Registry**<br>M.F. Özervarli, (TR) |
| A0426 | **Managing urolithiasis in pregnancy: can machine learning refine our surgical strategy?**<br>C. Nedbal, Milan (IT) |
| A0427 | **AI Laser-Integrated Vision System for Lithotripsy: Real-time Stone Composition Detection**<br>A.G. Martov, Moscow (RU) |
| **11:35 - 11:55** | **AI in stone disease: Treatment** |

A0430 **Convolutional Neural Network for CT-Based Kidney Stone Detection and Needle Trajectory Mapping in Percutaneous Nephrolithotomy**
R. Touma Sawaya, Beirut (LB)

A0431 **Apple vision pro used in retrograde intrarenal surgery: the pioneer experience in the real world**
C-Y. Wen, Changhua City (TW)

A0432 **From Artifact-Laden Signals to Reliable IRP on LithoVue Elite via AI Correction**
T. Yanase, Nagoya (JP)

A0433 **Feasibility of AI-assisted respiratory synchronization independent of operator timing in robotic laser lithotripsy**
J.C. Kim, Seoul (KR)

**11:55 - 12:00** **Robotics in Stones**

A0434 **Ultrasound Navigation in Robot-Assisted Percutaneous Access**
N.S Sene, Modena (IT)

## EAU Lab extended abstract presentations: Innovations in molecular diagnostics & AI

EAU26 Lab

Abstract Session 27

**Sunday 15 March**
**10:30 - 12:00**

**Location** Blue Area, Victoria 4

**Chairs**
C. Jerónimo, Porto (PT)
Z. Tippu, London (GB)
T. Zuiverloon, Nootdorp (NL)

**10:30 - 11:30** **Innovations in molecular diagnostics & AI**

A0453 **Plasma Proteomic Profiling Identifies HAVCR1 and CXADR as Early Predictive Biomarkers for Kidney Cancer**
Y. Chen, Beijing (CN)

A0454 **RenalCLIP□a visual-language foundation model for characterization, diagnosis and prognosis of renal tumors**
Y. Xiong, Shang Hai (CN)

A0455 **Deep learning-based CD8+ T cell inflammation model for predicting prognosis and combination of targeted and immunotherapy benefit from digital pathology in clear cell renal cell carcinoma**
S. Chen, Shanghai (CN)

A0457 **External validation of an AI-assisted bladder tumor segmentation model on mpMRI in patients with muscle-invasive bladder cancer: towards improved response assessment and personalized management**
J. Greidanus, Amsterdam (NL)

A0458 **Expanding the treatment landscape of FGFR-targeted therapy in bladder cancer: Integrative genomic and functional profiling of patient-derived organoids**
V. Solanki, Rotterdam (NL)

| | | |
|---|---|---|
| A0456 | **Innovative Preclinical Models For Precision Medicine In Advanced Prostate Cancer: Preliminary Results From The INSIDE Study**<br>S.T. De Cillis, Turin (IT) | |
| **11:30 - 11:37** | State-of-the-art lecture | **Innovation in molecular diagnostics & AI** |
| | *Case presenter* | G. Attard, London (GB) |
| **11:37 - 11:40** | **Discussion** | |

# Sutureless and off-clamp robotic partial nephrectomy

Video Session 09

**Sunday 15 March**
**10:30 - 12:00**

**Location** Blue Area, Victoria 1

**Chairs**
U. Capitanio, Milan (IT)
O. Katzendorn, Hannover (DE)
To be confirmed

V060 (▢1: 8 min.)
**Off-Clamp Robot-Assisted Partial Nephrectomy: The Paradox of Complexity**
R. Mastroianni, Rome (IT)

V061 (▢1: 8 min.)
**Purely Off-Clamp Robotic Partial Nephrectomy: Perioperative and Functional after 1000 Cases**
R. Mastroianni, Rome (IT)

V062 (▢1: 7 min.)
**Off-clamp sutureless robotic-assisted partial nephrectomy for small renal masses**
P. Shao, Nanjing (CN)

V063 (▢1: 8 min.)
**Sutureless retroperitoneal robot assisted partial nephrectomy: initial experience with Veriset™ hemostatic patch**
A.K. Pal, Kolkata (IN)

V064 (▢1: 6 min.)
**Robotic Sutureless Partial Nephrectomy Using a 3D-Conformed Renal Sutureless Device: A Step-by-Step Video of a Trifecta-Oriented Innovation**
M. André, Almada (PT)

V065 (▢1: 8 min.)
**Sutureless Robotic Partial Nephrectomy: Adoption, Learning Curve and Propensity-Score Matched Outcomes in a Large Single-Center Cohort**
L. Misuraca, Rome (IT)

V066 (▢1: 8 min.)
**Single-port Off-clamp Robotic Partial Nephrectomy: Surgical Technique, perioperative, pathologic and early functional outcomes of a single center series**
G. Tuderti, Roma (IT)

# Innovations in BPH surgery: From AR-guided training to robotic and single-port adenomectomy

Video Session 11

**Sunday 15 March**
**10:30 - 12:00**

**Location** Orange Area, EGPT 1

**Chairs**
J. O'Riordan, Cork (IE)
F. Porpiglia, Turin (IT)
C. Würnschimmel, Lucerne (CH)

V075 (▢1: 7 min.)
**Eye-tracking and latency-free AR visualization with HoloLase MD**
G. Magistro, Hamburg (DE)

V076 (▢1: 3 min.)
**Exploring the role of eye-tracking technology in surgical education: Insights from HoLEP**
L. Viola, Florence (IT)

V077 (▢1: 6 min.)
**SIAMLEP: an Anatomical simulator for prostate enucleation and morcellation in the same training device**
S. Fernández-Pello Montes, Gijón (ES)

V079 (▢1: 6 min.)
**Urethra-Sparing Robotic Adenomectomy: Redefining Sexual Function Preservation in the Surgical Treatment of Large Benign Prostatic Hyperplasia**
J. Romero-Otero, Madrid (ES)

V080 (▢1: 7 min.)
**Single-Port Transvesical Simple Prostatectomy: Technical Insights and Early Outcomes with the Da Vinci SP System introducing the force bipolar instrument**
K. Schnell, Lucerne (CH)

V081 (▢1: 7 min.)
**Single-port robot-assisted simple prostatectomy: Techniques via an extraperitoneal approach**
J. Hershenhouse, Los Angeles (US)

## Complex reconstructive urology: From transplant robotics to gender-affirming and functional genital surgery

Video Session 10

**Sunday 15 March**
**10:30 - 12:00**

**Location** Blue Area, Victoria 6

**Chairs**
A.J. Figueiredo, Coimbra (PT)
To be confirmed
W. Verla, Ghent (BE)

V068 (▢1: 8 min.)
**Robotic approach for graft-to-native ureteroureterostomy in a kidney transplant recipient with previous Boari flap reconstruction**
N. Ortiz Benitez, Cadiz (ES)

V069 (▢1: 6 min.)
**Robot-Assisted Partial Nephrectomy for Allograft Renal Cell Carcinoma: A Case Report**
S. Forte, Bari (IT)

V070 (▢1: 5 min.)
**The outcomes of augmented dorsal inlay graft metoidioplasty**
E. Zupo, Turin (IT)

V071 (▢1: 7 min.)
**Re-do Salvage Colon Vaginoplasty After Vaginal Canal Stenosis**
M. Garcia, Los angeles (US)

V072 (▢1: 7 min.)
**Reduction of Dysphoria-Causing Erections in Transgender Women – A Novel Surgical Technique to Gender Dysphoria Caused by Penile Erection: Bilateral Crural Artery Ligation & Transection**
M. Garcia, Los angeles (US)

V074 (▢: 6 min.)

**A Multicenter Comparative Study of Microsurgical Spermatic Cord Revascularization (shunt) and Microsurgical Ligation of the Spermatic Veins for Severe Varicocele**
Z. Wan, Guangzhou (CN)

## Controversial topics in the field of medical and surgical andrology

eau Andrology

EAU Section of Andrological Urology

**Sunday 15 March**
**10:30 - 12:00**

**Location** Blue Area, George 3

**Chair** C. Bettocchi, Foggia (IT)

**Learning objectives**
The main targets are education and best practice on controversial topics in the field of male infertility, male hormones and sexual dysfunction, either focused on medical and surgical management.

**10:30 - 10:31** **Welcome and introduction**
C. Bettocchi, Foggia (IT)

**10:31 - 11:05** **Sexual dysfunction**

*Moderators*
C. Bettocchi, Foggia (IT)
R. Djinovic, Belgrade (RS)
D.J. Ralph, London (GB)

10:31 - 10:36 **Regenerative treatments for ED and Peyronie's – results from monotherapy and combined treatments**
A. Cocci, Florence (IT)

10:36 - 10:41 **Botox and erectile dysfunction**
A. Faix, Montpellier (FR)

10:41 - 10:46 **Andrology uncovered: What it means now, and where the field is heading?**
M.M. Fode, Herlev (DK)

10:46 - 10:51 **Andrology in the age of Instagram: How social media is disrupting the field?**
G.I. Russo, Catania (IT)

10:51 - 10:56 **Penile size: A real issue or do we have a solution?**
O. Sedigh, Torino (IT)

10:56 - 11:01 **Penile Doppler: Tips and tricks behind understanding the investigation**
P.A.S. Vendeira, Porto (PT)

11:01 - 11:05 **Discussion**

**11:05 - 11:55** **Male hormones and infertility**

*Moderators*
G. Corona, Bologna (IT)
M. Dinkelman-Smit, Rotterdam (NL)
N. Sofikitis, Ioannina (GR)

11:05 - 11:10 **Male infertility: A warning sign for men's overall health?**
P. Sangster, London (GB)

| | |
|---|---|
| 11:10 - 11:15 | **Sperm under attack: Can drugs hijack male fertility?**<br>A. Zachariou, Ioannina (GR) |
| 11:15 - 11:20 | **Varicocele and testicular pain: When is surgery the right call?**<br>D. Mai Ba Tien, Ho Chi Minh City (VN) |
| 11:20 - 11:25 | **Treatment with antioxidants before or after the varicocele surgery?**<br>A. Salonia, Milan (IT) |
| 11:25 - 11:30 | **Varicocele surgery 2.0: Expert hacks for a successful second round**<br>A. Kadioglu, Istanbul (TR) |
| 11:30 - 11:35 | **Sperm sorting... ICSI/PIMSI/PICSI, is there science or just profit behind them?**<br>R.W. Rees, Southampton (GB) |
| 11:35 - 11:40 | **Epididymovasostomy – where and why along the epididymis to reconstruct?**<br>G. Franco, Roma (IT) |
| 11:40 - 11:45 | **Male fertility treatments: Why are we stagnant while IVF booms?**<br>E. Ruiz-Castañé, Barcelona (ES) |
| 11:45 - 11:50 | **FSH stimulation to improve spermatogenesis**<br>S. Minhas, London (GB) |
| **11:55 - 12:00** | **Discussion and closing remarks**<br>C. Bettocchi, Foggia (IT) |

## Bladder cancer innovations: Personalised therapies and advanced diagnostics

EGPT 36

**Sunday 15 March**
**10:30 - 12:00**

**Location** Orange Area, EGPT 3

**Chairs**
T. Bivalacqua, Philadelphia (US)
B. Der, Budapest (HU)
S. Shariat, Vienna (AT)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

| | |
|---|---|
| **10:30 - 11:00** | **Towards improved diagnostics and surveillance of muscle-invasive bladder cancer** |
| P0629 | **Urothelial cancer prevalence in microscopic hematuria patients following the national guideline**<br>Y.L. Tomassen, Amsterdam (NL) |
| P0630 | **A visually interpretable radiomics model for bladder cancer grading using white light cystoscopy images**<br>Y. Choi, Seoul (KR) |
| P0631 | **Single-cell analysis on H&E slides enables robust prognostic stratification and tumor biology assessment in patients with bladder cancer**<br>S. Semko, Cologne (DE) |
| P0632 | **Prospective evaluation of [68Ga]-FAPI-PET/MRI for loco-regional staging of muscle-invasive bladder cancer**<br>E. Laukhtina, Vienna (AT) |

P0633 **Tumour-agnostic ctDNA monitoring: a clinically feasible approach for post-cystectomy surveillance in muscle-invasive bladder cancer**
L. Mengual, Barcelona (ES)

P0634 **Clinical and genomic correlates of circulating tumor DNA in muscle-invasive bladder cancer after curative-intent therapy**
C. Aydogdu, München (DE)

**11:00 - 11:45** **Radical cystectomy and urinary diversion**

P0635 **Teaching robot-assisted radical cystectomy (RARC) is safe - Results from the prospective Swiss Society of Urology database**
L. Schneidewind, Berne (CH)

P0636 **A machine learning algorithm for survival prediction in bladder cancer patients undergoing radical cystectomy**
P. Russo, Roma (IT)

P0637 **Performance of FRAX® to Guide DXA Use and Anti-osteoporotic Treatment in Men with Ileal Urinary Diversion after Radical Cystectomy: Underestimation of Fracture Risk and the Added Value of BMD and TBS Adjustments**
M.E. Zegri de Olivar, Barcelona (ES)

P0638 **Robot-Assisted Partial Cystectomy, Distal Ureterectomy, and Reimplantation for Organ Preservation in Ureterovesical Junction Tumors**
Q. Lei, Shanghai (CN)

P0639 **Reproductive organ-sparing radical cystectomy is associated with maintained quality-of-life and sexual function in women**
S. Wang, Philadelphia (US)

P0640 **Impact of histologic variants on nodal involvement, lymphadenectomy outcomes, and survival after radical cystectomy for bladder cancer.**
L.C. Licari, Rome (IT)

P0641 **Would you choose a neobladder again? Impact of quality of life and continence on long-term decision regret after radical cystectomy with ileal neobladder reconstruction**
N. Pyrgidis, München (DE)

P0642 **Prognostic Impact of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer in patients with Low Geriatric Nutritional Risk Index: A Retrospective Cohort Study**
S. Omizo, Hirosaki (JP)

P0643 **Development and preliminary validation of the HARPI Index. A promising questionnaire to support decisions on urinary diversion in patients with bladder cancer**
N. Carl, Mannheim (DE)

**11:45 - 12:00** **Socio-economic background of patients with bladder cancer**

P0644 **Financial Toxicity in Uro-Oncology at a Public Tertiary Centre: Prevalence and Determinants Using the Spanish FACIT-COST**
H.E. Lagos Beitz, Ciudad de Mexico (MX)

P0645 **Suicide risk among patients with urologic malignancies: A population-based study using Canadian census-linked cohorts**
M. Kailavasan, London (GB)

# Intraoperative margin assessment during radical prostatectomy

EGPT 35

**Sunday 15 March**
**10:30 - 12:00**

**Location** Orange Area, EGPT 2

**Chairs**
F. Ambrosini, Genova (IT)
M. Kivi, Tallinn (EE)
Z. Tandoğdu, London (GB)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**10:30 - 10:35** **Introduction**

P0611 **Frozen Section vs Confocal Microscopy in Surgical Margin Assessment: Meta-Analysis of Diagnostic Test Accuracy**
W.T. Tomczak, Pietrzykowice (PL)

**10:35 - 11:10** **NeuroSAFE**

P0612 **Effect of NeuroSAFE-guided RARP versus standard RARP on erectile and overall sexual function recovery in patients with localized prostate cancer: a longitudinal follow-up analysis from the NeuroSAFE PROOF study**
X. Zhang, London (GB)

P0613 **NeuroSAFE PROOF study: 24-month functional and oncological outcomes from a patient-blinded, multicentre, randomised controlled phase 3 trial**
R. Almeida-Magana, London (GB)

P0614 **Assessing the accuracy of intra-operative frozen section during NeuroSafe robotic prostatectomy to predict final margin histology and guide subsequent neurovascular bundle excision**
M. Feyissa, London (GB)

P0615 **Margin analysis accuracy metrics of the NeuroSAFE technique: a frozen section versus final paraffin analysis comparison within the NeuroSAFE PROOF Study**
R. Almeida-Magana, London (GB)

P0616 **Cost-utility of NeuroSAFE-guided RARP versus standard RARP in men with localised prostate cancer in England**
R. Almeida-Magana, London (GB)

P0617 **Impact of NeuroSAFE results on biochemical recurrence after radical prostatectomy: positive NeuroSAFE margins matter**
X. van de Mortel, Nijmegen (NL)

**11:10 - 11:25** **Fluorescence confocal microscopy (Histolog scanner)**

P0619 **Initial Experience with Large Field-Of-View Confocal Laser Scanning Microscopy for Real-Time Margin Assessment During Robotic-Assisted Radical Prostatectomy**
J. Wang, San Jose (US)

P0620 **Development and validation of a deep learning tool for automated reading of fluorescence confocal microscopy images in radical prostatectomy**
N. Mayor, London (GB)

P0621 **Performance Comparison and Downstream Workflow Analysis of Fluorescence Confocal Microscopy Versus Frozen Section During Robot-Assisted Nerve Sparing Radical Prostatectomy**
L. Scheipner, Graz (AT)

**11:25 - 11:30** **Confocal laser scanning microscopy (VivaScope)**

P0622 **Randomized trial on real-time surgical margin evaluation with confocal microscopy in robot-assisted radical prostatectomy: preliminary results**
N. Rodriguez, Modena (IT)

**11:30 - 12:00** **Surgical margins**

P0623 **PSMA Radioguided Surgery for Predicting Tumor Location, Positive Surgical Margins and Local Staging in Prostate Cancer Patients Undergoing RARP with ePLND: Final Results of a Prospective Phase 2 Study**
L. Quarta, Milano (IT)

P0624 **An international delphi consensus on the use of ex-vivo fluorescent confocal microscopy for intraoperative margin assessment during robot-assisted radical prostatectomy**
E. Beatrici, Rozzano (IT)

**Study Group**
International Delphi Consensus Group on Fluorescent Confocal Microscopy during Robot-Assisted Radical Prostatectomy(Melle, Belgium)

P0625 **Early versus delayed specimen inking: the impact on margin status in Retzius-sparing robot-assisted radical prostatectomy - a comparative analysis**
A.K. Pal, Kolkata (IN)

P0627 **Development and Validation of a Machine Learning–Enhanced Preoperative Nomogram for Predicting Positive Surgical Margins after Radical Prostatectomy**
J. Zhou, Beijing (CN)

P0628 **Prognostic Impact of Surgical Margin Status on Biochemical Recurrence-Free Survival after Robot-Assisted Radical Prostatectomy: Stratification by Stage, Grade, and Nodal Involvement**
U.M. Merani, Moncalvo (IT)

## NMIBC: From basic and translational studies to clinical practice

EGPT 37

**Sunday 15 March**
**10:30 - 12:00**

**Location** Blue Area, EGPT 4

**Chairs**
J. Bjerggaard Jensen, Aarhus (DK)
J. Gadu Campos Salcedo, Huixquilucan (MX)
G. Pignot, Marseille (FR)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**10:30 - 11:05** **Liquid biopsy and precision diagnostics**

P0647 **Machine learning–based analysis of urinary exosomal miRNAs for the detection, prognosis, and immune profiling of urological malignancies**
Y. Baba, Tokyo (JP)

P0648 **A Plasma Metabolomic Signature for Non–Muscle-Invasive Bladder Cancer Independent of Hematuria Status**
V. Iacovelli, Rome (IT)

P0649 **Precision diagnostics of FGFR pathway activation by simultaneous mutation, fusion and overexpression assessment across all bladder cancer stages - the Bladder BRIDGister Experience**
R. Wirtz, Cologne (DE)

P0650 **Epigenetic Profiling of Peripheral Blood Mononuclear Cells (PBMC) Methylation Patterns in Bladder Cancer and Healthy Subjects**
B. Taam, Singapore (SG)

P0651 **World wide experience in urine based diagnostics for bladder cancer: Results from the UBioBCa project**
T. Ecke, Bad Saarow (DE)

P0652 **Digital PCR (dPCR) Enhances the Diagnostic Accuracy of Uromonitor® for Detecting Recurrence of Bladder Cancer Compared with quanitative PCR (qPCR) and Cytology**
T. Ecke, Bad Saarow (DE)

P0653 **Urinary exosomal netrin-1 as a novel biomarker for diagnosis and prognosis in bladder cancer: A multi-center study**
Z. Yuyan, Shenyang (CN)

---

**11:05 - 11:20** **Antibody-drug conjugates and organoid-guided intravesical therapy**

P0654 **Thermo-sensitive Hydrogel System Enables Sustained Intravesical Delivery of Antibody–Drug Conjugates for Effective Treatment of Non–Muscle-Invasive Bladder Cancer**
S. Fu, Kunming (CN)

P0655 **Intravesical Disitamab Vedotin (RC48) for BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicenter Phase I Trial**
X. Chen, Guangzhou (CN)

P0656 **Organoid-on-a-Chip Guided Postoperative Intravesical Instillation for Early Bladder Cancer: Feasibility and Safety Study of EV-ADC and SG-ADC**
L. Zhang, Beijing (CN)

---

**11:20 - 11:40** **Novel intravesical agents and immune modulation**

P0658 **Therapy-Induced Tertiary Lymphoid Structures Reflect Immune Reprogramming After Intravesical Bacillus Calmette-Guerin for non-muscle invasive bladder cancer**
D. Ikarashi, Iwate (JP)

P0659 **Androgen receptor blockade enhances intravesical BCG efficacy in non-muscle invasive bladder cancer: a propensity score-matched cohort study**
Z. Ou, Changsha (CN)

P0660 **Efficacy of epirubicin versus gemcitabine as a single, immediate, post-operative intravesical instillation after TURB: Preliminary results of a double-blind randomized prospective study**
E. Telli, Kocaeli (TR)

---

**11:40 - 12:00** **Optimising TURBT and perioperative management**

P0661 **Therapeutic intervention for control of LUTS after TURBT: prospective comparison between tamsulosin, oxybutynin and control**
M. Capinha, Braga (PT)

P0663 **Utility of restaging TURBT in patients with primary high grade Ta NMIBC**
S. Mebroukine, Bordeaux (FR)

P0664 **Prognostic Value of the Extent of Lymphadenectomy for Overall Survival Among Patients with Non-muscle Invasive Bladder Cancer, A Retrospective Cohort Study**
C-H. Lai, Beijing (CN)

## Male LUTS/BPO: mechanisms, biomarkers and modern surgery

EGPT 38

**Sunday 15 March**
**10:30 - 12:00**

**Location** Blue Area, EGPT 5

**Chairs**
A. Giammò, Torino (IT)
M. Hennenberg, Munich (DE)
To be confirmed

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**10:30 - 11:00** **Mechanisms**

P0665 **Local hydrogel delivery of antifibrotic agents blocks DDX3X-NLRP3 inflammasome activation and reduces wound fibrosis after BPH surgery**
Z. Chenghao, Shanghai (CN)

P0666 **Hormonal imbalance–induced CNR1 activation drives stromal fibrosis progression in benign prostatic hyperplasia via the Rap1 pathway**
Z. Liu, Beijing (CN)

P0667 **Mechanism of the Piezo1/Notch1/CTGF signaling axis mediating urothelial cell-fibroblast crosstalk in bladder fibrosis after bladder outlet obstruction**
Z. Li, Wuhan City (CN)

P0669 **Differential Downregulation of PIEZO1 and PIEZO2 in Patients With BPH and Chronic Urinary Retention**
L. Albuquerque, São Paulo (BR)

P0670 **Dysregulation of DNA repair processes in persistent detrusor overactivity after transurethral resection of the prostate (TURP) and in SCI-induced NDO**
K. Monastyrskaya, Bern (CH)

**11:00 - 11:30** **Biomarkers and beyond**

P0671 **Targeting of CDC42BPA by siRNA or the inhibitor BDP9066 suppresses contraction and growth-related functions in cultured prostate stromal cells and in human prostate tissues**
Y. Xu, Munich (DE)

P0672 **Plasma Proteomic Profiling Identifies TSPAN1 as a Key Predictor of Benign Prostatic Hyperplasia Risk in a Large Prospective Cohort**
Y. Chen, Beijing (CN)

P0675 **TRMT61A-mediated tRNA m1A modification promotes benign prostatic hyperplasia via efficient Hippo pathway translation**
Y. Liu, Munich (DE)

P0676 **Neuronal myosins as potential novel drug targets in lower urinary tract symptoms, identified by off-target inhibition of neurogenic prostate and bladder smooth muscle contractions by the myosin inhibitor mavacamten**
M. Hennenberg, Munich (DE)

**11:30 - 12:00** **AI, perioperative care and sustainability**

P0677 **Noise in the operating room (OR) and new laser technologies: a prospective comparative study in Endoscopic Enucleation of the Prostate**
S. Doizi, Paris (FR)

P0679 **Clinical evaluation of AI-based software for predicting pharmacologic response in benign prostatic hyperplasia**
S.H. Sung, Seoul (KR)

P0680 **Development of a Cognitive Task Analysis and Delphi Consensus on Transurethral Resection of the Prostate (TURP): An Educational Project of the European School of Urology**
T.E. Şener, Istanbul (TR)

P0681 **Life Cycle Assessment of HoLEP: Quantifying Environmental Impact and Opportunities for Sustainable Urologic Surgery**
C. Klein, Bordeaux CEDEX (FR)

P0682 **Clean intermittent self-catheterization versus indwelling catheter before endoscopic surgery for benign prostatic hyperplasia: impact on perioperative outcomes**
I. Chaoui, Tours (FR)

## Hormone sensitive metastatic prostate cancer

Thematic Session

**Sunday 15 March**
**10:45 - 12:15**

**Location** Orange Area, eURO Auditorium 1

**Chairs** E. Castro, Madrid (ES)
G. Giannarini, Udine (IT)

**Learning objectives**
Upon completion of this session, participants should be able to: 1) Describe the discrepancies between evidence generated in randomised trials and real-world outcomes in patients with mHSPC. 2) Assess the indications, benefits, and limitations of treatment intensification strategies, including systemic therapies and local approaches. 3) Evaluate emerging data on novel agents and optimal timing of treatment escalation or de-escalation. 4) Integrate patient-, disease-, and treatment-related factors into personalised therapeutic decision-making in mHSPC.

**10:45 - 10:55** **Disconnect between evidence and real-world data in metastatic prostate cancer**
C. Sweeney, Adelaide (AU)

**10:55 - 10:59** **Clinical case presentation & voting: Controversial high-volume disease**
S. Hallamies, Helsinki (FI)

| | |
|---|---|
| **10:59 - 11:49** | **Round-table discussion** |
| 10:59 - 11:09 | **Who benefits from intensification with docetaxel?**<br>G. Kramer, Vienna (AT) |
| 11:09 - 11:19 | **What evidence do we have from intensification with SBRT?**<br>V. Fonteyne, Ghent (BE) |
| 11:19 - 11:29 | **RT to primary tumor, what for?**<br>A. Bossi, La Garenne Colombes (FR) |
| 11:29 - 11:39 | **PARPi in mHSPC or should we wait until mCRPC?**<br>G. von Amsberg, Hamburg (DE) |
| 11:39 - 11:49 | **Other intensification strategies in mHSPC**<br>D. Murphy, Melbourne (AU) |
| **11:49 - 11:51** | **Re-do voting case 1**<br>S. Hallamies, Helsinki (FI) |
| **11:51 - 11:55** | **Clinical case presentation and voting: Recurrent low volume >5 years after RP, that achieves negative PSA at 3months of apalutamide**<br>P. Rajwa, Warsaw (PL) |
| **11:55 - 12:05** | **Treatment de-intensification: Reality or myth?**<br>B. Tombal, Brussels (BE) |
| **12:05 - 12:07** | **Re-do voting case 2**<br>P. Rajwa, Warsaw (PL) |
| **12:07 - 12:15** | **Questions and answers** |

## High-risk NMIBC and UTUC: Real-world decisions

Thematic Session

**Sunday 15 March**
**10:45 - 12:15**

**Location** Orange Area, eURO Auditorium 2

**Chairs** J. Boormans, Rotterdam (NL)
B.A. Inman, London (CA)

**Learning objectives**
This thematic session addresses important challenges and clinical dilemmas of NMIBC and metachronous UTUC with respect to diagnosis and treatment. An interactive format using a clinical scenario will guide the discussion among international renowned panellists.

| | |
|---|---|
| **10:45 - 10:50** | **Clinical case presentation - Part I**<br>L. Afferi, Aarau (CH) |
| **10:50 - 10:55** | Voting I **What treatment would you recommend?**<br>L. Afferi, Aarau (CH) |

| | | |
|---|---|---|
| **10:55 - 11:15** | **Panel discussion I** | |
| | *Moderator* | B.A. Inman, London (CA) |
| | *Panel* | J. Aning, Bristol (GB)<br>M. Eckstein, Erlangen (DE)<br>S. Psutka, Seattle (US)<br>A. Vilaseca, Barcelona (ES) |
| **11:15 - 11:20** | **Continuation clinical case - Part II**<br>L. Afferi, Aarau (CH) | |
| **11:20 - 11:25** | **Voting II What treatment would you recommend?**<br>L. Afferi, Aarau (CH) | |
| **11:25 - 11:45** | **Panel discussion II** | |
| | *Moderator* | J. Boormans, Rotterdam (NL) |
| | *Panel* | J. Baard, Amsterdam (NL)<br>E. Compérat, Vienna (AT)<br>M. Costin, Chinnor (GB)<br>O. Rodriguez Faba, Barcelona (ES) |
| **11:45 - 11:50** | **Continuation clinical case - Part III**<br>L. Afferi, Aarau (CH) | |
| **11:50 - 11:55** | **Voting III What treatment would you recommend?**<br>L. Afferi, Aarau (CH) | |
| **11:55 - 12:15** | **Panel discussion III** | |
| | *Moderator* | B.A. Inman, London (CA) |
| | *Panel* | A.J Birtle, Preston (GB)<br>A. Masson-Lecomte, Paris (FR)<br>A. Territo, Barcelona (ES) |

# Patient advocacy plaza - Humanizing nutrition: Humanizing nutrition means providing care with empathy, connecting clinical science to patients' lives, culture, and identity

Special Session

**Sunday 15 March**
**10:45 - 11:15**

**Location** Patient Advocacy Plaza

**Chair** R. Greene, Amsterdam (NL)

**Learning objectives**
- Define humanized nutrition and distinguish it from traditional, protocol-driven nutritional care. - Recognize how food intersects with identity, culture, dignity, and quality of life in patients with urological conditions - Indentify common gaps between clinical nutritional recommendations and patients' lived realities. - Integrate patient-reported experiences into nutritional assessment and care planning. - Apply practical communication strategies that promote empathy, shared decision-making, and cultural sensitivity.

**Patient Inclusive Advocacy Foundation (PIAF)**
R. Greene, Amsterdam (NL)

# Hands-on Training in Botulinum Toxin Injection

HOT Botox - 3.2

**Sunday 15 March**
**10:45 - 12:15**

**Location** Red Area, Room 3

**Chairs** H. Hashim, Bristol (GB)
C. Ochoa Vargas, Bristol (GB)

**Learning objectives**
Botulinum toxin type A has become established in urological practice over the past decades. Onabotulinum-toxin A (BTX-A) is licensed for the treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO) refractory to conservative and medical therapy.

This European Association of Urology (EAU) Hands-on Training (HOT) course is procedure-focused and teaches the practical aspects of intradetrusor onabotulinum-toxin-A administration through hands-on training using bladder models. Participants will learn safe reconstitution, injection techniques, using flexible and rigid cystoscopic equipment.

**10:45 - 11:00** **Introduction**
C. Ochoa Vargas, Bristol (GB)

Learning objectives of this presentation
- Role of onabotulinumtoxinA (BTX-A) in the OAB and NDO treatment pathway
- Evidence-base and EAU guideline recommendations
- Injection paradigms, dosing, and patient counselling
- Overview of other functional urological applications (off-label)

**11:00 - 12:00** **Hands-on Rotation**

| | | |
|---|---|---|
| 11:00 - 12:00 | **Station 1: Onabotulinum-toxin-A reconstitution** | |
| | *Tutor* | M.G. Çulha, Istanbul (TR) |
| 11:00 - 12:00 | **Station 2: Intradetrusor injection using flexible cystoscopy** | |
| | *Tutor* | T. Tarcan, Istanbul (TR) |
| 11:00 - 12:00 | **Station 3: Intradetrusor injection using rigid cystoscopy** | |
| | *Tutor* | P. Bueno Garcia Reyes, Mexico City (MX) |

**12:00 - 12:15** **Wrap-up and Q&A**

H. Hashim, Bristol (GB)

Learning objectives of this presentation

- Key learning points
- Discussion of complications and practical considerations

## Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 3.3

**Sunday 15 March**
**11:00 - 11:50**

**Location** Red Area, Room 1

**Tutors** N.C. Grossmann, Lucerne (CH)
A. Tsaturyan, Yerevan (AM)

**Learning objectives**

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# E-BLUS Exam

HOT EBLUS EXAM - 3.3

**Sunday 15 March**
**11:00 - 11:55**

**Location** Red Area, Room 1

**Coordinator** D. Oliveira Reis, Lisboa (PT)

**Tutors** S. Erdem, Istanbul (TR)
L.M. Vendrell, Ciudad - Mendoza (AR)

**Learning objectives**
In this exam, your psychomotor skills such as depth perception and bimanual dexterity will be tested and your mastery of basic laparoscopy skills such as instrument handling, pattern cutting and intracorporeal suturing will be assessed by experienced examiners.
The exam is aimed at candidates with intermediate and advanced laparoscopy experience or those who have sufficiently trained to meet the exercises time and quality criteria. Passing the E-BLUS exam will be rewarded with a certificate that serves as a recommendation to continue your laparoscopy training by assisting laparoscopic procedures in the OR.

# ESTs1 Exam

HOT EST EXAM 3.3

**Sunday 15 March**
**11:00 - 11:50**

**Location** Red Area, Room 1

**Tutors** A.C. Bouma - Houwert, Amsterdam (NL)
M. Henderickx, Wilrijk (BE)
A. Papatsoris, Athens (GR)

**Learning objectives**
In this exam, candidates' psychomotor and endoscopic skills are assessed, with a focus on the safe and effective performance of core endourological procedures such as rigid cystoscopy, flexible cystoscopy, semi-rigid ureteroscopy, and flexible ureteroscopy. Candidates are evaluated by experienced examiners on instrument handling, scope control, orientation, and respect for tissue within a simulated setting. The exam is aimed at candidates with basic to intermediate endourology experience or those who have completed sufficient training to meet the required performance standards, and successful completion is rewarded with a certificate recommending progression to supervised endourological procedures in the operating room.

# Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 3.3

**Sunday 15 March**
**11:00 - 11:50**

**Location** Red Area, Room 1

**Tutors**
K. Dilen, Heusden-Zolder (BE)
M. Jarzemski, Bydgoszcz (PL)

**Learning objectives**
The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 3.3

**Sunday 15 March**
**11:00 - 11:50**

**Location** Red Area, Room 1

**Tutors**
M. Arslan, Istanbul (TR)
G. Bozzini, Como (IT)
D. Perri, Como (IT)

**Learning objectives**
This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

## Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 3.3

**Sunday 15 March**
**11:00 - 11:50**

**Location** Red Area, Room 1

**Tutors**
H. Ismail, Cottbus (DE)
D. Oliveira Reis, Lisboa (PT)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## Non-Technical Skills for Surgical Excellence: Immersive Simulation

HOT NTS - 3.1 VR Sim

**Sunday 15 March**
**11:00 - 12:00**

**Location** EAU Square

**Tutors**
C.S. Biyani, Leeds (GB)
M. Pears, Barnsley (GB)
K. Wadhwa, Wickham Bishops (GB)

**Learning objectives**
Participants will be assigned to one of two simulation-based activities: a simulated operating room session or a computer-based virtual patient interaction. Both formats are designed to enhance non-technical skills, including communication, teamwork, and clinical decision-making.

# Patient advocacy plaza - The language of care: Why words matter in patient experience

Special Session

**Sunday 15 March**
**11:30 - 12:00**

**Location** Patient Advocacy Plaza

**Chair** S. Richardson, Amsterdam (NL)

**Learning objectives**

Why The Language of Care Matters It's not just what you say, but how you say it that shapes the quality of care. Person-centred communication strengthens relationships, builds trust, and improves outcomes. The way we communicate directly affects an individual's dignity, confidence, emotional wellbeing, and sense of safety. Thoughtful, inclusive communication ensures that people feel: • Valued • Respected • Heard • Understood • In control of their own care

**Patient Inclusive Advocacy Foundation (PIAF)**
S. Richardson, Amsterdam (NL)

# Patient advocacy plaza - Patient and partner involvement in prostate cancer research – Insights from the PRO-ACT study

Special Session

**Sunday 15 March**
**13:30 - 14:00**

**Location** Patient Advocacy Plaza

**Chair** J. Daly, Galway (IE)

**Learning objectives**

- Engaging with NCCP to influence and inform future policy on prostate cancer (PCa) care in Ireland, e.g. National Cancer Strategy 2027 and National Clinical Guidelines for PCa Treatment 2026. - Informing clinicians of unmet needs of PCa patients and their loved ones, as evidenced in PRO-ACT, especially regarding support, advice and information provided at diagnosis, and outlining areas where improvements can be achieved. - Raising public awareness of the real impact of PCa treatment on men, their partners and families, in Ireland.

**East Galway & Midlands (EGM) Cancer Support**
J. Daly, Galway (IE)

# Hands-on Training in prostate MRI reading for urologists

HOT MRI - 3.2

**Sunday 15 March**
**13:30 - 17:00**

**Location** Red Area, Room 6

**Learning objectives**

This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on a provided computer using realistic software, followed by a reference reading provided by expert radiologists and pathological verification.

| | |
|---|---|
| **13:30 - 13:35** | **Course overview**<br>F. Sanguedolce, Barcelona (ES) |
| **13:35 - 13:45** | **Lecture: The importance of prostate MRI to the Urologist**<br>L. Boesen, Herlev (DK) |
| **13:45 - 14:15** | **Lecture: Introduction to MRI sequences, scoring systems, PI-RADS**<br>F. Giganti, London (GB) |
| **14:15 - 14:45** | **Lecture: Interactive case discussion – reporting MRI using PI-RADS**<br>G. Brembilla, Milan (IT) |
| **14:45 - 14:50** | **Introduction to the software for MRI interpretation**<br>F. Sanguedolce, Barcelona (ES) |
| **14:50 - 15:20** | **Diagnosis I: Practical MRI diagnosis** |
| **15:20 - 15:50** | **Review of the findings I**<br>F. Giganti, London (GB) |
| **15:50 - 16:20** | **Diagnosis II: Practical MRI diagnosis** |
| **16:20 - 16:50** | **Review of the findings II**<br>G. Brembilla, Milan (IT) |
| **16:50 - 17:00** | **Discussion, feedback, & closure**<br>L. Boesen, Herlev (DK) |

# Non-Technical Skills for Surgical Excellence: Immersive Simulation

HOT NTS - 3.2

**Sunday 15 March**
**13:30 - 14:30**

**Location** EAU Square

**Tutors**
A. Aydin, London (GB)
S.M. Haensel, Rotterdam (NL)
N. Raison, London (GB)
G. Zanovello, Verona (IT)

**Learning objectives**
Participants will be assigned to one of two simulation-based activities: a simulated operating room session or a computer-based virtual patient interaction. Both formats are designed to enhance non-technical skills, including communication, teamwork, and clinical decision-making.

**13:30 - 13:40** **Concept of learning**
S.M. Haensel, Rotterdam (NL)

# Joint session of the EAU, EANM, ESMO and ESTRO

Thematic Session

**Sunday 15 March**
**13:45 - 15:15**

**Location** Orange Area, eURO Auditorium 2

**Chairs**
P. Erba, Milan (IT)
B.A. Jereczek-Fossa, Milan (IT)
Y. Loriot, Villejuif (FR)
J. Walz, Marseille (FR)

**Learning objectives**
Lear how to deliver the best oncological care based on the multidisciplinary approach and specific patient situation in genitourinary cancer

**13:45 - 13:49** Case I - Bladder **CR after EV-Pembro for M1 disease: Local treatment? How to restage? Follow-up?**
L.S. Mertens, Amsterdam (NL)

**13:49 - 13:59** **Round-table discussion**

*Panel*
M. Bauckneht, Genoa (IT)
J.W.F. Catto, Sheffield (GB)
V. Fonteyne, Ghent (BE)
Y. Loriot, Villejuif (FR)
A. Masson-Lecomte, Paris (FR)

**13:59 - 14:03** Case II - Bladder **High-risk UTUC (T1 HG): Staging? Neoadjuvant vs. adjuvant vs. conservative treatment?**
L.S. Mertens, Amsterdam (NL)

**14:03 - 14:15** **Round-table discussion**

*Panel*

M. Bauckneht, Genoa (IT)
J.W.F. Catto, Sheffield (GB)
V. Fonteyne, Ghent (BE)
Y. Loriot, Villejuif (FR)
A. Masson-Lecomte, Paris (FR)

**14:15 - 14:19** Case I - Testis **Stage I seminoma high risk: Staging? Surveillance vs. chemo vs. RT?**

M. Christodoulidou, Leicester (GB)

**14:19 - 14:29** **Round-table discussion**

*Panel*

Y. Che, Düsseldorf (DE)
Y. Loriot, Villejuif (FR)
L. Nappi, Vancouver (CA)
A. Papachristofilou, Basel (CH)

**14:29 - 14:33** Case II - Testis **Stage II seminoma: Staging?; Surgery vs. chemo vs. RT?**

M. Christodoulidou, Leicester (GB)

**14:33 - 14:45** **Round-table discussion**

*Panel*

Y. Che, Düsseldorf (DE)
Y. Loriot, Villejuif (FR)
L. Nappi, Vancouver (CA)
A. Papachristofilou, Basel (CH)

**14:45 - 14:50** Case I - Renal **Cystic kidney with solid mass: Staging? Diagnosis, treatment?**

G. Margue, Bordeaux (FR)

**14:50 - 15:00** **Round-table discussion**

*Panel*

M. Bauckneht, Genoa (IT)
A. Bex, London (GB)
G. De Velasco, Madrid (ES)
G. Francolini, Firenze (IT)
G. Pignot, Marseille (FR)

**15:00 - 15:05** Case II - Renal **T3b ccRCC, solitary bone lesion: Staging? Neoadjuvant treatment? Surgery + RT? Adjuvant treatment**

G. Margue, Bordeaux (FR)

**15:05 - 15:15** **Round-table discussion**

*Panel*

M. Bauckneht, Genoa (IT)
A. Bex, London (GB)
G. De Velasco, Madrid (ES)
G. Francolini, Firenze (IT)
G. Pignot, Marseille (FR)

# Future of robotic surgery

Thematic Session

**Sunday 15 March**
**13:45 - 15:15**

**Location** Orange Area, eURO Auditorium 1

**Chairs** C. Fiori, Orbassano (IT)
A. Mottrie, Aalst (BE)

**Learning objectives**
This session provides an overview of emerging technologies in robotic urological surgery, focusing on augmented reality, telesurgery, and artificial intelligence. Experts will address technical, legal, and educational implications, with a particular focus on telementoring as a tool to expand surgical expertise. A comparative debate on robotic platforms will highlight key features. Delegates will gain up-to-date insights into current trends and future directions in training, innovation, and clinical application.

| | |
|---|---|
| **13:45 - 13:46** | **Introduction** |
| **13:46 - 13:54** | State-of-the-art lecture **Augmented reality in robotic surgery: Enhancing precision, vision and outcomes**<br>P. De Backer, Ghent (BE) |
| **13:54 - 14:24** | Panel discussion **Telesurgery/telementoring** |
| 13:54 - 13:59 | **Where do we stand in 2026?**<br>A. Breda, Barcelona (ES) |
| 13:59 - 14:04 | **Technical implications**<br>X. Ma, Beijing (CN) |
| 14:04 - 14:09 | **Legal implications**<br>B. Leigh, London (GB) |
| 14:09 - 14:14 | **Is telementoring a way to expand surgical expertise beyond the borders?**<br>S. Nathan, London (GB) |
| 14:14 - 14:24 | **Discussion** |
| **14:24 - 14:42** | Debate **Which robot to choose?** |
| 14:24 - 14:30 | **Open console**<br>J.M. Gaya Sopena, Barcelona (ES) |
| 14:30 - 14:36 | **Closed console**<br>V. Phé, Paris (FR) |
| 14:36 - 14:42 | **Discussion** |
| **14:42 - 15:06** | Panel discussion **Artificial intelligence in urological surgery** |
| 14:42 - 14:48 | **Diagnostic**<br>P. Dasgupta, London (GB) |
| 14:48 - 14:54 | **Surgery: The European experience**<br>K-F. Kowalewski, Mannheim (DE) |

| | |
|---|---|
| 14:54 - 15:00 | **Surgery: The US experience**<br>L. Zhao, New York (US) |
| 15:00 - 15:06 | Urological Association of Asia Lecture (UAA) **Surgery: The Asian experience**<br>X. Ma, Beijing (CN) |
| **15:06 - 15:14** | State-of-the-art lecture **Education in robotic surgery: What is the future of training?**<br>A. Mottrie, Aalst (BE) |
| **15:14 - 15:15** | **Conclusion** |

## Redefining mHSPC management: From diagnosis and risk assessment to optimising treatment

Abstract Session 31

**Sunday 15 March**
**13:45 - 15:15**

**Location** Blue Area, Victoria 2

**Chairs**
S. Akamatsu, Nagoya (JP)
K. Goffin, Leuven (BE)
A. Omlin, Zürich (CH)

| | |
|---|---|
| **13:45 - 14:00** | **Diagnosis of metastatic disease by PSMA-PET** |
| A0512 | **Redefining EMBARK-like Patients in the PSMA Era: Impact of PSMA-PET Restaging on Disease Classification and Management**<br>A. Viti, Milan (IT) |
| A0514 | **PSMA PET/CT for staging favourable intermediate-risk prostate cancer: an international multicenter study**<br>L. Han, Beijing (CN) |
| A0515 | **Triple-tracer comparison of 18F-FDG, 68Ga-PSMA, and 18F-FAPI PET for tumor heterogeneity detection and treatment response assessment in newly diagnosed high-risk prostate cancer**<br>L. Dong, Shanghai (CN) |
| **14:00 - 14:15** | **Management of oligometastatic prostate cancer** |
| A0516 | **Outcomes of local treatment for oligometastatic prostate cancer diagnosed using PSMA PET imaging: the OLIGOMET study**<br>M. Miszczyk, Vienna (AT)<br>**Study Group**<br>YAU Prostate Cancer Working Group(Arnhem, The Netherlands) |
| A0517 | **Duration of systemic treatment as part of MDT in metachronous PSMA PET-staged oligometastatic prostate cancer**<br>R. Erard, Herent (BE) |
| A0518 | **PSMA-PET Staging Refines Patient Selection in Oligometastatic Prostate Cancer: Translating RAMPP Trial Findings into Contemporary Practice**<br>S.L.A. Scuderi, Stockholm (SE) |
| **14:15 - 14:45** | **Systemic treatment of mHSPC** |

A0519 **Uptake of doublet and triplet therapy for men with de novo metastatic castration sensitive prostate cancer. Population-based study**
P. Zaurito, Milan (IT)

A0520 **Whole-body Tumor burden stratification via 18F-PSMA-1007 PET/CT identifies optimal candidates with de novo high-volume metastatic hormone-sensitive prostate cancer for intensified triplet therapy**
W. Kaijie, Xi'an (CN)

A0521 **Risk stratification in high-volume mHSPC: Challenges in applying prognostic models to the triplet era**
K Miyajima, Vienna (AT)

A0522 **Complete pathological response of the primary tumour and implications for cytoreductive treatment in de novo metastatic prostate cancer: Analysis from the IP2-ATLANTA phase II randomised study**
A. Gopalakrishnan, Geneva (CH)

**Study Group**
IP2-ATLANTA Trial Investigators(London, United Kingdom)

A0523 **Efficacy and feasibility of new generation androgen receptor signaling inhibitors in very elderly patients (≥80 years) with metastatic castration-sensitive prostate cancer**
K. Suzuki, Kobe (JP)

A0524 **Time to subsequent chemotherapy with capivasertib (capi) + abiraterone (abi) versus placebo (pbo) + abi in patients (pts) with PTEN deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281**
N. Clarke, Manchester (GB)

---

**14:45 - 15:05** **Prognostic factors and competing health risks in metastatic prostate cancer**

A0525 **Prostate cancer stage vs. leading causes of death**
F. Falkenbach, Heidelberg (DE)

A0526 **Identifying and Predicting Non-Cancer Mortality risk in mHSPC following Doublet Therapy in the STAMPEDE Trial**
O. El-Taji, Liverpool (GB)

A0527 **Skeletal muscle index as a prognostic and predictive biomarker in de novo hormone sensitive prostate cancer: an exploratory analysis of four trials embedded within the STAMPEDE platform.**
S. Gray, Manchester (GB)

A0528 **The impact of metformin on body composition in metastatic hormone sensitive prostate cancer: exploratory analysis of the STAMPEDE metformin trial**
S. Gray, Manchester (GB)

---

**15:05 - 15:15** **Late-breaking abstract presentation**

LB022 **Efficacy and safety of darolutamide combined with trans-arterial chemoperfusion by docetaxel in metastatic hormone-sensitive prostate cancer**
J. Ouyang, Zhaoqing, Guangdong (CN)

# Voiding dysfunction: The catheter revolution?

Abstract Session 30

**Sunday 15 March**
**13:45 - 15:15**

**Location** Blue Area, George 4

**Chairs**
Y-C. Chen, Kaohsiung (TW)
E. Finazzi Agrò, Rome (IT)
C. Hentzen, Paris (FR)

**13:45 - 14:00** **Catheterisation**

A0495 **Patient-reported outcomes of reusable versus single-use catheters in intermittent catheterization for urinary retention: a prospective, randomized, multicenter study (COMPaRE-trial)**
C.H.H. Christiaans, Rotterdam (NL)

A0496 **A randomised trial comparing combined reusable and single-use catheters (Mixed-use) with single-use catheters only**
M. Fader, London (GB)

A0497 **A health economic analysis of mixed-use (multi- and single-use) intermittent catheter management compared with single-use only.**
S. McCloskey, Southampton (GB)

**14:00 - 14:20** **Non-neurogenic voiding dysfunction**

A0498 **Association Between Psoas Muscle Index and Bladder Contractility Index in Men**
H.O.D. Santos, São Paulo (BR)

A0499 **Diagnostic Clues for Low-Pressure Female Bladder Outlet Obstruction Missed by Conventional Urodynamics**
K.F. Chen, Taipei City (TW)

A0500 **Post-Micturition Dribbling: New Insights into the Role of Post-Void Residual Volume and After-Contractions — A Prospective Study**
Y. Yacobi, Zerifin (IL)

A0501 **External Validation of a Simple Office-Based Model to Predict Detrusor Underactivity in Women With LUTS**
O. Schwarztuch Gildor, Hod HaSharon (IL)

**14:20 - 14:40** **Neuromodulation**

A0502 **A Structured Management Protocol to Sustain Sacral Neuromodulation (SNM) for Lower Urinary Tract Dysfunction (LUTD): 8-Year Outcomes**
C. Ng, London (GB)

A0503 **Multimodal Image-Guided Optical Navigation for Precision Sacral Neuromodulation Electrode Implantation: A Randomized Controlled Trial**
R. Lyu, Shanghai (CN)

A0505 **Sacral Neuromodulation Device Explantation: A 12-Year Experience from a High-Volume Tertiary Center**
M. Henrique Bitar Siqueira, Toronto (CA)

**14:40 - 15:10** **Neurourology**

| | |
|---|---|
| A0506 | **NEUDOTOX Project: Toward a Urinary Microbiota Signature Associated with Response to Intradetrusor Botulinum Toxin in Neurogenic Detrusor Overactivity after Spinal Cord Injury**<br>M-A. Perrouin Verbe, Nantes (FR) |
| A0507 | **Pelvic organ prolapse is highly prevalent in women with spina bifida**<br>A. Dubois, Rennes (FR) |
| A0508 | **Upper Urinary Tract Protection and Patient Classification Following Sacral Neuromodulation in Neurogenic Bladder with Hydronephrosis: A Multicenter Study with 2-Year Follow-Up**<br>P. Chen, Guangzhou (CN) |
| A0509 | **A multi-disciplinary approach to managing ketamine uropathy**<br>S. Sarna, London (GB) |
| A0510 | **Functional outcomes and complication rates following Mitrofanoff stoma creation in adults: a 15-year institutional experience**<br>D. Stelzl, Hamburg (DE) |
| A0511 | **Long-term adherence to intermittent catheterisation in people with multiple sclerosis: findings from a multi-country retrospective survey**<br>K.B. Barken, Humlebaek (DK) |
| **15:10 - 15:15** | **Late-breaking abstract presentation** |
| LB021 | **Efficacy and Safety of Transurethral Water Vapor Thermal Therapy under Local Anesthesia for Benign Prostatic Hyperplasia Across Different Prostate Volumes**<br>Q. Yuming, Guangzhou (CN) |

## Navigating the spectrum of BPO management: Surgical advances and patient-reported outcomes

Abstract Session 32

**Sunday 15 March**
**13:45 - 15:15**

**Location** Blue Area, Victoria 5

**Chairs**
M.S. Guemmoudi, Bir Mourad Rais (DZ)
L. Moris, Leuven (BE)
A.L. Pastore, Rome (IT)

| | |
|---|---|
| **13:45 - 14:10** | **BPO standard surgical techniques are still on the block** |
| A0529 | **Perioperative outcomes and prevalence of urethral strictures during surgery for benign prostatic hyperplasia: results from the GRAND study**<br>N. Pyrgidis, München (DE) |
| A0530 | **When TURP Meets PVP(XPS): Superior Flow and Resection Efficiency in Large-Volume BPH (>80 g)**<br>D.G. Moon, Seoul (KR) |
| A0531 | **Ejaculation-Preserving Bladder Neck Simmetrical Incision at 3 and 9 o'clock: Insights from a Large Multicenter Experience**<br>F. Dagnino, Pieve Emanuele (IT) |

A0532 **Endoscopic enucleation of the prostate in patients on blood thinners: outcomes, a real-life prospective multicenter study of 932 cases.**
D. Castellani, Ancona (IT)

**Study Group**
Enucleation in Anticoagulated Patients (EAP)(Singapore, Singapore)

A0533 **Prospective Multicentre Analysis of Prostate Enucleation in Patients with Prostate Volumes Below and Above 100 ml: 3-Year Follow-Up on Safety and Efficacy**
S.H. Hook, Hamburg (DE)

---

**14:10 - 14:55** **Ablative MISTs: outcomes, retreatments and comparative trials**

A0534 **Pharmacological re-treatment after minimally invasive surgical treatments for benign prostate obstruction.**
D. Campobasso, Rieti (IT)

A0535 **Predictors of Surgical Retreatment Following Rezūm Water Vapor Therapy: A Multi-Center Real-World Analysis**
M. Henrique Bitar Siqueira, Toronto (CA)

A0536 **Modified Clavien-Dindo Classification for Hematuria Assessment in Rezūm Therapy with Continued Antithrombotic Therapy**
T. Moriwake, Okayama (JP)

**Study Group**
Okamura isshindo hospital(Okayama, Japan)

A0537 **Comparative study of the effect of holmium laser enucleation of the prostate versus water vapor therapy on sexual function**
H. Ahmed, Beni suef (EG)

A0538 **12 Month CLEAR RCT: Better Early Recovery with UroLift PUL vs Rezum with Comparable 12-Month Durability**
M. Rochester, Norwich (GB)

A0539 **Clinical Prostate Score (CLIPS) Prediction Outcome for 3 Year Follow-up Minimal Invasive Surgical Therapy (MIST) of Prostate**
X.W.G. Pek, Singapore (SG)

A0540 **Three-Year Outcomes of EchoLaser Transperineal Ablation for Benign Prostatic Hyperplasia: The First Middle Eastern Experience in 245 Patients**
A.A. Abou Taleb, Cairo (EG)

A0541 **Functional and sexual middle-term outcomes following transperineal laser ablation (TPLA) vs TURP for benign prostatic obstruction: a randomized trial**
U. Carbonara, Triggiano (IT)

A0542 **Assessing efficacy and safety of transperineal laser ablation of the prostate (TPLA) in patients with large prostate volumes (≥80ml): Results from a prospective single-center registry**
P. Polverino, Florence (IT)

---

**14:55 - 15:15** **Patients' perspectives and regrets**

A0543 **Treatment regret in patients undergoing minimally invasive treatments for benign prostatic hyperplasia**
M. Santioni, roma (IT)

A0544 **Surgical outcomes and satisfaction of patients with unfavourable UPSTREAM criteria**
A. Romagnoli, Genoa (IT)

A0545 **Integrating patient priorities into personalized surgical decision-making for BPH: A patient-centered digital interactive decision aid**
C. Wetterauer, Basel (CH)

A0546 **Association Between Symptom Improvement and Patients' Willingness to Pay After Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms**
D. Elterman, Toronto (CA)

## The future of prostate cancer diagnosis

Abstract Session 29

**Sunday 15 March**
**13:45 - 15:15**

**Location** Blue Area, George 1

**Chairs**
R. Arnsrud Godtman, Göteborg (SE)
G. Giannarini, Udine (IT)
To be confirmed

**13:45 - 14:05** **Epidemiological trends**

A0477 **Fewer hospitalizations after the shift to transperineal prostate biopsy: real world evidence from a Danish Prostate Cancer Registry.**
G. Fojecki, Odense (DK)

A0478 **Trends in the prevalence of prostate cancer among U.S. men with diabetes from 2003 to 2023**
B. Liu, Guangzhou (CN)

A0479 **Nationwide population-based longitudinal data on magnetic resonance imaging of the prostate and subsequent prostate biopsy results**
P. Zaurito, Milan (IT)

A0480 **Prospective associations of smoking and body mass index with prostate cancer: A UK Biobank cohort study**
X. Yang, Shen Zhen (CN)

**14:05 - 14:25** **Ultrasound based imaging**

A0481 **External Validation of the PRI-MUS Scoring System: A Secondary Analysis of the OPTIMUM Randomized Controlled Trial**
A.Y. Lazarovich, Edmonton (CA)

**Study Group**
OPTIMUM(Edmonton, Canada)

A0482 **Incremental value of micro-ultrasound targeted prostate biopsy cores - a secondary analysis of the OPTIMUM randomized trial**
A. Kinnaird, Edmonton (CA)

**Study Group**
For the OPTIMUM Investigators(Edmonton, Canada)

A0484 **Enhanced Diagnostic Accuracy of Micro-Ultrasound in Prostate Cancer Detection: An Updated Series from a Single-Center Prospective Study**
B. Calabrese, Pieve Emanuele MI (IT)

**14:25 - 14:45** **AI in prostate cancer diagnosis**

A0485 **Improving biopsy decision-making in prostate cancer using AI-assisted biparametric MRI**
N. Testori, Rome (IT)

A0486 **AI-assisted planning for mpMRI-guided transperineal prostate biopsy: A prospective cohort study**
Z. Zeng, Guangzhou (CN)

A0487 **A Foundation Model for Prostate Pathological Evaluation to Assist Urologist in Clinical Work**
R. Chen, shanghai (CN)

A0488 **A prospective, paired-cohort, blinded, validation of the Ibex Prostate Artificial Intelligence Pathology system compared to expert uro-pathology reporting of prostate biopsies: the Cancer Histology Artificial Intelligence Reliability Study (IP6-CHAIROS)**
H.U. Ahmed, London (GB)

**Study Group**
IP6-CHAIROS Study Group(London, United Kingdom)

**14:45 - 15:15** **Diagnostic pathways**

A0489 **Impact of a Fast-Track Diagnostic Pathway on Psychological and Physiological Stress in Men with Suspected Prostate Cancer: A Randomized Clinical Trial**
H. Ugge, Örebro (SE)

A0490 **The Impact of PI-QUAL Score on Diagnostic and Economic Efficiency of mpMRI for Prostate Cancer: Results from a Prospective Evaluation of External Scans After Central Review**
M. Longoni, Milan (IT)

A0491 **Impact of pubic bone anatomy on targeted biopsy misses in transperineal fusion-prostate biopsy using a template-guided approach**
B. Mori, Tokyo (JP)

A0492 **Transperineal biopsy septicaemia is associated with less antimicrobial resistance than transrectal biopsy: insights from real world bacteriology evidence**
A.Q. Liu, Hong Kong (HK)

A0494 **Does periprostatic lidocaine block add value during sedated prostate biopsy? A randomized prospective trial**
J.F.A. Fernández Alberti, Buenos Aires (AR)

## Innovation in paediatric urology and kidney transplantation

Video Session 13

**Sunday 15 March**
**13:45 - 15:15**

**Location** Blue Area, Victoria 6

**Chairs** To be confirmed
A.O. Noah, London (GB)
S. Tekgül, Ankara (TR)

V089 (▢↕: 6 min.) **First results of the daVinci SP Robot in adolescence**
S. Rogenhofer, Aschaffenburg (DE)

V090 (▢1: 5 min.)

**Dextran/Paclitaxel-Coated Balloon Dilation in Pediatric Posterior Urethral Valve**

J. Pizzarello, Caba (AR)

V092 (▢1: 7 min.)

**Pneumovesicoscopic Politano-Leadbetter Ureteral Reimplantation for Children with Veiscoureteral Reflux**

P-S. Liang, Kaohsiung (TW)

V094 (▢1: 3 min.)

**Development of a Multilingual Animated Educational Video for Patient Information in Live Donor Kidney Transplantation**

M.E. Polat, Ankara (TR)

# Emerging minimally invasive therapies in urology: From endoscopic reconstruction to novel prostate interventions

Video Session 14

**Sunday 15 March**
**13:45 - 15:15**

**Location** Orange Area, EGPT 1

**Chairs**
C.V. Kesch, Essen (DE)
A. Larcher, Milan (IT)
G. Ploussard, Toulouse (FR)

V096 (▢: 7 min.)
**High-Intensity Focused Ultrasound (HIFU) For Prostate Cancer - Step by Step Technique**
N.E. Paesano, Madrid (ES)

V097 (▢: 6 min.)
**Holmium Laser Peripheric Endoscopic Prostatectomy (HoLPEP) as a Focal Therapy for Prostate Cancer with Concomitant LUTS**
L. Labairu Huerta, Lumbier (ES)

V098 (▢: 8 min.)
**ROBOT ASSISTED TRANSVESICAL RADICAL PROSTATECTOMY WITH MULTIPORT DA VINCI XI SYSTEM**
A. Pansadoro, Rome (IT)

V099 (▢: 5 min.)
**An initial experience of Peri-Rectal spacer use for Prostate Radiotherapy: An Instructional Video**
L.T.Y. Benjamin, Singapore (SG)

V100 (▢: 8 min.)
**Step-by-step perineal repair of post-prostatectomy urethrorectal fistula with gracilis muscle interposition flap**
A. Escoffier, Dijon (FR)

V101 (▢: 8 min.)
**Balloon Dilation of a Ureteral Stricture using Near Eye Augmented Reality (NEAR)**
N. Stone, Vail (US)

V102 (▢: 8 min.)
**Minimally Invasive Transurethral Treatment of Large and Recurrent Renal Sinus Cysts Using a Thulium Fiber Laser**
A.G. Martov, Moscow (RU)

V103 (▢: 6 min.)
**Endoscopic treatment of ureteroileal anastomosis structures with the use of metallic, self-expanding stents.**
F. Kowalski, Bydgoszcz (PL)

# New approaches and intraoperative problem solving in robotic renal and retroperitoneal surgery

Video Session 12

**Sunday 15 March**
**13:45 - 15:15**

**Location** Blue Area, Victoria 1

**Chairs**
S. Albisinni, Rome (IT)
N. Liakos, Freiburg (DE)
R.J.A. Van Moorselaar, Amsterdam (NL)

V082 (▢: 8 min.) **Single-Port Robotic Surgery in Awake Patients Using Virtual Reality: A Case Series of Patients Treated for Kidney and Prostate Cancer.**
F. Lavagno, Turin (IT)

V083 (▢: 7 min.) **Elbow Wide: Optimizing Dexterity and Ergonomics in Single-Port Robotic Surgery**
A. Turcan, Calenzano (IT)

V084 (▢: 5 min.) **Early intravesical control of the ureteral orifice during minimally invasive nephroureterectomy for upper urinary tract cancer**
V Sobenin, Tyumen (RU)

V085 (▢: 8 min.) **Intraoperative complications and management of robotic-assisted renal tumor surgery**
Z. Wang, Beijing (CN)

V086 (▢: 8 min.) **First reported clinical case series on ETHIZIA hemostatic patch use in partial nephrectomy: Different scenarios, different techniques, different effects**
C.H.F. Wong, Hong Kong (HK)

V087 (▢: 7 min.) **Intraoperative vascular complications in minimally invasive retroperitoneal lymph node dissection**
H.O.D. Santos, São Paulo (BR)

V088 (▢: 7 min.) **Retroperitoneal robot-assisted partial nephrectomy in prone position: an option for posterior tumors**
D. Vazquez-Martul, A Coruña (ES)

# Current controversies of urethral reconstruction and male incontinence

EAU Section of Genitourinary Reconstructive Surgeons

**Sunday 15 March**
**13:45 - 15:15**

**Location** Blue Area, George 3

**Chair** D.J. Ralph, London (GB)

**Learning objectives**

This session aims to enhance participants' understanding of contemporary controversies in urethral reconstruction and male incontinence by reviewing evidence-based approaches to bulbar strictures, including minimally invasive options, non-transecting techniques, and anastomotic repair. Learners will explore decision-making in complex scenarios such as lichen sclerosus–associated panurethral disease and compare strategies ranging from perineal urethrostomy to full-length reconstruction. The programme also seeks to deepen knowledge of male incontinence management by clarifying indications for artificial urinary sphincters versus male slings, examining advanced AUS techniques, and introducing emerging device innovations. Through case discussions and expert perspectives, attendees will refine their ability to select and tailor reconstructive and continence procedures to individual patient needs.

**13:45 - 13:46** **Welcome and introduction**
D.J. Ralph, London (GB)

**13:46 - 14:03** **Urethral reconstruction**

*Moderators* F. Campos Juanatey, Santander (ES); M. Waterloos, Ghent (BE)

13:46 - 13:48 Case presentation **3 cm bulbar stricture/1.5 cm recurrent bulbar stricture: Minimally invasive techniques for bulbar strictures. Which one is the best?**
F. Campos Juanatey, Santander (ES)
M. Waterloos, Ghent (BE)

13:48 - 13:53 **Internal urethrotomy**
D. Hernández Hernández, San Cristóbal de La Laguna (ES)

13:53 - 13:58 **Optilume balloon dilatation**
N.I. Osman, Sheffield (GB)

13:58 - 14:03 **Discussion**

**The best approach for a short bulbar stricture?**

14:03 - 14:08 **Non-transecting dorsal approach**
M. Bandini, Milan (IT)

14:08 - 14:13 **Non-transecting ventral approach**
H. Veiby Holm, Oslo (NO)

14:13 - 14:18 **Anastomotic repair**
O.J. Nilsen, Oslo (NO)

14:18 - 14:23 **Discussion**

**How would I manage a lichen sclerosus panurethral stricture?**

14:23 - 14:28 **Perineal urethrostomy**
L. Karapanos, Leverkusen (DE)

14:28 - 14:33 **Full-length reconstruction**
P. Joshi, Pune (IN)

14:33 - 14:38 **Discussion**

**14:38 - 15:15** **Male incontinence**

*Moderators* T.J. Greenwell, London (GB)
K. Van Renterghem, Hasselt (BE)

14:38 - 14:46 **AUS or male sling? Indications and contraindications**
M.W. Vetterlein, Hamburg (DE)

14:46 - 14:54 **Complex AUS surgery: Double cuff, transcorporeal**
E. Lledó García, Madrid (ES)

14:54 - 15:02 **AUS combined with IPP, sling, mini-jupette**
S. Ward, Bruxelles (BE)

15:02 - 15:10 **New AUS devices**
L. Lenfant, Paris (FR)

15:10 - 15:15 **Discussion and closing remarks**

## EAU Lab: New horizons in genitourinary cancers: from molecular mechanisms to precision therapies

EAU26 Lab EAU Pathology EAU Translational Research

EAU Section of Uropathology and EAU Section of Urological Research

**Sunday 15 March**
**13:45 - 15:15**

**Location** Blue Area, Victoria 4

**Chairs** M. Colecchia, Milan (IT)
C. Jerónimo, Porto (PT)

**Learning objectives**
This EAULab session, shared by the Translational Research and Uropathology Sections, explores emerging mechanisms and therapies in genitourinary cancers, from metabolic and epigenetic reprogramming to advanced disease modeling. It also highlights novel treatment strategies, including synthetic lethality, biomarker-guided trials, and new therapies for bladder cancer, advancing precision medicine in the GU diseases. Also, the EAU Chopin Award for Non-Urologist Researchers 2026, which celebrates excellence and achievements in translational research in urology, will be presented to Prof. Monique Roobol.

**13:45 - 13:48** **Welcome and introduction**
M. Colecchia, Milan (IT)
C. Jerónimo, Porto (PT)

**13:48 - 14:30** **Metabolic and biological drivers of urological diseases**

*Moderators* M. Albersen, Leuven (BE)
Y. Allory, Saint-Cloud (FR)
C. Le Magnen, Basel (CH)

13:48 - 14:00 **Metabolic adaptation in prostate cancer: Beyond androgen signaling**
A. Carracedo, Bilbao (ES)

14:00 - 14:12 **Metabolic vulnerabilities in pediatric kidney tumours**
J. Drost, Utrecht (NL)

14:12 - 14:24 **The impact of biological sex on bladder diseases**
M. Ingersoll, Paris (FR)

14:24 - 14:30 **Discussion**

**14:30 - 15:12** **Emerging cancer therapies in genitourinary cancers**

*Moderators* M. Eckstein, Erlangen (DE)
J. Paramio, Madrid (ES)

14:30 - 14:42 **Synthetic lethality strategies for genitourinary cancers**
F. Demichelis, Trento (IT)

14:42 - 14:54 **Biomarker driven trials in mPCa**
H. Gronberg, Stockholm (SE)

14:54 - 15:06 **New therapeutic options in bladder cancer**
S. Membribes, London (GB)

15:06 - 15:12 **Discussion**

**15:12 - 15:15** **Chopin Award**

*Winner* M.J. Roobol, Rotterdam (NL)

**Final Remarks**

## European Urology meets The Lancet: The future of urological care

Special Session

**Sunday 15 March**
**13:45 - 14:40**

**Location** Orange Area, Room 3

**Chairs** A. Briganti, Milan (IT)
V. Wisdom, London (GB)

**Learning objectives**
An update on the The Lancet–European Urology collaborative review series, highlighting transformative developments in surgical urological care and fostering dialogue to help shape future clinical practice and policy.

**13:45 - 13:55** **Introduction**
A. Briganti, Milan (IT)
V. Wisdom, London (GB)

**13:55 - 14:05** **Global trends and impact of benign urological conditions**
C. Gratzke, Freiburg (DE)

**14:05 - 14:15** **Ensuring long term sustainability in urological care**
J. N'Dow, Aberdeen (GB)

| | |
|---|---|
| **14:15 - 14:25** | **Transformation in urological surgery: innovations and advances**<br>J.W.F. Catto, Sheffield (GB) |
| **14:25 - 14:40** | **Discussion** |

## Complications in endourology: Causes, management and prevention

ESU Course 43

**Sunday 15 March**
**13:45 - 16:45**

**Location** Red Area, Room 13

**Chair** V.M.J. De Coninck, Brasschaat (BE)

**Learning objectives**

The aims and objectives of this course are to provide a complete overview of complications related to endourological procedures.

- Extracorporeal shock wave lithotripsy (ESWL)
- Retrograde intrarenal surgery (RIRS)
- Percutaneous nephrolithotomy (PCNL)
- Transurethral resection of the bladder (TURB) and prostate (TURP), anatomical endoscopic enucleation of the prostate (AEEP), cystolithotripsy/cystolitholapaxy, internal urethrotomy/urethral dilation

This ESU course has the goal to fill the knowledge gap for early identification of complications during endourological procedures and to describe their management, in order to prevent further harm. At the end of the course, the participants will be able to increase their knowledge about complications in endourology and to identify them according to their etiology. They will also know how most endourological complications can be managed and prevented. Lastly, clinicians will use the increased knowledge to provide better care to their patients.

**Extracorporeal shock wave lithotripsy**
E.X. Keller, Zürich (CH)

**RIRS**
V.M.J. De Coninck, Brasschaat (BE)

**PCNL**
E.X. Keller, Zürich (CH)

**TURB, TURP, AEEP, cystolithotripsy/cystolitholapaxy**
K. Lehrich, Berlin (DE)

**Internal urethrotomy, urethral dilation**
K. Lehrich, Berlin (DE)

**Complications related to fluoroscopy and imaging**
V.M.J. De Coninck, Brasschaat (BE)

# Improving prostate cancer screening - From implementation pilots to improved interventions

EGPT 39

**Sunday 15 March**
**13:45 - 15:15**

**Location** Orange Area, EGPT 2

**Chairs**
A.S. Rannikko, Espoo (FI)
M.J. Roobol, Rotterdam (NL)
I. Tomašković, Zagreb (HR)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**13:45 - 14:05** **Organised testing in Europe**

P0683 **Prospective multicentre pilot study on prostate cancer risk-based screening in Estonia**
P. Veskimäe, Tartu (EE)

P0684 **CROState pilot program for prostate cancer screening in Croatia – eighteen-month results**
T. Kuliš, Zagreb (HR)

P0685 **Pre-MRI risk stratification in a population-based PCa screening setting: first results of the PRAISE-U initiative**
M.J. van Harten, Rotterdam (NL)

**Study Group**
PRAISE-U consortium(Arnhem, The Netherlands)

P0686 **From Pilot to Practice: Lessons from European PRAISE-U Sites on Implementing Risk-Stratified Prostate Cancer Screening**
S. Palaniraja, Lyons (FR)

**14:05 - 14:15** **Early prostate cancer detection beyond Europe**

P0688 **COMPACT Study: Real-World Impact of Community-Based PSA Screening on Prostate Cancer in China**
D. Gu, Guangzhou (CN)

**14:15 - 14:30** **Testing behaviour and psychological consequences**

P0689 **Re-Attendance in Prostate Cancer Screening: Associations with Investigations in the First Screening Round and Individual-Level Factors**
L. Svensson, Gothenburg (SE)

P0690 **PSA retesting behaviour and prostate cancer incidence by risk group during 10 years of follow-up: the STHLM3 screening trial**
C. Micoli, Solna (SE)

P0691 **Psychological consequences associated with the diagnostic process in the Göteborg-2 prostate cancer screening trial in men with raised PSA**
L. Svensson, Gothenburg (SE)

**14:30 - 15:00** **Interventions in prostate cancer screening - from MRI to biopsies**

P0692 **Acquisition, reporting, and outcomes of upfront screening MRI in prostate cancer: a systematic review and meta-analysis**
N. Mayor, London (GB)

P0693 **Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): international consensus recommendations**
N. Mayor, London (GB)

P0694 **AI-assigned versus radiologist-assigned PI-RADS in population-based prostate cancer screening: results from the ProScreen trial**
T. Shadbahr, Helsinki (FI)

P0695 **Limited benefit of contralateral biopsies in PSA- and MRI-based prostate cancer screening**
M. Alterbeck, Malmö (SE)

P0696 **Low Infection Rate After Transrectal Ultrasound Prostate Biopsy in Population-based Screening with PSA and MRI – Results from the Göteborg Prostate Cancer Screening 2 Trial**
A. Andreasson, Göteborg (SE)

P0697 **Impact of a PSA density threshold as a criterion for referral to secondary care for suspected prostate cancer**
K.O. Adasonla, London (GB)

**15:00 - 15:10** **Understanding screening - from healtheconomy to bayesian re-analysis of screening outcomes**

P0698 **Post-Hoc Bayesian Re-Analysis of 21-Year Follow-Up Data from the Rotterdam Section of the ERSPC: Examining robustness of findings to varying prior assumptions**
D-D. Nguyen, Toronto (CA)

**Study Group**
ERSPC Rotterdam Investigators(Rotterdam, The Netherlands)

P0699 **Cost-effectiveness of early detection for prostate cancer: evidence from rescreening in the STHLM3-MRI trial**
D. Skalt, Solna (SE)

## Rare male genital tumors: Testis and penile cancers

EGPT 40

**Sunday 15 March**
**13:45 - 15:15**

**Location** Orange Area, EGPT 3

**Chairs**
A. Parnham, Manchester (GB)
A. Thor, Stockholm (SE)
Y. Zhu, Shanghai (CN)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**13:45 - 14:20** **Testis cancer: Early tumours and diagnosis**

P0709 **A Decade of RPLND for Testicular Germ Cell Tumors: Survival Outcomes from India's Largest Institutional Experience**
N. Thimiri Mallikarjun, Chennai (IN)

P0700 **Germline HOXB13 G84E Mutation and Risk of Testicular Cancers: results from the UK Biobank**
B-E. Jong, New Taipei (TW)

P0702 **Machine learning–based prognostic evaluation of diagnostic delay in testicular cancer**
A. Anceno, Los Angeles (US)

P0704 **Testicular Prosthesis and Decisional Regret Following Radical Orchifunicolectomy: Real-World Experience from a High-Volume Oncologic Center**
R. Mastroianni, Rome (IT)

P0705 **Can ChatGPT-5 Match the Experts? Second Opinions in Early Testicular Cancer**
C. Hirtsiefer, Dresden (DE)

---

**14:20 - 14:35** **Testis Cancer: RPLND considerations**

P0706 **Salvage Post-Chemotherapy Retroperitoneal Lymph-Node Dissection: Evolving Paradigm for Marker-Positive non-seminomatous germ-cell tumors management.**
S. Nazzani, Milan (IT)

P0707 **Same-Day Discharge Following Robotic Retroperitoneal Lymph Node Dissection: A Single-Institution Case Series**
G. Musso, Milan (IT)

P0708 **Contemporary trends of primary retroperitoneal lymph node dissection in stage I and IIa-b nonseminomatous germ cell tumors of the testis**
N. Lee, Montreal (CA)

---

**14:35 - 14:55** **Penile cancer: Risk factors, primary treatment and surgical staging**

P0710 **Association Between Neighborhood Deprivation and Stage at Diagnosis in Penile Squamous Cell Carcinoma**
C. Silvani, Milan (IT)

P0711 **Contemporary outcomes of extramammary Paget's disease: a single-institution retrospective analysis**
J. Kang, Seoul (KR)

P0713 **BelPen study: Prospective evaluation of MRI with Magtrace for sentinel node biopsy in penile cancer**
A. Semal, Reet (BE)

---

**14:55 - 15:15** **Treatment of advanced penile cancer and new therapies**

P0714 **Transition from Open to Multi- and Single-Port Robotic Inguinal Lymphadenectomy for Bulky Nodal Disease in Penile Cancer: A Consecutive Series Comparison**
A. Brassetti, Rome (IT)

P0715 **Survival of the fittest: Outcomes in node positive penile cancer patients where non-surgical management is utilised in place of RILND**
V. Hyett, Glasgow (GB)

P0716 **Lymph node surgery after centralization of penile cancer care in Sweden – extent of use and complications**
A. Gerdtsson, Lund (SE)

P0717 **Target-dependent in-vitro efficacy of Sacituzumab govitecan and Enfortumab vedotin in penile cancer**
J. Mink, Homburg/Saar (DE)

## Male LUTS/BPO: From care pathways to procedures

EGPT 41

**Sunday 15 March**
**13:45 - 15:15**

**Location** Blue Area, EGPT 4

**Chairs**
M. Karavitakis, Pagkrati - Athens (GR)
M. Tutolo, Milan (IT)
P.D. Violette, Woodstock (CA)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**13:45 - 14:20** **Care pathways, diagnostics & patient priorities**

P0718 **Impact and burden of postponing elective surgeries in patients with urological conditions**
I. Simunovic, Graz (AT)

P0719 **Unplanned Healthcare Utilization after Benign Prostate Intervention**
MU Uy, Ann Arbor (US)

P0720 **Clinical Applicability and Extended Symptom Profiling with the LURN SI-10 Questionnaire in Spanish Men with LUTS**
R. España Navarro, Málaga (ES)

P0721 **Clinical evaluation of AI-based software for diagnosing bladder outlet obstruction and detrusor underactivity in men with lower urinary tract symptoms**
S.H. Sung, Seoul (KR)

P0723 **Understanding Patient and Surgeon Priorities in Prostate Enucleation Surgery: Insights from the ENUC-TR Multicenter Cross-Sectional Study**
H.O. Kazan, istanbul (TR)

P0724 **Beyond LUTS: Broad Mental Health and Cognitive Benefits of BPH Surgery—Evidence from the TriNetX Global Network.**
W.Y. Cheng, Taina (TW)

**14:20 - 14:50** **Efficacy, durability and outcomes of modern interventions**

P0727 **Sexual function outcomes of the 5-year treatment with Rezum compared to doxazosin, finasteride and combination drug therapy for men with BPH: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial.**
M. Feffer, Maywood (US)

P0728 **Durability of contemporary BPH Surgery: Real-World Reoperation Rates Across Eight Procedures**
MU Uy, Ann Arbor (US)

P0729 **ROLE OF PROSTATIC ANTERIOR APEX PRESERVATION: SHORT-TERM FUNCTIONAL OUTCOMES OF MODIFIED HOLEP TECHNIQUE**
J. Pagnotta, Perugia (IT)

P0731 **Influence of Intraoperative Tranexamic Acid on Bleeding Outcomes in Patients Receiving Antithrombotic Therapy Undergoing Endoscopic Enucleation of the Prostate: A Multicenter Prospective Study by the Endourology Section of EAU.**
A. Cormio, Ancona (IT)

P0726 **Long-Term Real-World Efficacy of Rezūm Therapy: Three-Year Multicentre International**
M. Henrique Bitar Siqueira, Toronto (CA)

**14:50 - 15:10** **Bladder injury and bladder neck contracture**

P0732 **Bladder Injury During Anatomic Endoscopic Enucleation of the Prostate: A Prospective Multicenter Evaluation Using the BICEP Classification (EAU Endo Study)**
G. Ortner, Innsbruck (AT)

P0734 **Risk factors for bladder neck contracture after holmium laser enucleation of the prostate**
C. Gossler, Regensburg (DE)

P0735 **Fifteen-Year Retrospective Multivariate Analysis of Predictors for Bladder Neck Contracture Following Transurethral Prostate Surgery**
C.C. Hung, Taipei (TW)

**15:10 - 15:15** **Late-breaking abstract presentation**

## Basic science and artificial intelligence in lower urinary tract dysfunction

EGPT 42

**Sunday 15 March**
**13:45 - 15:15**

**Location** Blue Area, EGPT 5

**Chairs**
T. Antunes Lopes, Porto (PT)
L. Birder, Pittsburgh (US)
R. Lombardo, Rome (IT)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**13:45 - 14:55** **Basic science in functional urology**

P0736 **Anchoring Gene Therapy to the Bladder: A Mucoadhesive Microsphere System for Effective Intravesical TLR3 Gene Silencing in Inflammatory Bladder Diseases**
X. Xu, Chengdu (CN)

P0739 **"From Urine, For the Bladder": Intravesical Delivery of Urine-Derived Stem Cell Extracellular Vesicles via Adhesive Microspheres for Treating Bladder Inflammation**
X. Xu, Chengdu (CN)

P0740 **Hyaluronic acid-based composite nanoparticles promote urothelium repair in interstitial cystitis/ bladder pain syndrome**
M. Liu, Beijing (CN)

P0742 **Selective Androgen Receptor Modulation Restores Detrusor Contractility in an Animal Model of Detrusor Underactivity**
H.C. Yang, Puzi City Chiayi County (TW)

P0743 **Antler Stem Cell Exosomes Ameliorate Interstitial Cystitis via Mitochondrial Component Transfer to Reprogramming Macrophage Polarization**
Y. Wan, Guangzhou (CN)

P0744 **VesiVis™ (multi–molecular-weight hyaluronic acid) restores urothelial barrier and voiding function in a murine model of ketamine-induced cystitis**
S. Tseng, New Taipei City (TW)

P0745 **Restorative Effects of Urine-Derived Stem Cells Combined with Platelet Lysate on Bladder Dysfunction in a Neurogenic Bladder Model**
O.J. Yun, Daegu (KR)

P0748 **Mechanism of hydroxyapatite/hyaluronic acid composite hydrogel in promoting urethral repair in stress urinary incontinence**
M. Liu, Beijing (CN)

P0749 **Functional neuroimaging of the interaction between the periaqueductal gray and the pontine micturition center during a strong desire to void**
N. van Houtum, Maastricht (NL)

**14:55 - 15:15** **Artificial intelligence in functional urology**

P0750 **Performance assessment of large language models in urodynamic study trace interpretation**
J. Peralta, Porto (PT)

P0751 **Reliability of ChatGPT response in clinical decision-making for neurogenic bladder cases: A preliminary evaluation of its compliance with international guidelines**
M. Hegazy, Mansoura (EG)

P0753 **Can AI Judge Urodynamic Study Quality? Validation Using the Bristol UTraQ Scale**
J.P. Oliveira, Porto (PT)

## Hands-on Training in TP Biopsy and MRI fusion

HOT TPB - MRI - 3.2

**Sunday 15 March**
**14:00 - 17:00**

**Location** Red Area, Room 2

**Chair** L. Budäus, Hamburg (DE)

**Learning objectives**

This course is designed to provide a comprehensive overview of office based transperineal (TP) biopsy techniques in local anaesthesia. It includes the integration of MRI fusion technology into daily clinical practice. Participants will begin with an introduction to the importance of TP biopsy and detailed instructions on performing the procedure by themself..

The hands-on training sessions are the core of the course, where participants will practice:

- Basics of superficial local anesthesia
- Deep periprosthetic block
- Basics of targeting and fusion
- Grid based / free hand / single incision biopsies

| | |
|---|---|
| **14:00 - 14:05** | **Introduction**<br>L. Budäus, Hamburg (DE) |
| **14:05 - 14:20** | **Why TP biopsy & how to do TP biopsy & different needles**<br>L. Budäus, Hamburg (DE) |
| **14:20 - 14:30** | **Technical comparison**<br>C. Kastner, Cambridge (GB) |
| **16:25 - 16:55** | **Circulate among stations** |
| **16:55 - 17:00** | **Closing remarks**<br>L. Budäus, Hamburg (DE) |

## Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 3.4

**Sunday 15 March**
**14:00 - 14:50**

**Location** Red Area, Room 1

**Tutors**
A.J. Antunes Loureiro Nunes, Lisbon (PT)
C. Netsch, Hamburg (DE)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# E-BLUS Exam

HOT EBLUS EXAM - 3.4

**Sunday 15 March**
**14:00 - 14:55**

**Location** Red Area, Room 1

**Coordinator** T.M. Ribeiro De Oliveira, Lisbon (PT)

**Tutors** S. Erdem, Istanbul (TR)
L.M. Vendrell, Ciudad - Mendoza (AR)

**Learning objectives**
In this exam, your psychomotor skills such as depth perception and bimanual dexterity will be tested and your mastery of basic laparoscopy skills such as instrument handling, pattern cutting and intracorporeal suturing will be assessed by experienced examiners.
The exam is aimed at candidates with intermediate and advanced laparoscopy experience or those who have sufficiently trained to meet the exercises time and quality criteria. Passing the E-BLUS exam will be rewarded with a certificate that serves as a recommendation to continue your laparoscopy training by assisting laparoscopic procedures in the OR.

# ESTs1 Exam

HOT EST EXAM 3.4

**Sunday 15 March**
**14:00 - 14:50**

**Location** Red Area, Room 1

**Tutors** L.B. Dragoş, Cambridge (GB)
P.M. Kronenberg, Lisbon (PT)
A. Pietropaolo, Southampton (GB)

**Learning objectives**
In this exam, candidates' psychomotor and endoscopic skills are assessed, with a focus on the safe and effective performance of core endourological procedures such as rigid cystoscopy, flexible cystoscopy, semi-rigid ureteroscopy, and flexible ureteroscopy. Candidates are evaluated by experienced examiners on instrument handling, scope control, orientation, and respect for tissue within a simulated setting. The exam is aimed at candidates with basic to intermediate endourology experience or those who have completed sufficient training to meet the required performance standards, and successful completion is rewarded with a certificate recommending progression to supervised endourological procedures in the operating room.

# Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 3.4

**Sunday 15 March**
**14:00 - 14:50**

**Location** Red Area, Room 1

**Tutors**
J. Gómez Rivas, Madrid (ES)
M. Jarzemski, Bydgoszcz (PL)

**Learning objectives**

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 3.4

**Sunday 15 March**
**14:00 - 14:50**

**Location** Red Area, Room 1

**Tutors**
E.D. Demirkiran, Zonguldak (TR)
M.I. Gökce, Ankara (TR)
T.E. Şener, Istanbul (TR)

**Learning objectives**
This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

# Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 3.4

**Sunday 15 March**
**14:00 - 14:50**

**Location** Red Area, Room 1

**Tutors**
R.A. Coman, cluj napoca (RO)
M.F. Frascheri, Southampton (GB)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# Patient advocacy plaza - Testicular self-examination: TSE or not TSE-monthly or regularly

Special Session

**Sunday 15 March**
**14:15 - 14:45**

**Location** Patient Advocacy Plaza

**Chair** R. Cornes, London (GB)

**Learning objectives**
Should we advocate for monthly testicular self examination?

**ORCHID**
R. Cornes, London (GB)

# Enucleation of the prostate for BPO treatment: The anatomical solution to various challenges

ESU Course 38

**Sunday 15 March**
**14:30 - 17:30**

**Location** Red Area, Room 8

**Chair** T.R.W. Herrmann, Frauenfeld (CH)

Voting will be available via the EAU26 App or via www.qna.at/eau

**Learning objectives**
Subject of the course is the content of the surgical chapter of the EAU Non Neurogenic Male Luts Guidelines.
The Course will display:

- The surgical treatment algorythm of the EAU Guidelines
- The Rational behind the subdiversion in Vaporisation, Resection and Enucleation
- Positioning and leverage of each surgical modality and evidence
- Enucleating modalities: endoscopic enucleation, vs Robotic / laparoscopic adenomectomy vs. Open adenomectomy
- Treatment related side effects, esp. QOL, sexual function

**Introduction: Why enucleation is a good idea for now and the future**
T.R.W. Herrmann, Frauenfeld (CH)

**Surgical treatment pattern of the current EAU guidelines**
T.R.W. Herrmann, Frauenfeld (CH)

**Worldwide standard for the treatment of large prostates: Technqiue and outcome of contemporary open prostatectomy**
L. Lusuardi, Salzburg (AT)

**What to know and not to know about current lasers for BPO treatment?**
C.M. Scoffone, Turin (IT)

**Endoscopic enucleation of the prostate: Surgical principles & outcomes**
T.R.W. Herrmann, Frauenfeld (CH)

**Defining the role of laparoscopic and robotic surgery in BPO surgery: Different techniques and ouctome**
L. Lusuardi, Salzburg (AT)

**Ejaculation-preserving techniques: Technique and outcomes, patient selection and critical comparison to MIST**
C.M. Scoffone, Turin (IT)

**Interactive case discussions**
T.R.W. Herrmann, Frauenfeld (CH)
L. Lusuardi, Salzburg (AT)
C.M. Scoffone, Turin (IT)

## Office management of male sexual dysfunction

ESU Course 42

**Sunday 15 March**
**14:30 - 17:30**

**Location** Red Area, Room 12

**Chair** M.M. Fode, Herlev (DK)

**Learning objectives**
The course will enable participants to perform a basic diagnostic evaluation and give knowledge of advanced diagnostic methods. Participants will learn when testosterone replacement therapy is indicated and how to apply it and how to tailor PDE5-Is to the individual patient. Further, participants will gain insight into more advanced medical and mechanical ED treatments. The course will also include discussions of management/controversies regarding:

- Ejaculatory dysfunction
- Priapism
- Recurrent priapism
- Sexual rehabilitation following radical prostatectomy

**Introduction**
M.M. Fode, Herlev (DK)

**Diagnostics: What is necessary?**
D. Hatzichristou, Thessaloniki (GR)

**Testosterone replacement**
E.C. Şerefoğlu, Istanbul (TR)

**Oral therapy for erectile dysfunction**
M.M. Fode, Herlev (DK)

**Therapy of erectile dysfunction when pills fail**
D. Hatzichristou, Thessaloniki (GR)

**Management of ejaculatory dysfunction**
E.C. Şerefoğlu, Istanbul (TR)

**Peyronie's disease**
D. Hatzichristou, Thessaloniki (GR)

**What to do after radical prostatectomy?**
M.M. Fode, Herlev (DK)

**Tips, tricks and questions from the audience**
M.M. Fode, Herlev (DK)
D. Hatzichristou, Thessaloniki (GR)
E.C. Şerefoğlu, Istanbul (TR)

## Transgender surgery course

ESU Course 39

**Sunday 15 March**
**14:30 - 17:30**

**Location** Red Area, Room 9

**Chair** M. Garcia, Los angeles (US)

Voting will be available via the EAU26 App or via www.qna.at/eau

**Learning objectives**
1. Describe common primary and salvage feminising & masculinising genital gender affirming surgeries (gGAS)
2. Recognise and explain the most common complications associated with feminizing & masculinizing gGAS, and management
3. Describe at least 3 ways that the *general* urologist can provide effective care to transgender women/men
4. Summarise at least 4 key organisational features and practices of a successful trans-surgery programme

**Feminizing genital gender affirming surgery**

**Overview of primary vaginoplasty surgery options**
M. Garcia, Los angeles (US)
S. Riechardt, Itzehoe (DE)

**Pre-surgery preparation & post-surgery care**
S. Riechardt, Itzehoe (DE)

**Complications: Incidence, diagnosis, and management**
M. Garcia, Los angeles (US)
S. Riechardt, Itzehoe (DE)

**Revision & salvage surgeries: Care algorithms & surgical techniques**
M. Garcia, Los angeles (US)

**Topics open for debate: Role of peritoneal vaginoplasty? Non-standard genital surgery requests?**
M. Garcia, Los angeles (US)
S. Riechardt, Itzehoe (DE)

**Masculinizing genital gender affirming surgery**

**Overview of primary surgery options: Metoidioplasty & phalloplasty**
M. Falcone, Turin (IT)
M. Garcia, Los angeles (US)
W.G. Lee, London (GB)

**Pre-surgery preparation and post-surgery care**
M. Falcone, Turin (IT)
M. Garcia, Los angeles (US)
W.G. Lee, London (GB)

**Complications: Incidence, diagnosis, and management**
M. Falcone, Turin (IT)
M. Garcia, Los angeles (US)
W.G. Lee, London (GB)

**Penile and testicle prosthetics: Primary & revision**
M. Falcone, Turin (IT)
M. Garcia, Los angeles (US)
W.G. Lee, London (GB)

**Topics open for debate: Surgery staging; Choice for vascular pedicle?**
M. Falcone, Turin (IT)
M. Garcia, Los angeles (US)
W.G. Lee, London (GB)

**Panel discussion**
M. Falcone, Turin (IT)
M. Garcia, Los angeles (US)
W.G. Lee, London (GB)
S. Riechardt, Itzehoe (DE)

## Prostate cancer update: 2025-2026

ESU Course 40

**Sunday 15 March**
**14:30 - 17:30**

**Location** Red Area, Room 10

**Chair** M. Graefen, Hamburg (DE)

**Learning objectives**
This course is aimed at critically reviewing key manuscripts published during the previous 12 months and devoted to the management of prostate cancer patients with a particular focus on basic research, screening, diagnosis, staging, and local and systemic therapies. Practice-changing manuscripts published in peer-reviewed journals will be identified and discussed for each topic. For every paper a clear take home message applicable to the every-day clinical practice will be identified and discussed. The main objective of the course is to inform participants on the latest and most significant novelties related to the contemporary management of prostate cancer patients.

**Clinical implications of basic research**
C. Moore, London (GB)

**Screening: Novel biomarkers and strategies**
C. Evans, Reno NV (US)

**Diagnosis: Role of mpMRI and PET PSMA in detecting prostate lesions. Fusion biopsies**
C. Moore, London (GB)

**Staging: Imaging and predictive models**
M. Graefen, Hamburg (DE)

**Treatment of localised prostate cancer: Radical prostatectomy**
M. Graefen, Hamburg (DE)

**Treatment of localised prostate cancer: Focal therapy**
C. Moore, London (GB)

**Treatment of localised prostate cancer: Radiation therapy**
M. Graefen, Hamburg (DE)

**Management of recurrence after curative treatment**
M. Graefen, Hamburg (DE)

**Management of hormone sensitive metastatic prostate cancer**
C. Evans, Reno NV (US)

**Management of castration-resistant prostate cancer**
C. Evans, Reno NV (US)

## Practical management of non-muscle invasive bladder cancer (NMIBC)

ESU Course 41

**Sunday 15 March**
**14:30 - 17:30**

**Location** Red Area, Room 11

**Chair** E.N. Xylinas, Paris (FR)

**Learning objectives**

Our main objective is to not only enrich what you know about NMIBC, but to also equip you with frontline strategies when dealing with common and complex patient cases.

This course will commence with discussions on NMIBC diagnostic opportunities and then proceed to the best practices and the pitfalls to avoid in transurethral resection (TUR). Get to know the techniques, tips and tricks, potential problems/complications, TUR with enhanced imaging, en-bloc resection and more through videos and lively discussions with key opinion leaders.

Further into the course, you will familiarise yourself with the new modalities and the limitations of recommendations on additional risk-adapted intravesical treatment. These will be followed by deliberations on typical problems encountered, complications during and after intravesical therapy, and strategies on how you can prevent them.

Another course highlight you can look forward to is how you can deal with abnormal cytology including locations outside the bladder.

**Introduction**
E.N. Xylinas, Paris (FR)

**Urine-based markers ready for prime time?**
E.N. Xylinas, Paris (FR)

**Optimal TURB: Tips and tricks; En bloc resection; Re-TUR; Optical enhancement**
P. Gontero, Turin (IT)

**Discussion**
P. Gontero, Turin (IT)
F. Guerrero-Ramos, Madrid (ES)
E.N. Xylinas, Paris (FR)

**Risk-stratification**
F. Guerrero-Ramos, Madrid (ES)

**Standard of care treatment for low- and intermediate risk patients**
F. Guerrero-Ramos, Madrid (ES)

**Discussion**
P. Gontero, Turin (IT)
F. Guerrero-Ramos, Madrid (ES)
E.N. Xylinas, Paris (FR)

**Standard of care treatment for high- and very-high risk patients**
E.N. Xylinas, Paris (FR)

**BCG-unresponsive disease definition and therapeutic options**
P. Gontero, Turin (IT)

**Case-based discussion**
P. Gontero, Turin (IT)
F. Guerrero-Ramos, Madrid (ES)
E.N. Xylinas, Paris (FR)

**Take home messages and conclusion**
E.N. Xylinas, Paris (FR)

# The infertile couple: Urological aspects

ESU Course 37

**Sunday 15 March**
**14:30 - 17:30**

**Location** Red Area, Room 7

**Chair** M. Dinkelman-Smit, Rotterdam (NL)

Voting will be available via the EAU26 App or via www.qna.at/eau

**Learning objectives**

This course provides state-of-the-art information on urological aspects of diagnosis and therapy of modern reproductive medicine. Diagnostic procedures should be standardised and coordinated in a timely fashion for both partners, focusing on the possible urological, hormonal and genetic causes of male infertility.
In terms of therapy, this course will provide updated information on evidence-based data and discuss the importance of varicoceles in male infertility. We will show microsurgical techniques on video and explain why proper training and skills perfection is key to successful case management. A successful IVF/ICSI outcome depends upon the use of state-of-the-art techniques for sperm retrieval and sperm preparation.
We will also provide information on genetic aspects and stress the responsibility of the urologist as an adviser and gatekeeper for the treatment of the infertile couple.

**Introduction. Couple infertility: The rationale for male reproductive health assessment for all**
M. Dinkelman-Smit, Rotterdam (NL)

**Part 1: Diagnostic modalities in male infertility assessment: Interpretation, pitfalls and updates**

**Semen analysis. WHO parameters, sperm DNA fragmentation, oxidative stress biomarker testing**
P. Sangster, London (GB)

**Male reproductive endocrinology. Endocrine regulation of spermatogenesis, hypogonadism, prolactine**
D. Hauptman, Zagreb (HR)

**Physical examination and imaging. What not to miss, when to look for what**
P. Sangster, London (GB)

**Genetics. Phenotype driven genetic testing oligospermia, sperm motility/morphology, azoospermia**
M. Dinkelman-Smit, Rotterdam (NL)

**Part 2: Treatment modalities to improve male reproductive potential for natural and assisted reproduction**

**Preconceptional lifestyle modification, weight loss, GLP1 agonist**
M. Dinkelman-Smit, Rotterdam (NL)

**Medical treatment, including hormonal stimulation, antioxidants, hormonal therapy, and new agents**
D. Hauptman, Zagreb (HR)

**(micro)Surgical treatment of varicocele and obstructive azoospermia**
P. Sangster, London (GB)

**Sperm retrieval methods in ejaculation disorders, obstructive and non-obstructive azoospermia, Klinefelter Syndrome, re-do cases**
D. Hauptman, Zagreb (HR)

## Patient advocacy plaza - Understanding and overcoming patient barriers to discussing urinary symptoms linked to bladder cancer

Special Session

**Sunday 15 March**
**15:00 - 15:30**

**Location** Patient Advocacy Plaza

**Chair** A. Filicevas, Brussels (BE)

**Learning objectives**
This session will explore why many patients hesitate to discuss urinary symptoms with healthcare professionals and how these delays may affect bladder cancer diagnosis. Drawing on findings from a multinational survey, the presentation will highlight psychological, social, and informational barriers influencing help-seeking behaviour. Delegates will gain insight into how patients interpret symptoms and respond emotionally to them. The session will also outline practical approaches to improve communication, strengthen trust in patient–doctor interactions, and encourage earlier presentation of potential bladder cancer symptoms.

**World Bladder Cancer Patient Coalition (WBCPC)**
A. Filicevas, Brussels (BE)

## Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 3.5

**Sunday 15 March**
**15:00 - 15:50**

**Location** Red Area, Room 1

**Tutors** A.J. Antunes Loureiro Nunes, Lisbon (PT)
C. Netsch, Hamburg (DE)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## E-BLUS Exam

HOT EBLUS EXAM - 3.5

**Sunday 15 March**
**15:00 - 15:55**

**Location** Red Area, Room 1

**Coordinator** T.M. Ribeiro De Oliveira, Lisbon (PT)

**Tutors** O. Stakhovskyi, Kyiv (UA)
P. Umari, London (GB)

**Learning objectives**
In this exam, your psychomotor skills such as depth perception and bimanual dexterity will be tested and your mastery of basic laparoscopy skills such as instrument handling, pattern cutting and intracorporeal suturing will be assessed by experienced examiners.
The exam is aimed at candidates with intermediate and advanced laparoscopy experience or those who have sufficiently trained to meet the exercises time and quality criteria. Passing the E-BLUS exam will be rewarded with a certificate that serves as a recommendation to continue your laparoscopy training by assisting laparoscopic procedures in the OR.

## ESTs1 Exam

HOT EST EXAM 3.5

**Sunday 15 March**
**15:00 - 15:50**

**Location** Red Area, Room 1

**Tutors** P.M. Kronenberg, Lisbon (PT)
A. Pietropaolo, Southampton (GB)
T. Tokas, Heraklion (GR)

**Learning objectives**
In this exam, candidates' psychomotor and endoscopic skills are assessed, with a focus on the safe and effective performance of core endourological procedures such as rigid cystoscopy, flexible cystoscopy, semi-rigid ureteroscopy, and flexible ureteroscopy. Candidates are evaluated by experienced examiners on instrument handling, scope control, orientation, and respect for tissue within a simulated setting. The exam is aimed at candidates with basic to intermediate endourology experience or those who have completed sufficient training to meet the required performance standards, and successful completion is rewarded with a certificate recommending progression to supervised endourological procedures in the operating room.

# Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 3.5

**Sunday 15 March**
**15:00 - 15:50**

**Location** Red Area, Room 1

**Tutors** J. Gómez Rivas, Madrid (ES)
P.J. Zondervan, Amsterdam (NL)

**Learning objectives**
The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Sacral Neuromodulation (SNM)

HOT SNM - 3.1

**Sunday 15 March**
**15:00 - 17:00**

**Location** Red Area, Room 3

**Chair** H. Hashim, Bristol (GB)

**Learning objectives**
This Hands-on Training is designed to equip participants with the fundamental skills to perform sacral neuromodulation (SNM) procedures effectively. Participants will have the opportunity to practice each step of the SNM procedure, including primary percutaneous nerve evaluation, tined lead and battery implantation, programming, and troubleshooting.

| | |
|---|---|
| **15:00 - 15:05** | **Welcome and introduction**<br>H. Hashim, Bristol (GB) |
| **15:05 - 15:20** | **SNM indications, guidelines, and outcomes**<br>H. Hashim, Bristol (GB) |
| **15:20 - 15:35** | **SNM patient selection, technique, and complications**<br>H. Hashim, Bristol (GB) |
| **15:35 - 16:00** | **Hands-on Training 1** |
| 15:35 - 16:00 | **PNE Station 1** |
| | *Tutor* D. Elterman, Toronto (CA) |
| 15:35 - 16:00 | **PNE Station 2** |
| | *Tutor* G. Sampogna, Milan (IT) |

| | | |
|---|---|---|
| 15:35 - 16:00 | **PNE Station 3** | |
| | *Tutor* | M-A. Perrouin Verbe, Nantes (FR) |
| 15:35 - 16:00 | **Tined Lead Station 1** | |
| | *Tutor* | S. Arlandis, Valencia (ES) |
| 15:35 - 16:00 | **Tined Lead Station 2** | |
| | *Tutor* | P. Bueno Garcia Reyes, Mexico City (MX) |
| 15:35 - 16:00 | **Tined Lead Station 3** | |
| | *Tutor* | E. Huri, Ankara (TR) |
| 15:35 - 16:00 | **Programming Station** | |
| | *Tutor* | L. Thomas, Bristol (GB) |
| **16:00 - 16:25** | **Hands-on Training 2** | |
| 16:00 - 16:25 | **PNE Station 1** | |
| | *Tutor* | D. Elterman, Toronto (CA) |
| 16:00 - 16:25 | **PNE Station 2** | |
| | *Tutor* | G. Sampogna, Milan (IT) |
| 16:00 - 16:25 | **PNE Station 3** | |
| | *Tutor* | M-A. Perrouin Verbe, Nantes (FR) |
| 16:00 - 16:25 | **Tined Lead Station 1** | |
| | *Tutor* | S. Arlandis, Valencia (ES) |
| 16:00 - 16:25 | **Tined Lead Station 2** | |
| | *Tutor* | P. Bueno Garcia Reyes, Mexico City (MX) |
| 16:00 - 16:25 | **Tined Lead Station 3** | |
| | *Tutor* | E. Huri, Ankara (TR) |
| 16:00 - 16:25 | **Programming Station** | |
| | *Tutor* | L. Thomas, Bristol (GB) |
| **16:25 - 16:50** | **Hands-on Training 3** | |
| 16:25 - 16:50 | **PNE Station 1** | |
| | *Tutor* | D. Elterman, Toronto (CA) |
| 16:25 - 16:50 | **PNE Station 2** | |
| | *Tutor* | G. Sampogna, Milan (IT) |
| 16:25 - 16:50 | **PNE Station 3** | |
| | *Tutor* | M-A. Perrouin Verbe, Nantes (FR) |
| 16:25 - 16:50 | **Tined Lead Station 1** | |
| | *Tutor* | S. Arlandis, Valencia (ES) |

| | | |
|---|---|---|
| 16:25 - 16:50 | **Tined Lead Station 2** | |
| | *Tutor* | P. Bueno Garcia Reyes, Mexico City (MX) |
| 16:25 - 16:50 | **Tined Lead Station 3** | |
| | *Tutor* | E. Huri, Ankara (TR) |
| 16:25 - 16:50 | **Programming Station** | |
| | *Tutor* | L. Thomas, Bristol (GB) |

| | |
|---|---|
| **16:50 - 17:00** | **Discussions and conclusions**<br>H. Hashim, Bristol (GB) |

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 3.5

**Sunday 15 March**
**15:00 - 15:50**

**Location** Red Area, Room 1

**Tutors**

E.D. Demirkiran, Zonguldak (TR)

M.I. Gökce, Ankara (TR)

T.E. Şener, Istanbul (TR)

**Learning objectives**

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

# Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 3.5

**Sunday 15 March**
**15:00 - 15:50**

**Location** Red Area, Room 1

**Tutors**

R.A. Coman, cluj napoca (RO)

M.F. Frascheri, Southampton (GB)

**Learning objectives**

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# Non-Technical Skills for Surgical Excellence: Immersive Simulation

HOT NTS - 3.3

**Sunday 15 March**
**15:00 - 16:00**

**Location** EAU Square

**Tutors**
A. Aydin, London (GB)
S.M. Haensel, Rotterdam (NL)
N. Raison, London (GB)
G. Zanovello, Verona (IT)

**Learning objectives**
Participants will be assigned to one of two simulation-based activities: a simulated operating room session or a computer-based virtual patient interaction. Both formats are designed to enhance non-technical skills, including communication, teamwork, and clinical decision-making.

**15:00 - 15:10** **Concept of learning**
S.M. Haensel, Rotterdam (NL)

# Challenge the Guidelines - Infections and RCC

Thematic Session

**Sunday 15 March**
**15:30 - 16:45**

**Location** Orange Area, eURO Auditorium 1

**Chairs**
A. Bex, London (GB)
J. Kranz, Aachen (DE)

**Learning objectives**
This session will review the role of antibiotics in preventing and managing infections in urology while balancing efficacy and safety. Participants will explore the benefits and potential harms of perioperative antibiotic prophylaxis, including antimicrobial resistance and unintended consequences. The session will also address the impact of antibiotics on renal health and discuss evidence-based strategies for optimal use. Finally, current guideline-based approaches to the management of urinary tract infections and pyelonephritis will be highlighted through expert discussion and clinical cases.

**15:30 - 15:55** **Infections: Prophylactic antibiotics in renal cancer surgery**

15:30 - 15:33 **Case presentation**
J. Kranz, Aachen (DE)

15:33 - 15:41 **Pro: Safeguarding patients from postoperative infection**
F.M.E. Wagenlehner, Giessen (DE)

15:41 - 15:49 **Con: Questioning necessity and unintended harms**
M. Vallée, Poitiers (FR)

15:49 - 15:55 **Discussion**

**15:55 - 16:17** **Infections - Antibiotics and renal health: Balancing efficacy and safety**

| | |
|---|---|
| 15:55 - 15:58 | **Case presentation**<br>F.P. Stangl, Berg (DE) |
| 15:58 - 16:05 | **Antibiotics & renal health: Striking the perfect balance between benefit and risk**<br>M. Lambregts, Leiden (NL) |
| 16:05 - 16:10 | **Discussion** |
| 16:10 - 16:17 | **Infections - Pyelonephritis 2026: Advancing care with evidence-based Guidelines**<br>G. Bonkat, Basel (CH) |
| **16:17 - 16:42** | **RCC - Thermal ablation for small renal masses: A standard of care?** |
| 16:17 - 16:20 | **Case presentation**<br>C. Palumbo, Novara (IT) |
| 16:20 - 16:28 | **Pro - European perspective**<br>P.J. Zondervan, Amsterdam (NL) |
| 16:28 - 16:36 | **Con - European perspective**<br>Y. Abu Ghanem, London (GB) |
| 16:36 - 16:42 | **Discussion** |
| **16:42 - 16:45** | **Closing remarks** |

## Prostate cancer: PARPIs finally explained

Thematic Session

**Sunday 15 March**
**15:30 - 17:00**

**Location** Orange Area, eURO Auditorium 2

**Chairs** E. Castro, Madrid (ES)
I. Van Oort, Groningen (NL)

**Learning objectives**
After this session, participants will be able to:
• Identify when genetic testing is indicated in prostate cancer.
• Interpret germline and somatic alterations in a clinical context.
• Select appropriate biopsy and ctDNA approaches for molecular diagnostics.
• Understand the mechanism, timing, and clinical application of PARP inhibitors in mHSPC and mCRPC.

| | |
|---|---|
| **15:30 - 15:34** | **Welcome and introdution** |
| **15:34 - 16:24** | **Round-table discussion** |
| | *Moderator* H. Beltran, Boston (US) |
| 15:34 - 15:41 | **Indications of genetic testing in prostate cancer**<br>I. Van Oort, Groningen (NL) |
| 15:41 - 15:48 | **How to optimise tissue biopsy acquisition?**<br>M. Gleave, Vancouver (CA) |
| 15:48 - 15:55 | **When to use ctDNA in prostate cancer?**<br>A. Wyatt, Vancouver (CA) |

15:55 - 16:02 **How to read a genetic report for clinical practice?**
H. Beltran, Boston (US)

16:02 - 16:09 **How to optimise germline and somatic testing in prostate cancer?**
N. Mehra, Nijmegen (NL)

16:09 - 16:24 **Discussion**

**16:24 - 16:34** State-of-the-art lecture **Why are germline and somatic alterations in PC important?**
D. Olmos, Madrid (ES)

**16:34 - 16:44** State-of-the-art lecture **PARPi in mHSPC and mCRPC-**
G. Attard, London (GB)

**16:44 - 16:54** **Challenging the expert (PARPi)**

*Interviewer* H. Beltran, Boston (US)

*Speaker* G. Attard, London (GB)

**16:54 - 17:00** **Take home messages**
E. Castro, Madrid (ES)

## ERN eUROGEN: Update on rare & complex urology

Thematic Session

**Sunday 15 March**
**15:30 - 17:00**

**Location** Blue Area, Victoria 6

**Chairs** M. Battye, Nijmegen (NL)
P. Mulders, Nijmegen (NL)

**Learning objectives**
Learn about the European Reference Network for rare uro-rectal genital diseases and complex conditions - ERN eUROGEN - and how it collaborates with patient representatives to improve care.

**15:30 - 15:40** **Introduction and ERN eUROGEN update**
P. Mulders, Nijmegen (NL)

**15:40 - 16:00** **ERN eUROGEN Patient Advocacy Group (ePAG)**

15:40 - 15:50 **Penile cancer patient survey: Report**

*Speakers* R. Cornes, London (GB)
J. Osborne, Nottingham (GB)

15:50 - 16:00 **Urological concerns in anorectal malformation: The importance of lifelong care**

*Speakers* D. Aminoff, Rome (IT)
K. Tyler, Hanwood (GB)

**16:00 - 16:20** **ERN eUROGEN Workstream 1: Rare congenital uro-recto-genital anomalies**

16:00 - 16:10 **Mapping centres for rare and complex diseases: How to improve management of Spina Bifida and other malformations**
G. Mosiello, Rome (IT)

16:10 - 16:20 **Surgical and non-surgical treatment options for creation of neovagina in patients with XX-DSD, XY-DSD and vaginal reconstruction options in patients with complex obstructing Müllerian duct malformations**
A. Höller, Tuebingen (DE)

**16:20 - 16:40** **ERN eUROGEN Workstream 2: Functional urogenital conditions requiring highly specialised surgery**

16:20 - 16:30 **Genital lichen sclerosis: Complex reconstruction beyond the urethra**
F. Campos Juanatey, Santander (ES)

16:30 - 16:40 **Phalloplasty in cripple penis: The last resort?**
A-F. Spinoit, Ghent (BE)

**16:40 - 17:00** **ERN eUROGEN Workstream 3: Rare urogenital tumours**

16:40 - 16:50 **Using PROMS to promote holistic consultations and help address unmet psychosocial needs in patients with penile cancer**
B.E. Ayres, London (GB)

16:50 - 17:00 **Surgical management of retroperitoneal sarcoma**
J. Oates, Manchester (GB)

## BCG meets immunotherapy in high-risk NMIBC: Key lessons for urologists from POTOMAC, ALBAN, and CREST

Thematic Session

**Sunday 15 March**
**15:30 - 17:00**

**Location** Orange Area, Room 3

**Chairs** M. Babjuk, Prague (CZ)
A. Van Der Heijden, Nijmegen (NL)

**Learning objectives**
The POTOMAC, ALBAN, and CREST trials evaluated the addition of durvalumab, atezolizumab, and sasanlimab, respectively, to BCG in patients with BCG-naïve high-risk NMIBC. The outcomes of these studies may have practice-changing implications for urologists. However, several factors — including the quality and completeness of (re-)TURBT, the BCG strain and treatment schedule used, and heterogeneity in study endpoints — may introduce bias. In this session, we will discuss these potential biases and their clinical implications.

**15:30 - 15:35** **Welcome word**
M. Babjuk, Prague (CZ)

**15:35 - 16:10** **Trial highlights**

15:35 - 15:45 **1 POTOMAC - Durvalumab + BCG (Positive)**
M. De Santis, Berlin (DE)

15:45 - 15:55 **2 ALBAN - Atezolizumab + BCG (Negative)**
M. Rouprêt, Paris (FR)

15:55 - 16:05 **CREST — Sasanlimab + BCG (Positive)**
N. Shore, Myrtle Beach (US)

16:05 - 16:10 **Questions and Answers**

---

**16:10 - 16:10** **Round-table discussions**

---

**16:10 - 16:25** **Round-table 1: Quality of TURBT and baseline bias**

*Discussant* M. Babjuk, Prague (CZ)

*Panel* M. De Santis, Berlin (DE)
Y. Loriot, Villejuif (FR)
J. Palou, Barcelona (ES)
M. Rouprêt, Paris (FR)
N. Shore, Myrtle Beach (US)

**- Second-look TURBT and residual tumour rates**

**- Impact of pathology centralisation on EFS**

**- How "surgical quality bias" may explain differences between trials**

---

**16:25 - 16:40** **Round-table 2: Endpoints and BCG Schedules**

*Discussant* E. Grande, Madrid (ES)

*Panel* M. De Santis, Berlin (DE)
Y. Loriot, Villejuif (FR)
J. Palou, Barcelona (ES)
M. Rouprêt, Paris (FR)
N. Shore, Myrtle Beach (US)

**- Harmonising EFS vs. DFS definitions for regulatory acceptance**

**- BCG strain and duration (1- vs. 2-year maintenance)**

**- Toward EAU/EMA consensus on future academic-industry designs**

---

**16:40 - 16:55** **Round-table 3: Systemic toxicity and biomarker selection**

*Discussant* A.J Birtle, Preston (GB)

*Panel* M. De Santis, Berlin (DE)
Y. Loriot, Villejuif (FR)
J. Palou, Barcelona (ES)
M. Rouprêt, Paris (FR)
N. Shore, Myrtle Beach (US)

**- TRAEs ≥ G3 and immune-related AEs: How to quantify "acceptable toxicity" in localised disease**

**- Biomarker approaches (PD-L1 SP263, immune gene signatures, ctDNA)**

**- Framework for next-generation biomarker-driven EAU/GETUG trials**

---

**16:55 - 17:00** **Closing remarks**
M. Babjuk, Prague (CZ)
A. Van Der Heijden, Nijmegen (NL)

# Exploring the frontier of upper tract urothelial carcinoma: Diagnostic tools, adjuvant therapies, and surgical approaches

Abstract Session 34

**Sunday 15 March**
**15:30 - 17:00**

**Location** Blue Area, Victoria 2

**Chairs**
M.R. Hassler-Di Fratta, Vienna (AT)
G. Marcq, Lille (FR)
To be confirmed

**15:30 - 15:55** **Endoscopic management of upper tract urothelial carcinoma**

A0565 **Comparative performance of EAU and AUA risk stratification systems in predicting recurrence and progression after nephron-sparing management of upper-tract urothelial carcinoma – A YAU Urothelial Group Study**
A. Belarmino, Barcelona (ES)

**Study Group**
YAU Urothelial Group(Barcelona, Spain)

A0566 **Validation of the Diagnostic Accuracy of a Urine-based DNA Methylation Marker Test in Patients with Upper Urinary Tract lesions**
E. Kaufmann, Lucerne (CH)

A0567 **Risk of recurrence and progression after endoscopic kidney-sparing surgery for upper tract urothelial carcinoma: a EAU-YAU Urothelial proposal**
A. Gallioli, Barcelona (ES)

**Study Group**
EAU-YAU Urothelial Working Group and Ureteroscopic Treatment of upper tract Urothelial Carcinoma (UTUC) registry(Barcelona, Spain)

A0568 **Efficacy and Safety of Padeliporfin Vascular-Targeted Photodynamic Therapy (VTP) in the ENLIGHTED Phase 3 Study for Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC)**
S. Psutka, Seattle (US)

A0569 **The impact of II-look ureteroscopy on survival in upper tract urothelial carcinoma: results from EAU-YAU experience**
F. Di Bello, Napoli (IT)

**Study Group**
EAU-YAU Urothelial Working Group and Ureteroscopic Treatment of upper tract Urothelial Carcinoma (UTUC) registry(Barcelona, Spain)

**15:55 - 16:30** **Radical surgery for upper tract urothelial carcinoma**

A0570 **Predictable Patterns of Lymph Node Metastasis in Upper Tract Urothelial Carcinoma: Implications for Surgical Planning**
Y. Jianjun, Chengdu (CN)

A0571 **The Impact of Surgical Approach on the Performance of Adequate Lymph Node Dissection During Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma: Results From a Large Multicenter International Cohort**
A. Bosio, (IT)

A0572 **Transperitoneal versus Retroperitoneal Single Port Robotic Nephroureterectomy: Multi-Institutional Comparison Analysis from the Single Port Advanced Research Consortium (SPARC).**
F. Lavagno, Turin (IT)

A0573 **Comparative Performance of EUA and AUA Risk Stratification Models and Development of an Integrated Model for Predicting ≥pT2 Upper Tract Urothelial Carcinoma: A ROBUUST Analysis**
G. Musso, Milan (IT)

A0574 **Prognostic value of histological subtypes in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from the ROBUUST database**
R. Contieri, Naples (IT)

A0575 **Nephroureterectomy for Upper Tract Urothelial Carcinoma Recurrence among Bladder Cancer Patients previously treated with Radical Cystectomy: An International Multicentre Propensity-Score Matched Analysis on Survival Outcomes**
F. Del Giudice, Rome (IT)

A0576 **Impact of atherosclerosis on acute kidney injury after radical cystectomy or nephroureterectomy**
N. Ishii, Hirosaki (JP)

---

**16:30 - 17:00** **Adjuvant strategies for upper tract urothelial carcinoma**

A0577 **Development and validation of DNA Methylation-Based machine-learning models to guide adjuvant therapy in nonmetastatic high risk upper tract urothelial carcinoma: A multicenter, bidirectional cohort study.**
S. Fu, Beijing (CN)

A0578 **Adjuvant Radiotherapy Combined Immunotherapy and Lymphovascular Invasion Associate With Better Disease-free Survival of Locally Progressive Upper Tract Urothelial Carcinoma**
C. Xu, Beijing (CN)

A0579 **Efficacy and safety of disitamab vedotin (DV) combined with tislelizumab as adjuvant therapy after radical surgery for patients with HER2-expression upper tract urothelial carcinoma (UTUC): a prospective, controlled, phase II study**
G. Liangyou, Beijing (CN)

A0580 **Preliminary results of a phase II study to evaluate the efficacy and safety of disitamab vedotin (RC48-ADC) in combination with radiotherapy for adjuvant therapy in upper tract urothelial carcinoma**
Z. Tao, Beijing (CN)

A0581 **Peritumoral tertiary lymphoid structures foster potent antitumor immunity and predict clinical outcomes in upper tract urothelial carcinoma**
Y. Huang, Beijing (CN)

A0582 **Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma (CURATE-UTUC): A Multicenter Prospective Longitudinal Cohort Study**
J. Huang, Shanghai (CN)

# Lymphadenectomy during radical prostatectomy: Predictive tools and comparative outcomes

Abstract Session 33

**Sunday 15 March**
**15:30 - 17:00**

**Location** Blue Area, George 3

**Chairs**
F. Abdollah, Detroit (US)
P. Cathcart, London (GB)
R. Eapen, Melbourne (AU)

**15:30 - 16:10** **PSMA-PET-CT for assessment of lymph node invasion**

A0547 **Assessing the Risk of False Positive Findings of PSMA-PET in Nodal Staging in Patients Treated With Radical Prostatectomy and Extend Pelvic Lymph-Node Dissection**
M. Brancaccio, Milan (IT)

A0548 **Assessing the Number Needed to Treat for an Extended Pelvic Lymph Node Dissection in PSMA-PET Negative Patients: Contextualizing MSKCC Trial Findings in The Molecular Imaging Era**
P. Zaurito, Milan (IT)

A0549 **Pelvic Lymph Node Dissection Can Be Omitted in PSMA-PET/CT–Negative Prostate Cancer: Evidence from a Multicenter Study**
F. Zattoni, Padova (IT)

A0550 **Impact of Negative PSMA PET on the Decision to Perform a Pelvic Lymph Node Dissection during Radical Prostatectomy for Intermediate to High-Risk Prostate Cancer Patients. Results of an International Survey**
G. Reitano, Acireale (IT)

A0551 **Diagnostic accuracy of preoperative PSMA PET/CT for nodal staging in patients undergoing radical prostatectomy and extended lymph node dissection (ePLND)**
A. Piccolini, Vigevano (IT)

A0552 **Impact of PSMA-PET on pelvic lymph node dissection trends in Australia: national compared with insights from the largest single-centre cohort in Australia**
J. Yang, Rosebery (AU)

A0553 **Recurrence Patterns in PSMA-Negative Prostate Cancer with High preoperative Lymph Node Invasion Risk: Comparing Outcomes with and without Pelvic Lymph Node Dissection**
G. Reitano, Acireale (IT)

A0554 **Identifying Candidates for Radical Prostatectomy and Extended Pelvic Lymph Node Dissection among Prostate Cancer Patients with PSMA-PET–Detected Nodal Disease (miN1): The Combined Role of MRI Staging and Quantitative PSMA Parameters**
S.L.A. Scuderi, Stockholm (SE)

**16:10 - 16:45** **Nomograms predicting lymph node invasion**

A0555 **Multicentre validation of the 2019 Briganti nomogram: one threshold does not fit all**
A. Peyrottes, Paris (FR)

A0556 **Predicting lymph node invasion risk according to Briganti nomogram 2019 using unilateral biopsy scheme. A retrospective multicenter study.**
G. Graps, Tricase (IT)

A0557 **Comparative study of four predictive nomograms for the indication of lymph node dissection in prostate cancer**
F. Taha, Reims (FR)

A0558 **Incorporating PSMA PET/CT Parameters into Clinicopathologic Nomograms for Predicting Lymph Node Involvement in Intermediate- and High-Risk Prostate Cancer**
M. Ahmed, Rochester (US)

A0559 **Nomogram-Guided Omission of Pelvic Lymph Node Dissection at Robotic Radical Prostatectomy: What Are We Really Missing?**
U. Anceschi, Rome (IT)

A0560 **Evaluation of new cut-off values for nerve-sparing radical prostatectomy and lymphadenectomy based on a prospective external validation of the MSKCC and Martini nomograms**
J. Bierlein, Mainz (DE)

A0561 **Stress-Testing PLND Nomograms against Adverse Pathology after Robotic Radical Prostatectomy: results from a 5-year tertiary-centre series**
U. Anceschi, Rome (IT)

**16:45 - 17:00** **Complications**

A0562 **Comparative Perioperative Outcomes of Extended Versus Limited Pelvic Lymph Node Dissection in Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer: A Phase III Randomized Trial**
M. Ruggeri, São Paulo (BR)

A0563 **The Impact of the Peritoneal Flap on Lymphocele Formation Following Robotic Assisted Radical Prostatectomy with Pelvic Lymph Node Dissection: A Systematic Review and Meta-analysis**
M.Z.U. Adhoni, London (GB)

A0564 **Evaluation of the frequency of postoperative lymphatic complications after robot-assisted radical prostatectomy and pelvic lymph node dissection using radioguided surgery**
M. Trishkin, Moscow (RU)

## EAU Lab: Molecular diagnostics, biomarkers & AI

EAU26 Lab

Abstract Session 35

**Sunday 15 March**
**15:30 - 17:00**

**Location** Blue Area, Victoria 4

**Chairs**
R.T. Bryan, Birmingham (GB)
B. Kiemeney, Nijmegen (NL)
To be confirmed

**15:30 - 16:15** **Urothelial cancer**

A0583 **Urinary TERT Promoter Mutations as a Non-Invasive Biomarker for Early Detection of Bladder Cancer Recurrence and Progression**
H.P. Avogbe, Lyons (FR)

A0584 **Early detection of treatment failure and disease dissemination in BCG-treated NMIBC using liquid biopsies and urine proteomics**
T. Strandgaard, Aarhus (DK)

A0585 **BlaDimiR and BlaDimiRplus: Clinically validated urine-based assays for diagnosis, monitoring, and immunotherapy response prediction in bladder cancer**
M. Dueñas, Madrid (ES)

A0586 **Circulating Tumor DNA Detection and Dynamics Predict Early Response to Neoadjuvant Immunotherapy and Survival in Muscle-Invasive Bladder Cancer – An Exploratory Analysis in the AURA Trial.**
J. Blanc, brussels (BE)

A0587 **Non-luminal molecular subtypes demonstrate highest complete response rates after neoadjuvant chemo-immune therapy for Muscle-invasive Bladder Cancer: Biomarker Analyses of NURE-combo & BLASST-01 phase 2 clinical trials**
J. De Jong, Rotterdam (NL)

A0588 **Application of transcriptomic bladder-cancer subtypes to upper-tract urothelial carcinoma (UTUC) across international cohorts reveals racial differences and translational limitations**
J.M. Scurll, Vancouver (CA)

A0589 **Establishment and Multidimensional Validation of a Rapid Drug Screening Platform Using a Patient-Derived Zebrafish Xenograft Model of Upper Tract Urothelial Carcinoma**
X. Long, Guangzhou (CN)

A0591 **Longitudinal assessment of urine tumor DNA in high-risk non-muscle invasive bladder cancer patients**
J.W.F. Catto, Sheffield (GB)

---

**16:15 - 16:30** **Renal cancer**

A0593 **A prospective diagnostic cohort study of longitudinal plasma ctDNA based tumor-informed MRD detection for recurrence monitoring in nonmetastatic ccRCC**
Z. Wu, Shanghai (CN)

A0594 **Drug-Testing in Patient-Derived Renal Cell Carcinoma Organoids Reveals Pathways of Vulnerability and Resistance**
S. Monda, Ann Arbor (US)

---

**16:30 - 17:00** **Prostate cancer**

A0595 **Early Metabolic Biomarker Changes with GnRH Agonist versus Antagonist Therapy in Prostate Cancer: Results from a Single Centre Prospective Study**
A. Viti, Milan (IT)

A0597 **Application of a PSMA/STEAP1 Dual-Targeted Smart Liposomal Nanoplatform Loaded with AIE-MNPs for Integrated Diagnosis and Therapy of Prostate Cancer**
X. Jingyu, Wuhan (CN)

A0598 **Comprehensive Genomic Landscape of Prostate Cancer and Clinical Outcomes of BRCA1/2 Pathogenic Variants in the Metastatic Castration-Resistant Setting**
F. Urabe, Tokyo (JP)

A0599 **Purinergic Signaling Modulation: A Novel  Promising Therapeutic Strategy for Prostate Cancer**
A. Viti, Milan (IT)

A0600 **Impact of homologous recombination repair gene alterations on treatment and survival in metastatic castration-resistant prostate cancer**
N. Mehra, Nijmegen (NL)

## Therapeutic strategies and surgical outcomes in prostate cancer and BPH

Abstract Session 36

**Sunday 15 March**
**15:30 - 17:00**

**Location** Blue Area, Victoria 5

**Chairs**
S. Ahyai, Graz (AT)
S. Guillaumier, Dunfermline (GB)
R. Sosnowski, Olsztyn (PL)

**15:30 - 15:40** **Early phase and minimal invasive treatments**

A0601 **A Phase 1 Safety, PK and Preliminary Efficacy Study of Localized Therapy using Enolen® (Enzalutamide) Implants for Early-Stage Prostate Cancer**
B. Millan, Bethesda (US)

A0602 **Patient Experience with Water Vapor Therapy for The Management of Prostate Cancer: The VAPOR 2 Study**
A.K. George, Baltimore (US)

**15:40 - 16:40** **Radical treatment**

A0603 **PSMA Radioguided Surgery for Lymph Node Metastases Detection in Prostate Cancer Patients Undergoing RARP with ePLND: Final Results of a Prospective Phase 2 Study**
L. Quarta, Milano (IT)

A0604 **A phase I/IIa, single-arm, open-label trial of DGPR1008 for intraoperative fluorescence imaging of prostate-specific membrane antigen-positive prostate cancer**
X. Yang, Qindao (CN)

A0605 **Dehydrated Human Amniotic Membrane for Early Return of Erectile Function After Robotic Radical Prostatectomy: A 10-Year Journey and Lessons Learned**
S. Razdan, Doral (US)

A0606 **Indications for robot-assisted laparoscopic radical prostatectomy based on postoperative urinary function**
Y. Tabata, Ise (JP)

A0607 **Developing a Periprostatic Vascular Map to Optimize Nerve-Sparing for Robot-Assisted Radical Prostatectomy: Initial Report from a Prospective Feasibility Study**
K. Hanna, Irvine (US)

A0608 **An Innovative AI System Combining Machine Learning and Generative AI for Tailored Surgical Planning and Outcome Forecasting in Robot-Assisted Radical Prostatectomy**
D. Amparore, Orbassano (Turin) (IT)

A0609 **Anterior vs Posterior Robot-assisted radical prostatectomy: insights from 10 years follow-up of a randomized controlled trial**
A. Santangelo, Milan (IT)

A0610 **Survivorship after curative treatment: Results of 20 years of follow-up from ERSPC Rotterdam**
S. Remmers, Rotterdam (NL)

**Study Group**
ERSPC Rotterdam Study Group(Rotterdam, The Netherlands)

A0611 **Complications and Retreatment Rates of Radiation Therapy for Prostate Cancer compared to Radical Prostatectomy: A Real-Life, Nation-Wide Observational Study using the Epic Cosmos Collaborative Database**
V. Santarelli, Roma (IT)

A0613 **Celecoxib Combined with Low-dose-rate Brachytherapy Improves Long-term Metastasis-free Rate in Non-metastatic Prostate Cancer: 10-year Post-hoc Randomized Study**
Y. Nakai, Kashihara-Shi (JP)

A0614 **Prior TURP does not affect perioperative outcomes at radical prostatectomy: a pair-matched analysis of a single center series**
M. Nicolazzini, Novara (IT)

A0612 **Incisional hernia after minimally invasive radical prostatectomy: an underestimated complication requiring greater awareness**
A. Peyrottes, Paris (FR)

**16:40 - 17:00** **BPH**

A0615 **Automatic object detection in prostate morcellation using deep learning**
K. Albrechts, Oldenburg (DE)

A0616 **Pelvic floor muscle thickness as a predictor of transient urinary incontinence after prostatic laser enucleation: a prospective study with MRI correlation**
M. Menozzi, (IT)

A0617 **Membranous urethral length as a predictor for urinary incontinence after Holmium Enucleation of the Prostate (HoLEP) for benign prostatic hyperplasia**
N. Lee, Montreal (CA)

## Robotics at its best

EAU Robotic Urology Section

**Sunday 15 March**
**15:30 - 18:00**

**Location** Blue Area, George 4

**Chair** A. Breda, Barcelona (ES)

**Learning objectives**
To provide to the audience a practical guide to perform the most common surgeries in urology. The audience will be able to learn from among the best surgeons in the world.

**15:30 - 16:00** **New technology**

*Moderators* S. Nathan, London (GB)
H.G. Van Der Poel, Amsterdam (NL)

15:30 - 15:40 **Should we train surgeons on the new systems?**
A. Mottrie, Aalst (BE)

15:40 - 15:50 **Telesurgery: What now?**
A. Breda, Barcelona (ES)

15:50 - 16:00 **Single port surgery: Where do we stand?**
B.J. Challacombe, London (GB)

---

**16:00 - 16:56** **Nightmare cases in robotic surgery**

*Moderators* V. Phé, Paris (FR)
S. Secco, Milan (IT)

16:00 - 16:14 **Prostate cancer**
M.C. Sighinolfi, Milan (IT)

16:14 - 16:28 **Kidney cancer**
J-C. Bernhard, Bordeaux (FR)

16:28 - 16:42 **Bladder cancer**
P. Wiklund, Stockholm (SE)

16:42 - 16:56 **Functional urology**
B. Peyronnet, Rennes (FR)

---

**16:56 - 17:55** **Tips and tricks from the expert**

*Moderators* N.N. Harke, Hannover (DE)
C. Wagner, Gronau (DE)

16:56 - 17:06 **Tips and tricks of retroperitoneal LDN for testis cancer**
J. Porter, Seattle (US)

17:06 - 17:16 **Tips and tricks of renal enucleation surgery**
A. Minervini, Florence (IT)

17:16 - 17:26 **Tips and tricks of nerve sparing surgery**
R. Gaston, Bordeaux (FR)

17:26 - 17:36 **Tips and tricks of vescico-urethral anastomosis**
B.M.C. Rocco, Rome (IT)

17:36 - 17:46 **Tips and tricks of vesico-vaginal fistula repair**
V. Phé, Paris (FR)

17:46 - 17:55 **Tips and tricks of robotic kidney transplantation**
M. Musquera Felip, Barcelona (ES)

---

**17:55 - 18:00** **Closing and final remarks**
A. Breda, Barcelona (ES)

# Expanding the donor pool and preserving graft quality in kidney transplantation

EAU Section of Transplantation Urology

**Sunday 15 March**
**15:30 - 17:00**

**Location** Blue Area, Victoria 1

**Chair** M. Musquera Felip, Barcelona (ES)

**Learning objectives**

This session explores strategies to expand the kidney donor pool while maintaining graft quality through advances in policy, technology, and surgical practice. Participants will review the current state of cadaveric donation in Europe, evaluate emerging techniques such as regional normothermic reperfusion, and examine best practices in organ procurement and preservation. The programme also addresses the growing role of robotics in kidney transplantation and highlights approaches to strengthen urologist involvement to optimise donor utilisation and long-term outcomes.

**15:30 - 15:32** **Opening remarks**
M. Musquera Felip, Barcelona (ES)

**15:32 - 15:52** **Saving lives, shaping the future: Organ donation across Europe and beyond**

*Moderators* S Drouin, Paris (FR); O. Rodriguez Faba, Barcelona (ES)

15:32 - 15:42 **Cadaveric donation in Europe: Policies and realities**
C. Antoine, (FR)

15:42 - 15:52 **Regional normothermic reperfusion – is it the future?**
A. Romano, Stockholm (SE)

**15:52 - 16:13** **Protecting the gift: How surgeons keep donated kidneys working**

*Moderators* J. Branchereau, Nantes (FR); V. Gomez Dos Santos, Madrid (ES)

15:52 - 16:02 **Harvesting techniques: How to avoid graft loss**
A.J. Figueiredo, Coimbra (PT)

16:02 - 16:13 **Preservation techniques: What works best for kidney grafts?**
M. Foguenne, (BE)

**16:13 - 16:38** **A high-tech helping hand: How robotics is changing kidney transplants**

*Moderators* T. Prudhomme, Toulouse (FR); R.H. Zakri, London (GB)

16:13 - 16:23 **Starting a robotic cadaveric kidney transplant programme**
R. Campi, Florence (IT)

16:23 - 16:31 **Semi-live: Robotic cadaveric kidney transplantation**
T. Ajami Fardoun, Barcelona (ES)

16:31 - 16:38 **Semi-live: Robotic approach for ureteral complications**
B.R. Etcheverry Giadrosich, Barcelona (ES)

**16:38 - 16:48** **Increasing urologist involvement in kidney transplantation**
R. Boissier, Marseille (FR)

**16:48 - 16:53** **Rene Küss Award**

*Presenters* F.J. Burgos Revilla, Madrid (ES)
E. Lledó García, Madrid (ES)

*Winner* J. Kassir, Lyons (FR)

**16:53 - 17:00** **Panel discussion and Q&A**
M. Musquera Felip, Barcelona (ES)

## From molecules to machines: The endourology experience

EAU Section of Endourology

**Sunday 15 March**
**15:30 - 18:00**

**Location** Blue Area, George 1

**Chairs** B. Somani, Southampton (GB)
O. Traxer, Paris (FR)

**Learning objectives**
This session aims to provide participants with a comprehensive update on contemporary and emerging practices in endourology. Attendees will gain insights into medical and imaging-based management of urinary stones, including drug therapies, imaging assessment, and vitamin D's role in stone risk. Surgical topics will explore advancements in PCNL vs. RIRS, robotic platforms, and sustainable engineering. The programme also covers innovations in laser settings, outpatient bladder tumor treatment, robotic techniques for UTUC, and focal therapies for prostate cancer. Additionally, debates on BPH management strategies and the future role of AI and simulation in endourological training and practice will equip clinicians with critical knowledge for evidence-based decision-making and future readiness.

**15:30 - 15:31** **Welcome and introduction**
O. Traxer, Paris (FR)

**15:31 - 16:01** **Stone medical: Image and medication**

*Moderators* M. Straub, Munich (DE)
C.A. Wagner, Zurich (CH)

15:31 - 15:32 **Introduction**
M. Straub, Munich (DE)
C.A. Wagner, Zurich (CH)

15:32 - 15:39 **Drug-based therapy of stones**
C.A. Wagner, Zurich (CH)

15:39 - 15:46 **Structured assessment in stone imaging**
H.U. Jung, Vejle (DK)

15:46 - 15:53 **Vitamin D and stone risk**
P.M. Ferraro

15:53 - 16:01 **Discussion**

---

**16:01 - 16:22** **Stone surgical: PCNL vs. RIRS – the final fight?**

*Moderators*
O. Angerri Feu, Barcelona (ES)
H.U. Jung, Vejle (DK)
B. Turney, Oxford (GB)

16:01 - 16:02 **Introduction**
O. Angerri Feu, Barcelona (ES)

16:02 - 16:07 **Integrated suction and IRP monitoring - fact or myth?**
O. Wiseman, Cambridge (GB)

16:07 - 16:12 **Is PCNL dead?**
M.S. Pearle, Dallas (US)

16:12 - 16:17 **Intelligent new robotic ureteroscopy platform**
S. Yuen, Hong Kong (HK)

16:17 - 16:22 **Sustainable engineering in endourolgy: Revolutionary ureteroscopy systems**
V. Gauhar, Singapore (SG)

---

**16:22 - 16:36** Debate **Lasers pre-settings for stone treatment – should we trust or not?**

16:22 - 16:27 **Yes, we trust**
G. Kamphuis, Amsterdam (NL)

16:27 - 16:32 **No, we don't**
A. Sierra Del Rio, Barcelona (ES)

16:32 - 16:36 **Discussion**

---

**Bladder, BPH, UTUC, focal and LAP**

*Moderators*
J. Baard, Amsterdam (NL)
E. Barret, Paris (FR)
G. Bozzini, Como (IT)

---

**16:36 - 16:55** **Bladder and UTUC: What's new?**

16:36 - 16:37 **Introduction**
J. Baard, Amsterdam (NL)
G. Bozzini, Como (IT)

16:37 - 16:42 **Outpatient laser ablation of bladder tumours**
J.L. Vásquez, Copenhagen (DK)

16:42 - 16:47 **Robotic ERBT: A paradigm shift**
J.Y.C. Teoh, Hong Kong (HK)

16:47 - 16:52 **UTUC: Evolution of guidelines in the last 15 years**
M. Brehmer, Stockholm (SE)

16:52 - 16:55 **Discussion**

---

**16:55 - 17:09** **Management of favorable intermediate-risk prostate cancer**

16:55 - 16:56 **Introduction**
E. Barret, Paris (FR)

| | | |
|---|---|---|
| 16:56 - 17:01 | **Focal therapy**<br>C. Orczyk, London (GB) |
| 17:01 - 17:06 | **Minimally invasive surgery**<br>A. Gallioli, Barcelona (ES) |
| 17:06 - 17:09 | **Discussion** |
| **17:09 - 17:28** | **BPH MIST vs. enucleation: The real-world debate** |
| 17:10 - 17:15 | **Is morcellation the Achilles heel of prostatic enucleation?**<br>S. Doizi, Paris (FR) |
| 17:15 - 17:20 | **The downside of MIST: Are we just delaying the "real" surgery? What is the future of MIST and is it really what patients want?**<br>M.S. Agrawal, Agra (IN) |
| 17:25 - 17:28 | **Discussion** |
| **17:28 - 17:54** | Round-table discussion **AI and simulation everywhere** |
| | *Moderators* | P. Kallidonis, Patras (GR)<br>T. Tailly, Ghent (BE) |
| 17:28 - 17:29 | **Introduction** |
| 17:29 - 17:34 | **AI in endourology: Is it ready for clinical application**<br>C. Nedbal, Milan (IT) |
| 17:34 - 17:39 | **Smart endoscopy: AI-assisted composition recognition of kidney stones**<br>V. Estrade, Angouleme Cedex 9 (FR) |
| 17:39 - 17:44 | **Revolutionising surgical training via virtual reality and simulation protocols: How to train the endourologists of tomorrow** |
| 17:44 - 17:49 | **AI assisted robotic puncture**<br>G.H. Zeng, Guangzhou (CN) |
| 17:49 - 17:54 | **Discussion** |
| **17:54 - 17:55** | **Conclusions**<br>O. Traxer, Paris (FR) |

## Urolithiasis: Epidemiology and outcomes

EGPT 43

**Sunday 15 March**
**15:30 - 16:45**

| | |
|---|---|
| **Location** | Orange Area, EGPT 1 |
| **Chairs** | To be confirmed<br>F. Esperto, Rome (IT)<br>M.L. Letouche, Tours (FR) |

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

| | |
|---|---|
| **15:30 - 15:50** | **Demographic and epidemiological factors** |

| | |
|---|---|
| P0754 | **Air pollution and kidney stone risk: A large-scale nationwide case-crossover study**<br>Z-J. Zhu, Tainan (TW) |
| P0755 | **Age and gender characteristics of urolithiasis: analysis of 5-year prevalence rates among men and women**<br>O. Nesterova, Moscow (RU) |
| P0756 | **Age-Related Decline in Male-to-Female Risk Ratio of Kidney Stone Incidence**<br>C-Y. Huang, Taipei (TW) |
| **15:50 - 16:00** | **Drugs and stone risk** |
| P0758 | **Comparative Risk of Nephrolithiasis in Obesity Pharmacotherapy: A Real-World Analysis of Semaglutide, Tirzepatide, and Orlistat in Type 2 Diabetes**<br>P-H. Lee, Tainan (TW) |
| P0759 | **The association between GLP-1 and dual GIP/GLP-1 agonists and severe urolithiasis requiring surgery: a global real-world cohort study**<br>S.E. Lee, Taichung (TW) |
| **16:00 - 16:15** | **Obesity and dietary factors** |
| P0760 | **Adiposity increases risk of kidney stone disease via effects on renal fat depots and urinary sodium excretion**<br>C. Lovegrove, Glasgow (GB) |
| **16:15 - 16:45** | **Outcomes** |
| P0765 | **External Validation of the MIMIC calculator for predicting successful spontaneous stone passage in patients managed conservatively for ureteric colic**<br>I. Hussein, Edinburgh (GB) |
| P0767 | **High-risk Pathogens and Factors to Postoperative Infection after Upper Urinary Tract Calculi Surgery: A Retrospective Analysis of 4,018 Patients**<br>L-F. Ye, Fuzhou,fujian Province (CN) |
| P0768 | **The experience of post operative flank pains at elevated intrarenal pressures**<br>A. Hong, Heidelberg, Melbourne (AU) |
| P0769 | **MATCH Score: A Predictive Model for Intraoperative Conversion During Ureteroscopic Laser Lithotripsy for Impacted Ureteral Stones**<br>Y.B. Wang, Changchun (CN) |
| P0770 | **One-year outcomes of flexible ureterorenoscopy using a flexible and navigable suction access sheath (FANS): An EAU-Endourology initiative**<br>K.Y. Fong, Singapore (SG) |
| P0771 | **Global Pilot Prospective Multicentre study to classify Flexible ureteroscopy with FANS and report peri and 30 day post operative ouctomes in a multicentre real world setup by EAU Endourlogy**<br>V. Gauhar, Singapore (SG)<br>**Study Group**<br>Flexible ureteroscopy with Flexible and navigable suction access sheath registry (FLEXOR-F)(Hongkong, Hong Kong) |

# Refining active surveillance: Predictive factors and long-term results

EGPT 44

**Sunday 15 March**
**15:30 - 17:00**

**Location** Orange Area, EGPT 2

**Chairs**
S. Knipper, Berlin (DE)
R. Van Den Bergh, Rotterdam (NL)
A.R. Zlotta, Toronto (CA)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**15:30 - 16:00** **Predictors of Progression**

P0772 **Predictors of Progression and Clinical Outcomes in Men Managed with Active Surveillance for Prostate Cancer**
I.A. Khalil, Doha (QA)

P0773 **Long-term prognostic value of the Prostate Urine Risk (PUR) biomarker in an active surveillance cohort**
O.H. Ali, Norwich (GB)

P0774 **Do we need the PRECISE score when we already have the PI-RADS score to predict upgrading on active surveillance?**
F.B. Denijs, Rotterdam (NL)

P0776 **Circulating biomarkers related to progression in low-risk prostate cancer monitored by active surveillance**
J. Cockburn, Toronto (CA)

P0777 **Micro-Ultrasound as a complementary imaging modality for clinically significant PCa detection in active surveillance: A prospective clinical trial**
R. Roldan Testillano, Montreal (CA)

P0778 **Predictors of Progression During Active Surveillance for Grade Group 1 Prostate Cancer in the mpMRI Era: Implications for Follow-up Strategies**
L. Bonavia, Milano (IT)

**16:00 - 16:25** **Follow-up**

P0779 **Favorable Grade Group 1 Prostate Cancer at Confirmatory Biopsy: Toward Personalized Active Surveillance Follow-up Strategies**
M.E. Porzi, Milan (IT)

P0781 **When can we stop monitoring men on active surveillance: results from the PRIAS study**
J. Lodder, Amsterdam (NL)

P0782 **A Risk-Based Model to Identify Active Surveillance Patients Requiring Confirmatory Biopsy: A Contemporary MRI-Based Cohort Study**
M.E. Porzi, Milan (IT)

P0783 **The Diagnostic Benefit of Perilesional Sampling at the Time of Confirmatory Biopsy in Patients Managed with Active Surveillance for ISUP-GG 1 Prostate Cancer**
V. Maestroni, Milan (IT)

| | |
|---|---|
| **16:25 - 16:40** | **Outcomes** |
| P0784 | **Does Active Surveillance Prior to Radical Prostatectomy Affect Pathological or Oncological Outcomes?**<br>I. Hannestad, 0464 Oslo (NO)<br>**Study Group**<br>Institute of Clinical Medicine, University of Oslo(Oslo, Norway) |
| P0785 | **Long-Term outcomes of low-risk prostate cancer managed with active surveillance: the Brazilian experience**<br>A. Souza, Rio De Janeiro (BR) |
| P0786 | **Is Extraprostatic Extension Truly Rare in Patients with Gleason Score 6 Prostate Cancer?**<br>U.C. Karaarslan, Istanbul (TR) |
| **16:40 - 16:50** | **Active surveillance in Grade Group 2 patients** |
| P0787 | **Active surveillance in ISUP grade 2 prostate cancer: a retrospective analysis of discontinuation rates and predictive factors.**<br>L. Rodriguez-Sanchez, Paris (FR)<br>**Study Group**<br>EAU-YAU Prostate Cancer Working Party(Amsterdam, The Netherlands) |
| P0788 | **Risk Factors for Adverse Pathology in Biopsy Gleason 3+4 Prostate Cancer: Refining Criteria for Safe Active Surveillance**<br>M. Montesi, Roma (IT) |
| P0789 | **How much pattern 4 is too much? Defining the threshold for safe active surveillance in ISUP grade 2 prostate cancer**<br>C. Perez, Amposta (ES) |
| **16:50 - 16:55** | **Late-breaking abstract presentation** |
| LB025 | **Adaptive recurrence risk predictions to optimise prostate cancer follow-up: Results of model validation and clinical impact**<br>J. Schoorlemmer, Nijmegen (NL) |

## Advancing urethral and bladder neck stenosis management

EGPT 45

**Sunday 15 March**
**15:30 - 17:00**

**Location** Orange Area, EGPT 3

**Chairs**
L. De Kort, Utrecht (NL)
S. Kulkarni, Pune (IN)
N. Pavan, Santa Flavia (IT)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

| | |
|---|---|
| **15:30 - 15:45** | **The role of Imaging vs endoscopy in urethral strictures diagnosis and follow-up** |

P0791 **Value of systematic uroflowmetry and cystoscopy in the follow-up after oral mucosa graft urethroplasty: are they necessary in asymptomatic patients?**
L. Dieguez-Alvarez, Valencia (ES)

P0792 **: Magnetic Resonance Urethrography–Derived Geometric Predictors of Surgical Complexity and Outcomes in Pelvic Fracture Urethral Injury Repair**
M. Gupta, New delhi (IN)

**15:45 - 16:05** **Treatment pathways: Internal urethrotomy vs drug-coated balloon**

P0794 **Direct Vision Internal Urethrotomy vs Urethroplasty for Uncomplicated Bulbar Strictures (<2cm): A Proposed Decision Making Tool**
M. Garcia, Los angeles (US)

P0795 **“Direct Vision Internal Urethrotomy vs. Non-Transecting Urethroplasty in Short Bulbar Strictures: 1-Year Patient-Reported Outcomes”**
A.K. Chawla, Manipal (IN)

**16:05 - 16:35** **Patient reported outcomes and risk of retreatment**

P0797 **An observational study on the evaluation of the sexual functions in post urethroplasty Patients**
T Pal, HOWRAH (IN)

P0799 **Patient expectations prior to first-time anterior urethroplasty: preliminary results from an international multi-institutional prospective study**
J. Klemm, Hamburg (DE)

**Study Group**
Trauma and Reconstructive Urology Working Party of the European Association of Urology Young Academic Urologists(Amsterdam, The Netherlands)

P0800 **Routine Low-Dose Tadalafil Following Buccal Mucosal Graft Urethroplasty for Bulbar Urethral Strictures: Influence on Urinary, Sexual, and Patient-Reported Functional Outcomes — A Prospective Cohort of 170 Patients**
S. Bafna, Ayanavaram Chennai (IN)

P0801 **Predictors of recurrence after bulbar urethroplasty following BPH surgery: A multicenter retrospective study**
O. Gülpinar, Ankara (TR)

**Study Group**
Reconstructive Urology, Minimally Invasive and "Hands-on Training" Working Group of Turkish Continence Society(Ankara, Turkey)

**16:35 - 17:00** **Innovations in complex bladder neck stenosis**

P0805 **Effect of early detubularization on urethro-intestinal anastomosis during robot-assisted radical cystectomy and intracorporeal neobladder among bladder cancer patients**
J.H. Park, SeongNam Si (KR)

# Testosterone frontiers: Therapy, aging, and urological health

EGPT 46

**Sunday 15 March**
**15:30 - 17:00**

**Location** Blue Area, EGPT 4

**Chairs**
A. Kadioglu, Istanbul (TR)
J.P. Mulhall, New York (US)
E. Pozzi, Milan (IT)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**15:30 - 15:50** **Testosterone replacement therapy**

P0808 **Clomiphene Citrate versus Testosterone Replacement Therapy in Late-Onset Hypogonadism: A Systematic Review of the Literature and Meta-Analysis**
B. Constantinou Taveira, Sao Bernardo do Campo (BR)

P0809 **Up to 17 years of testosterone therapy in men with functional hypogonadism and diabetes type 2 is associated with improved voiding function**
K.S. Haider, Bremerhaven (DE)

P0810 **Hypogonadism and Testosterone Replacement Therapy in advanced Bladder Cancer – Improving Quality of Life and Symptom Control**
N. Macdonald, London (GB)

P0811 **Risk factors of osteoporosis in transgender men receiving long-term testosterone therapy**
Y. Tominaga, Okayama (JP)

**15:50 - 16:10** **Translational biomedicine**

P0812 **Prediction of Intratesticular Testosterone Concentrations Following Exogenous Testosterone Administration Using Serum Testosterone Precursors in a Rat Model**
I-S. Huang, Taipei (TW)

P0813 **Single-cell RNA-seq Suggests a Shift in Cholesterol Transport Mechanisms during Human Leydig Cell Aging**
K. Sato, Kobe (JP)

P0814 **Establishment of a human leydig cell senescence model using human iPS cell-derived cells and comprehensive gene expression analysis**
C. Kin, Kobe (JP)

**16:10 - 17:00** **Testosterone deficiency**

P0816 **The Longitudinal Association Between Lower Urinary Tract Symptoms Severity and Sarcopenia Progression in Community-Dwelling Men: A 4-Year Study**
T. Okamoto, Hirosaki (JP)

P0817 **Testosterone-symptom severity associations in men evaluated for hypogonadism: an analysis of over 2,000 men**
D. Reisel, London (GB)

P0818 **Testosterone deficiency and sexual performance in the setting of radical prostatectomy: a lead for sexual rehabilitation?**
J.N.H. van Drumpt, Nijmegen (NL)

P0819 **Trends and dynamics of total serum testosterone decline: a systematic review and meta-regression analysis**
F. Negri, Milan (IT)

P0820 **Association Between Serum Testosterone Levels and Calcium Oxalate Stone Formation: A Propensity Score–Matched Case–Control Study**
S. Park, Cardiff (GB)

P0821 **Association of Lifestyle and Body Composition with Steroid Profiles and Prostate Cancer Risk– Results from the Prospective Promic-study**
P.J. Boström, Turku (FI)

**Study Group**
Promic-Study Group(Turku, Finland)

P0823 **Are reference intervals for free testosterone in healthy men reliable also in infertile men? Findings from a cross-sectional study**
F. Passarelli, Milano (IT)

P0824 **Association Between Dietary Viable Microorganism Intake and the Risk of Testosterone Deficiency in Men**
F. Xingliang, Changzhou (CN)

P0825 **Prevalence of testosterone deficiency and surgical impact on testosterone levels in robot-assisted radical prostatectomy patients**
A. Van den Wildenberg, Nijmegen (NL)

## Urothelial carcinoma - Basic and translational research

EGPT 47

**Sunday 15 March**
**15:30 - 17:00**

**Location** Blue Area, EGPT 5

**Chairs** J. Damrauer, Durham (US)
To be confirmed
A. Vlahou, Athens (GR)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

P0901 **MRI radiomic phenotypes stratify response and define immune states in very high-risk non–muscle-invasive bladder cancer treated with tislelizumab plus nab-paclitaxel**
H. Hu, Tianjin (CN)

P0903 **Predicting neoadjuvant chemotherapy response in bladder cancer patients using an artificial intelligence deep learning model**
R. Zhang, Shanghai (CN)

P0906 **Impact of Disease Stage and Genetic Alterations on Clinical Outcomes in Micropapillary Variant Urothelial Carcinoma**
S. McSweeney, Cleveland (US)

P0907 **Vitamin D and its receptor VDR regulate the invasive capacity of bladder cancer cells through physical interactions with AKT kinases**
C. Bolenz, Ulm (DE)

P0908 **RNA based liquid biopsy testing of urine to monitor response of muscle invasive bladder cancer towards neoadjuvant chemotherapy - the NeoBRIDGister experience**
R. Wirtz, Cologne (DE)

P0909 **A composite biomarker approach to withhold neoadjuvant chemotherapy in select muscle-invasive bladder cancer patients**
J. De Jong, Rotterdam (NL)

P0912 **A spatially resolved atlas of upper tract urothelial carcinoma characterizes immunosuppressive niches driving tumor progression**
S. Xiong, Beijing (CN)

P0914 **HER2 Protein Expression and its Clinicopathological Significance in Upper Urinary Tract Urothelial Carcinoma**
G. Bao, Beijing (CN)

P0915 **Longitudinal utDNA Dynamics Predict Recurrence Risk in UTUC**
W. Zuo, Beijing (CN)

## Patient advocacy plaza - Closing the diagnostic and care gaps for women with urinary cancers and conditions

Special Session

**Sunday 15 March**
**15:45 - 16:15**

**Location** Patient Advocacy Plaza

**Chair** A. Filicevas, Brussels (BE)

**Learning objectives**
This session will examine the gender disparities affecting women with bladder cancer and the factors contributing to poorer outcomes. Drawing on evidence from patient experience data and the international “Women Unseen” call-to-action report, the presentation will explore why women frequently experience delays in diagnosis and misinterpretation of symptoms. Delegates will gain insight into the clinical and systemic drivers of these disparities and review practical recommendations to improve awareness, strengthen diagnostic pathways, and advance more equitable bladder cancer care for women.

**World Bladder Cancer Patient Coalition (WBCPC)**
A. Filicevas, Brussels (BE)

## Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 3.6

**Sunday 15 March**
**16:00 - 16:50**

**Location** Red Area, Room 1

**Tutors**
C. Netsch, Hamburg (DE)
A. Tsaturyan, Yerevan (AM)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

## E-BLUS Exam

HOT EBLUS EXAM - 3.6

**Sunday 15 March**
**16:00 - 16:55**

**Location** Red Area, Room 1

**Coordinator** T.M. Ribeiro De Oliveira, Lisbon (PT)

**Tutors**
O. Stakhovskyi, Kyiv (UA)
P. Umari, London (GB)

**Learning objectives**
In this exam, your psychomotor skills such as depth perception and bimanual dexterity will be tested and your mastery of basic laparoscopy skills such as instrument handling, pattern cutting and intracorporeal suturing will be assessed by experienced examiners.
The exam is aimed at candidates with intermediate and advanced laparoscopy experience or those who have sufficiently trained to meet the exercises time and quality criteria. Passing the E-BLUS exam will be rewarded with a certificate that serves as a recommendation to continue your laparoscopy training by assisting laparoscopic procedures in the OR.

## ESTs1 Exam

HOT EST EXAM 3.6

**Sunday 15 March**
**16:00 - 16:50**

**Location** Red Area, Room 1

**Tutors**

A. Pietropaolo, Southampton (GB)

T.M. Ribeiro De Oliveira, Lisbon (PT)

T. Tokas, Heraklion (GR)

**Learning objectives**

In this exam, candidates' psychomotor and endoscopic skills are assessed, with a focus on the safe and effective performance of core endourological procedures such as rigid cystoscopy, flexible cystoscopy, semi-rigid ureteroscopy, and flexible ureteroscopy. Candidates are evaluated by experienced examiners on instrument handling, scope control, orientation, and respect for tissue within a simulated setting. The exam is aimed at candidates with basic to intermediate endourology experience or those who have completed sufficient training to meet the required performance standards, and successful completion is rewarded with a certificate recommending progression to supervised endourological procedures in the operating room.

## Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 3.6

**Sunday 15 March**
**16:00 - 16:50**

**Location** Red Area, Room 1

**Tutors**

B.P. Rai, Newcastle upon Tyne (GB)

L.M. Vendrell, Ciudad - Mendoza (AR)

**Learning objectives**

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 3.6

**Sunday 15 March**
**16:00 - 16:50**

**Location** Red Area, Room 1

**Tutors**
E.D. Demirkiran, Zonguldak (TR)
M.I. Gökce, Ankara (TR)
T.E. Şener, Istanbul (TR)

**Learning objectives**
This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

# Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 3.6

**Sunday 15 March**
**16:00 - 16:50**

**Location** Red Area, Room 1

**Tutors**
R.A. Coman, cluj napoca (RO)
P. Diana, Barcelona (ES)

**Learning objectives**
This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

# Patient advocacy plaza - Radio-ligand-therapy in prostate cancer, patient view on access-availability and affordability

Special Session

**Sunday 15 March**
**16:30 - 17:00**

**Location** Patient Advocacy Plaza

**Chair** E. Briers, Hasselt (BE)

**Europa Uomo**
E. Briers, Hasselt (BE)

# Surgery in Motion: Ejaculation-sparing BPO surgery illustrated

Thematic Session

**Sunday 15 March**
**17:15 - 18:15**

**Location** Orange Area, eURO Auditorium 1

**Chairs** M. Rieken, Zürich (CH)
J. Romero-Otero, Madrid (ES)

**Learning objectives**
This thematic session focuses on various ejaculated sparing techniques for BPO surgery. Pathophysiology, indications, functional outcomes and treatment-associated comorbidities will be discussed. Experts will share their experience and provide helpful guidance by showcasing selected videos of the respective techniques.

| | |
|---|---|
| **17:15 - 17:22** | Semi-live video **Ejaculation: Importance and physiology**<br>B. Pradère, Toulouse (FR) |
| **17:22 - 17:25** | **Discussion** |
| **17:25 - 17:32** | Semi-live video **Aquablation**<br>M. Ritter, Bonn (DE) |
| **17:32 - 17:35** | **Discussion** |
| **17:35 - 17:42** | Semi-live video **Rezum**<br>I. Schwartzmann, Barcelona (ES) |
| **17:42 - 17:45** | **Discussion** |
| **17:45 - 17:52** | Semi-live video **Ejaculation-sparing TURP**<br>I. Sokolakis, Thessaloniki (GR) |
| **17:52 - 17:55** | **Discussion** |
| **17:55 - 18:02** | Semi-live video **Seminal vesiculoscopy**<br>M.K.M. Omar, Shibin El Kom (EG) |

| | |
|---|---|
| **18:02 - 18:05** | **Discussion** |
| **18:05 - 18:12** | Semi-live video **UROlift + iTind**<br>S. Secco, Milan (IT) |
| **18:12 - 18:15** | **Discussion** |

## Surgery in Motion: Renal and bladder transplant

Thematic Session

**Sunday 15 March**
**17:15 - 18:15**

**Location** Orange Area, Room 3

**Chairs**
A.J. Figueiredo, Coimbra (PT)
J.D. Olsburgh, London (GB)

**Learning objectives**
Current state of the art semi-live video presentations of key transplant surgical topics including those relevant to general and robotic urologists: Bench preparation, surgical complications and nightmare situations in kidney transplant will be shown and discussed. Latest developments in robotic heterotopic and orthotopic kidney transplant Step by step robotic surgical techniques for kidney auto-transplant Latest update on bladder transplantation - indications, approach and developments

| | |
|---|---|
| **17:15 - 17:22** | Semi-live video presentation **Bench surgery: How to prepare the kidney for transplantation**<br>A. Territo, Barcelona (ES) |
| **17:22 - 17:29** | Semi-live video presentation **Robotic assisted kidney transplantation: Step-by-step**<br>M. Musquera Felip, Barcelona (ES) |
| **17:29 - 17:32** | **Discussion** |
| **17:32 - 17:39** | Semi-live video presentation **Robotic assisted kidney auto-transplantation: Indications and step-by-step**<br>K. Decaestecker, Gent (BE) |
| **17:39 - 17:42** | **Discussion** |
| **17:42 - 17:49** | Semi-live video presentation **Robotic orthotopic kidney transplantation: The best choice for impossible transplants**<br>F. Vigues Julia, Barcelona (ES) |
| **17:49 - 17:52** | **Discussion** |
| **17:52 - 17:59** | Semi-live video presentation **Surgical complications and nightmares in kidney transplantation**<br>F.J. Burgos Revilla, Madrid (ES) |
| **17:59 - 18:02** | **Discussion** |

| | |
|---|---|
| **18:02 - 18:09** | Semi-live video presentation **Bladder transplantation**<br>A. Belarmino, Barcelona (ES) |
| **18:09 - 18:15** | **Discussion** |

## Management of major genitourethral trauma

eau Andrology eau Reconstruction

Joint session of EAU section of Andrological Urology and EAU Section of Genitourinary reconstructive surgeons

**Sunday 15 March**
**17:15 - 18:15**

**Location** Blue Area, George 3

**Chairs**
C. Bettocchi, Foggia (IT)
D.J. Ralph, London (GB)

**Learning objectives**
This session will address the contemporary management of major genitourethral trauma, with an additional focus on injuries arising in war and conflict settings — sadly an increasingly relevant challenge even in Europe today. Delegates will gain insights into reconstructive strategies for penile, urethral, scrotal, and testicular trauma, as well as the management of complex ureteral and pelvic injuries. Expert discussions will enhance understanding of surgical decision-making and multidisciplinary care in severe trauma scenarios.

| | |
|---|---|
| **17:15 - 17:25** | **Mine-explosive trauma of male genital organs and possibilities of reconstructive urology**<br>M. Panasovskyi, Kharkiv (UA) |
| **17:25 - 17:27** | **Discussion** |
| **17:27 - 17:37** | **Treatment of combat-related ureteral injuries in the modern era**<br>D. Shchukin, Kharkiv (UA) |
| **17:37 - 17:39** | **Discussion** |
| **17:39 - 17:46** | **The management of penile amputation**<br>A. di Giovanni, london (GB) |
| **17:46 - 17:48** | **Discussion** |
| **17:48 - 17:55** | **Current management of pelvic fracture and urethral disruption injuries**<br>P. Anderson, Dudley (GB) |
| **17:55 - 17:57** | **Discussion** |
| **17:57 - 18:05** | **Scrotal / testicular trauma**<br>G.I. Russo, Catania (IT) |
| **18:05 - 18:13** | **Catastrophic complications during penile prosthesis insertion**<br>O. Sedigh, Torino (IT) |

| | |
|---|---|
| 18:13 - 18:15 | Q&A and closing remarks |

# From Studio to Stage: GU Cast LIVE at EAU26

Special Session

**Sunday 15 March**
**17:15 - 18:00**

**Location** Orange Area, eURO Auditorium 2

**Chair** M. Albersen, Leuven (BE)

**Learning objectives**

GU Cast will be broadcasting LIVE from #EAU26 in London - and this is one event you do not want to miss! For six years, GU Cast has been one of the world's leading urology podcasts, reaching a huge global audience with sharp insights, big ideas, and plenty of laughs. Now, hosts Declan Murphy and Renu Eapen are leaving their cosy Melbourne studio behind to deliver a very special GU Cast Live experience at the EAU Annual Meeting.

Expect a fast-paced, high-energy session packed with fantastic guests, controversial topics, behind-the-scenes stories, unexpected moments, and GU Cast's trademark humour. Add in lots of great giveaways and a buzzing live audience, and you've got one of the most entertaining events of the congress.

 GU Cast Live at EAU - see you there!

**17:15 - 18:00** **GU Cast**

*Speakers*
R. Eapen, Melbourne (AU)
D. Murphy, Melbourne (AU)

# Managing advanced disease in renal and rare cancers

Plenary Session

**Monday 16 March**
**08:00 - 10:00**

**Location** Orange Area, eURO Auditorium 1

**Chairs** M. Albersen, Leuven (BE)
M.C. Mir Maresma, New York (US)

**08:00 - 08:02** **Introduction**

**08:02 - 08:29** Debate **Cut, zap, or chill? Tackling the primary tumour in mRCC**

08:02 - 08:04 Introduction **Would you treat the primary tumour in a patient with mRCC today?**
T. Kuusk, London (GB)

08:04 - 08:09 **You can't ignore the beast in the kidney**
P.J. Zondervan, Amsterdam (NL)

08:09 - 08:14 **Why cut when you can zap?**
A.K. Lalani, Hamilton (CA)

08:14 - 08:19 **What if we asked the patient first? Surveillance of primary**
W. Yip, Duarte (US)

08:19 - 08:29 **Discussion**

| | |
|---|---|
| **08:29 - 08:34** | Live interview **Adaptative clinical trial design in kidney cancer**<br>*Interviewer* V. Parry, Carterton (GB)<br>*Speaker* A. Bex, London (GB) |
| **08:34 - 08:44** | State-of-the-art lecture **Decoding the evolutionary biology of kidney cancer: Insights from the primary tumour to precision therapy**<br>Z. Tippu, London (GB) |
| **08:44 - 08:54** | State-of-the-art lecture **Reprogramming immunity: Microbiota-centered approaches in kidney cancer**<br>L. Derosa, Villejuif (FR) |
| **08:54 - 09:09** | **Rare cancers** |
| 08:54 - 08:57 | **Case presentation**<br>A. Larcher, Milan (IT) |
| 08:57 - 08:59 | **Voting** |
| 08:59 - 09:09 | Society of Urologic Oncology (SUO) lecture **Rare renal tumours: What should the general urologist know?**<br>B. Shuch, (US) |
| **09:09 - 09:25** | **Penile cancer: Patient reported outcomes** |
| 09:09 - 09:19 | **Penile cancer and quality of life: Hearing the patient's voice**<br>J. Osborne, Nottingham (GB) |
| 09:19 - 09:25 | **Discussant: How will PROMs shape the future guidelines?**<br>J.K. Jakobsen, Aarhus N (DK) |
| **09:25 - 09:48** | **Testicular cancer: Stage II Seminoma** |
| 09:25 - 09:33 | **De-escalation approaches: Can we do less?**<br>A. Thor, Stockholm (SE) |
| 09:33 - 09:38 | **RPLND: Tips and tricks for a speedy recovery - Open**<br>S. Daneshmand, Los Angeles (US) |
| 09:38 - 09:43 | **RPLND: Tips and tricks for a speedy recovery - Robot**<br>Y. Che, Düsseldorf (DE) |
| 09:43 - 09:48 | **Discussion** |
| **09:48 - 09:58** | **Ongoing trials in rare genitourinary cancers**<br>F.C. Maluf, Sao Paulo (BR) |
| **09:58 - 10:00** | **Closing remarks** |

# Global men's health crisis

Plenary Session

**Monday 16 March**
**08:00 - 10:00**

**Location** Orange Area, eURO Auditorium 2

**Chairs** C.F.S. Jensen, Herlev (DK)
G.I. Russo, Catania (IT)

**Learning objectives**
This session will provide delegates with an overview of the key challenges driving the global men's health crisis, including disparities in life expectancy, lifestyle-related risk factors, and access to preventive care. Participants will gain insights into the biological, psychological, and social determinants that shape men's health worldwide. The session will also highlight evidence-based strategies and policies aimed at improving outcomes, fostering awareness, and promoting equity in men's health across diverse populations.

**08:00 - 08:02** **Introduction**

**08:02 - 08:10** State-of-the-art lecture **Testicular health in decline: Trends in sperm quality, testicular dysgenesis syndrome, cancer incidence and hypogonadism**
M. Dinkelman-Smit, Rotterdam (NL)

**08:10 - 08:18** State-of-the-art lecture **The future of fertility: Social, economic, and genetic drivers of declining birth rates**
R. Cannarella, Catania (IT)

**08:18 - 08:44** Panel debate **Obesity and male sexual and reproductive health: Lifestyle vs. GLP-1 receptor agonists vs. testosterone**

*Moderator* M.M. Fode, Herlev (DK)

08:18 - 08:20 **Introduction**
M.M. Fode, Herlev (DK)

08:20 - 08:24 **Lifestyle modification - "Go to the gym"**
E. Maseroli, Florence (IT)

08:24 - 08:28 **GLP1 receptor agonist - "Take the pill"**
G. Rastrelli, Florence (IT)

08:28 - 08:32 **Testosterone therapy - "Top up your levels"**
J.P. Mulhall, New York (US)

08:32 - 08:44 **Discussion and voting**

*Moderators* M.M. Fode, Herlev (DK)
C.F.S. Jensen, Herlev (DK)
G.I. Russo, Catania (IT)

*Panel* E. Maseroli, Florence (IT)
J.P. Mulhall, New York (US)
G. Rastrelli, Florence (IT)

**08:44 - 09:12** Round-table discussion **Global male fertility crisis**

*Moderator* J.O.R. Sønksen, Herlev (DK)

08:44 - 08:45 **Introduction**
J.O.R. Sønksen, Herlev (DK)

08:45 - 08:50 **Genvironment: The genetics–environment interface in male fertility**
D.J. Lamb, Kansas City (US)

08:50 - 08:55 **Environmental toxicology and microplastics: Hidden threats to reproductive health**
P. Sangster, London (GB)

08:55 - 09:00 **Genetics and male aging: Biological limits to fertility**
F. Tüttelmann, Münster (DE)

09:00 - 09:12 **Discussion and voting**

*Moderators*
C.F.S. Jensen, Herlev (DK)
G.I. Russo, Catania (IT)
J.O.R. Sønksen, Herlev (DK)

---

**09:12 - 09:22** Spotlight talk **About male sexuality: Does SoMe help to uncover pathology in men or turn them into patients?**
F. Milhouse, Chicago (US)

---

**09:22 - 09:50** Round-table discussion **Global male sexual health crisis: Modern challenges in male sexual health**

*Moderator*
G. De Win, Edegem (BE)

09:22 - 09:23 **Introduction**
G. De Win, Edegem (BE)

09:23 - 09:27 **Modern challenges in male sexual health: Understanding pressures, pathology and prespectives**

*Sidekick*
F. Castiglione, London (GB)

09:27 - 09:31 **Decline in sexual health in young men: Mental Health, masculinity, and modern pressures**
W.G. Lee, London (GB)

09:31 - 09:35 **Treating sexual symptoms: Navigating normal psychosexual development, pathology, and the impact of social media**
M.P.J. Nicolai, Amsterdam (NL)

09:35 - 09:39 **The highs and lows of modern relationships**
G. Polloni, Como (IT)

09:39 - 09:50 **Discussion and voting**

*Moderators*
G. De Win, Edegem (BE)
C.F.S. Jensen, Herlev (DK)
G.I. Russo, Catania (IT)

---

**09:50 - 09:58** State-of-the-art lecture **Reversing the men's health crisis: Strategies for the next decade**
A. Salonia, Milan (IT)

---

**09:58 - 10:00** **Closure**

# POP (pelvic organ prolapse) surgery in real life: Tips, tricks & troubleshooting

ESU Course 45

**Monday 16 March**
**08:30 - 11:30**

**Location** Red Area, Room 8

**Chair** V. Phé, Paris (FR)

**Learning objectives**

The objective of this course is to provide a complete overview of pelvic organ prolapse diagnosis, investigations (place of urodynamics) and treatment including conservative management and surgeries from open to laparoscopic and robotic approaches.

Clinical cases of POP, POP associated with stress and urge urinary incontinence and complications of surgeries will be discussed methodically.

At the end, the participants will know the diagnostic strategies, the techniques to perform POP surgeries and how to counsel the patients.

- To learn about clinical diagnosis of POP
- To learn about urodynamics and indications
- To learn step by step how to perform a sacrocolpopexy and tips and tricks
- To learn how to manage POP surgery complications

**Patient selection & procedure planning (conservative vs vaginal vs abdominal)**
F. Cancrini, Rome (IT)

**Vaginal native-tissue repair — Step-by-step**
N. Khalil, Beirut (LB)

**Robotic/laparoscopic sacrocolpopexy, the tips to make it right — Step-by-Step**
V. Phé, Paris (FR)

**Complications, redo & guidelines — Pitfalls, rescue & what to apply tomorrow (complications of vaginal surgery, complications of abdominal surgery, interactive videos, case discussions)**
F. Cancrini, Rome (IT)
N. Khalil, Beirut (LB)
V. Phé, Paris (FR)

# Advanced indications in robotic reconstructive surgery

ESU Course 46

**Monday 16 March**
**08:30 - 11:30**

**Location** Red Area, Room 9

**Chair** H. John, Frauenfeld (CH)

**Learning objectives**

Reconstructive and re-do robotic urology is a rapidly evolving field. Growing experience and new technology allow to reconstruct lower and upper urinary tract more and more by minimal invasive robotic technology with good functional outcomes, thus preventing often relaparotomies.

**Introduction**
H. John, Frauenfeld (CH)

**Distal ureteric strictures – overview of techniques**
H. John, Frauenfeld (CH)

**Proximal ureteric strictures – overview of techniques**
B. McGuire, Dublin (IE)

**Alternative options: Appendix onlay, round ligament and bladder ureteroplasty**
B. McGuire, Dublin (IE)

**Anti-Reflux techniques in ureteral reconstruction: Yes or no**
B. McGuire, Dublin (IE)

**Retroperitoneal fibrosis - technique for ureterolysis and omental wrap**
B. McGuire, Dublin (IE)

**Fascia lata sacrocolpopexy**
B. Peyronnet, Rennes (FR)

**Mesh removal-full TOT removal**
B. Peyronnet, Rennes (FR)

**Vesico-vaginal and vesico-rectal fistulae**
H. John, Frauenfeld (CH)

**YV plasty technique for bladder neck stenosis**
H. John, Frauenfeld (CH)

**Augmentation cystoplasty and mitrofanoff**
B. Peyronnet, Rennes (FR)

**Closure**
H. John, Frauenfeld (CH)

# Robotic renal surgery

ESU Course 44

**Monday 16 March**
**08:30 - 11:30**

**Location** Red Area, Room 7

**Chair** A. Breda, Barcelona (ES)

**Learning objectives**

This course will cover all principal indications for robotic surgery of the upper urinary tract. The standard techniques will be explained in a video-based fashion and will be followed by discussing advanced cases as well as troubleshooting and complication management. On top of that, technical innovations and new applications will be discussed as well.

Don't miss this course, a must for all robotic surgeons expect:

- Video-based step-by-step approach
- Standard techniques
- Complex cases
- Troubleshooting and complication management
- Technical innovations: What's new in robotics?

**Introduction**
A. Breda, Barcelona (ES)

**Patient positioning, trocar positioning, trans- and retroperitoneal access in renal robotic surgery**
A. Breda, Barcelona (ES)

**Robotic pyeloplasty: Multichannel or single technique**
A. Antonelli, Verona (IT)

**Renal surgery: Nephrectomy and nephroureterectomy: How I do it**
A. Breda, Barcelona (ES)

**Partial nephrectomy I: Step 1: Isolation of renal hilum; Step 2: Mobilisation of the kidney; Step 3: Clamping of renal pedicle: Different techniques**
A. Antonelli, Verona (IT)

**Partial nephrectomy II: Step 4: Different tumour resection techniques**
R. De Groote, Aalst (BE)

**Partial nephrectomy III: Step 5: Different renography techniques**
A. Breda, Barcelona (ES)

**Partial nephrectomy IV: Special and difficult indications**
R. De Groote, Aalst (BE)

**Complications, new tools and advanced radical nephrectomy**
R. De Groote, Aalst (BE)

**Wrap up and conclusions**
A. Breda, Barcelona (ES)

# Surgical complications during laparoscopic/robotic urological procedures: Prevention, diagnosis, management and complications

ESU Course 49

**Monday 16 March**
**08:30 - 11:30**

**Location** Red Area, Room 12

**Chair** B.M.C. Rocco, Rome (IT)

**Learning objectives**

- The risk of complication is a major issue for laparoscopic and robotic surgeons; the knowledge of complication is key to maximize the safety of urological procedures.

- The course provides a comprehensive overview about the topic, summarizing how to prevent, recognize, grade and fix surgical issues. - An interactive video session will merge trainees' and experts' experience to approach minor, major and harmful drawback of common urological interventions.

**Introduction - Aims of the course**
B.M.C. Rocco, Rome (IT)

**Lectures: Frequency, risk factors, prevention and key aspects**

**Vascular lesions**
A.E. Canda, Istanbul (TR)

**Intestinal lesions**
B.M.C. Rocco, Rome (IT)

**Urinary, neuronal and solid organ lesions**
T. Tokas, Heraklion (GR)

**How to minimize the risk of complications in robotic surgery? - Tricks of the trade**
B.M.C. Rocco, Rome (IT)

**Risk factors and grading of complications: The patient's and the surgeon's factor**
T. Tokas, Heraklion (GR)

**How to train complications management: Tips and tricks from the training models**
A.E. Canda, Istanbul (TR)

**Video presentation and case management - A video collection from experts**
A.E. Canda, Istanbul (TR)
T. Tokas, Heraklion (GR)

**Questions and answers**
B.M.C. Rocco, Rome (IT)

# Flexible ureterorenoscopy and retrograde intrarenal surgery: Instrumentation, technique, tips, tricks and indications

ESU Course 47

**Monday 16 March**
**08:30 - 11:30**

**Location** Red Area, Room 10

**Chair** B. Somani, Southampton (GB)

**Learning objectives**

The aims and objectives of this course is to provide a complete overview of instruments, endoscopes, indications, technique and special tips and tricks concerning Retrograde IntraRenal Surgery (RIRS) using flexible ureterorenoscopes and Holmium YAG lasers. At the end the participants will know the equipment and the technique to perform flexible ureterorenoscopy in the best conditions. • To learn about equipment. • To learn about technique and indications. • To learn how to use an Holmium Laser. • To learn tips and tricks for special circumstances.

**Welcome and introduction**
B. Somani, Southampton (GB)

**Instrumentation: Endoscopes**
N. Davis, Dublin (IE)

**Instrumentation: Laser and lithotripsy devices**
B. Somani, Southampton (GB)

**Instrumentation: Disposable (wires, retrieving devices, ureteral access sheath (UAS), irrigation devices and others)**
H.U. Jung, Vejle (DK)

**Technique: Stones**
N. Davis, Dublin (IE)

**Technique: Urothelial tumours and strictures**
B. Somani, Southampton (GB)

**Tips and tricks and special circumstances**
N. Davis, Dublin (IE)

**Indications (guidelines) and clinical cases**
H.U. Jung, Vejle (DK)

**Conclusions**
B. Somani, Southampton (GB)

# Metabolic workup and non-surgical management of urinary stone disease: What a urologist must know

ESU Course 48

**Monday 16 March**
**08:30 - 11:30**

**Location** Red Area, Room 11

**Chair** O. Traxer, Paris (FR)

**Learning objectives**

Urolithiasis is an increasingly prevalent worldwide disease with recurrence rates up to 50% over 5 years. Metabolic assessment to identify predisposing factors and prevention therefore play an important role in patient management. This course will address common findings on dietary and metabolic workup and highlight medical and non-medical treatment options for these metabolic abnormalities in the prevention of stone recurrence.

The goal of the course is for participants to be able to:
• Identify patients that would benefit from metabolic workup.
• Interpret standard metabolic workup, including dietary and medical history and biochemical analyses.
• Understand what the guidelines say on targeted medical treatment for prevention of urinary stone disease.
• Understand the influence of dietary changes on metabolic urinary values and provide dietary counselling.

**Introduction**
O. Traxer, Paris (FR)

**Metabolic evaluation: What the Guidelines say? A summary**
A. Sierra Del Rio, Barcelona (ES)

**Stone composition: What the stones are telling you?**
O. Traxer, Paris (FR)

**Metabolic evaluation: Back to the basics**
O. Wiseman, Cambridge (GB)

**Diet and stones**
O. Traxer, Paris (FR)

**Medical treatment: What, when and for which patient?**
O. Wiseman, Cambridge (GB)

**How to manage a patient with hypercalciuria**
O. Traxer, Paris (FR)

**Cystinuria**
A. Sierra Del Rio, Barcelona (ES)

**Stones and metabolic syndrome**
O. Wiseman, Cambridge (GB)

**Clinical cases**
A. Sierra Del Rio, Barcelona (ES)
O. Traxer, Paris (FR)
O. Wiseman, Cambridge (GB)

## Hands-on Training in prostate MRI reading for urologists

HOT MRI - 4.1

**Monday 16 March**
**09:00 - 12:30**

**Location** Red Area, Room 6

**Learning objectives**
This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on a provided computer using realistic software, followed by a reference reading provided by expert radiologists and pathological verification.

| | |
|---|---|
| **09:00 - 09:05** | **Course overview**<br>J. Gómez Rivas, Madrid (ES) |
| **09:05 - 09:15** | **Lecture: The importance of prostate MRI to the Urologist**<br>C.V. Kesch, Essen (DE) |
| **09:15 - 09:45** | **Lecture: Introduction to MRI sequences, scoring systems, PI-RADS**<br>M. Pecoraro, Rome (IT) |
| **09:45 - 10:15** | **Lecture: Interactive case discussion – reporting MRI using PI-RADS**<br>J.A. Hernández Mancera, Barcelona (ES) |
| **10:15 - 10:20** | **Introduction to the software for MRI interpretation**<br>J. Gómez Rivas, Madrid (ES) |
| **10:20 - 10:50** | **Diagnosis I: Practical MRI diagnosis** |
| **10:50 - 11:20** | **Review of the findings I**<br>M. Pecoraro, Rome (IT) |
| **11:20 - 11:50** | **Diagnosis II: Practical MRI diagnosis** |
| **11:50 - 12:20** | **Review of the findings II**<br>J.A. Hernández Mancera, Barcelona (ES) |

| | |
|---|---|
| **12:20 - 12:30** | **Discussion, feedback, & closure**<br>C.V. Kesch, Essen (DE) |

# Hands-on Training in TP Biopsy and MRI fusion

HOT TPB - MRI - 4.1

**Monday 16 March**
**09:00 - 12:00**

**Location** Red Area, Room 2

**Chair** L. Budäus, Hamburg (DE)

**Learning objectives**

This course is designed to provide a comprehensive overview of office based transperineal (TP) biopsy techniques in local anaesthesia. It includes the integration of MRI fusion technology into daily clinical practice. Participants will begin with an introduction to the importance of TP biopsy and detailed instructions on performing the procedure by themself..

The hands-on training sessions are the core of the course, where participants will practice:

- Basics of superficial local anesthesia
- Deep periprosthetic block
- Basics of targeting and fusion
- Grid based / free hand / single incision biopsies

| | |
|---|---|
| **09:00 - 09:05** | **Introduction**<br>L. Budäus, Hamburg (DE) |
| **09:05 - 09:20** | **Why TP biopsy and how to do TP biopsy & different needles**<br>L. Budäus, Hamburg (DE) |
| **09:20 - 09:30** | **Technical comparison**<br>A. Bilé Silva, London (GB) |

**09:30 - 11:25** **Hands-on Training**

*Tutors*

M. Bergman, Stockholm (SE)
S. Bolomytis, Bristol (GB)
M. Essam El Din, Basingstoke (GB)
J.L. Hohenhorst, Hamburg (DE)
M. Jahnen, Munich (DE)
C. Kastner, Cambridge (GB)
L.A. Mambu, Ilford (GB)
H. Qazi, London (GB)
J.P. Radtke, Düsseldorf (DE)
M.E. Rodríguez Socarrás, Madrid (ES)
C. Wetterauer, Basel (CH)

Learning objectives of this presentation

- Basics of superficial local anesthesia
- Deep periprosthetic block
- Basics of targeting and fusion
- Grid based / free hand / single incision biopsies

**11:25 - 11:55** **Circulate among stations**

**11:55 - 12:00** **Closing remarks**
L. Budäus, Hamburg (DE)

## Game Changer Session

**Monday 16 March**
**10:00 - 10:15**

**Location** Orange Area, eURO Auditorium 1

**Chairs**
M. Albersen, Leuven (BE)
M.C. Mir Maresma, New York (US)

**10:00 - 10:15** **Enhanced Diagnostic Accuracy and Earlier Relapse Detection with Sequential MicroRNA-371 Testing in Stage I Testicular Germ Cell Tumors: A Prospective Multi-Institutional Cohort Study**

*Speaker* E. Kaufmann, Lucerne (CH)

*Discussant* L. Nappi, Vancouver (CA)

# Guidelines Controversies - Paeds and MIBC

Thematic Session

**Monday 16 March**
**10:45 - 12:15**

**Location** Orange Area, eURO Auditorium 2

**Chairs**
B. Burgu, Ankara (TR)
A. Van Der Heijden, Nijmegen (NL)

**Learning objectives**
The first part of the session addresses two current debates in MIBC. First, should checkpoint inhibitors replace chemotherapy as first-line treatment for metastatic bladder cancer? And can immunotherapy become standard care, even though not all patients respond? The second topic concerns possible gender bias in bladder cancer diagnosis and treatment. Do women experience more delays and misdiagnosis, resulting in worse outcomes? Or do biological differences partly explain outcome disparities between men and women?

| | |
|---|---|
| **10:45 - 11:10** | **MIBC - Checkpoint inhibitors should replace chemotherapy in the frontline treatment of metastatic bladder cancer** |
| 10:45 - 10:48 | **Case presentation**<br>A. Van Der Heijden, Nijmegen (NL) |
| 10:48 - 11:00 | **Pro & con: Durable responses, better tolerability vs. Not all patients respond; chemo still standard with broader efficacy**<br>R. Cathomas, Chur (CH) |
| 11:00 - 11:10 | **Discussion** |
| **11:10 - 11:37** | **MIBC - There is a gender bias in bladder cancer diagnosis and treatment** |
| 11:10 - 11:13 | **Case presentation**<br>A. Van Der Heijden, Nijmegen (NL) |
| 11:13 - 11:20 | **Pro: Women experience delays, misdiagnosis, worse outcomes**<br>N. Lobo, Cambridge (GB) |
| 11:20 - 11:27 | **Con: Biology, not bias, accounts for many outcome differences**<br>L.S. Mertens, Amsterdam (NL) |
| 11:27 - 11:37 | **Discussion** |
| **11:37 - 11:49** | State-of-the-art lecture **Ureterocele in duplex systems: Early incision vs minimally invasive surgery vs. observation**<br>B. Burgu, Ankara (TR) |
| **11:49 - 11:56** | **Discussion** |
| **11:56 - 12:08** | State-of-the-art lecture **UPJ - Obstruction and poor functioning kidney**<br>A. Zachou, London (GB) |
| **12:08 - 12:15** | **Discussion** |

# Risk stratification for prostate cancer diagnosis

Abstract Session 41

**Monday 16 March**
**10:45 - 12:15**

**Location** Blue Area, Victoria 4

**Chairs** To be confirmed
To be confirmed
L. Rodriguez-Sanchez, Paris (FR)

**10:45 - 11:20** **Biomarkers influencing biopsy strategy**

A0691 **To biopsy or not to biopsy? The utility of Prostate Health Index in men with PIRADS 4 lesions**
W.C. Tsang, Singapore (SG)

A0693 **Normalized periprostatic adipose tissue thickness: an imaging marker associated with prostate biopsy outcomes among patients with PI-RADS 3 and PSA 4–10 ng/mL**
T. Xiong, Beijing (CN)

A0694 **Effect of recent ejaculation on prostate-specific antigen levels in middle-aged men: implications for patient counselling prior prostate-specific antigen testing**
V.H. Meissner, Munich (DE)

A0695 **Utilization of Biomarkers to Guide Biopsy Decisions for PI-RADS 3 Prostate Lesions**
M. Knoerzer, Irvine (US)

A0696 **Associations of 2923 plasma proteins with incident prostate cancer in a prospective cohort study and genetic analysis**
L. Yichen, Chengdu (CN)

A0697 **Can PHI and mpMRI-targeted biopsy alone avoid systematic biopsy in patients suspicious for prostate cancer? An interim analysis of the prospective multicenter PROSPIN study.**
S. Meiser, Bregenz (AT)

**11:20 - 11:55** **Risk stratification**

A0699 **Effect of 5-Alpha Reductase Inhibitor Therapy on Second MRI and Re-biopsy Results after an Initial Negative mpMRI-Targeted and Systematic Biopsy for PI-RADS ≥3 Lesions**
G. Reitano, Acireale (IT)

A0700 **Is There a Need for PSA Re-testing Before Specialist Referral? Insights from from the Norwegian Prostate Cancer Consortium (NPCC)**
K. Aas, Lørenskog (NO)

A0702 **Does lesion volume play a role in the decision to perform targeted biopsy in pirads 3 lesions? A new psa derivative**
S. Cetin, Ankara (TR)

A0704 **A Comprehensive Decision-Making Framework for Prostate Biopsy in PI-RADS 3 Patients: Integrating Periprostatic Adipose Tissue Thickness and PSA Density**
T. Xiong, Beijing (CN)

A0701 **Exploring the Diagnostic Yield of Prostate MRI for Prostate Cancer Detection in Younger Men: Implications for MRI interpretation across Different Age Thresholds**
M. Brancaccio, Milan (IT)

| | |
|---|---|
| **11:55 - 12:00** | **PSMA PET in diagnosis** |
| A0705 | **Fully hybrid 18F-PSMA PET/MRI as a One-Stop Approach for the Diagnosis of Clinically-Significant Prostate Cancer: Preplanned Interim Results from a Phase II Prospective Trial**<br>S.L.A. Scuderi, Stockholm (SE) |
| **12:00 - 12:05** | **Learning curve for biopsy** |
| A0706 | **Evaluating the learning curve of transperineal MRI-guided prostate biopsies: procedure efficiency and diagnostic outcomes in a single-center cohort of more than 3,300 cases**<br>B. Hoeh, Dresden (DE) |
| **12:05 - 12:05** | **Late-breaking abstract presentation** |
| LB026 | **Radical Prostatectomy Without Prior Biopsy: A Multicentre Study in Mexico**<br>D.R. Magdaleno Rodriguez, (MX) |

## Focal therapy of prostate cancer: Patient selection, long-term outcomes and emerging techniques

Abstract Session 40

**Monday 16 March**
**10:45 - 12:15**

**Location** Blue Area, Victoria 2

**Chairs**
C. Moore, London (GB)
R. Sanchez-Salas, Montreal (CA)
C. Varol, Sydney (AU)

| | |
|---|---|
| **10:45 - 11:10** | **Patient selection** |
| A0674 | **Presence of Contralateral Clinically Significant Prostate Cancer in Radical Prostatectomy Specimens of Patients with Unilateral MRI Lesions and Its Influence on eligibility Patient Selection for Focal Therapy**<br>M. Marques Monteiro, Porto (PT) |
| A0675 | **Can we avoid contralateral biopsies when considering focal therapy? What can we miss?**<br>M. Marques Monteiro, Porto (PT) |
| A0676 | **Concordance Between MRI, Biopsy, and Radical Prostatectomy in Assessing Prostate Cancer Laterality for Focal Therapy Candidates**<br>M. Marques Monteiro, Porto (PT) |
| A0677 | **Focal Therapy for Localised Prostate Cancer: Clinical and Imaging Predictors of Failure in a 4-Year Prospective Cohort**<br>A. Tallari, Torino (IT) |
| A0673 | **Comparison of contemporary patient selection criteria for focal therapy: An analysis of 2658 patients from the prospective HEAT and ICE registries**<br>A. Light, London (GB)<br>**Study Group**<br>HEAT and ICE Users Group(London, United Kingdom) |

| | |
|---|---|
| **11:10 - 11:50** | **HIFU and cryoablation** |
| A0678 | **10-year oncological outcomes following focal HIFU and cryotherapy for treatment of non-metastatic prostate cancer: An analysis of 3471 patients from the prospective HEAT and ICE registries**<br>A. Light, London (GB)<br>**Study Group**<br>HEAT and ICE Users Group(London, United Kingdom) |
| A0683 | **5-year outcomes after index lesion ablation of multifocal prostate cancer using focal HIFU and cryotherapy: An analysis of 1050 patients**<br>A. Light, London (GB) |
| A0679 | **Prognostic value of preoperative SUV in patients who underwent focal therapy HIFU: early prospective results from a single-center cohort**<br>V. Mallia, Rozzano (IT) |
| A0680 | **Single-tap versus double-tap high-intensity focused ultrasound (HIFU) for localized prostate cancer: a propensity score–matched analysis.**<br>L. Rodriguez-Sanchez, Paris (FR) |
| A0681 | **Microultrasound for Post-HIFU Surveillance in Localized Prostate Cancer: A Prospective Experience**<br>V. Mallia, Rozzano (IT) |
| A0682 | **Hemigland vs. Whole Gland Primary Cryoablation for Localised Prostate Cancer: a Comparative Analysis Evaluating Perioperative, Oncological, and Functional Outcomes**<br>L. Misuraca, Rome (IT) |
| A0684 | **A multicenter evaluation of infield recurrence rates in patients treated with focal HIFU or cryotherapy**<br>D.T. Reddy, London (GB) |
| A0685 | **A multi-institution analysis of oncological and safety outcomes following focal therapy in the USA**<br>D.T. Reddy, London (GB) |
| **11:50 - 12:05** | **Cooled focal laser ablation (ProFocal)** |
| A0686 | **ProFocal™ cooled focal laser ablation for localised prostate cancer: 12-month outcomes from the PFLT-PC trial.**<br>H. McAuliffe, Sydney (AU) |
| A0687 | **Evaluating Safety and Efficacy of Focal Laser Ablation with ProFocal® in Localised Prostate Cancer: Histopathological and Adverse Outcomes at Three Months**<br>Y. Bushati, Sydney (AU)<br>**Study Group**<br>Nepean Urology Research Group(Kingswood, Australia) |
| A0688 | **Validation of the ePI-FAB Score to Predict Residual Disease Following Cooled Focal Laser Ablation with ProFocalTM in Prostate Cancer**<br>Y. Bushati, Sydney (AU) |
| **12:05 - 12:10** | **IRE** |
| A0689 | **Combination of PSA kinetics and MRI for the diagnosis of Persistent Prostate Cancer following Irreversible Electroporation Focal Therapy**<br>K. Zhang, Rotterdam (NL) |

| | |
|---|---|
| **12:10 - 12:15** | **Head-to-head comparison** |
| A0690 | **Hemigland Cryoablation versus HIFU for Localized Prostate Cancer: A Propensity-Weighted 2-yrs Comparison of Functional and Oncologic Outcomes from a single tertiary-care center**<br>U. Anceschi, Rome (IT) |

# Urolithiasis: Ureteroscopy

Abstract Session 39

**Monday 16 March**
**10:45 - 12:15**

**Location** Blue Area, George 4

**Chairs**
E. Beltran Suarez, Mexico City (MX)
M. Talso, Milan (IT)
S. Yuen, Hong Kong (HK)

**10:45 - 11:05** **Gaining access up the ureter**

A0655 **Predictive model for failure in primary ureteroscopy insertion during retrograde intrarenal surgery: Development and validation of a dynamic nomogram**
J Li, Chongqing (CN)

A0656 **Balancing Cost and Benefit: Pre-Stenting, Alpha-Blockers, or No Pre-Treatment Before RIRS for Intrarenal Stones**
K. Pauwaert, Gent (BE)

A0657 **Comparison of stone-free rate and surgical outcomes between pre-stented and non-pre-stented patients undergoing Retrograde Intrarenal Surgery (RIRS) for renal stones: A prospective randomized study**
A. Sharma, Mumbai (IN)

A0658 **Application of flexible and navigable suction ureteral access sheaths (FANS) in the treatment of impacted ureteral stone in the middle and lower segments**
D. Wang, Kunming (CN)

**11:05 - 11:25** **Ureteroscope design**

A0659 **Real-World Cost and Environmental Impact Analysis of Reusable versus Single-Use Flexible Ureteroscopes in High-Volume European Centre**
F. Zorzi, Trieste (IT)

A0660 **RIRS-ZS SYSTEM(DSA+DISS):: Novel RIRS system making “total endoluminal endourology” practice a reality in future**
M. Saleem, Kanhangad (IN)

A0661 **MacroLux 7.5F Single-Use Digital Ureteroscope with Enhanced Deflection in Treating 2–4 cm Lower Pole Renal Stones: A Multicenter Randomized Controlled Trial**
C. Hairui, Beijing (CN)

A0662 **Does Ureteroscope Miniaturization Affect the Efficacy of Thulium Fiber Laser Flexible Ureteroscopy in Non-Pre-Stented Patients? A Randomized Comparative Study**
F. Zorzi, Trieste (IT)

**11:25 - 11:35** **Single use ureteroscopes**

A0663 **Comprehensive Comparative Evaluation of 18 Single-Use Flexible Ureteroscopes: Preliminary In Vitro and In Vivo Results from a Multimodal Performance Study**
E.D. Demirkiran, Zonguldak (TR)

A0664 **Preliminary experience with a 6.3-Fr single-use flexible ureteroscope for pediatric upper urinary tract stones**
Q. Hu, Hangzhou (CN)

**11:35 - 11:55** **Irrigation and fluid management**

A0665 **Intrarenal pressure and flow dynamics in an ex vivo kidney perfusion model using different suction ureteral access sheaths**
A. Folcia, Milan (IT)

A0666 **Fluid Dynamics of Gravel Removal in Flexible Ureteroscopic Lithotripsy with FANS**
B. Zhang, Taiyuan (CN)

A0667 **Functional Evaluation of the TIDOR Fluid Management System for Ureteroscopy in Simulated Clinical Settings**
R. Menzies-Wilson, Oxford (GB)

A0668 **Closed-loop Temperature and Pressure Control Ureteroscopy Combined With Moses Laser for Ureteroscopic Lithotripsy: An Innovative Technology Integrating Laser Dynamics and Fluid Management**
L. Jun, Beijng (CN)

**11:55 - 12:15** **Improving stone-free rates**

A0669 **Reassessing the 90-Minute Limit: Impact of Operative Duration on Outcomes Using Flexible and Navigable Suction Access Sheaths (FANS) in Ureteroscopy**
M.Z.U. Adhoni, London (GB)

A0670 **Feasibility and cross-validation of fURS video-based fiducial-marker analysis of respiratory ureteroscope–kidney motion interaction for robotic respiratory synchronization**
J.C. Kim, Seoul (KR)

A0671 **Beyond Stone Diameter: Volumetric cutoff point and the role of stone density in predicting stone free rate in Flexible Ureteroscopy**
A. Benitez-Filselcker, SANTIAGO (CL)

A0672 **Simultaneous Bilateral Endoscopic Surgery (SBES): a Seven-Year Retrospective Analysis from a High-Volume Tertiary Center**
L. Fila, La Plata (AR)

## Urology trials in bladder and prostate cancer

Abstract Session 38

**Monday 16 March**
**10:45 - 12:15**

**Location** Blue Area, George 3

**Chairs** To be confirmed
F. Liedberg, Malmö (SE)
A. Mortezavi, Zürich (CH)

**10:45 - 11:00** **Improving outcomes by frailty-assessment: Coping-strategies and pre-habilitation**

A0637 **DaBlaCa-19: Comprehensive geriatric assessment for perioperative optimization in older, frail patients undergoing radical cystectomy (COMPETENCE-study) – A national randomized controlled trial**
K. Skovhus, Aarhus N (DK)

A0638 **Geriatric prehabilitation prior to surgery for kidney tumors: Study protocol for Pre-KiT - a randomized controlled trial**
M. Juul-Haslund, Frederiksberg C (DK)

A0639 **Improving Coping and Quality of Life Through Digital Psycho-Oncology: The COPE-WELL Study**
B. Enzinger, Munich (DE)

**11:00 - 11:40** **Prostate cancer**

A0640 **Prostate cancer and diet – a randomized controlled trial assessing the effect of a dietary intervention on quality of life of men and serum nutrient levels in their blood**
L.D.F. Venderbos, Rotterdam (NL)

A0642 **DISSECTION 2.0 Extended pelvic lymph node dissection vs. no pelvic lymph node dissection at radical prostatectomy in PSMA PET negative staged men: A multicenter, randomized phase III trial**
C.H. Engesser, Allschwil (CH)

A0643 **A study protocol to evaluate the accuracy metrics of en-face fluorescence confocal microscopy (LaserSAFE) for margin analysis during radical prostatectomy.**
A. Yousaf, London (GB)

A0644 **PRESIDENT: PRostatEctomy Surgery In Disseminated low-volume metastatic hormone sensitive prostate cancer with Endpoint assessment using Nuclear imaging Technology using PSMA (Prostate-Specific Membrane Antigen) PET/CT (Positron Emission Tomography/Computed Tomography) imaging: a definitive randomised controlled trial**
P. Sooriakumaran, London (GB)

A0645 **A Randomized, Double-Blind, Prospective, Multicenter Trial of LIPUS Therapy for Urinary Incontinence Recovery Following Robot-Assisted Radical Prostatectomy**
D. Cui, Shanghai (CN)

A0646 **Prostate Progress: A UK-based patient-centric data platform integrating patient-reported outcomes and clinical data for prostate cancer research**
F. Vegliani, (GB)

A0647 **Building and Application of a Prostate Cancer Specialty Database: A Real-World Data Platform for Clinical Research and Precision Medicine**
H. Zhu, Shanghai (CN)

A0641 **Evaluation of intra-operative contrast-enhanced ultrasound during focal therapy for localised prostate cancer: The Imperial Prostate 14-FOcal therapy using Contrast-enhanced UltraSound (IP14-FOCUS) trial**
A. Light, London (GB)

**11:40 - 12:15** **Non-muscle-invasive bladder cancer**

A0648 **VI-RADS & PDD-TURBT to avoid Second-look and Resection (Re-TURBT) in Non-Muscle Invasive Bladder Cancers: The CUT-less Randomized Clinical Trial**
V. Asero, Rome (IT)

A0649 **Trial in progress: Evaluation of urinary minimal residual disease and outcomes in high-risk non-muscle invasive bladder cancer surveilled with blue light compared to white light cystoscopy**
M. McNamara, Washington (US)

A0650 **A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with FGFR3-Altered Low-Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)**
N. Shore, Myrtle Beach (US)

A0651 **A phase III randomised controlled clinical trial of radiotherapy with radiosensitisation versus intravesical Bacillus Calmette-Geurin therapy for high-risk non-muscle invasive bladder cancer: TRAIN (Trials in Progress)**
S. Crabb, Southampton (GB)

A0652 **CORE-008 Cohort B: Evaluating Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk, BCG-Exposed Non-Muscle Invasive Bladder Cancer**
T. Bivalacqua, Philadelphia (US)

A0653 **A Phase III, Randomized, Open-Label Trial of Disitamab Vedotin (DV) Plus Bacillus Calmette–Guérin (BCG) in BCG-Naïve Patients with HER2-Expressing High-Risk Non–Muscle Invasive Bladder Cancer(HERO)**
Y.J. Shen, Shanghai (CN)

A0654 **The COBRA study: Chemoablation or bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer**
S. Klingenberg, Aarhus N (DK)

## Understanding penile cancer: From biology to prognosis

Abstract Session 43

**Monday 16 March**
**10:45 - 12:15**

**Location** Blue Area, Victoria 6

**Chairs** F.L. Heldwein, Florianopolis (BR)
To be confirmed
K. Vandermaesen, Leuven (BE)

**10:45 - 11:20** **Carcinogensis and biomarkers**

A0725 **The Heterogenous Genomic Landscape of HPV-Positive Squamous Cell Carcinoma: An Analysis of 30 Cases.**
X.X Lim, Preston (GB)

A0727 **Immune Checkpoint Status and the Tumour Immune Microenvironment in Primary and Lymph Node Metastatic Penile Cancer**
F. Azhar, Manchester (GB)

A0729 **Construction of an integrated proteomic atlas for penile squamous cell carcinoma**
F. Yin, YUNNAN (CN)

A0730 **Expression of HER2, EGFR and HDAC6 as Potential Therapeutic Targets in Penile Cancer**
J. Mink, Homburg/Saar (DE)

**11:20 - 11:55** **Diagnosis and risk of nodal disease**

A0733 **Surveillance of clinically negative groins in penile cancer using (18F) FDG PET-CT: Single-centre evaluation of its non-invasive accuracy in identifying early inguinal lymph node metastasis and guiding timely management.**
T.B. Yuvaraja, Mumbai (IN)

A0734 **Machine-learning prediction of lymph node metastasis after dynamic sentinel node biopsy in penile cancer: a gradient boosting analysis**
C. Saitta, Pieve Emanuele (IT)

A0735 **Optimizing Sentinel Node Mapping in Penile Cancer: Triple Dye versus Dual Dye Prospective Evaluation**
S. Gopal Krishna, HYDERABAD (IN)

A0736 **Incidence and outcomes of non-visualisation during dynamic sentinel lymph node biopsies for penile cancer: A contemporary high volume centre retrospective analysis**
C. Saitta, Pieve Emanuele (IT)

A0737 **Which penile cancer patients with positive sentinel node metastases can be spared of lymphadenectomy without compromising oncological safety? - Development of a prediction model**
J. Mølsted, Aarhus N (DK)

A0738 **18F-FAPI-42 PET/CT Outperforms 18F-FDG PET/CT in Detecting Inguinal Nodal Metastasis in Penile Squamous Cell Carcinoma: A Prospective Head-to-Head Comparison Study**
L. Wang, Changsha (CN)

**11:55 - 12:15** **Prognosis, follow-up and QOL**

A0739 **Survival trends in HPV-independent and HPV-associated PSCC at a large single site centre: A retrospective analysis of 800 patients.**
N.T. Tuffa, Salford (GB)

A0740 **Inguinal extranodal extension and pelvic lymph node metastases are prognostically equivalent in N3 penile cancer patients staged with PET/CT**
R.W.A. Verdijk, Amsterdam (NL)

A0741 **Mapping penile cancer recurrence patterns: Data-Driven surveillance strategies**
A. Kadam, Nanded (IN)

A0742 **Audit of ePROMs uptake and patient-reported outcomes following penectomy and nodal surgery**
M. Chowdhury, Manchester (GB)

## Urotechnology, complications, AI and prostate cancer outcomes

Abstract Session 42

**Monday 16 March**
**10:45 - 12:15**

**Location** Blue Area, Victoria 5

**Chairs**
A. Galfano, Milano (IT)
R. Sosnowski, Olsztyn (PL)
I. Tsaur, Tuebingen (DE)

**10:50 - 11:05** **Complications**

A0716 **Adverse events and device malfunctions in da Vinci robotic surgery: Analysis of MAUDE data from the recent ten years**
T.Y. Hsieh, Taipei (TW)

A0721 **Reduced Incidence of Incisional Hernia with Left Paramedian Access During RARP: A UK-Based Analysis**
A.W. Orrason, London (GB)

A0723 **De novo lower urinary tract symptoms after Robot Assisted Radical Prostatectomy: Evaluation Of incidence and risk factors**
A.L. Pastore, Rome (IT)

**11:05 - 11:30** **AI in prostate cancer diagnosis, treatment, outcome prediction**

A0708 **Development of an AI organ recognition system to support pelvic lymph node dissection in the field of pelvic surgery**
Y. Nakanishi, Chiba (JP)

A0714 **Enhancing prostate cancer molecular analysis through near real-time MRI targeted prostate biopsy risk stratification with stimulated Raman histology paired with artificial intelligence**
M. Mannas, Vancouver (CA)

A0712 **Navigating the gray zone: Machine learning can differentiate malignancy in PI-RADS 3 lesions**
E. Altintas, Konya (TR)

A0710 **The Role of an AI-based Model to Predict Long-Term Oncological Outcomes in Prostate Cancer Treated with Radical Prostatectomy**
A. Occhi, (IT)

A0711 **Artificial intelligence-derived transition zone PSA density as a triage tool to reduce unnecessary prostate systematic biopsies in MRI-negative men**
J. Shang, Beijing (CN)

**11:30 - 11:40** **Training and education**

A0713 **Predicting trainee responses to live intraoperative feedback during vesicourethral anastomosis in robot-assisted radical prostatectomy**
L. Cella, Milan (IT)

A0709 **Kinematic Biomarkers Predict Surgical Expertise and Clinical Outcomes in Robot-Assisted Surgery: A Universal Framework**
H. Ueki, Kobe (JP)

**11:40 - 12:15** **Treatment of complications of prostate cancer interventions**

A0720 **Surgical indication at 6 months for post-prostatectomy urinary incontinence risks overtreatment and inappropriate sling vs AUS selection**
R. Domínguez, Santiago (CL)

A0715 **Utilization and Reasons for Discontinuation of Erectile Aids Following Radical Prostatectomy: Insights from a Five-Year Follow-Up Register-Study**
L.J. Schmalbrock, Munich (DE)

A0718 **Minimal invasive lymphatic embolization – a game changer in therapy refractory pelvic lymphoceles after prostatectomy?**
P. Krausewitz, Bonn (DE)

A0719 **Evaluation study on the effectiveness of Uroletics® in patients after radical prostatectomy (EUPROS)**
C. Thomas, Dresden (DE)

A0717 **Low-intensity Extracorporeal Shockwave Therapy on penile rehabilitation after nerve sparing Robot-Assisted Radical Prostatectomy: preliminary results from a Randomized Controlled Trial**
R. Mastroianni, Rome (IT)

A0724 **Hyperbaric oxygen therapy in patients with radiation-induced hemorrhagic cystitis**
A. Strikic, Split (HR)

| | |
|---|---|
| **12:15 - 12:15** | **Pain relief during biopsy** |
| A0707 | **Application of transcutaneous electrical nerve stimulation (TENS) for pain relief in patients undergoing transperineal MRI–ultrasound fusion-guided prostate biopsy under local anesthesia: A monocentric, prospective, randomized, placebo-controlled trial**<br>B. Marczak, Gdynia (PL) |

## Cutting-edge strategies in bladder cancer: Trials, techniques, and predictive tools

Abstract Session 37

**Monday 16 March**
**10:45 - 12:15**

**Location** Orange Area, Room 3

**Chairs**
K.K. Bree, Houston (US)
R. Meijer, Utrecht (NL)
N. Vasdev, Stevenage (GB)

| | |
|---|---|
| **10:45 - 11:10** | **Clinical staging of muscle-invasive bladder cancer** |
| A0619 | **Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Final survival analysis from the BladderPath trial**<br>J.W.F. Catto, Sheffield (GB) |
| A0620 | **Redefining the muscle invasive bladder cancer pathway: a multicentre study examining the real world potential impact of implementing BladderPath**<br>T. Malik, Bristol (GB) |
| A0622 | **VI-RADS Score Performance in the Post-TURBT Setting: Exploring the Need for Modification**<br>A. Dehghanpour, Rome (IT) |
| A0623 | **Comparison of Diagnostic Efficacy Between Post-Treatment VI-RADS Based on Biparametric MRI and Multiparametric MRI in Assessing Residual Tumor and Muscle Invasion After Treatment for Bladder Cancer**<br>Q. Lyu, Nanjing (CN) |
| **11:10 - 11:40** | **Pre-operative strategies in radical surgery for muscle-invasive bladder cancer** |
| A0629 | **10-year Urothelial Fellowship in Robotic-assisted Radical Cystectomy and Intracorporeal Ileal Conduit (RARC/ICIC) Urinary Diversion: Trends in Surgical Practice, Perioperative Outcomes, and Predictors of ERUS Clinical Modular Competency**<br>F. Del Giudice, Rome (IT) |
| A0624 | **Preoperative Circulating Tumor DNA as a Predictor of Recurrence Following Radical Cystectomy for Bladder Cancer: Revisiting the Role of Clinical Stage in the Molecular Era**<br>A. Zhu, New York (US) |
| A0626 | **Naloxegol does not improve gastrointestinal recovery after radical cystectomy within contemporary ERAS protocols: a multicenter prospective cohort study**<br>J. Ringia, Amsterdam (NL) |

A0627 **Structured prehabilitation reduces ICU admission and transfusion rates after radical cystectomy – interim analysis of the PRACTICE randomized trial (NCT06806059)**
Y. Volz, München (DE)

A0628 **Impact of Prior Pelvic irradiation on Peri-operative Safety, Early and Late Complications of Robotic-assisted Cystectomy with Intra-corporeal Diversion: A Matched Paired comparison.**
Y. Ibrahim, London (GB)

**11:40 - 12:15** **Strategies to improve patient outcomes after radical cystectomy**

A0630 **Risk of lymph-node invasion after radical cystectomy according to histological subtypes: results from a large multi-institutional cohort**
A. Santangelo, Milan (IT)

A0631 **Extended versus Standard Lymphadenectomy in Muscle-Invasive Bladder Cancer: Real-World data confirming trial-Based evidence and the Prognostic Role of Pathological Staging**
M. De Angelis, Milan (IT)

A0632 **Perioperative Outcomes and Survival of Plasmacytoid Variant Urothelial Carcinoma after Radical Cystectomy: A Multicenter Real-World Cohort**
S.H. Kim, Cheonan (KR)

A0633 **The impact of manual vs stapler sewn ileoileal anastomosis on the incidence and the management of the postoperative complications in patients underwent radical cystectomy with ileal conduit: a randomized prospective single center trial (PUMA trial)**
G. Avesani, Milan (IT)

A0634 **Urodynamic and Functional Outcomes After Δ-Shaped Versus Y-Shaped Robotic Intracorporeal Orthotopic Neobladder Reconstruction**
S.T. De Cillis, Turin (IT)

A0635 **Functional updates after 4 years of the Stentless Florence Robotic Intracorporeal Neobladder (FloRIN) randomized clinical trial**
L. Lambertini, Florence (IT)

A0636 **Contemporary Practice Patterns in Female Radical Cystectomy: Results of a UK and Ireland Survey**
E. Day, Ayr (GB)

## Robotic RPLND and inguinal LND redefined

Video Session 16

**Monday 16 March**
**10:45 - 12:15**

**Location** Blue Area, Victoria 1

**Chairs**
M. Bandini, Milan (IT)
J. Chorbińska, Wroclaw (PL)
P. Pongratanakul, Düsseldorf (DE)

V110 (▢: 8 min.) **Transitioning from Open to Robotics in Challenging RPLND: Top Ten Tips**
Y. Ibrahim, London (GB)

V111 (▢: 8 min.)

**AUGMENTED REALITY-GUIDED ROBOT ASSISTED RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR POST-CHEMOTHERAPY NSGCT: A HIGH-VOLUME CENTRE CASE DEMONSTRATION**

G. Spena, Naples (IT)

V112 (▢: 9 min.)

**RAISN – Robotic-assisted ICG-guided sentinel lymph node biopsy in patients with stage I testicular cancer**

M. Vermeulen-Spohn, Düsseldorf (DE)

V113 (▢: 7 min.)

**Post chemotherapy retroperitoneal lymph node dissection for testicular cancer with Single Port robotic approach**

E. Lievore, Milan (IT)

V114 (▢: 8 min.)

**Robotic Excellence: Supine Extra peritoneal RPLND for testicular cancer (RASE-RPLND Technique ):Step by Step**

G.K. Pooleri, Kochi (IN)

V115 (▢: 8 min.)

**Robot-Assisted Salvage Retroperitoneal Lymphadenectomy for Testicular Cancer: Experience from a Tertiary Referral Center**

F. Proietti, Rome (IT)

V116 (▢: 7 min.)

**SINGLE PORT ROBOT-ASSISTED INGUINAL LYMPHADENECTOMY: A STEP-BY-STEP SURGICAL TECHNIQUE**

E. Lievore, Milan (IT)

## Beyond daily routine: Managing large, hilar and anatomically variant renal tumors robotically

Video Session 15

**Monday 16 March**
**10:45 - 12:15**

**Location** Blue Area, George 1

**Chairs**

I. Andras, Cluj (RO)

C.A. Bravi, Northampton (GB)

R. De Groote, Aalst (BE)

V104 (▢: 7 min.)

**Head-to-head comparison of robot-assisted partial nephrectomy for upper versus lower pole renal masses using the Hugo™ RAS System: surgical set-up and initial experience**

F. Tedesco, Rome (IT)

V105 (▢: 7 min.)

**Hugo™ RAS System robot-assisted partial nephrectomy for moderate to highly complex renal masses: oncological and functional outcomes at short-term follow-up**

F. Tedesco, Rome (IT)

V106 (▢: 6 min.)

**Robotic Surgical Approach for Very Large Upper Tract Masses ≥10 cm (Renal and Adrenal): Tips and Outcome Adrenal): Tips and Outcome**

A. Almuhrij, Dammam (SA)

V108 (▢: 8 min.) **Pre and intraoperative planning with 3D virtual models for challenging oncological cases in horseshoe kidneys**
F.J. Burgos Revilla, Madrid (ES)

V109 (▢: 8 min.) **Approaching Horseshoe Kidney for Off-Clamp Partial Nephrectomy: surgical insights from a tertiary referral centre**
M. Ferriero, Rome (IT)

## EAU26 Abstract prizes: An expert discussion

Special Session

**Monday 16 March**
**10:45 - 11:45**

**Location** Orange Area, eURO Auditorium 1

**Chairs**
M. Albersen, Leuven (BE)
A. Stenzl, Stuttgart (DE)
F. Van Der Aa, Leuven (BE)

**10:45 - 10:50** **Introduction**

**10:50 - 11:07** **Best oncology abstracts**

10:50 - 10:57 **First prize - A0413: Stockholm3 test performance for reducing MRI in Organised Prostate Cancer Testing (OPT)**
U.G. Falagario, Bari (IT)

10:57 - 11:07 **Discussion**

*Discussant* R. Van Den Bergh, Rotterdam (NL)

11:07 - 11:07 **Second prize - A0127: Gut microbiome shapes the tumour immune microenvironment and predicts benefit to RC-48 plus tislelizumab in urothelialbladder cancer: A multicentre cohort with translational validation**
B. Cheng, Guangzhou (CN)

**11:07 - 11:24** **Best non-oncology abstract**

11:07 - 11:14 **First prize- A0798: VeSpAR trial: a randomized controlled trial comparing vessel-sparing anastomotic repair and transecting anastomotic repair in isolated, short, bulbar urethral strictures**
W. Verla, Ghent (BE)

11:14 - 11:24 **Discussion**

*Discussant* D.E. Andrich, London (GB)

**11:24 - 11:41** **Best video abstract**

11:24 - 11:31 **V001 - Augmented Reality PSMA-3D guided robotic pelvic lymph node dissection (PLND) in prostate cancer patients**
L. Bianchi, Bologna (IT)

11:31 - 11:41 **Discusson**

*Discussant* R. Eapen, Melbourne (AU)

| | |
|---|---|
| **11:41 - 11:45** | **Closing remarks** |

# From radical interventions to postoperative quality of life in prostate cancer

EGPT 48

**Monday 16 March**
**10:45 - 12:15**

**Location** Orange Area, EGPT 1

**Chairs** To be confirmed
A. Lantz, Danderyd (SE)
P.B. Østergren, Copenhagen (DK)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

| | |
|---|---|
| **10:55 - 11:40** | **Functional outcomes after treatment** |
| P0831 | **Sexual activity and practices five years after radical prostatectomy**<br>V.A. Goeldner, Munich (DE) |
| P0837 | **Impact of Prostate Weight on Return to Potency in Prepotent Men Following RARP**<br>H. Yeagyeong, Orange (US) |
| P0834 | **Safety, Efficiency and Environmental Impact of Virtual At-Home Catheter Removal Following Robotic-Assisted Radical Prostatectomy**<br>S. Tolbert, Rochester (US) |
| P0830 | **A Qualitative Study on the Avoidance Behavior of Seeking Help for Sexual Health after Radical Prostatectomy from the Perspectives of Patients and Physicians**<br>M. Peng, Guangzhou (CN) |
| P0826 | **Effect of different treatment options on the urinary function of prostate cancer patients in the TrueNTH Global (UK dataset): a multicentre cohort analysis study**<br>B. Adebusoye, London (GB) |
| P0843 | **Ten-Year Patient-Reported Outcomes After Low-Dose-Rate Brachytherapy for Prostate Cancer: Quality of Life and Treatment Satisfaction**<br>Y. Nakai, Kashihara-Shi (JP) |
| **11:40 - 12:15** | **Oncological outcomes after localised treatment** |
| P0840 | **Cribriform pattern correlates with adverse pathological features and predicts biochemical recurrence after radical prostatectomy**<br>M. Plata, Bogota (CO) |
| P0838 | **A comprehensive analysis of the role and potential targets of plasticizer exposure in prostate cancer progression: evidence from Chinese and American populations and preclinical studies.**<br>X. Zhou, Chengdu (CN) |
| P0841 | **From Prediction to Clinical Value: Decision-Analytic Validation of the Focal Risk Group (FRG) Score in Men Undergoing Focal Therapy for Localized Prostate Cancer**<br>U. Anceschi, Rome (IT) |

P0835 **Racial impact (Asians vs. Caucasians/Whites) on biochemical recurrence-free survival after robot-assisted radical prostatectomy: A propensity score matching study from 2012 to 2018**
T. Sasaki, Tsu (JP)

P0839 **Clinical characteristics of secondary bladder cancer following low-dose-rate brachytherapy for localized prostate cancer**
T. Kawada, Okayama (JP)

P0833 **Perineural Invasion Density: A Novel Quantitative Prognostic Marker in Prostate Cancer**
B. Liu, Guangzhou (CN)

P0832 **The prognostic value of PTEN expression in localized prostate cancer**
A. Bellouti, Luxembourg (LU)

P0828 **BCR definitioto compare prostate cancer mortality between Radiotherapy and Radical prostatectomy**
U.G. Falagario, Bari (IT)

P0836 **Impact of Preoperative TT–cFT Discordance on Oncological Outcomes in Men with Prostate Cancer Post-RARP Under 65 Years of Age**
H. Yeagyeong, Orange (US)

P0842 **Post-diagnosis smoking and risk of all-cause and prostate cancer-specific mortality: Evidence from the UK Biobank**
X. Yang, Shen Zhen (CN)

**12:15 - 12:15** **Locally advanced prostate cancer**

P0829 **The Evolving Management of pN1 Prostate Cancer: Temporal Trends in Adjuvant Radiotherapy versus Observation ± Salvage RT Over 20 Years at a Tertiary Referral Centre**
P. Zaurito, Milan (IT)

P0827 **Impact of Negative Primary Staging with PSMA-PET versus Conventional Imaging Among Patients With Lymph Node Invasion After Radical Prostatectomy**
F.M. Barletta, Milan (IT)

## Prostate cancer: Imaging, biopsy and targeted treatments

EGPT 49

**Monday 16 March**
**10:45 - 12:15**

**Location** Orange Area, EGPT 2

**Chairs** D. Eberli, Zürich (CH)
To be confirmed
F. Zattoni, Padova (IT)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**11:05 - 11:25** **Biopsy strategy**

P0859 **TRANSRECTAL SOFTWARE-GUIDED FUSION PROSTATE BIOPSY: DOES SYSTEMATIC BIOPSY ADD VALUE? A RETROSPECTIVE ANALYSIS.**
A. Marchant, Santiago (CL)

| | |
|---|---|
| P0844 | **Real-world impact of omitting standard biopsies in MRI-targeted prostate biopsy**<br>G. Malavasi, Roma (IT) |
| P0860 | **Perineal Prostate Biopsies in Lateral Decubitus Position Under Sedation: A Novel Approach Improving Safety, Efficiency, and Patient Comfort**<br>S. Beukens, Drachten (NL) |
| P0861 | **Perilesional biopsy in – systematic out? Comparative analysis of targeted, perilesional and systematic approaches with robotic-assisted transperineal MRI/US fusion prostate biopsy**<br>V. Alargkof, Basel (CH) |
| **11:25 - 11:35** | **MRI and PSMA PET** |
| P0852 | **Can mpMRI and PSMA PET Predict Contralateral Clinically Significant Prostate Cancer at Biopsy and Radical Prostatectomy? Implications for Focal Therapy Candidate Selection**<br>M.E. Porzi, Milan (IT) |
| **11:35 - 11:45** | **Targeted staging and targeted treatments** |
| P0857 | **Target pelvic lymph node dissection in robot-assisted radical prostatectomy using combined techniques of MRI-US fusion and ICG injection**<br>Y. Yamada, Tokyo (JP) |
| P0856 | **Oncological outcomes 1 year after targeted 3D cartography-based microwave ablation of localized prostate cancer: results of the VIOLETTE trial**<br>N. Barry De Longchamps, Paris (FR) |
| **11:45 - 11:55** | **Functional outcomes post treatment** |
| P0855 | **Effect of different treatment options on the bowel function of prostate cancer patients in the TrueNTH Global Registry (UK dataset): a multicentre cohort analysis study**<br>D. Maffei, London (GB) |
| P0858 | **First Clinical Application of the IMPACT Score: A Novel, Practical Grading System for Erectile Function Recovery Following Robotic Prostatectomy**<br>O. Amusat, Canterbury (GB) |
| **11:55 - 12:05** | **Factors influencing biopsy yield** |
| P0854 | **Prostate MRI Quality Strongly Influences the Diagnostic Yield of Systematic and Targeted Biopsies: Insights from a Prospective Study**<br>M.E. Porzi, Milan (IT) |
| P0849 | **The impact of Race and physician's specialty on performing work-up in patients first tested with a PSA > 4 ng/ml**<br>A. Santangelo, Milan (IT) |
| **12:05 - 12:10** | **Microultrasound** |
| P0850 | **Assessing the diagnostic performance of micro-ultrasound guided biopsy in clinically significant prostate cancer**<br>M. Plata, Bogota (CO) |
| **12:10 - 12:15** | **Robotic biopsy platforms** |

P0846 **Accuracy Testing of the REGOLUS Robotic Platform for MRI/TRUS Fusion-Guided Prostate Biopsy: A Phantom Study**
J. Franz, Freiburg (DE)

**12:15 - 12:15** **Improving diagnostic strategies**

P0848 **Magnetic Resonance Imaging at Initial Suspicion of Prostate Cancer: Experience and Mid-Term Outcomes.**
M.D.L.P. Estella Lucena, Madrid (ES)

P0851 **Unveiling the Paradox: lower urinary PSA levels as a stronger indicator of Prostate Cancer risk compared to blood PSA elevation**
S.T. De Cillis, Turin (IT)

## Bladder cancer surgery evolving: From neoadjuvant strategies to long-term survival analysis

EGPT 50

**Monday 16 March**
**10:45 - 12:15**

**Location** Orange Area, EGPT 3

**Chairs** R. Contieri, Naples (IT)
K. Mouw, Boston (US)
T. Szarvas, Budapest (HU)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**10:45 - 11:10** **Technical developments in radical cystectomy**

P0862 **Temporal trends in urinary diversion selection after radical cystectomy: A 25-year single-center analysis**
L. Nocera, Milan (IT)

P0864 **Five-year oncologic outcomes of Open vs Robot-Assisted Radical Cystectomy with totally intracorporeal Urinary Diversion: results from a single centre Randomized Controlled Trial**
R. Mastroianni, Rome (IT)

P0865 **Single Port Robotic Radical Cystectomy: A Multi-Institutional Experience of the Single Port Advanced Research Consortium (SPARC)**
R. Contieri, Naples (IT)

P0866 **Early experience with the Toumai® robotic system in radical cystectomy: results of the first 10 cases at a high-volume European centre**
A. Guidotti, Rome (IT)

**11:10 - 11:45** **Patient outcomes after radical surgery for muscle-invasive bladder cancer**

P0867 **Radical cystectomy and orthotopic neobladder in patients with pre-operative chronic kidney disease: peri-operative and functional outcomes**
G. Tuderti, Roma (IT)

P0869 **Marked Variation in Cystectomy Outcomes Across Swiss Hospitals: A Machine Learning-Based National Morbidity Assessment Using Administrative Data**
M. Hecker, Biel (CH)

P0870 **Closing the Gender Gap: Standardized Multidisciplinary Care Achieves Equal Survival After Radical Cystectomy**
F. Ceria, Milan (IT)

P0871 **Role of inflammatory markers and frailty index as predictors of adverse pathological stage and complications in patients undergoing radical cystectomy for bladder cancer: a multicenter analysis**
C. De Nunzio, Rome (IT)

P0872 **Time to treatment Initiation and Survival in patients with Muscle-Invasive Bladder Cancer: a National Cancer Database (NCDB) analysis**
A. Piccolini, Vigevano (IT)

**11:45 - 12:10** **Neoadjuvant strategies in muscle-invasive bladder cancer**

P0875 **Cost-Effectiveness Analysis of New Perioperative Treatment Regimens for Muscle-Invasive Bladder Cancer**
C. Rieger, Cologne (DE)

P0876 **Evaluating the Surrogacy of Intermediate Clinical Endpoints for Overall Survival after Perioperative Treatment in Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy**
P. Scilipoti, Milan (IT)

P0878 **Impact of Neoadjuvant Therapy on Oncologic Outcomes in Patients With Undetectable Pre-Cystectomy Circulating Tumor DNA**
A. Zhu, New York (US)

P0879 **Utility of nacVI-RADS for predicting pathological complete response after chemoradiotherapy in muscle-invasive bladder cancer**
M. Kobayashi, Tokyo (JP)

## Urolithiasis: Percutaneous nephrolithotomy

EGPT 51

**Monday 16 March**
**10:45 - 12:15**

**Location** Blue Area, EGPT 4

**Chairs** M.S. Agrawal, Agra (IN)
M.C. Rassweiler-Seyfried, Mannheim (DE)
To be confirmed

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**10:45 - 10:55** **PCNL - Trends and learning curve**

P0880 **Resident Learning Curve in Percutaneous Nephrolithotomy (PCNL): A Prospective Evaluation Using Objective Structured Assessment of Technical Skills (OSATS)**
A. Patil, Mumbai (IN)

P0881 **Perioperative Complications of Percutaneous Nephrolithotomy and Combined Percutaneous Nephrolithotomy with Uni- and Bilateral Ureterorenoscopic Stone Therapy: Results of the GRAND Study**
N. Pyrgidis, München (DE)

**10:55 - 11:15** **PCNL Access**

P0882 **Integrating Virtual-Reality Imaging into Pre-operative PCNL Planning: Early Clinical Outcomes in Patients with Abnormal Renal Anatomy**
S. Kothapalli, CHENNAI (IN)

P0883 **Ultrasound guided percutaneous nephrolithotomy : is it better than flouroscopic guided percutaneous nephrolithotomy?**
R.A. Mughal, islamabad (PK)

P0884 **A Novel CT–Ultrasound Fusion Navigation System Enhances Precision and Safety of Percutaneous Nephrolithotomy: Results from a Multicenter Randomized Trial**
F. Cheng, Wuhan (CN)

P0885 **Occupational Exposure Reduction in Endoscopic Combined Intrarenal Surgery in fresh frozen cadaver study**
K. Shiozaki, tokushima (JP)

**Study Group**
Tokushima University Graduate School of Biomedical Sciences(Tokushima, Japan)

**11:15 - 11:45** **Mini PCNL**

P0889 **Clinical comparison of vacuum-assisted mini PCNL versus standard PCNL with multiple access tracts for large kidney stones: a real-life study**
S.P. Zanetti, Milan (IT)

P0890 **MINI-PCNL AS A DAY CASE; A CLINICAL AUDIT IN A SINGLE NHS TRUST**
M.K. Faheem, Basildon (GB)

P0891 **Comparison of Suction Sheath-Assisted Mini Percutaneous Nephrolithotomy and Conventional Ultra-Mini PCNL: Shortened Operative Time With Comparable 3-Month Outcomes**
H.K. Chae, Seoul (KR)

**11:45 - 12:15** **PCNL - Outcomes**

P0892 **Value of Nephrolithiasis Treatment in AGEd patients: the “ViNTAGE study” on the safety and efficacy of mPCNL in the geriatric population**
F. Passarelli, Milano (IT)

P0893 **Predicting complications and hospitalization after percutaneous nefrolithotomy using machine learning models**
J. Espinosa Vano, Valencia (ES)

P0894 **Staff workload comparison in percutaneous nephrolithotomy with versus without intraoperative cone-beam CT: 18-month randomized trial follow-up**
C.A. Suijker, Groningen (NL)

P0895 **Predictors of Stone-Free Rate After Supine Percutaneous Nephrolithotomy (S-PCNL) With or Without Endoscopic Combined Intrarenal Surgery (ECIRS): A Nomogram to Guide Preoperative Counseling and Surgical Planning**
K. Pauwaert, Gent (BE)

P0896 **Sepsis after percutaneous nephrolithotomy - the significance of kidney stone endotoxin**
D. Tzou, San Francisco (US)

P0897 **Comparative Impact of Retrograde Intrarenal Surgery and Mini-Percutaneous Nephrolithotomy on Postoperative Renal Function**
L. Candela, Paris (FR)

# Renal cancer - Basic and translational research

EGPT 52

**Monday 16 March**
**10:45 - 12:15**

**Location** Blue Area, EGPT 5

**Chairs**
I.L. Heimann, Aarhus (DK)
K. Junker, Homburg (DE)
T. Mitchell, Cambridge (GB)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

P0990 **CT Radiomics and AI for Differentiating Oncocytoma from Renal Cell Carcinoma**
V. Gomez Dos Santos, Madrid (ES)

P0995 **Targeting tRNA-Derived Fragment tRF-21 Enhances Immunotherapy Efficacy by Reducing PMN-MDSCs Accumulation in Renal Cell Carcinoma**
X. Qin, Jinan (CN)

P0996 **Combinatorial Immunotherapy with IL-12/shVEGF-Expressing Oncolytic Adenovirus for Renal Cell Carcinoma: Organ-on-a-Chip and In Vivo Evaluation**
J. Shim, Daejeon (KR)

P1000 **Hyperspectral Imaging Reveals Superior Preservation of Renal Microcirculatory Oxygenation With Crystalloid-Based Resuscitation During Hemorrhagic Shock in a Porcine Model**
P. Grützner, Worms (DE)

P1007 **Nuclear translocation of TFEB enhances autophagy and PD-L1 expression promoting invasion, metastasis, and immune escape of FH-deficient renal cell carcinoma**
W. Tao, beijing (CN)

P1008 **TRANSLATING TUMOR BIOLOGY INTO CLINICAL PRACTICE USING PATIENT-DERIVED ORGANOIDS IN RENAL CELL CARCINOMA**
A. Shahini, Montreal (CA)

P1012 **Tumor-infiltrating intracellular microbiota promote metastatic colonization in clear cell renal cell carcinoma**
B. You, Harbin (CN)

P1014 **The role of piR-1742 in malignant progression and clinical translation of renal cell carcinoma**
W. Zhang, Shanghai (CN)

P1016 **A TLS-Based Molecular Signature Predicts Prognosis and Immune Escape in Clear Cell Renal Cell Carcinoma**
W. Liu, Beijing (CN)

P1019 **Spatially Resolved Myeloid Cell Driven Tissue Reorganization Shapes Immunotherapy Outcomes in Advanced Renal Cell Carcinoma**
To be confirmed

## Non-Technical Skills for Surgical Excellence: Immersive Simulation

HOT NTS - 4.1 VR Sim

**Monday 16 March**
**11:00 - 12:00**

**Location** EAU Square

**Tutors**
C.S. Biyani, Leeds (GB)
M. Pears, Barnsley (GB)
K. Wadhwa, Wickham Bishops (GB)

**Learning objectives**
Participants will be assigned to one of two simulation-based activities: a simulated operating room session or a computer-based virtual patient interaction. Both formats are designed to enhance non-technical skills, including communication, teamwork, and clinical decision-making.

## Prostate cancer survivorship and sexuality: A session in collaboration with the ISSM/ESSM & Movember

Thematic Session

**Monday 16 March**
**12:30 - 14:00**

**Location** Orange Area, eURO Auditorium 2

**Chairs**
C. Bettocchi, Foggia (IT)
E. Rogers, Roscommon (IE)
R. Wang, Houston (US)

**Learning objectives**
To introduce what ISSM Movember partnership is and has done to promote Sexual Health related to prostate cancer treatment. To provide brief about guidelines recently published about managing sexual dysfunction after prostate cancer treatment.

**12:30 - 12:35** **Introduction to the ISSM Movember partnership**
R. Wang, Houston (US)

**12:35 - 12:44** State-of-the-art lecture **Sexual problems in prostate cancer: Looking beyond ED**
M.M. Fode, Herlev (DK)

**12:44 - 12:53** State-of-the-art lecture **Psychological issues and pearls of treatment for the clinician**
A. Matthew, Toronto (CA)

**12:53 - 13:25** Case-based discussion **Shared decision making**

12:53 - 12:58 **Case presentation** **Intermediate risk prostate cancer in sexually active patient**
E. Briers, Hasselt (BE)

12:58 - 13:03 **Pro: Active surveillance**
S. Knipper, Berlin (DE)

13:03 - 13:08 **Pro: Radical prostatectomy & intraoperative margin assessment**
N.N. Harke, Hannover (DE)

13:08 - 13:13 **Pro: RT + ADT: The quiet power of combination therapy**
N. Sundahl, Kortrijk (BE)

13:13 - 13:25 **Panel discussion** **Patient challenges panel with discussions**

*Moderator* J.P. Mulhall, New York (US)

*Panel* E. Briers, Hasselt (BE)
N.N. Harke, Hannover (DE)
S. Knipper, Berlin (DE)
N. Sundahl, Kortrijk (BE)

---

**13:25 - 14:00** **Panel discussion** **What is new in sexual rehabilitation**

13:25 - 13:30 **Preparing patients for their road ahead**
P. Capogrosso, Varese (IT)

13:30 - 13:35 **Partner issues and lifestyle**
S. Loeb, New York (US)

13:35 - 13:40 **Dyadic aspects and couple issues**
D. Wittmann, Ann Arbor (US)

13:40 - 13:45 **Sexual orientation and gender identity**
T.L. Yap, London (GB)

13:45 - 13:50 **Novelties in sexual rehabilitation**
J.P. Mulhall, New York (US)

13:50 - 14:00 **Panel discussion** **What entails modern sexual rehabilitation for prostate cancer patients**

*Panel* P. Capogrosso, Varese (IT)
S. Loeb, New York (US)
J.P. Mulhall, New York (US)
D. Wittmann, Ann Arbor (US)
T.L. Yap, London (GB)

# Incontinence uncovered: Managing urgency without stress

Thematic Session

**Monday 16 March**
**12:30 - 14:00**

**Location** Orange Area, eURO Auditorium 1

**Chairs** E. Finazzi Agrò, Rome (IT)
B. Peyronnet, Rennes (FR)

**Learning objectives**
In this session, it will be possible to discuss the latest prevention strategies, diagnostic pathways and treatments of overactive bladder (in both male and female patients) and stress urinary incontinence in female patients. Well known experts will bring their experience to the audience to provide the most updated evidence on the management of these common conditions.

| | |
|---|---|
| **12:30 - 12:32** | **Welcome and introduction** |
| **12:32 - 12:42** | State-of-the-art lecture **Update on the Urge to Act campaign**<br>M.R. Van Balken, Arnhem (NL) |
| **12:42 - 13:18** | Round-table discussion **What is the best first-line treatment for OAB?** |
| 12:42 - 12:47 | **App-based self management**<br>L. Wiemer, Berlin (DE) |
| 12:47 - 12:52 | **Physiotherapy**<br>P. Igualada-Martinez, London (GB) |
| 12:52 - 12:57 | **Transcutaneous tibial nerve stimulation**<br>C. Hentzen, Paris (FR) |
| 12:57 - 13:02 | **Antimuscarinics**<br>M.C. Lapitan, Manila (PH) |
| 13:02 - 13:07 | **Beta 3 agonists**<br>S.Y. Cho, Seoul (KR) |
| 13:07 - 13:12 | **We need to move to a tailored "non-step" approach**<br>G. Bou Kheir, Gent (BE) |
| 13:12 - 13:18 | **Panel discussion** |
| **13:18 - 13:34** | Debate **Beyond the future (trial): Current role of urodynamics in OAB** |
| 13:18 - 13:24 | **Very limited**<br>M.S. Abdel-Fattah, Aberdeen (GB) |
| 13:24 - 13:30 | **Still paramount**<br>T. Tarcan, Istanbul (TR) |
| 13:30 - 13:34 | **Discussion** |
| **13:34 - 13:44** | State-of-the-art lecture **The importance of shared decision making nowadays**<br>M. Belal, Birmingham (GB) |
| **13:44 - 14:00** | Debate **Should we still implant synthetic midurethral slings for female SUI?** |

13:44 - 13:50 **Yes, of course**
E. Costantini, Perugia (IT)

13:50 - 13:56 **No, that's too risky**
T.J. Greenwell, London (GB)

13:56 - 14:00 **Discussion**

## Innovations in muscle invasive bladder cancer management: From neoadjuvant therapies to preservation strategies

Abstract Session 51

**Monday 16 March**
**12:30 - 14:00**

**Location** Blue Area, Victoria 6

**Chairs**
Y. Abu Ghanem, London (GB)
R. De Carvalho Fernandes, Perdizes (BR)
J.L. Domínguez Escrig, Valencia (ES)

**12:30 - 12:50** **Bladder preservation strategies for non-metastatic muscle-invasive bladder cancer**

A0866 **Radical Cystectomy vs Trimodal Therapy for Non-Metastatic Bladder Cancer in the United States: Contemporary Trends of Practice Patterns, Perioperative/Health-care Costs and Progression-Free Survival Outcomes**
F. Del Giudice, Rome (IT)

A0867 **Bladder preservation in patients with muscle-invasive bladder cancer who refused/unwilling to radical cystectomy after complete response to neoadjuvant systemic and local (chemo/immune) therapy. A 24-years single centre experience.**
S.M. Di Stasi, Rome (IT)

A0868 **Mapping real-world recurrence and treatment patterns after trimodal therapy in older adults with muscle invasive bladder cancer using a novel SEER-Medicare algorithm**
N. Davis, NASHVILLE (US)

A0869 **Efficacy of RC48-ADC in combination with toripalimab in patients with HER2-positive muscle-invasive urothelial bladder cancer and the prospect of bladder preservation**
C. Li, Wuhan (CN)

**12:50 - 13:15** **Treatment strategies for node-positive muscle-invasive bladder cancer**

A0871 **Natural History of cN2 M0 Bladder Cancer: Implications for Patient Selection for Consolidative Surgery**
M. von Deimling, Hamburg (DE)

**Study Group**
CLIPOLY(Vienna, Austria)

A0870 **Sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – interim results of the CHASIT study**
V. Rutten, Rotterdam (NL)

A0872 **Diagnostic Value of [$^{18}$F]FDG-PET/CT in Staging Histological Subtypes of Invasive Bladder Cancer**
R. Lijnen, Amsterdam (NL)

A0873 **Lymphovascular invasion and nodal positivity as useful markers for selecting candidates for adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma**
H. Shimoda, Tokyo (JP)

A0874 **Oncological and survival outcomes after Robot Assisted Radical Cystectomy wiht Totally Intracorporeal Urinary Diversion in cN+ patients, a single high-volume center experience**
L. Lambertini, Florence (IT)

**13:15 - 13:30** **Antibody drug conjugates in localised muscle-invasive bladder cancer**

A0876 **Enfortumab Vedotin-related Skin Toxicity as a Predictor of Survival among Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-analysis**
A. Alqahtani, Vienna (AT)

A0877 **Final results of a multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive bladder cancer（Hope-03）**
P. Zhang, Chengdu (CN)

A0878 **Temporal and Spatial Dynamics of ADC Targets and Immune Contexture in Bladder Cancer**
M. Kato, Osaka-fu (JP)

**13:30 - 13:55** **Neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer**

A0879 **Histologic subtypes as a prognostic factor for postoperative survival outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy**
R. Fujiwara, Tokyo (JP)

A0880 **Impact of Neoadjuvant Chemotherapy Cycle Number on Nutritional Status and Perioperative Risk in Robot-Assisted Radical Cystectomy: A Multicenter Analysis**
Y. Atagi, Tokushima (JP)

A0881 **Evaluation of the MODAPLEX multiplex mRNA assay in muscle-invasive bladder cancer: comparison of responders and non-responders after neoadjuvant gemcitabine/cisplatin therapy**
P.C. Rausch, Bochum (DE)

A0882 **Subsequent treatment patterns and outcomes among patients with Muscle Invasive Bladder Cancer (MIBC) receiving neoadjuvant treatments: a real-world data analysis**
S. Bhanvadia, Horsham (US)

A0883 **Comparable Prognostic Utility of Circulating Tumor DNA in Patients with Pure and Variant Histology Bladder Cancer Undergoing Radical Cystectomy**
A. Zhu, New York (US)

# Biochemical recurrence and persistent PSA after local treatment of prostate cancer

Abstract Session 44

**Monday 16 March**
**12:30 - 14:00**

**Location** Orange Area, Room 3

**Chairs**
A. Henry, Leeds (GB)
U. Mete, Chandigarh (IN)
M. Roberts, Brisbane (AU)

**12:30 - 12:40** **PSA follow-up and definition of BCR**

A0743 **Optimizing PSA Follow-Up After Radical Prostatectomy: A Population-Based Analysis of Biochemical Recurrence Patterns**
F. Pellegrino, Stockholm (SE)

A0744 **Defining biochemical recurrence after Radiotherapy for Prostate Cancer with PSA cut-offs below Phoenix criteria**
U.G. Falagario, Bari (IT)

**12:40 - 13:00** **Risk classification of BCR**

A0745 **Are the EAU risk categories for biochemical recurrence in prostate cancer after primary radiotherapy still clinically applicable?**
E.J.E. van Altena, Amsterdam (NL)

A0746 **Development and Validation of a Risk Model to Identify Clinically Insignificant Biochemical Recurrence After Radical Prostatectomy**
A.A. Pellegrino, Milan (IT)

A0747 **Outcomes and Treatment Patterns of Prostate Cancer Patients with Low Risk Biochemical Recurrence After Radical Prostatectomy Managed With Initial Observation**
A. Galdieri, (IT)

A0748 **Refining PSA Doubling Time Thresholds to Predict Metastases after Biochemical Recurrence in Prostate Cancer Patients Treated with Radical Prostatectomy**
P. Zaurito, Milan (IT)

**13:00 - 13:10** **PSMA PET Imaging**

A0749 **The Role of PSMA PET for PSA Persistence After Radical Prostatectomy In Patients Primarily Staged with PSMA PET/CT**
U.C. Karaarslan, Istanbul (TR)

A0750 **Prospective comparison of 64Copper [64Cu]SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for prostate cancer detection in patients with biochemical recurrence after radical prostatectomy (Co-PSMA trial).**
L. Emmett, Sydney (AU)

**13:10 - 13:45** **Prediction of BCR**

A0751 **Validation of the Cambridge, EAU, and STARCAP Prognostic Score in Predicting Biochemical Recurrence in Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy in the MRI Era**
S.L.A. Scuderi, Stockholm (SE)

A0752 **Machine Learning-Based Prediction of Biochemical Recurrence in Localized Prostate Cancer using Radiogenomic Data**
T. Ajami Fardoun, Barcelona (ES)

A0753 **Validation of the EAU Favorable and Unfavorable Intermediate-Risk Prognostic Groups for Predicting Biochemical Recurrence After Radical Prostatectomy in Contemporary Prostate Cancer Patients: The Added Value of MRI-Features**
M. Brancaccio, Milan (IT)

A0754 **Validation of a Multimodal Deep Learning Model for Predicting Biochemical Recurrence in Men Undergoing Radiation Therapy**
A. Camilloni, Solna (SE)

A0755 **Deep learning-based multimodal biochemical recurrence risk classification score (BRICS) for prostate cancer: An International Multicenter Study**
R. Chen, shanghai (CN)

A0756 **Biochemical Recurrence after Radical Prostatectomy According to Cancer Origin: Peripheral Zone vs Transition Zone. Ten-Year Outcomes Based on Preoperative MRI and Targeted Biopsy-Derived Grade Quantification**
J. Olivier, Lille (FR)

A0757 **Influence of Positive Surgical Margin Status and Characteristics on Biochemical Recurrence After Robotic Radical Prostatectomy: Insights from a High-Volume Center**
F. Piramide, Turin (IT)

**13:45 - 14:00** **Outcomes after BCR**

A0758 **Incidence and prognostic implications of PSA relapse after radical radiotherapy for prostate cancer. A population-based study**
P. Zaurito, Milan (IT)

A0760 **Late Biochemical Recurrence and Mortality in Patients with 10 years of Recurrence-Free Survival after Radical Prostatectomy**
J.J. Werner, Munich (DE)

A0759 **Cancer-Specific Mortality Outcomes in patients with Biochemical Recurrence After Radical Prostatectomy vs Radiation Therapy: Report from a Single Tertiary Referral Center**
C. Silvani, Milan (IT)

## Targets and strategies for prostate biopsy

Abstract Session 49

**Monday 16 March**
**12:30 - 14:00**

**Location** Blue Area, Victoria 4

**Chairs**
P.K-F. Chiu, Hong Kong (HK)
J. Olivier, Lille (FR)
To be confirmed

**12:30 - 13:15** **Biopsy strategy: targeted, systematic, peri-lesional biopsies**

A0833 **Targeted, perilesional, and distant biopsies in prostate cancer: prospective multicentre results from the MIRAGE study**
A. Peyrottes, Paris (FR)

**Study Group**
MIRAGE(Marseille, France)

A0834 **Optimizing Targeted and Perilesional Biopsy Scheme with Spatial Analysis for Prostate Cancer Detection: Evidence From PERI-PRO RCT**
R.Y. Deng, Beijing (CN)

A0835 **Prostate Biopsies per Lesion: The Real World Stockholm**
H. Söderbäck, Stockholm (SE)

A0836 **Reassessing the Role of Contralateral Sampling in MRI-Fusion Transperineal Prostate Biopsy For Unilateral PI-RADS Lesions**
J. Wang, San Jose (US)

A0837 **Diagnostic Value of Contralateral Systematic Biopsy and MRI Local Staging (rT) in Predicting Bilateral Prostate Cancer in Radical Prostatectomy Specimens**
M.A. Rodríguez Cabello, Boadilla del Monte (ES)

A0838 **Concomitant MRI-detected and MRI-undetected prostate cancer with implications for biopsy strategies and focal therapy planning: An analysis of the PROMIS and PICTURE trials**
A. Light, London (GB)

A0840 **Effect of ipsilateral-only systematic biopsy in unifocal MRI-visible prostate lesions on the estimation of adverse final pathology by the Gandaglia 2019 nomogram**
D. Chernysheva, Tashkent (UZ)

A0841 **The role of additional targeted biopsies in detecting clinically significant prostate cancer in patients with multiple lesions: insights from a single-center cohort of over 3,400 prostate biopsies**
B. Hoeh, Dresden (DE)

---

**13:15 - 13:30** **Factors influencing biopsy yield**

A0842 **Comparison of prostate cancer yield per MRI target lesion for LATP versus TRUS prostate biopsy: new insights from the TRANSLATE randomised clinical trial**
N. Ranasinha, Oxford (GB)

**Study Group**
TRANSLATE Trial Study Group(Oxford, United Kingdom)

---

**13:30 - 13:50** **Detection of locally advanced disease**

A0845 **Evaluation of ProstaScore™ and Magnetic Resonance Imaging for preoperative prediction of Lymph Node Involvement determined by Extended Lymph Node Dissection**
A. Valeri, Brest Cedex 2 (FR)

A0846 **Accuracy of Indocyanine Green Fluorescence in Detecting Lymph Node Metastases in High-Risk Prostate Cancer**
A.J. De Carvalho Fazoli, Sao Paulo (BR)

A0847 **Comparative Analysis of a Machine Learning-Based Model for Predicting Lymph Node Involvement in Prostate Cancer Against Traditional Nomograms**
M. Demirbilek, Diyarbakir (TR)

A0848 **Effect of ipsilateral-only systematic biopsy on predicted risk of extracapsular extension and seminal vesicle invasion using the Gandaglia nomogram**
D. Chernysheva, Tashkent (UZ)

**13:50 - 13:50** **Late-breaking abstract presentation**

LB029 **Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial**
N. Vasdev, Stevenage (GB)

**Study Group**
Univeristy of Hertfordshire Collaborators(Stevenage, United Kingdom)

## The evolving landscape of metastatic urothelial carcinoma

Abstract Session 50

**Monday 16 March**
**12:30 - 14:00**

**Location** Blue Area, Victoria 5

**Chairs**
S. Crabb, Southampton (GB)
F.C. Maluf, Sao Paulo (BR)
To be confirmed

**12:30 - 13:10** **Outcomes of metastatic urothelial carcinoma in the real world**

A0849 **Treatment patterns and survival in local-regional (cN1-3) and distant (cM1a) lymph node positive bladder cancer: Insights from a Dutch nationwide cohort**
J. Bosveld, Amsterdam (NL)

A0851 **Treatment outcomes of enfortumab vedotin plus pembrolizumab in lymph node–positive urothelial carcinoma patients fit for cystectomy: Real-world data from an enfortumab registry**
M.R. Hassler-Di Fratta, Vienna (AT)

A0852 **Real-world survival improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras**
A. Cigliola, Milan (IT)

A0854 **Real-world clinical outcomes of avelumab (A), pembrolizumab (P) or enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC) with squamous differentiation (UCSD): results from the Aron-2 study.**
V. Mollica, Bologna (IT)

A0855 **Efficacy and Safety of a Novel Treatment Scheme of RC48-ADC Plus PD-1 Inhibitors in Metastatic Urothelial Carcinoma: A Multicenter Real-world Study**
J. lin, Fuzhou (CN)

A0856 **Real-world efficacy of Avelumab maintenance therapy in advanced urothelial carcinoma: survival impact of early transition after 2–3 cycles of chemotherapy**
N. Ishii, Hirosaki (JP)

**13:10 - 13:25** **Improving metastasis detection in urothelial carcinoma**

A0857 **The comparison of CT and MRI based Node-RADS in predicting lymph node metastasis bladder cancer**
X. Yang, Nanjing (CN)

A0858 **A non-invasive preoperative fusion model for predicting lymph node metastasis in bladder cancer: a multicenter study**
Q. Cao, Nanjing (CN)

A0859 **89Zirconium-labelled girentuximab PET in patients with urothelial cancer (ZiPUP) - a phase 1 study of a novel staging modality for urothelial carcinoma**
D. Hayne, East Fremantle (AU)

**Study Group**
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (Sydney, Australia)

---

**13:25 - 13:35** **Prognostic factors in metastatic urothelial carcinoma**

A0861 **Factors associated with inferior outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with first-line enfortumab vedotin plus pembrolizumab (1L EV+P): results from UNITE**
A. Nizam, Cleveland (US)

---

**13:35 - 13:45** **Preventing side effects from new therapies in urothelial carcinoma**

A0863 **A simple risk score incorporating pan-immune-inflammation value, albumin, and KL-6 effectively stratifies risk of immune-related interstitial lung disease in genitourinary cancer**
S. Hata, Yufu (JP)

---

**13:45 - 13:55** **New developments in metastatic urothelial cancer**

A0864 **Noninvasive Evaluation of HER2 Expression AND Heterogeneity in Urothelial Carcinoma on 68Ga-HER2-affibody PET/CT**
Z. Tao, Beijing (CN)

A0865 **Phase 1 Study of B440, an Oral Bifidobacterium-Engineered WT1 Cancer Vaccine, in Patients with Metastatic Urothelial Cancer**
H. Ueki, Kobe (JP)

---

**13:55 - 13:55** **Late-breaking abstract presentations**

LB030 **Detection of Bladder Cancer in Patients with Microscopic Hematuria using Oncuria-Detect, Analysis of an International Prospective Study**
Y. Lotan, Dallas (US)

LB031 **Surveillance for recurrent urothelial cancer using Oncuria-Monitor, a urine-based multiplex immunoassay Analysis of a Prospective international Multicenter Study**
Y. Lotan, Dallas (US)

# Advancements in upper tract urothelial carcinoma: From surgical outcomes to endoscopic management

Abstract Session 45

**Monday 16 March**
**12:30 - 14:00**

**Location** Blue Area, George 3

**Chairs** To be confirmed
M. Rouprêt, Paris (FR)
Q. Wei, Chengdu (CN)

**12:30 - 12:55** **Endoscopic management of upper urinary tract urothelial carcinoma**

A0761 **A proposal of EAU-YAU trifecta score for upper tract urothelial patients treated with endoscopic kidney sparing approach**
F. Di Bello, Napoli (IT)

**Study Group**
EAU-YAU Urothelial Working Group and Ureteroscopic Treatment of upper tract Urothelial Carcinoma (UTUC) registry(Barcelona, Spain)

A0762 **Perioperative Disitamab Vedotin and Tislelizumab Followed by Nephron-Sparing Surgery in High-Risk Upper Tract Urothelial Carcinoma: A Phase 2 Trial (DISTINCT-I)**
J. Huang, Shanghai (CN)

A0763 **Conservative treatment of high risk Transitional Cell Carcinoma (TCC) of the Ureter is safe and should be adopted more frequently: results of a retrospective and prospective study**
M. Brausi, Modena (IT)

A0764 **Tumor-Related Risk Factors in Imperative Indications for Endoscopic Management of Upper Tract Urothelial Carcinoma**
T. Yoshida, Osaka (JP)

A0765 **How Accurate Is Ureteroscopic Biopsy in Predicting Grade and Stage of UTUC? An Updated Systematic Review and Meta-Analysis on Behalf of the PACE Group**
S. Moretto, Paris (FR)

**12:55 - 13:30** **Radical surgery for upper tract urothelial carcinoma**

A0767 **Anatomical refinement matters: Ureteropelvic junction location confers survival benefit for patients with upper tract urothelial carcinoma after radical nephroureterectomy**
G. Bao, Beijing (CN)

A0768 **Predicting recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: Development and validation of the novel risk score**
Y. Iwamoto, Kanagawa (JP)

A0769 **A preoperative nomogram for predicting postoperative renal function decline after radical nephroureterectomy: Guiding neoadjuvant chemotherapy decisions in upper tract urothelial carcinoma**
P. Hong, Haidian District (CN)

A0770 **Open vs Minimally Invasive Radical Nephroureterectomy for Clinical T3–T4 Upper Tract Urothelial Carcinoma: Results from a Large Multicenter International Cohort**
G. Fertitta, Torino (IT)

A0771 **Regional Disparities in Overall and Cancer-Specific Survival after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multi-Institutional Cohort Study across European and Taiwanese Centers**
N. Rössler, Hamburg (DE)

A0772 **Tailored Cystoscopic Surveillance Intervals Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results from a Multicenter Cohort Study**
Y Koike, Tokyo (JP)

**13:30 - 14:00** **Clinical and molecular correlates of high-risk upper tract urothelial carcinoma**

A0773 **Synergistic impact of LRRC15⁺ stroma and CD163⁺ macrophage infiltration on metastasis in upper tract urothelial carcinoma**
C.H. Lo, Tainan (TW)

A0774 **International Delphi Consensus on UTUC Management: The IMPACT UTUC Project**
S.D. Pandolfo, Naples (IT)

**Study Group**
IMPACT UTUC(Cleveland, United States of America)

A0775 **Clinical Outcomes of Neoadjuvant Chemotherapy Combined with Adjuvant Nivolumab in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Comparison with Adjuvant Chemotherapy**
I. Tomisaki, Kitakyushu (JP)

A0777 **The impact of Area Deprivation Index on Adjuvant Chemotherapy utilization in UTUC patients, results from a retrospective analysis.**
A. Santangelo, Milan (IT)

A0778 **Clinical Link Between Renal Interstitial Fibrosis and Tumor Stroma Activation in Predicting Metastasis of Upper Tract Urothelial Carcinoma**
C.H. Lo, Tainan (TW)

## Surgical and non-surgical treatment of non-muscle invasive bladder cancer

Abstract Session 48

**Monday 16 March**
**12:30 - 14:00**

**Location** Blue Area, Victoria 2

**Chairs**
G. Kulkarni, Toronto (CA)
K.E.M. Van Kessel, Rotterdam (NL)
E.N. Xylinas, Paris (FR)

**12:30 - 12:55** **Intravesical therapies for non-muscle invasive bladder cancer**

A0815 **Treatment of high-grade (HG) non-muscle-invasive urothelial carcinoma (NMIBC): Results from the VERSUS study by d-uo (Germany)**
C. Doehn, Lübeck (DE)

**Study Group**
Deutsche Uro-Onkologen (d-uo)(Berlin, Germany)

A0816 **Reduced vs full dose BCG maintenance in NMIBC patients treated with full dose induction: A matched analysis**
A.R. Zlotta, Toronto (CA)

A0817 **Consistent Efficacy of Durable Response in BCG Relapse, Refractory and Unresponsive Disease in a Pre-Determined Subgroup Analysis of ANKTIVA (NAI) plus BCG in BCG-Unresponsive NMIBC CIS With or Without Ta/T1 Papillary Disease**
S. Chang, Nashville (US)

A0818 **Impact of BCG Failure Pattern on Oncologic Outcomes of Intravesical Gemcitabine and Docetaxel in High-Risk NMIBC: A Multicenter European Study**
P. Scilipoti, Milan (IT)

A0819 **Periprocedural Prophylactic Antibiotic Use with Gemcitabine Intravesical System (Gem-iDRS) Monotherapy: Analysis of Data from SunRISe-1**
E.N. Xylinas, Paris (FR)

---

**12:55 - 13:30** **Auxilliary strategies of transurethral resection of the bladder**

A0820 **How reliable is intraoperative judgment during TURBT? An inter-observer concordance analysis across key surgical parameters**
G. Tremolada, Milan (IT)

A0821 **Transurethral resection of bladder tumor performance between curriculum-trained vs traditionally-trained residents: results from the EuropeaN TRaining in urologY (ENTRY) project**
P. Diana, Barcelona (ES)

A0822 **Impact of repeat TUR on oncological outcomes in patients with pT1 bladder cancer treated with en bloc TUR: the JET study**
A. Matsukawa, Tokyo (JP)

A0823 **Blue-light–Guided Transurethral Laser Ablation (TULA) for Non-Muscle-Invasive Bladder Cancer: First UK Single-Centre Experience on Recurrence-Free Survival**
A. Sandhu, London (GB)

A0824 **Nectin4-Targeted Fluorescence Imaging for Enhanced TURBT: From Preclinical Validation to First-in-Human Application**
Y. He, Beijing (CN)

A0825 **Impact of Surgeon Experience on Perioperative and Oncological Outcomes Following En Bloc Resection of Bladder Tumors: The Japan En bloc TUR (JET) Study**
Y. Taneda, Tokyo (JP)

---

**13:30 - 14:00** **Clinical outcome of non-muscle invasive bladder cancer patients**

A0827 **Large-scale external validation of a fully automated AI system for urine cytology**
M. Kaneko, Los Angeles (US)

A0829 **Disparities in guideline-concordant care and outcomes in non-muscle invasive bladder cancer: The impact of age and socioeconomic marginalization in a universal healthcare system**
J. Kwong, Toronto (CA)

A0830 **Impact of detrusor muscle sampling on clinical outcomes following en bloc resection of non-muscle invasive bladder cancer: the JET study**
H. Kondo, tokyo (JP)

A0831 **Survival outcomes of BCG only, BCG plus EMDA-MMC, or upfront radical cystectomy in high-risk Non-Muscle Invasive Bladder Cancers (NMIBCs): A multicentre collaborative study from two independent tertiary referral institutions from United Kingdom and Italy**
E. Razeto, Rome (IT)

A0832 **Predicting progression in BCG-naïve high-risk non-muscle invasive bladder cancer using PROGRxN-BCa: An international evaluation study**
J. Kwong, Toronto (CA)

**14:00 - 14:05** **Late-breaking abstract presentation**

LB028 **Clinical Validation of a Urine-based PENK DNA Methylation Assay (EarlyTect BCD Plus) for Primary and Recurrent Bladder Cancer Detection**
T. deVos, Irvine (US)

## Innovations in urethral stricture management: Techniques and long term outcomes

Abstract Session 47

**Monday 16 March**
**12:30 - 14:00**

**Location** Blue Area, Victoria 1

**Chairs**
F.E. Martins, Lisbon (PT)
M. Matuszewski, Gdansk (PL)
M.W. Vetterlein, Hamburg (DE)

**12:30 - 13:15** **From primary repair to graft substitution**

A0797 **Nationwide patterns and detailed morphology of urethral stricture disease: ten-year analysis of prevalence, treatment approaches, and etiology from a German reconstructive center**
R.J. Schulz, Hamburg (DE)

A0798 **VeSpAR trial: a randomized controlled trial comparing vessel-sparing anastomotic repair and transecting anastomotic repair in isolated, short, bulbar urethral strictures**
W. Verla, Ghent (BE)

A0799 **Preserving the Urethra! Early Experience with Mucosal-Sparing Augmented Non-Transected Anastomotic Urethroplasty**
F. Negri, Milan (IT)

A0800 **Comparative Outcomes of Dorsal Onlay Urethroplasty Using Labia Minora, Buccal Mucosal, and Vaginal Wall Grafts in Female Urethral Stricture**
M. Singh, jodhpur (IN)

A0801 **Long-term follow-up in urethroplasty: a methodological approach to minimizing bias and defining success beyond recurrence rates**
J. Klemm, Hamburg (DE)

A0802 **Crafting the Graft: An Umbrella Review of Long-Term Outcomes and Complications for Various Graft Usage in Urethral Reconstruction**
A.A. Soeroto, Central Jakarta (ID)

A0803 **Long-Term Outcomes of Minced Buccal Mucosal Graft Endo-urethroplasty: A Prospective Study**
S. Mandal, Lucknow (IN)

A0804 **From Graft to Growth: Success Rates and Functional Outcomes of Tissue-Engineered Biomaterials in Urethral Surgery**
P.G. Silva, Almada (PT)

A0805 **The New Graft Era in Panurethral Reconstruction: Long-Term Outcomes of Split-Thickness Thigh Skin Urethroplasty**
B. Bucca, Rome (IT)

**13:15 - 13:40** **Drug-coated balloon: Outcomes and comparative trials**

A0807 **5-Year Outcomes of Optilume for recurrent anterior urethral strictures: Pooled results from the ROBUST I, II and III trials**
S.P. Elliott, Minneapolis (US)

**Study Group**
ROBUST I, II, III Investigators(Portsmouth, United States of America)

A0809 **Buccal Mucosa Graft Urethroplasty Versus Optilume™ Drug-Coated Balloon for the Management of Anterior Penile Urethral Strictures**
G.L. De Giorgi, Liestal (CH)

A0810 **Efficacy of Drug-coated Balloon Dilation Versus Endoscopic Standard Treatment in Posterior Urethral Stenosis: A Real-world Comparative Study**
E. Berg, München (DE)

**13:40 - 14:00** **Challenges and solutions in female urethral reconstruction**

A0811 **Optilume® drug-coated balloon dilation in the treatment of female urethral stricture disease**
L.A. Jelisejevas, Innsbruck (AT)

A0812 **Clinical Determinants of Urethroplasty Failure in Female Urethral Stricture: Insights From a 91-Patient Cohort**
M. Huzaifa, Bhubaneswar (IN)

A0813 **Outcomes of Female Urethral Stricture Management: Augmentation Urethroplasty versus Incision Urethrotomy – Results from a Randomized Controlled Trial.**
S. Singh, Patna (IN)

A0814 **Female urethroplasty: What did the 100 consecutive cases over nine years teach us?**
S. R, Bhubaneswar (IN)

## Advances in prostate cancer management: Technology, toxicity, and survivorship

Abstract Session 46

**Monday 16 March**
**12:30 - 14:00**

**Location** Blue Area, George 4

**Chairs**
G. Carrieri, Foggia (IT)
R.A. Castillejos-Molina, Mexico City (MX)
G. Fiard, Grenoble (FR)

**12:30 - 12:50** **Patient experience**

A0788 **Exploring Supportive Care Needs Among Men Living With and Beyond Prostate Cancer: A Qualitative Study to Inform Supportive Care and Survivorship Programmes in Ireland**
N. Gordon, Dublin (IE)

A0789 **Impact of perceived disease severity and cancer-related identity on fear of cancer recurrence and disease progression in long-term prostate cancer survivors: a longitudinal study**
V.H. Meissner, Munich (DE)

A0793 **Determinants of Decision Regret After Robot-Assisted Radical Prostatectomy: The Key Role of Oncologic and Functional Recovery**
M.E. Porzi, Milan (IT)

A0795 **Patient and Partner Experiences of Prostate Cancer Care in Ireland: Findings from the Co-created PRO-ACT Study (CTRIAL-IE 24-45)**
M. Sweeney, Dublin 2 (IE)

---

**12:50 - 13:25** **Functional outcomes after prostate cancer interventions**

A0780 **Efficacy of a Computerized Urinary Control Rehabilitation System on Post-Prostatectomy Urination Recovery: A Randomized Controlled Study**
X. Li, Chongqing (CN)

A0792 **Haematuria after Intensity-Modulated Radiotherapy for Prostate Cancer**
J. den Hartog, Leuven (BE)

A0781 **Late Genitourinary Toxicity after Intensity-Modulated Radiotherapy for Prostate Cancer: focus on others than macroscopic hematuria**
J. den Hartog, Leuven (BE)

A0786 **PRO-P: Evaluating the effect of electronic patient-reported outcome measures monitoring compared with standard care in prostate cancer patients undergoing surgery — results from a randomized controlled trial**
R. Al Monajjed, Düsseldorf (DE)

**Study Group**
PROP Study Group(Düsseldorf, Germany)

A0784 **PC-PEP Phase 4: International Implementation of a Digital Whole-Person Survivorship Program for Men with Prostate Cancer**
R. Rutledge, Halifax (CA)

**Study Group**
PC-PEP Phase 4 Pan-Canadian and International Implementation Trial(Halifax, Canada)

A0787 **Is urinary loss truly the main determinant of quality-of-life impact after radical prostatectomy?**
R. Domínguez, Santiago (CL)

A0790 **Effect of different treatment options on the sexual function of prostate cancer patients in the TrueNTH Global (UK dataset): a multicentre cohort analysis study**
B. Adebusoye, London (GB)

---

**13:25 - 13:30** **Data linkage methods**

A0779 **PCBase Xtend, nationwide, population-based cohort of 5 million men in Sweden with PSA, prostate biopsies, MRI prostate, and use of chemotherapy**
E. Ventimiglia, Uppsala (SE)

---

**13:30 - 13:50** **Risk stratification and prognosis**

A0796 **A Rapid Dual-Urine Biomarker Test for Accurate Prostate Cancer Risk Stratification**
S.T. De Cillis, Turin (IT)

A0785 **Delaying Biochemical Recurrence Post-RP: The Long-term Impact of Testosterone Replacement Therapy vs. No Treatment**
E. Haddadin, Orange (US)

A0794 **Integrative Analysis of the Kinesin Superfamily Identifies Immune-Relevant Subtypes and a Prognostic Nomogram in Prostate Cancer: Bioinformatic and Experimental Validation**
Y. Wu, GuangZhou (CN)

A0791 **Prognostic Significance of Gleason Pattern 4 Tumor Volume Quantified by Deep-Learning based image analysis in Patients Undergoing Radical Prostatectomy**
B. Kang, Busan (KR)

**13:50 - 14:00** **Other**

A0783 **Secondary bladder cancer after radiotherapy in localized prostate cancer: Long-term prospective data from two Phase III Trials**
A. Nabid, Sherbrooke (CA)

A0782 **PSA Thresholds for Salvage Therapy After Radical Prostatectomy in PSMA-Negative Patients: Toward a Redefinition of Early Salvage Radiation Therapy**
F.M. Barletta, Milan (IT)

## From UTUC to bladder tumours: En-bloc resection, cryobiopsy and robotic solutions for complex cases

Video Session 17

**Monday 16 March**
**12:30 - 14:00**

**Location** Blue Area, George 1

**Chairs** To be confirmed
E. Grobet-Jeandin, Geneva (CH)
F. Soria, Turin (IT)

V117 (▢: 7 min.) **Video-based en bloc resection of upper tract urothelial carcinoma using a flexible and navigable suction ureteral access sheath and thulium fiber laser with stereotactic ablative radiotherapy: Feasibility and early outcomes**
C. Tan, Beijing (CN)

V118 (▢: 8 min.) **Rotatable bi-channel en bloc resection of bladder tumors (RBC-ERBT): Overcoming challenging locations with traction**
Q. Yao, Suzhou (CN)

V120 (▢: 8 min.) **Delayed-onset bladder wall necrosis and pelvic abscess following single immediate intravesical Mitomycin C instillation after TURBT: a rare complication and challenges faced during robot assisted cystoproatectomy**
R. Chu, Kowloon (HK)

V121 (▢: 7 min.) **En-bloc transurethral resection of bladder tumor: Difficulties and complications**
M. Fernández, Santiago (CL)

V122 (▢: 5 min.) **Radical ureterectomy combined with autologous kidney transplantation for the treatment of ureteral tumor using robotic system KD-SR-2000□initial experience**
C. Lai, Beijing (CN)

# Pioneering imaging techniques for prostate cancer: AI, MRI, and PET

EGPT 53

**Monday 16 March**
**12:30 - 14:00**

**Location** Orange Area, EGPT 1

**Chairs**
G. Gandaglia, Milan (IT)
F. Giganti, London (GB)
To be confirmed

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**12:30 - 12:40** **AI for enhancing prostate MRI**

P0916 **Lightweight machine learning for prostate MRI image quality assessment**
M. Kaneko, Los Angeles (US)

P0917 **Artificial Intelligence Incorporating PI-RADS v2.1 reduce ambiguity in PI-RAD 3 lesion and prevent unnecessary prostate biopsies**
K-C. Lin, Tainan city (TW)

**12:40 - 13:00** **Image quality and lesion level analysis in prostate MRI**

P0919 **Real-world interrater agreement of PI-QUAL v2 for prostate MRI quality assessment and its association with diagnostic accuracy**
D.L. van den Kroonenberg, Amsterdam (NL)

P0920 **The PRIME trial: lesion level and high-grade cancer analysis**
A. Ng, London (GB)

**Study Group**
PRIME Trial Group(London, United Kingdom)

P0921 **HeatMap: a novel apparent diffusion coefficient-based mapping of intralesional heterogeneity in PI-RADS lesions validated against robotic-assisted prostate biopsy histology**
V. Alargkof, Basel (CH)

P0922 **From uniform risk to size-based stratification: challenging the dogma of mandatory biopsy for all PI-RADS 4 lesions**
A. Peyrottes, Paris (FR)

**Study Group**
MIRAGE(Marseille, France)

**13:00 - 13:10** **Head-to-head: US vs MRI vs PET in prostate cancer detection**

P0923 **Artificial intelligence-assisted multiparametric ultrasound versus MRI to detect prostate cancer (PCAVISION): a prospective, multicentre, paired, non-inferiority diagnostic study**
D.L. van den Kroonenberg, Amsterdam (NL)

P0924 **PROSPET-BX Trial: Comparison of [ 68 [68Ga]PSMA PET/CT vs. mpMRI in patients with suspicion of prostate cancer and previously negative biopsy.**
E. Lopci, MILANO (IT)

**13:10 - 13:35** **Improving diagnosis using PSMA PET and SPECT/CT**

P0925 **Molecular Hallmarks of PSMA PET Visibility in Prostate Cancer Patients: A Secondary Analysis of The Next Generation Trial**
P. Albers, Edmonton (CA)

**Study Group**
Next Generation Trial investigators(Edmonton, Canada)

P0926 **Confirmed prognostic value of PROMISE and PRIMARY at initial PSMA-PET: Preliminary findings from an international, multicentre registry**
T. Maurer, Hamburg (DE)

**Study Group**
PROMISE REGISTRY STUDY GROUP(Essen, Germany)

P0927 **99mTc-MIP-1404 SPECT/CT is promising in local lymph node detection in subjects with newly identified, high risk prostate cancer**
O. Ettala, Kaarina (FI)

P0928 **99mTc-PSMA-SPECT/CT vs. PSMA PET for Nodal Metastases Detection in Prostate Cancer Patients Undergoing PSMA-Radioguided Surgery during RARP with ePLND**
L. Quarta, Milano (IT)

P0929 **The Role of SUVmax Ratio at 18F-PSMA-1007 PET for Predicting High Aggressive Pathologic Features and PSA Persistence after Radical Prostatectomy in Prostate Cancer Patients**
L. Quarta, Milano (IT)

**13:35 - 13:55** **MRI and PET post-treatment**

P0930 **The Ablation site IMaging (AIM) multicentre diagnostic accuracy study of MRI after focal therapy for localised prostate cancer**
A. Light, London (GB)

P0931 **The added value of diffusion-weighted imaging and dynamic contrast-enhanced sequences in the diagnosis of localised radiorecurrent prostate cancer: An analysis from the FORECAST trial**
A. Light, London (GB)

**Study Group**
FORECAST Trial Study Group(London, United Kingdom)

P0932 **PSMA PET/CT vs Conventional Imaging: Biochemical Recurrence-Free Survival After Radical Prostatectomy**
H. Zacho, Aalborg (DK)

**13:55 - 14:00** **Late-breaking abstract presentation**

LB032 **Dual Validation of Artificial Intelligence for Qualitative and Quantitative Intraoperative Assessment in Robotic Urologic Surgery**
A. Anceno, Los Angeles (US)

# Pioneering urothelial cancer treatments: Emerging techniques and prognostic markers

EGPT 54

**Monday 16 March**
**12:30 - 14:00**

**Location** Orange Area, EGPT 2

**Chairs**
D. D'Andrea, Vienna (AT)
S. Füssel, Dresden (DE)
A. Mattei, Luzern (CH)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**12:30 - 12:45** **Enhanced drug delivery strategies for muscle-invasive bladder cancer**

P0934 **Nanosecond pulsed electric fields selectively permeabilize urothelial cancer cell membranes, facilitating targeted intracellular delivery.**
A. Kielbik, Tübingen (DE)

P0935 **Unlocking Senolytic-Immunotherapy in Bladder Cancer: A Multi-Omics Roadmap from Senescence Subtyping to Combination Therapy**
T. Liu, Shenyang (CN)

**12:45 - 13:35** **Neoadjuvant therapeutic strategies in muscle-invasive bladder cancer**

P0937 **Does Modified 5-item Frailty Index predict postoperative complications in radical cystectomy?**
MA Mazloum, Beirut (LB)

P0938 **The Impact of neoadjuvant chemotherapy on Radical cystectomy Outcomes in Bladder Cancer: An ACS-NSQIP Analysis**
MA Mazloum, Beirut (LB)

P0939 **Does Neoadjuvant chemotherapy and radical cystectomy in muscle invasive bladder cancer obliterate survival differences between genders?**
G. Sidiqi, Umeå (SE)

P0940 **Reproducibility and predictive value of ADC for assessing response to neoadjuvant immunotherapy in muscle-invasive bladder cancer: An analysis from the phase-Ib NABUCCO trial**
J. Greidanus, Amsterdam (NL)

P0942 **Real-world data on perioperative systemic therapy for urothelial carcinoma: results from the VERSUS study by d-uo**
M. Johannsen, Berlin (DE)

P0944 **Thrombosis and major bleeding in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis**
A. Halme, Helsinki (FI)

P0945 **MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-Invasive Bladder Cancer: Accuracy and Reproducibility across 3 Prospective Clinical Trials**
J. Greidanus, Amsterdam (NL)

P0946 **Prehabilitation before robot-assisted radical cystectomy is associated with reduced 30-day complications and length of stay: a prospective, single-centre propensity-weighted cohort study**
H. Alfambra Fernandez, Barcelona (ES)

P0943 **Survival after Induction Chemotherapy and Radical Cystectomy in cN+/pN+ M0 Bladder Cancer: Implications for pretreatment patient selection**
M. von Deimling, Hamburg (DE)

**Study Group**
CLIPOLY(Vienna, Austria)

**13:35 - 14:00** **Histopathology of radical cystectomy specimens**

P0947 **Positive surgical margins in radical cystectomy: Incidence, anatomic patterns, and oncologic impact**
L. Nocera, Milan (IT)

P0948 **Prognostic significance of tertiary lymphoid structure-like lymphocyte aggregates identified on routine H&E-stained slides of radical cystectomy specimens in bladder cancer**
T. Sano, Kyoto (JP)

P0949 **Pattern and predictors of uretero-ileal stenosis after robot assisted radical cystectomy with totally intracorporeal urinary diversion. A single high-volume tertiary referral center experience**
F. Lipparini, Arezzo (IT)

P0950 **Development of a Transcriptome-Based Model for Predicting Adverse Pathology at Radical Cystectomy**
A. Viti, Milan (IT)

P0951 **Oncological survival in patients with pN+ muscle-invasive bladder blancer with or without neoadjuvant or adjuvant oncological treatments**
J. Rautiola, Solna (SE)

## Cutting-edge research in adrenal disorders: Surgery, therapies, and patient care

EGPT 55

**Monday 16 March**
**12:30 - 14:00**

**Location** Orange Area, EGPT 3

**Chairs** To be confirmed
H. Langenhuijsen, Nijmegen (NL)
D. Mai Ba Tien, Ho Chi Minh City (VN)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**12:30 - 12:45** **Epidemiology and imaging for adrenal gland**

P0952 **Adrenal incidentalomas in the 4–6 cm range: malignancy risk and surgical outcomes in a nationwide multicentre cohort**
A.H. Chaman Baz, Nijmegen (NL)

| | |
|---|---|
| P0953 | **Comparative performance of CXCR4-directed PET/CT and adrenal venous sampling for subtype classification and outcome prediction in primary aldosteronism**<br>Q. Dong, Chengdu (CN) |
| P0954 | **The reproducibility of 68Ga-PentixaFor PET/CT scanning for subtyping patients with primary aldosteronism**<br>D.W.A. Lamers, Nijmegen (NL) |
| **12:45 - 13:15** | **Pheocromocytoma latest updates** |
| P0955 | **Impact of Postoperative Hypertension on Coronary Artery Disease and Heart Failure After Resection of Pheochromocytoma or Paraganglioma**<br>Y.H. Tu, Taichung (TW) |
| P0958 | **Phenotypic Characteristics of Patients with FGFR1-Mutant Pheochromocytoma/Paraganglioma: A Multicenter Retrospective Study Based on 1001 Cases**<br>Z. Li, Zhuhai (CN) |
| P0960 | **Comparative Analysis of Laparoscopic Perioperative Hemodynamics in Pseudohypoxic versus Kinase-Signaling Pheochromocytoma/Paraganglioma Patients**<br>Y. Wang, Zhuhai (CN) |
| **13:15 - 14:00** | **Clinical and surgical outcomes for adrenal gland** |
| P0962 | **Performance of the ADRENAL and MAP Scores in Predicting Postoperative Complications After Laparoscopic Adrenalectomy**<br>S. Başboğa, Ankara (TR) |
| P0963 | **From Trial to Practice: No Survival Benefit from Adjuvant Mitotane in Low-Risk Adrenocortical Carcinoma, Insights from a Nationwide Cohort**<br>C. Silvani, Milan (IT) |
| P0964 | **The Impact of Perirenal Fat Thickness (PFT) and Other Factors on Perioperative Outcomes of Transperitoneal Laparoscopic and Robot-Assisted Adrenalectomy**<br>H. Fujinami, Yufu (JP) |
| P0965 | **Robotic Approach Is Associated with Lower Positive Margin Rates in Minimally Invasive Adrenalectomy for Adrenocortical Carcinoma: A Nationwide Analysis**<br>C. Silvani, Milan (IT) |
| P0967 | **The effects of centralized adrenal care on surgical expertise and patient outcomes**<br>D.W.A. Lamers, Nijmegen (NL) |
| P0969 | **Pushing boundaries in robotic adrenal surgery: the day-case ERAS experience**<br>A. Costa Silva, Porto (PT) |

# Infections 3: Controversies & novel treatments of urological infections

EGPT 56

**Monday 16 March**
**12:30 - 14:00**

**Location** Blue Area, EGPT 4

**Chairs**
G. Bonkat, Basel (CH)
K. Le Dinh, Hue (VN)
G. Mantica, Genoa (IT)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**12:30 - 12:55** **PROCEDURE-RELATED INFECTIONS**

P0970 **Incidence of Urinary Tract Infection Post Video-Urodynamics: A Prospective Audit of 2627 Patients 2014-2023**
S. Gill, London (GB)

P0971 **IS URS/RIRS UNDER A MAJOR AMBULATORY SURGERY REGIMEN SAFE IN PATIENTS WITH A POSITIVE PREOPERATIVE URINE CULTURE?**
B. Fernández Martínez, San Sebastian de los Reyes - Madrid (ES)

P0972 **A catheter-induced urinary tract infection microtissue model to study the role of mucoadhesion and microtrauma**
B. Murray, Harrow (GB)

P0974 **Beyond HbA1c: Dipstick Glycosuria as a Practical Biomarker of Delayed Recovery after Adult Circumcision in Diabetic Men**
S. Sun, Taipei (TW)

**12:55 - 13:25** **CONTROVERSIES**

P0975 **Schistosoma mansoni Soluble Egg Antigens Suppresses UPEC Invasion in Bladder Cells via Modulating the JAK/STAT Pathway**
C-W. Wu, Taipei (TW)

P0976 **GLP-1 receptor agonists and male genitourinary infections: A 3-year TriNetX comparative cohort study**
P.C. Liu, Taichung (TW)

P0978 **Is it too late to drain? Impact of timing of urinary drainage in acute obstructive uropathy: a retrospective cohort study**
F. Passarelli, Milano (IT)

P0979 **The UROME Study: Urological Microbes – Epidemiology over 7 years**
E. Edison, London (GB)

P0980 **The Predictive Value of Serum Procalcitonin for Identifying Therapeutic Failure in Urosepsis Caused by Multidrug-Resistant Uropathogens.**
A. Saldivar Luna, México City (MX)

**13:25 - 13:40** **INTERSTITIAL CYSTITIS**

P0981 **Treatment of interstitial cystitis with bladder perfusion of recombinant human collagen type 3**
S. Xiaokai, changzhou (CN)

P0982 **Clustering of Urinary Biomarkers to Identify Interstitial Cystitis Subtypes and Different Clinical Characteristics and Treatment Outcomes**
W.R. Yu

P0983 **Adding Triamcinolone on Platelet-Rich Plasma can Improve Treatment Outcome on Patients with Interstitial Cystitis**
W.R. Yu

**13:40 - 14:00** **RECURRENT UTI'S**

P0985 **Accuracy, readability, and understandability of EAU guidelines bot for urinary infections guidelines.**
L.M. Coppola, Rome (IT)

P0986 **Risk Factors and Microbial Etiology of Healthcare-Associated Urinary Tract Infections in Neurological Patients:Analysis of 1100 Cases**
S.V. Kotov, Moscow (RU)

P0987 **Bacteriophage therapy in women with chronic recurrent cystitis caused by multidrug-resistant bacteria: a prospective, observational, comparative study**
D. Krakhotkin, Kamenolomni (RU)

## Trauma and complex reconstruction

EGPT 57

**Monday 16 March**
**12:30 - 14:00**

**Location** Blue Area, EGPT 5

**Chairs** W. Atmoko, Jakarta (ID)
To be confirmed
M. Waterloos, Ghent (BE)

We recommend that participants review the abstracts before the session. Abstract bodies and posters, are available via the EAU26 Resource Centre or on the digital screens in front of the Orange & Blue Areas, EGPT.

**12:30 - 13:10** **Penis and urethra**

P0989 **FRACT'AFUF : nationwilde multicentric retrospective cohort of penile fracture, epidemiologic & circumtanses features and risk factor for size,multiple cavernosal and urethral fractures**
A. Boileau, Toulouse (FR)

P0991 **Penile Fracture Repair: Long-Term Erectile Function, Urinary Symptoms, and Penile Deformity**
A. Al-Mitwalli, London (GB)

P0992 **Penis "En Bloc": From Reproducible Harvesting to Transplantation - A Cadaveric Study**
P. Neuville, LYON (FR)

P0994 **Pelvic Fracture and Long-Term Urological Outcomes**
J. Shah, London (GB)

P1001 **An Ex-vivo Further Evaluation of the Venting Pressure Threshold of the Transurethral Catheterization Safety Valve (TUCSV) in a Porcine Urethral Model**
S.M. Croghan, Dublin (IE)

| | |
|---|---|
| P1003 | **Turning the Tide of Scarring: A Supramolecular Hydrogel Delivering BMSCs to Rebuild the Urethra.**<br>L. She, ZHU HAI (CN) |
| **13:10 - 13:25** | **Bladder and hematuria** |
| P1005 | **The WASHOUT study: early proactive intervention in emergency haematuria reduces length of stay, mortality and readmissions**<br>K. Byrnes, london (GB)<br>**Study Group**<br>British Urology Researchers in Surgical Training(London, United Kingdom) |
| P1006 | **The WASHOUT study:  workup and management of patients with emergency haematuria across the world**<br>K. Byrnes, london (GB)<br>**Study Group**<br>British Urology Researchers in Surgical Training(London, United Kingdom) |
| P1009 | **Routine cystography after bladder injury: Tradition or necessity?**<br>O. Sadeh, London (GB) |
| **13:25 - 14:00** | **Kidney and upper tract** |
| P1010 | **The Southern Denmark Ureteral Stricture Center: Establishing a Cross-Institutional Collaboration**<br>F. Abdellahi, Vejle (DK) |
| P1015 | **Changes in renal trauma management over two decades: A single-center study**<br>A.M. Ferreira, Anadia (PT) |
| P1017 | **Lingual mucosal graft ureteroplasty combined with ureteral reimplantation or boari flap ureteroneocystostomy for one-stage repair of long and multifocal ureteral strictures: Technique Description and the Medium-term Outcome**<br>B. Li, Wuhan (CN) |
| P1018 | **Posteriorly Augmented Anastomotic Ureteroplasty with Lingual Mucosal onlay Grafts: 8-Year Multi-institutional Experience in 61 Cases**<br>B. Li, Wuhan (CN) |
| P1022 | **Single-port robot-assisted pyeloplasty: multicenter international experience and early outcomes**<br>A. Finocchiaro, Catania (IT) |

# Take-Home Messages of EAU26

Special Session

**Monday 16 March**
**14:15 - 16:15**

**Location** Orange Area, eURO Auditorium 2

**Chairs** M. Albersen, Leuven (BE)
A. Stenzl, Stuttgart (DE)

| | |
|---|---|
| **14:15 - 14:20** | **Welcome and introduction** |
| **14:20 - 14:30** | **Functional and neuro-urology**<br>B. Peyronnet, Rennes (FR) |
| **14:30 - 14:40** | **NMIBC and UTUC**<br>J. Boormans, Rotterdam (NL) |
| **14:40 - 14:50** | **MIBC and advanced urothelial carcinoma**<br>M. Rouprêt, Paris (FR) |
| **14:50 - 15:00** | **Paediatric urology**<br>M.S. Silay, Istanbul (TR) |
| **15:00 - 15:10** | **EAU LAB: translational research @EAU**<br>L. Dyrskjøt, Aarhus (DK) |
| **15:10 - 15:20** | **Prostate cancer 1: imaging, screening and diagnosis**<br>T. Nordström, Stockholm (SE) |
| **15:20 - 15:30** | **Prostate cancer 2: treatment of localized and advanced disease**<br>D. Tilki, Hamburg (DE) |
| **15:30 - 15:40** | **Andrology**<br>G.I. Russo, Catania (IT) |
| **15:40 - 15:50** | **BPH/LUTS**<br>C. De Nunzio, Rome (IT) |
| **15:50 - 16:00** | **Stones**<br>B. Ballesta Martinez, Alicante (ES) |
| **16:00 - 16:10** | **Renal and rare cancers**<br>M.C. Mir Maresma, New York (US) |
| **16:10 - 16:15** | **Closing remarks by the chair of the EAU Scientific Congress Committee**<br>M. Albersen, Leuven (BE) |